FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Suehiro, TT
   Damke, GMZF
   Damke, E
   Ramos, PLRD
   Silva, MDP
   Pelloso, SM
   Huh, WK
   Franco, RAF
   da Silva, VRS
   Scarinci, IC
   Consolaro, MEL
AF Suehiro, Tamy Taianne
   Damke, Gabrielle Marconi Zago Ferreira
   Damke, Edilson
   de Azevedo Ramos, Paloma Luana Rodrigues
   de Andrade Pereira Silva, Marcela
   Pelloso, Sandra Marisa
   Huh, Warner K.
   Franco, Ricardo Argemiro Fonseca
   da Silva, Vania Ramos Sela
   Scarinci, Isabel Cristina
   Consolaro, Marcia Edilaine Lopes
TI Cervical and oral human papillomavirus infection in women living with
   human immunodeficiency virus (HIV) and matched HIV-negative controls in
   Brazil
SO INFECTIOUS AGENTS AND CANCER
LA English
DT Article
DE HPV; HIV; Oral; Cervical
ID 9-VALENT HPV VACCINE; RISK-FACTORS; GENOTYPES DISTRIBUTION;
   NATURAL-HISTORY; POSITIVE WOMEN; PREVALENCE; DISEASE; HEAD; IMPACT;
   CANCER
AB Background Despite the demonstrated role of human Papillomavirus (HPV) in the etiology of cervical cancer and the strong evidence suggesting the importance of HPV in the development of oropharyngeal cancer, several aspects of the interrelationship between HPV infection in both body sites remain unknown, specifically in female human immunodeficiency virus (HIV)-positive (HIV+) patients. We aimed to assess the prevalence, distribution, and concordance of cervical and oral HPV in HIV+ women and matched HIV-negative (HIV-) controls in Brazil. Material and methods Cervical and endocervical samples for cytological screening and HPV detection and oral samples were collected from 115 HIV+ women using highly active antiretroviral therapy (HAART) and 139 HIV-matched controls (HIV-) in Maringa City, Brazil. Risk factors were assessed using a standardized questionnaire, and the data regarding HIV infection were obtained from the patients' medical records. HPV detection and typing were performed using the Kit Multiplex XGEN Multi HPV Chip HS12. Results HIV infection was well controlled in this cohort, but women who exhibited detectable HIV loads were significantly associated with HPV-positive status overall (P = 0.03) and in cervical mucosa (P = 0.01). HIV+ women had significantly more abnormal cytological findings (P = 0.04) than HIV- women. Of the 115 HIV+ women, 48.7% were positive for cervical and/or oral HPV DNA; of the 139 HIV- women, 41% were positive for cervical and/or oral HPV (P = 0.25). Both HIV+ and HIV- women had a statistically higher prevalence of cervical HPV infection than oral infection. The concurrent HPV infection in two anatomical sites was similar in HIV+ and HIV- women; however, HPV type concordance was not observed. HPV type distribution was different between the anatomical sites in both groups, and HIV+ women presented less common types, mainly in oral mucosa. Conclusion Our data support the importance of testing HPV infection in HIV+ women, even when the HIV infection is well controlled. Prospective studies are required to better understand the natural history of HPV infection in both anatomical sites, specifically in HIV+ women.
C1 [Suehiro, Tamy Taianne; Damke, Gabrielle Marconi Zago Ferreira; Damke, Edilson; da Silva, Vania Ramos Sela; Consolaro, Marcia Edilaine Lopes] Univ Estadual Maringa, Lab Clin Cytol, Dept Clin Anal & Biomed, Maringa, Parana, Brazil.
   [de Azevedo Ramos, Paloma Luana Rodrigues; de Andrade Pereira Silva, Marcela; Pelloso, Sandra Marisa] Univ Estadual Maringa, Sch Nursing, Maringa, Parana, Brazil.
   [Huh, Warner K.; Franco, Ricardo Argemiro Fonseca; Scarinci, Isabel Cristina] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Lab Clin Cytol, Dept Clin Anal & Biomed, Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P30CA013148-43S2]
FX This work was supported through a research grant from the NCI
   (P30CA013148-43S2). The funder had no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adler DH, 2010, CURR HIV RES, V8, P493, DOI 10.2174/157016210793499240
   Beachler DC, 2015, AM J EPIDEMIOL, V181, P40, DOI 10.1093/aje/kwu247
   Beachler DC, 2014, ORAL ONCOL, V50, P1169, DOI 10.1016/j.oraloncology.2014.09.011
   Beachler DC, 2013, J INFECT DIS, V208, P330, DOI 10.1093/infdis/jit170
   Brisson M, 2020, LANCET
   Castellsague X, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv403
   D'Souza G, 2007, INT J CANCER, V121, P143, DOI 10.1002/ijc.22667
   de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716
   Dellar RC, 2015, J INT AIDS SOC, V18, P64, DOI 10.7448/IAS.18.2.19408
   Fakhry C, 2013, CYTOKINE, V64, P597, DOI 10.1016/j.cyto.2013.08.009
   Fakhry C, 2006, J CLIN MICROBIOL, V44, P4479, DOI 10.1128/JCM.01321-06
   Hennebery RB, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.7_suppl.185
   Hidalgo-Tenorio C, 2018, ENFERM INFEC MICR CL, V36, P555, DOI 10.1016/j.eimc.2017.10.014
   IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P1
   Irimie AI, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071558
   Isaakidis P, 2013, INT J WOMENS HEALTH, V5, P487, DOI 10.2147/IJWH.S47710
   Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044
   Konopnicki D, 2016, AIDS, V30, P425, DOI 10.1097/QAD.0000000000000929
   Kumar B, 2007, INT J RADIAT ONCOL, V69, pS109, DOI 10.1016/j.ijrobp.2007.05.072
   Lima MDM, 2014, INT J GYNECOL OBSTET, V126, P33, DOI 10.1016/j.ijgo.2014.01.017
   Liu G, 2018, AIDS, V32, P795, DOI [10.1097/qad.0000000000001765, 10.1097/QAD.0000000000001765]
   Luque AE, 2010, INT J INFECT DIS, V14, pE810, DOI 10.1016/j.ijid.2010.03.016
   Marais DJ, 2008, J MED VIROL, V80, P953, DOI 10.1002/jmv.21166
   Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6
   McKenzie ND, 2010, GYNECOL ONCOL, V116, P572, DOI 10.1016/j.ygyno.2009.10.058
   Menezes LJ, 2016, INT J STD AIDS, V27, P543, DOI 10.1177/0956462415587226
   Ndiaye C, 2014, LANCET ONCOL, V15, P1319, DOI 10.1016/S1470-2045(14)70471-1
   Ortiz AP, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.130361
   Palefsky J, 2009, CURR OPIN HIV AIDS, V4, P52, DOI 10.1097/COH.0b013e32831a7246
   Rajkumar T, 2006, INT J CANCER, V118, P1481
   Richter KL, 2008, J ORAL PATHOL MED, V37, P555, DOI 10.1111/j.1600-0714.2008.00670.x
   Rocha-Brischiliari SC, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-6
   Saffier IP, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2795-9
   Serrano B, 2014, CANCER EPIDEMIOL, V38, P748, DOI 10.1016/j.canep.2014.09.003
   Solomon D, 2005, BETHESDA SYSTEM CERV, P67
   Spangle JM, 2010, J VIROL, V84, P9398, DOI 10.1128/JVI.00974-10
   Stier EA, 2008, CURR OPIN ONCOL, V20, P541, DOI 10.1097/CCO.0b013e3283094ed8
   Syrjanen S, 2019, ACTA CYTOL, V63, P124, DOI 10.1159/000495727
   Syrjanen S, 2017, RECENT RESULTS CANC, V206, P3, DOI 10.1007/978-3-319-43580-0_1
   Taberna M, 2017, ANN ONCOL, V28, P2386, DOI 10.1093/annonc/mdx304
   Thorsteinsson K, 2018, J CLIN VIROL, V105, P64, DOI 10.1016/j.jcv.2018.05.010
   Thorsteinsson K, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2881-1
   Vacharotayangul P, 2015, CANCER EPIDEMIOL, V39, P917, DOI 10.1016/j.canep.2015.10.010
   Videla S, 2009, JAIDS-J ACQ IMM DEF, V50, P168, DOI 10.1097/QAI.0b013e3181938e63
   WHO, 2014, FACT SHEET AD HLTH
NR 45
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1750-9378
J9 INFECT AGENTS CANCER
JI Infect. Agents Cancer
PD MAY 11
PY 2020
VL 15
IS 1
AR 31
DI 10.1186/s13027-020-00301-y
PG 11
WC Oncology; Immunology
SC Oncology; Immunology
GA LP4ZL
UT WOS:000534327100001
PM 32426032
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Morelli, F
   Souza, RP
   da Cruz, TE
   Damke, GMZF
   Damke, E
   Suehiro, TT
   da Silva, VRS
   Consolaro, MEL
AF Morelli, Fabricio
   Souza, Raquel Pantarotto
   da Cruz, Tais Elisangela
   Ferreira Damke, Gabrielle Marconi Zago
   Damke, Edilson
   Suehiro, Tamy Tuani
   Sela da Silva, Vania Ramos
   Lopes Consolaro, Marcia Edilaine
TI Zika virus infection in the genital tract of non-pregnant females: a
   systematic review
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Review
DE Zika virus; Female; Non-pregnant; Genital tract
ID MALE SEXUAL TRANSMISSION; VAGINAL SECRETIONS; MOUSE MODEL
AB This review provides a general overview on the positivity and persistence of Zika virus (ZIKV) in female genital tract (FGT) of non-pregnant women and animals, as well as in cell cultures, and its influence on FGT health. We performed a systematic review based on the PRISMA statement to identify studies focused on "Zika virus" and "non-pregnant female" in PubMed, Embase. Scopus Scholar and Web of Knowledge databases of full-text papers and abstracts published in English, with no restrictions regarding the initial date of publication, up to August 2019. Our search terms yielded 625 records, that were 108 after removal of duplicates, leaving 517 items for title and abstract reviews. Of these, 475 did not meet the inclusion criteria, leaving 42 records for full-text review and resulting in the exclusion of 6 additional records. The remaining 36 met our inclusion criteria. Variations were observed regarding the presence and persistence of ZIKV in lower and upper genital samples. However, the FGT was the place in which ZIKV RNA has been detected, sometimes for relatively long periods, even after the clearance from blood and urine. In addition to the vagina and cervix, the endometrium, uterus and ovary (oocytes and follicles) could also be involved in persistent ZIKV infections. Further prospective studies are needed to assess the effect of ZIKV on FGT health.
C1 [Morelli, Fabricio; Souza, Raquel Pantarotto; da Cruz, Tais Elisangela; Ferreira Damke, Gabrielle Marconi Zago; Damke, Edilson; Suehiro, Tamy Tuani; Sela da Silva, Vania Ramos; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Anal Clin & Biomed, Programa Posgrad Biociencias & Fisiopatol, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin & Biomed, Programa Posgrad Biociencias & Fisiopatol, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lope/I-4932-2014
OI Consolaro, Marcia Edilaine Lope/0000-0001-9102-4865
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/CAPES,
   Brazilian GovernmentCAPES [88881.130822/201601]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico/CNPq, Brazilian
   GovernmentNational Council for Scientific and Technological Development
   (CNPq) [440521/2016-5]; Departamento de Ciencia e Tecnologia da
   Secretaria de Ciencia, Tecnologia e Insumos Estrategicos do Ministerio
   da Saude/DECIT/SCTIE/MS
FX This work was supported by grants from Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior/CAPES, Brazilian Government (Grant No
   88881.130822/201601), Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico/CNPq, Brazilian Government (Grant No 440521/2016-5) and
   Departamento de Ciencia e Tecnologia da Secretaria de Ciencia,
   Tecnologia e Insumos Estrategicos do Ministerio da Saude/DECIT/SCTIE/MS.
CR American Society for Reproductive Medicine, GUID PROV CAR WOM ME
   Amerson-Brown MH, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03340
   Araujo E, 2019, J BRAS REPROD ASSIST, V23, P172, DOI 10.5935/1518-0557.20180081
   Arsuaga M, 2016, LANCET INFECT DIS, V16, P1107, DOI 10.1016/S1473-3099(16)30320-6
   Barzon L., 2016, EUROSURVEILLANCE, V21, P2016, DOI DOI 10.2807/1560-7917.ES.2016.21.32.30316
   Barzon L, 2018, CLIN INFECT DIS, V66, P1173, DOI 10.1093/cid/cix967
   Beller EM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001419
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Blohm GM, 2018, CLIN INFECT DIS, V66, P1120, DOI 10.1093/cid/cix968
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Broughton DE, 2017, FERTIL STERIL, V108, pE35
   Cagno V, 2019, CLIN MICROBIOL INFEC, V25, DOI 10.1016/j.cmi.2019.04.016
   Caine EA, 2019, J INFECT DIS, V220, P1904, DOI 10.1093/infdis/jiz239
   Caine EA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07993-2
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Carroll T, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006537
   Chan JFW, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.99
   Chen JC, 2016, INT J INFECT DIS, V51, P139, DOI 10.1016/j.ijid.2016.07.015
   Clapham HE, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005926
   Cordeiro CN, 2017, CURR OPIN OBSTET GYN, V29, P175, DOI 10.1097/GCO.0000000000000366
   Cruz TE, 2019, AM J TROP MED HYG, V100, P183
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   da Silva SR, 2019, J MED VIROL, V91, P179, DOI 10.1002/jmv.25306
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dowall SD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004658
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Duggal NK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22840-6
   Epelboin S, 2017, HUM REPROD UPDATE, V23, P629, DOI 10.1093/humupd/dmx024
   Fink SL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27224-4
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   Grard G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002681
   Haddow AD, 2017, EMERG INFECT DIS, V23, P1274, DOI 10.3201/eid2308.170036
   Hastings AK, 2017, CELL REP, V19, P558, DOI 10.1016/j.celrep.2017.03.058
   Hirsch AJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006219
   Joguet G, 2017, LANCET INFECT DIS, V17, P1200, DOI 10.1016/S1473-3099(17)30444-9
   Khan S, 2016, J EXP MED, V213, P2913, DOI 10.1084/jem.20161289
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   Kurscheidt FA, 2019, NAT REV UROL, V16, P211, DOI 10.1038/s41585-019-0149-7
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Li L, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030093
   Ma WQ, 2016, CELL, V167, P1511, DOI 10.1016/j.cell.2016.11.016
   MACNAMARA FN, 1954, T ROY SOC TROP MED H, V48, P139, DOI 10.1016/0035-9203(54)90006-1
   MANDL AM, 1951, J ENDOCRINOL, V7, P112, DOI 10.1677/joe.0.0070112
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P405, DOI 10.1016/S1473-3099(16)00138-9
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Muller JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04442-y
   Murray KO, 2017, EMERG INFECT DIS, V23, P99, DOI 10.3201/eid2301.161394
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Nicastri E, 2016, EMERG INFECT DIS, V22, P2228, DOI 10.3201/eid2212.161280
   Osuna CE, 2016, NAT MED, V22, P1448, DOI 10.1038/nm.4206
   Pagani I, 2017, SCI REP-UK, V7, DOI 10.1038/srep44286
   Pan American Health Organization, 2018, ZIK CAS CONG SYNDR A
   Panchaud A, 2016, CLIN MICROBIOL REV, V29, P659, DOI 10.1128/CMR.00014-16
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Penot P, 2017, EUROSURVEILLANCE, V22, P8, DOI 10.2807/1560-7917.ES.2017.22.3.30444
   Petersen LR, 2010, VOX SANG, V98, P495, DOI 10.1111/j.1423-0410.2009.01286.x
   Prisant N, 2019, REPROD BIOMED ONLINE, V39, P624, DOI 10.1016/j.rbmo.2019.05.013
   Prisant N, 2016, LANCET INFECT DIS, V16, P1000, DOI 10.1016/S1473-3099(16)30193-1
   Reyes Y, 2019, EMERG INFECT DIS, V25, P808, DOI 10.3201/eid2504.180977
   Sanchez-Montalva A, 2018, TROP MED INT HEALTH, V23, P92, DOI 10.1111/tmi.13019
   Scott JM, 2018, J VIROL, V92, DOI 10.1128/JVI.00038-18
   Shankar A, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01761
   Sharp TM, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6801a1
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Sotelo JR, 2017, EMERG INFECT DIS, V23, P854, DOI 10.3201/eid2305.161538
   Tang WW, 2016, CELL REP, V17, P3091, DOI 10.1016/j.celrep.2016.11.070
   Tobar P, 2018, P R HEALTH SCI J, V37, pS96
   Tozetto-Mendoza TR, 2019, REV INST MED TROP SP, V61, DOI [10.1590/S1678-9946201961019, 10.1590/s1678-9946201961019]
   Tripathi S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006258
   Uraki R, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602899
   Winkler CW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07099-7
   World Health Organization (WHO), 2016, PREV SEX TRANSM ZIK
NR 77
TC 1
Z9 1
U1 0
U2 0
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PY 2020
VL 62
AR e16
DI 10.1590/S1678-9946202062016
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA KT1ZM
UT WOS:000518812000001
PM 32130356
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Venancio, PA
   Consolaro, MEL
   Derchain, SF
   Boccardo, E
   Villa, LL
   Maria-Engler, SS
   Campa, A
   Discacciati, MG
AF Venancio, Paloma Almeida
   Lopes Consolaro, Marcia Edilaine
   Derchain, Sophie Francoise
   Boccardo, Enrique
   Villa, Luisa Lina
   Maria-Engler, Silvya Stuchi
   Campa, Ana
   Discacciati, Michelle Garcia
TI Indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase expression in
   HPV infection, SILs, and cervical cancer
SO CANCER CYTOPATHOLOGY
LA English
DT Article
DE cervical cancer; cervical intraepithelial neoplasia; human
   papillomavirus 16; indolamine-2; 3-dioxygenase; squamous intraepithelial
   lesions; tryptophan 2; 3-dioxygenase
ID TUMORAL IMMUNE RESISTANCE; HUMAN-PAPILLOMAVIRUS; IDO1; NEUTROPHILS;
   RESPONSES; CELLS; MICROENVIRONMENT; POLARIZATION; INHIBITION
AB Background Human papillomavirus (HPV) infection is the central factor for cervical cancer, whereas epithelial immune mechanisms contribute to the progression of HPV infection and its associated lesions. The authors evaluated the expression of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) in cervicovaginal samples from women with normal cervical epithelium or with different degrees of squamous intraepithelial lesions (SILs) and cervical cancer. Methods IDO expression was analyzed by immunocytochemistry in liquid-based cytology samples from 165 women, of whom 42 had cervical changes subclassified as low-grade SIL (n = 6), high-grade SIL (n = 30), or squamous cell carcinoma (SCC) (n = 6), and 123 had negative Papanicolaou smears. IDO and TDO expression also were analyzed by immunohistochemistry, and HPV and other genital pathogens were evaluated by polymerase chain reaction analysis. Results Low IDO expression was observed in normal cervical epithelium irrespective of HPV status. Increased numbers of IDO-positive squamous cells and IDO-positive leukocytes were observed in women with SIL or SCC. TDO expression was detected in leukocytes infiltrating the stroma around intraepithelial or invasive cervical lesions. Higher IDO levels were detected in organotypic epithelial cultures established from keratinocytes transduced with the HPV16 E6/E7 oncoproteins. Conclusions The upregulation of IDO expression in leukocytes and squamous cells in HPV-associated SIL and SCC suggests that immunosuppressive mechanisms involving tryptophan metabolism may have a role in cervical carcinogenesis. Although previous studies have suggested the role of IDO in HPV pathogenesis, this is the first evidence of TDO involvement in the process. Furthermore, the current data emphasize the role of leukocytes, especially neutrophil-like cells, as an IDO source.
C1 [Venancio, Paloma Almeida; Maria-Engler, Silvya Stuchi; Campa, Ana; Discacciati, Michelle Garcia] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Anal & Toxicol, Sao Paulo, Brazil.
   [Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Clin Cytol Lab, Maringa, Parana, Brazil.
   [Derchain, Sophie Francoise; Discacciati, Michelle Garcia] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Campinas, SP, Brazil.
   [Boccardo, Enrique] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Sao Paulo, Brazil.
   [Villa, Luisa Lina] Univ Sao Paulo, Dept Radiol & Oncol, Fac Med, Sao Paulo, Brazil.
RP Discacciati, MG (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Chem & Toxicol, Lab Clin Cytopathol, Ave Lineu Prestes 580,Bl 17, BR-05508900 Sao Paulo, SP, Brazil.
EM michelle.garciadisc@gmail.com
RI Maria-Engler, Silvya/ABC-2016-2020; Consolaro, Marcia Edilaine
   Lopes/I-4932-2014; Boccardo, Enrique/A-3960-2012; Derchain, Sophie
   FM/I-9500-2014; Engler, Silvya Stuchi Maria/K-5936-2016; VILLA,
   LUISA/AAH-4761-2019; Discacciati, Michelle Garcia/B-4608-2014
OI Maria-Engler, Silvya/0000-0003-4771-6041; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865; Boccardo, Enrique/0000-0003-1900-0273;
   Derchain, Sophie FM/0000-0003-1029-9993; Engler, Silvya Stuchi
   Maria/0000-0003-4771-6041; VILLA, LUISA/0000-0003-4074-2335;
   Discacciati, Michelle Garcia/0000-0003-3660-3826; Venancio,
   Paloma/0000-0003-0668-9366
FU Sao Paulo Research Foundation (Fundacao de Apoio a Pesquisa do Estado de
   Sao Paulo) [2012/09746-2, 2017/04926-6]; National Council for Scientific
   and Technological Development (Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico)National Council for Scientific and
   Technological Development (CNPq) [CNPQ 134385/2016-0]; CAPES/PROCAD
   (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/Programa
   Nacional de Cooperacao Academica) [88881.068413/2014-01]
FX This work was supported by the Sao Paulo Research Foundation (Fundacao
   de Apoio a Pesquisa do Estado de Sao Paulo; (2012/09746-2 and
   2017/04926-6), the National Council for Scientific and Technological
   Development (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico; CNPQ 134385/2016-0), and CAPES/PROCAD (Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior/Programa Nacional de
   Cooperacao Academica) (88881.068413/2014-01).
CR Badalamenti G, CELL IMMUNOL, DOI [10.1006/j.cellimm.2018.01.013, DOI 10.1006/J.CELLIMM.2018.01.013]
   Bashaw AA, 2017, PAPILLOMAVIRUS RES, V4, P58, DOI 10.1016/j.pvr.2017.08.002
   Bilir C, 2017, J ONCOL SCI, V3, P52, DOI [10.1016/jons.2017.04.001, DOI 10.1016/j.jons.2017.04.001]
   Bosnyak E, 2015, EJNMMI RES, V5, DOI 10.1186/s13550-015-0136-9
   Bravo Ignacio G., 2015, Evolution Medicine and Public Health, P32, DOI 10.1093/emph/eov003
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brochez L, 2017, EUR J CANCER, V76, P167, DOI 10.1016/j.ejca.2017.01.011
   Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150
   Chen IC, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/8169724
   Chimal-Ramirez GK, 2013, J ONCOL, V2013, DOI 10.1155/2013/835956
   Dai XC, 2010, J HISTOCHEM CYTOCHEM, V58, P17, DOI 10.1369/jhc.2009.953604
   Discacciati MG, 2015, CANCER EPIDEM BIOMAR, V24, P1539, DOI 10.1158/1055-9965.EPI-15-0420
   Doorbar J, 2005, J CLIN VIROL, V32, pS7, DOI 10.1016/j.jcv.2004.12.006
   Alvarez KLF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09079-3
   Ferns DM, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.981457
   Franco E, 1999, Rev Panam Salud Publica, V6, P223, DOI 10.1590/S1020-49891999000900001
   Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017
   Galdiero MR, 2013, IMMUNOBIOLOGY, V218, P1402, DOI 10.1016/j.imbio.2013.06.003
   Hascitha J, 2016, CLIN BIOCHEM, V49, P919, DOI 10.1016/j.clinbiochem.2016.04.008
   Hjortso MD, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/21624011.2014.968480
   Inaba T, 2010, GYNECOL ONCOL, V117, P423, DOI 10.1016/j.ygyno.2010.02.028
   Kawano M, 2015, SCI REP-UK, V5, DOI 10.1038/srep18217
   Kobayashi A, 2008, MUCOSAL IMMUNOL, V1, P412, DOI 10.1038/mi.2008.33
   Kruger P, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004651
   Kurman RJ, 2014, WHO CLASSIFICATION T, V6
   Lob S, 2009, CANCER IMMUNOL IMMUN, V58, P153, DOI 10.1007/s00262-008-0513-6
   Loughman JA, 2012, J INFECT DIS, V205, P1830, DOI 10.1093/infdis/jis280
   Mittal D, 2013, J INVEST DERMATOL, V133, P2686, DOI 10.1038/jid.2013.222
   Moses K, 2016, SEMIN IMMUNOL, V28, P187, DOI 10.1016/j.smim.2016.03.018
   Munn DH, 2016, TRENDS IMMUNOL, V37, P193, DOI 10.1016/j.it.2016.01.002
   Munn DH, 2013, TRENDS IMMUNOL, V34, P137, DOI 10.1016/j.it.2012.10.001
   Nakamura T, 2007, CANCER SCI, V98, P874, DOI 10.1111/j.1349-7006.2007.00470.x
   Nayar R, 2015, J LOW GENIT TRACT DI, V19, P175, DOI 10.1097/LGT.0000000000000115
   Nino-Castro A, 2014, INNATE IMMUN-LONDON, V20, P401, DOI 10.1177/1753425913496442
   NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991
   Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491
   Orlando PA, 2012, J INFECT DIS, V205, P272, DOI 10.1093/infdis/jir717
   Patel S, 2009, CURR OPIN OBSTET GYN, V21, P54, DOI 10.1097/GCO.0b013e32831a9890
   Perobelli SM, 2015, BRAZ J MED BIOL RES, V48, P665, DOI 10.1590/1414-431X20154524
   Pilotte L, 2012, P NATL ACAD SCI USA, V109, P2497, DOI 10.1073/pnas.1113873109
   Platten M, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00673
   Prendergast GC, 2017, CANCER RES, V77, P6795, DOI 10.1158/0008-5472.CAN-17-2285
   Punt S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.984539
   Romani L, 2014, EUR J IMMUNOL, V44, P3192, DOI 10.1002/eji.201344406
   Schmidt SV, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00384
   Sedlmayr P, 2002, MOL HUM REPROD, V8, P385, DOI 10.1093/molehr/8.4.385
   Selvan SR, 2016, CURR CANCER DRUG TAR, V16, P755, DOI 10.2174/1568009615666151030102250
   Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004
   Souza RP, 2013, AM J TROP MED HYG, V89, P1199, DOI 10.4269/ajtmh.13-0315
   Steinbach A, 2018, INT J CANCER, V142, P224, DOI 10.1002/ijc.31027
   Termini L, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-29
   Theate I, 2015, CANCER IMMUNOL RES, V3, P161, DOI 10.1158/2326-6066.CIR-14-0137
   Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934
   Wu LL, 2018, ONCOL LETT, V15, P9507, DOI 10.3892/ol.2018.8532
   Yu CP, 2018, CELL PHYSIOL BIOCHEM, V49, P134, DOI 10.1159/000492849
   Yu JP, 2013, J IMMUNOL, V190, P3783, DOI 10.4049/jimmunol.1201449
   Yu P, 2006, LAB INVEST, V86, P231, DOI 10.1038/labinvest.3700389
   Zhai LJ, 2015, CLIN CANCER RES, V21, P5427, DOI 10.1158/1078-0432.CCR-15-0420
NR 58
TC 1
Z9 1
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1934-662X
EI 1934-6638
J9 CANCER CYTOPATHOL
JI Cancer Cytopathol.
PD SEP
PY 2019
VL 127
IS 9
BP 586
EP 597
DI 10.1002/cncy.22172
EA AUG 2019
PG 12
WC Oncology; Pathology
SC Oncology; Pathology
GA IW9AM
UT WOS:000480867000001
PM 31412167
DA 2020-12-08
ER

PT J
AU Rocha, RM
   Souza, RP
   Gimenes, F
   Consolaro, MEL
AF Rocha, Rodrigo M.
   Souza, Raquel P.
   Gimenes, Fabricia
   Consolaro, Marcia E. L.
TI The high-risk human papillomavirus continuum along the female
   reproductive tract and its relationship to infertility and endometriosis
SO REPRODUCTIVE BIOMEDICINE ONLINE
LA English
DT Article
DE Continuum; Endometriosis; Human papillomavirus; Infertility; Upper
   female genital tract
ID INTRAUTERINE MICROBIAL COLONIZATION; WOMEN; PREVALENCE; INFECTION;
   PATHOGENESIS; EPIDEMIOLOGY; BURDEN; IMPACT
AB Research question: Is there an association between the presence of sexually transmitted pathogens in the lower (LGT) and upper (UGT) female genital tract with endometriosis and infertility?
   Design: Case-control study with 60 women submitted to gynaecological laparoscopic surgery. Samples from the UGT and LGT were collected and analysed by single polymerase chain reaction (PCR) for human papillomavirus (HPV) and by multiplex PCR for other sexually transmitted infections (STI). Patients were initially divided into two clinical groups: infertile patients (n = 25) with conjugal infertility and fertile control patients (n = 35). After the surgical findings patients were further divided for additional analysis: an endometriosis group (n = 29) and non-endometriosis control group (n = 31).
   Results: Sixty per cent of patients were positive for DNA-HPV in some of the genital tract sites sampled. Infertile patients were associated with high-risk HPV (hrHPV) positivity in the UGT sites (P = 0.027). The endometriosis group was associated with hrHPV positivity in the LGT and UGT sites (P = 0.0002 and P = 0.03, respectively). Only hrHPV types were detected in the UGT in both groups. It may be that there is a hrHPV infection continuum, from LGT to UGT, in infertile and endometriosis patients. No association was observed among the other seven STI studied.
   Conclusions: This study shows both an association between hrHPV infections in the UGT with infertility and endometriosis, and a possible hrHPV infection continuum, from LGT to UGT. Larger studies are needed to fully investigate the role of hrHPV as a cause of endometriosis and infertility.
C1 [Rocha, Rodrigo M.] State Univ Western Parana, Med Sch, Reprod Endocrinol & Infertil, Cascavel, PR, Brazil.
   [Rocha, Rodrigo M.; Souza, Raquel P.; Gimenes, Fabricia; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol & STD Lab, Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol & STD Lab, Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Rocha, Rodrigo/AAN-6428-2020; Consolaro, Marcia Edilaine
   Lopes/I-4932-2014
OI Rocha, Rodrigo/0000-0002-1456-3483; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)/Brazilian GovernmentCAPES
FX This work was supported by grants from the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)/Brazilian
   Government.
CR Acien Pedro, 2013, ISRN Obstet Gynecol, V2013, P242149, DOI 10.1155/2013/242149
   Augoulea A, 2012, ARCH GYNECOL OBSTET, V286, P99, DOI 10.1007/s00404-012-2357-8
   Boivin J, 2007, HUM REPROD, V22, P1506, DOI 10.1093/humrep/dem046
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Burney RO, 2012, FERTIL STERIL, V98, P511, DOI 10.1016/j.fertnstert.2012.06.029
   Campos GB, 2018, FERTIL STERIL, V109, P549, DOI 10.1016/j.fertnstert.2017.11.009
   Castle PE, 2007, SEX TRANSM DIS, V34, P849, DOI 10.1097/OLQ.0b013e318064c8c5
   Chen C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00901-0
   Chen LH, 2013, J MED VIROL, V85, P1229, DOI 10.1002/jmv.23582
   Cousineau TM, 2006, FERTIL STERIL, V85, P1684, DOI 10.1016/j.fertnstert.2005.10.077
   Culley L, 2013, HUM REPROD UPDATE, V19, P625, DOI 10.1093/humupd/dmt027
   Dunselman GAJ, 2014, HUM REPROD, V29, P400, DOI 10.1093/humrep/det457
   Gao X, 2006, CURR MED RES OPIN, V22, P1787, DOI 10.1185/030079906X121084
   Gosvig CF, 2013, GYNECOL ONCOL, V131, P661, DOI 10.1016/j.ygyno.2013.09.002
   Gotz HM, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022793
   Heidarpour M, 2017, J OBSTET GYNAECOL RE, V43, P135, DOI 10.1111/jog.13188
   Hermonat PL, 1997, VIRUS GENES, V14, P13
   Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703
   Khan KN, 2016, EUR J OBSTET GYN R B, V199, P69, DOI 10.1016/j.ejogrb.2016.01.040
   Khan KN, 2014, HUM REPROD, V29, P2446, DOI 10.1093/humrep/deu222
   Kobayashi H, 2014, MOL MED REP, V9, P9, DOI 10.3892/mmr.2013.1755
   Larsen Bryan, 2010, Infect Dis Obstet Gynecol, V2010, DOI 10.1155/2010/521921
   Macer ML, 2012, OBSTET GYN CLIN N AM, V39, P535, DOI 10.1016/j.ogc.2012.10.002
   MANOS MM, 1994, J INFECT DIS, V170, P1096, DOI 10.1093/infdis/170.5.1096
   MEHAR A, 2013, NATL HLTH STAT REPOR, DOI DOI 10.1093/HUMREP/DES207
   Missmer Stacey A, 2003, Obstet Gynecol Clin North Am, V30, P1, DOI 10.1016/S0889-8545(02)00050-5
   Monsonego J, 2015, GYNECOL ONCOL, V137, P47, DOI 10.1016/j.ygyno.2015.01.551
   Oppelt P, 2010, FERTIL STERIL, V93, P1778, DOI 10.1016/j.fertnstert.2008.12.061
   Pelzer ES, 2011, HUM REPROD, V26, P1799, DOI 10.1093/humrep/der108
   Quaas Alexander, 2008, Rev Obstet Gynecol, V1, P69
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
   Senapati S, 2016, FERTIL STERIL, V106, P164, DOI 10.1016/j.fertnstert.2016.03.037
   Souza Raquel, 2017, WULFENIA J, V24, P49
   Souza RP, 2013, AM J TROP MED HYG, V89, P1199, DOI 10.4269/ajtmh.13-0315
   Theron E, 2007, SOC WORK-MAATSK WERK, V43, P283, DOI 10.15270/43-3-276
   Tota JE, 2011, PREV MED, V53, pS12, DOI 10.1016/j.ypmed.2011.08.017
   Vestergaard AL, 2010, ARCH VIROL, V155, P695, DOI 10.1007/s00705-010-0643-y
   Vinatier D, 2001, EUR J OBSTET GYN R B, V96, P21, DOI 10.1016/S0301-2115(00)00405-X
   Zacharis K, 2018, MEDICINA-LITHUANIA, V54, DOI 10.3390/medicina54040050
NR 39
TC 4
Z9 4
U1 0
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1472-6483
EI 1472-6491
J9 REPROD BIOMED ONLINE
JI Reprod. Biomed. Online
PD JUN
PY 2019
VL 38
IS 6
BP 926
EP 937
DI 10.1016/j.rbmo.2018.11.032
PG 12
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA HZ1PH
UT WOS:000468618600009
PM 30940433
DA 2020-12-08
ER

PT J
AU Kurscheidt, FA
   Mesquita, CSS
   Damke, GMZF
   Damke, E
   Carvalho, ARBD
   Suehiro, TT
   Teixeira, JJV
   da Silva, VRS
   Souza, RP
   Consolaro, MEL
AF Kurscheidt, Fabio A.
   Mesquita, Cristiane S. S.
   Damke, Gabrielle M. Z. F.
   Damke, Edilson
   Carvalho, Analine R. B. de A.
   Suehiro, Tamy T.
   Teixeira, Jorge J., V
   da Silva, Vania R. S.
   Souza, Raquel P.
   Consolaro, Marcia E. L.
TI Persistence and clinical relevance of Zika virus in the male genital
   tract
SO NATURE REVIEWS UROLOGY
LA English
DT Review
ID MALE SEXUAL TRANSMISSION; SERTOLI-CELLS; UNITED-STATES; BODY-FLUIDS;
   INFECTION; SEMEN; SPERM; RNA; PROLIFERATION; REPLICATION
AB Zika virus (ZIKV) is a re-emerging mosquito-transmitted flavivirus associated with congenital abnormalities in newborns and with Guillain-Barre syndrome in adults. The virus can also be sexually transmitted and can persist in the male genital tract. Studies evaluating the kinetics of ZIKV in seminal shedding of men who have been infected, as well as in animal and cellular models of infection, have shown that, in addition to the testis and epididymis, the prostate and seminal vesicles could also be involved in persistent ZIKV infection. Additionally, some studies have reported that men infected with ZIKV can present with genitourinary symptoms such as haematospermia, prostatitis, painful ejaculation, penile discharge, and oligospermia; however, little is known about the effect of ZIKV on fertility. Understanding the mechanisms that underlie persistent ZIKV infections in men is crucial to developing guidelines, effective vaccines, and therapies.
C1 [Kurscheidt, Fabio A.; Mesquita, Cristiane S. S.; Damke, Gabrielle M. Z. F.; Damke, Edilson; Carvalho, Analine R. B. de A.; Suehiro, Tamy T.; da Silva, Vania R. S.; Souza, Raquel P.; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Lab Clin Cytol & Semen Anal, Maringa, Parana, Brazil.
   [Teixeira, Jorge J., V] Univ Estadual Maringa, Div Epidemiol, Dept Clin Anal & Biomed, Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Clin Anal & Biomed, Lab Clin Cytol & Semen Anal, Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel superior (CAPES),
   Brazilian GovernmentCAPES
FX This work was supported by grants from Coordenacao de Aperfeicoamento de
   Pessoal de Nivel superior (CAPES), Brazilian Government.
CR Amann RP, 2008, J ANDROL, V29, P469, DOI 10.2164/jandrol.107.004655
   American Society for Reproductive Medicine, 2018, GUID PROV CAR WOM ME
   Andrade MCR, 2004, MEM I OSWALDO CRUZ, V99, P581, DOI 10.1590/S0074-02762004000600009
   Antony JM, 2015, VACCINE, V33, P3073, DOI 10.1016/j.vaccine.2014.12.004
   Armstrong P, 2016, MMWR-MORBID MORTAL W, V65, P286, DOI 10.15585/mmwr.mm6511e1
   Arsuaga M, 2016, LANCET INFECT DIS, V16, P1107, DOI 10.1016/S1473-3099(16)30320-6
   Atkinson B, 2017, EMERG INFECT DIS, V23, P611, DOI 10.3201/eid2304.161692
   Atkinson B, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.01116-16
   Atkinson B, 2016, EMERG INFECT DIS, V22, P940, DOI 10.3201/eid2205.160107
   Aubry M, 2017, EMERG INFECT DIS, V23, P669, DOI 10.3201/eid2304.161549
   Bachiller-Luque P, 2016, ENFERM INFEC MICR CL, V34, P243, DOI 10.1016/j.eimc.2016.02.012
   BAGASRA O, 1994, AIDS, V8, P1669, DOI 10.1097/00002030-199412000-00005
   Bagasra O, 2017, APPL IMMUNOHISTO M M, V25, P679, DOI 10.1097/PAI.0000000000000580
   Barzon L, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.32.30316
   Barzon L, 2018, CLIN INFECT DIS, V66, P1173, DOI 10.1093/cid/cix967
   Biava M, 2018, NEW MICROBIOL, V41, P30
   Breton S, 2015, GENOME, V58, P423, DOI 10.1139/gen-2015-0090
   Brooks RB, 2016, MMWR-MORBID MORTAL W, V65, P915, DOI 10.15585/mmwr.mm6534e2
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Centers for Disease Control and Prevention, GUID UD LAB TEST ZIK
   Chakhtoura N, 2018, CURR OPIN OBSTET GYN, V30, P116, DOI 10.1097/GCO.0000000000000440
   Chan JFW, 2016, J INFECTION, V72, P507, DOI 10.1016/j.jinf.2016.02.011
   Chan JFW, 2016, EBIOMEDICINE, V14, P112, DOI 10.1016/j.ebiom.2016.11.017
   Charrel RN, 2016, B WORLD HEALTH ORGAN, V94, P574, DOI 10.2471/BLT.16.171207
   Chen J, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.67
   Chui K, 2011, CELL TRANSPLANT, V20, P619, DOI 10.3727/096368910X536563
   COMHAIRE FH, 1989, J ANDROL, V10, P50
   Cordeiro CN, 2017, CURR OPIN OBSTET GYN, V29, P175, DOI 10.1097/GCO.0000000000000366
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   da Cruz TE, 2019, AM J TROP MED HYG, V100, P183, DOI 10.4269/ajtmh.18-0623
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Duggal NK, 2017, CELL REP, V18, P1751, DOI 10.1016/j.celrep.2017.01.056
   Dym M, 1970, Biology Reprod., V3, P308
   DYM M, 1973, ANAT RECORD, V175, P639, DOI 10.1002/ar.1091750402
   Epelboin S, 2017, HUM REPROD UPDATE, V23, P629, DOI 10.1093/humupd/dmx024
   Food and Drug Administration, 2016, DON SCREEN REC RED R
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Frank C, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.23.30252
   Freour T, 2016, EUROSURVEILLANCE, V21, P10, DOI 10.2807/1560-7917.ES.2016.21.23.30254
   Froeschl G, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2123-9
   Garcia-Bujalance S, 2017, J CLIN VIROL, V96, P110, DOI 10.1016/j.jcv.2017.10.006
   Gardner LM, 2016, LANCET INFECT DIS, V16, P522, DOI 10.1016/S1473-3099(16)00176-6
   Gaskell KM, 2017, EMERG INFECT DIS, V23, P137, DOI 10.3201/eid2301.161300
   Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   Griffin BD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15743
   Harrower J, 2016, EMERG INFECT DIS, V22, P1855, DOI 10.3201/eid2210.160951
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Hirsch AJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006219
   Huits R., 2016, B WORLD HEALTH ORGAN, V6, P1
   Huits R, 2017, B WORLD HEALTH ORGAN, V95, P802, DOI [10.2471/BLT.17.181370, 10.2471/blt.17.181370]
   Jang HC, 2016, J KOREAN MED SCI, V31, P1173, DOI 10.3346/jkms.2016.31.7.1173
   Joguet G, 2017, LANCET INFECT DIS, V17, P1200, DOI 10.1016/S1473-3099(17)30444-9
   Kaur G, 2014, SEMIN CELL DEV BIOL, V30, P36, DOI 10.1016/j.semcdb.2014.02.011
   Kawiecki AB, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0749-x
   Kim W, 2014, P NATL ACAD SCI USA, V111, P16389, DOI 10.1073/pnas.1407097111
   Koide F, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02028
   Kraemer MUG, 2015, ELIFE, V4, DOI 10.7554/eLife.08347
   Kumar A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23899-x
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Lee WT, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01591-17
   Lemke G, 2013, COLD SPRING HARB PER, V5, P1
   Li JD, 2016, EMERG INFECT DIS, V22, P1133, DOI 10.3201/eid2206.160273
   Li R, 2017, RADIOL INFECT DIS, V4, P88, DOI [10.1016/j.jrid.2017.01.002, DOI 10.1016/J.JRID.2017.01.002]
   Ma WQ, 2016, CELL, V167, P1511, DOI 10.1016/j.cell.2016.11.016
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P1106, DOI 10.1016/S1473-3099(16)30336-X
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P894, DOI 10.1016/S1473-3099(16)30153-0
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P405, DOI 10.1016/S1473-3099(16)00138-9
   Matheron S, 2016, CLIN INFECT DIS, V63, DOI 10.1093/cid/ciw509
   McCartney M., 2016, BMJ-BRIT MED J, V353, P1
   Mead PS, 2018, NEW ENGL J MED, V378, P1377, DOI [10.1056/nejmoa1711038, 10.1056/NEJMoa1711038]
   Meertens L, 2012, CELL HOST MICROBE, V12, P544, DOI 10.1016/j.chom.2012.08.009
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Morrison TE, 2017, J VIROL, V91, DOI 10.1128/JVI.00009-17
   Musso D, 2017, CLIN MICROBIOL INFEC, V23, DOI 10.1016/j.cmi.2017.07.006
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Nicastri E, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.32.30314
   Oliveira Souto I., 2016, ENFERM INFEC MICR CL, V36, P21
   Osuna CE, 2016, NAT MED, V22, P1448, DOI 10.1038/nm.4206
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Percivalle E, 2017, NEW MICROBIOL, V40, P197
   Perkasa A, 2016, EMERG INFECT DIS, V22, P924, DOI 10.3201/eid2205.151915
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Reusken C, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.23.30251
   ROBERT M, 1995, HUM REPROD, V10, P2192, DOI 10.1093/oxfordjournals.humrep.a136267
   Russell K, 2017, CLIN INFECT DIS, V64, P211, DOI 10.1093/cid/ciw692
   Sanchez-Montalva A, 2018, TROP MED INT HEALTH, V23, P92, DOI 10.1111/tmi.13019
   Sharpe RM, 2003, REPRODUCTION, V125, P769, DOI 10.1530/rep.0.1250769
   Sheng ZY, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00272
   Shimojima M, 2007, J INFECT DIS, V196, pS259, DOI 10.1086/520594
   Shimojima M, 2006, J VIROL, V80, P10109, DOI 10.1128/JVI.01157-06
   Siddharthan V, 2017, VIROLOGY, V507, P89, DOI 10.1016/j.virol.2017.04.013
   Spearman P, 2006, CURR PHARM DESIGN, V12, P1147, DOI 10.2174/138161206776055859
   Spencer JL, 2018, J INFECT DIS, V217, P538, DOI 10.1093/infdis/jix436
   Stefanovic KB, 2009, AM FAM PHYSICIAN, V80, P1421
   Takashima S, 2015, STEM CELL REP, V4, P489, DOI 10.1016/j.stemcr.2015.01.010
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Thomas DL, 2016, MMWR-MORBID MORTAL W, V65, P154, DOI 10.15585/mmwr.mm6506e2
   Torres JR, 2016, INT J INFECT DIS, V51, P127, DOI 10.1016/j.ijid.2016.08.025
   Turmel JM, 2016, LANCET, V387, P2501, DOI 10.1016/S0140-6736(16)30775-9
   Uraki R, 2017, J INFECT DIS, V215, P1720, DOI 10.1093/infdis/jix204
   Uraki R, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602899
   Venturi G, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.8.30148
   Washington CI, 2016, SEMIN REPROD MED, V34, P293, DOI 10.1055/s-0036-1592067
   Winkler CW, 2017, J IMMUNOL, V198, P3526, DOI 10.4049/jimmunol.1601949
   World Health Organisation, 2016, WHO DIR GEN SUMM OUT
   World Health Organization, 2018, ZIK VIR ZIKV CLASS T
   World Health Organization, 2018, EM ZIK VIR SIT REP
   World Health Organization, 2010, WHO LAB MAN EX PROC
   Xu K, 2018, J VIROL, V92, DOI [10.1128/JVI.01722-17, 10.1128/jvi.01722-17]
   Zammarchi L, 2015, J CLIN VIROL, V63, P32, DOI 10.1016/j.jcv.2014.12.005
   Zmurko J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004695
NR 120
TC 19
Z9 19
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4812
EI 1759-4820
J9 NAT REV UROL
JI Nat. Rev. Urol.
PD APR
PY 2019
VL 16
IS 4
BP 211
EP 230
DI 10.1038/s41585-019-0149-7
PG 20
WC Urology & Nephrology
SC Urology & Nephrology
GA HR3GL
UT WOS:000463024700007
PM 30696994
DA 2020-12-08
ER

PT J
AU Suehiro, TT
   Malaguti, N
   Damke, E
   Uchimura, NS
   Gimenes, F
   Souza, RP
   da Silva, VRS
   Consolaro, MEL
AF Suehiro, Tamy Tiemi
   Malaguti, Natalia
   Damke, Edilson
   Uchimura, Nelson Shozo
   Gimenes, Fabricia
   Souza, Raquel Pantarotto
   Sela da Silva, Vania Ramos
   Lopes Consolaro, Marcia Edilaine
TI Association of human papillomavirus and bacterial vaginosis with
   increased risk of high-grade squamous intraepithelial cervical lesions
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Article
ID INFECTION; MICROBIOME; WOMEN; CANCER
AB Objective To assess the rates of co-infections between human papillomavirus (HPV) and 13 key markers of bacterial vaginosis in cervical samples by multiplex polymerase chain reaction in a population with a high rate of abnormal cytology and a positive HPV test.
   Methods The study included a total of 213 women aged 18-72 years screened using Papanicolaou smears for determining cervical abnormalities and for HPV and bacterial vaginosis by single-target and multiplex polymerase chain reaction.
   Results A total of 83 (39%) women were negative for intraepithelial lesion or malignancy cytology and 130 (61%) had abnormal cytology. HPV-DNA prevalence was 69.9% and bacterial vaginosis was 72.7 %. Co-infections between bacterial vaginosis with HPV-DNA and high-risk HPV were associated with an increased risk for squamous intraepithelial lesions of low-grade cytology and high-grade squamous intraepithelial lesions plus cervical cancer. The most frequent bacterial vaginosis agent was Gardnerella vaginalis (33.8%), and co-infection with HPV-DNA and high-risk HPV increased the risk for squamous intraepithelial lesions of low grade cytology and high-grade squamous intraepithelial lesions plus cervical cancer. Co-infection between Megasphaera type I and high-risk HPV increased the risk for high-grade squamous intraepithelial lesions plus cervical cancer.
   Conclusions Our results reinforce the hypothesis that some bacterial vaginosis agents may play a role as co-factors in HPV-mediated cervical carcinogenesis, at least in some populations.
C1 [Suehiro, Tamy Tiemi; Malaguti, Natalia; Damke, Edilson; Uchimura, Nelson Shozo; Souza, Raquel Pantarotto; Sela da Silva, Vania Ramos; Lopes Consolaro, Marcia Edilaine] State Univ Maringa UEM, Dept Clin Anal & Biomed, Clin Cytol Lab, BR-87020900 Maringa, Parana, Brazil.
   [Gimenes, Fabricia] Univ Estadual Maringa, Dept Med, Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), State Univ Maringa UEM, Dept Clin Anal & Biomed, Clin Cytol Lab, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico,
   Parana State Government; Coordenacao de Aperfeicoamento de Pessoal de
   Nivel superior (CAPES), Brazilian GovernmentCAPES
FX This study was supported by by the Fundacao Araucaria de Apoio ao
   Desenvolvimento Cientifico e Tecnologico, Parana State Government, and
   Coordenacao de Aperfeicoamento de Pessoal de Nivel superior (CAPES),
   Brazilian Government.
CR Althani AA, 2016, J CELL PHYSIOL, V231, P1688, DOI 10.1002/jcp.25284
   Amorim AT, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2835-5
   Bautista CT, 2016, MILITARY MED RES, V3, DOI 10.1186/s40779-016-0074-5
   Braundmeier AG, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00097
   Carrillo-Garcia A, 2014, GYNECOL ONCOL, V134, P534, DOI 10.1016/j.ygyno.2014.06.018
   Castle Philip E, 2003, J Natl Cancer Inst Monogr, P29
   Chen LH, 2013, J MED VIROL, V85, P1229, DOI 10.1002/jmv.23582
   Di Paola M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09842-6
   Discacciati MG, 2015, CANCER EPIDEM BIOMAR, V24, P1539, DOI 10.1158/1055-9965.EPI-15-0420
   Ekiel AM, 2009, J KOREAN MED SCI, V24, P1177, DOI 10.3346/jkms.2009.24.6.1177
   Hay P., 2014, MEDICINE, V42, P359, DOI DOI 10.1016/J.MPMED.2014.04.011
   Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703
   Kjaer SK, 2010, JNCI-J NATL CANCER I, V102, P1478, DOI 10.1093/jnci/djq356
   Klomp JM, 2008, AM J OBSTET GYNECOL, V99, P481
   Koh WJ, 2015, J NATL COMPR CANC NE, V13, P395, DOI 10.6004/jnccn.2015.0055
   Malaguti N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/645853
   MANOS MM, 1994, J INFECT DIS, V170, P1096, DOI 10.1093/infdis/170.5.1096
   Marrazzo JM, 2007, CLIN INFECT DIS, V44, pS102, DOI 10.1086/511423
   McGowin CL, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-139
   Mitra A, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0203-0
   Monsonego J, 2015, GYNECOL ONCOL, V137, P47, DOI 10.1016/j.ygyno.2015.01.551
   Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3
   Morgan XC, 2013, TRENDS GENET, V29, P51, DOI 10.1016/j.tig.2012.09.005
   Rajkumar T, 2006, INT J CANCER, V118, P1481
   Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107
   Reid G, 2016, TRENDS ENDOCRIN MET, V27, P446, DOI 10.1016/j.tem.2016.04.004
   Romero-Morelos P, 2019, MED CLIN-BARCELONA, V152, P1, DOI 10.1016/j.medcli.2018.01.027
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
   Shipitsyna E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060670
   Solomon D, 2015, ANTICANCER RES, V35, P5708
   Srinivasan S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037818
   Turovskiy Y, 2011, J APPL MICROBIOL, V110, P1105, DOI 10.1111/j.1365-2672.2011.04977.x
   Zereu M, 2007, GYNECOL ONCOL, V105, P172, DOI 10.1016/j.ygyno.2006.11.006
NR 33
TC 5
Z9 6
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1048-891X
EI 1525-1438
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD FEB
PY 2019
VL 29
IS 2
BP 242
EP 249
DI 10.1136/ijgc-2018-000076
PG 8
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA HN0OB
UT WOS:000459887200004
PM 30630884
DA 2020-12-08
ER

PT J
AU da Cruz, TE
   Souza, RP
   Pelloso, SM
   Morelli, F
   Suehiro, TT
   Damke, E
   Bonfim-Mendonca, PD
   da Silva, VRS
   Consolaro, MEL
AF da Cruz, Tais E.
   Souza, Raquel P.
   Pelloso, Sandra M.
   Morelli, Fabricio
   Suehiro, Tamy T.
   Damke, Edilson
   Bonfim-Mendonca, Patricia de S.
   da Silva, Vania R. S.
   Consolaro, Marcia E. L.
TI Case Report: Prolonged Detection of Zika Virus RNA in Vaginal and
   Endocervical Samples from a Brazilian Woman, 2018
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID MALE SEXUAL TRANSMISSION; SECRETIONS; SEMEN
AB Zika virus (ZIKV) infection is an emerging public health problem, associated with increased risk for Guillain-Barre syndrome and adverse fetal outcomes, including congenital microcephaly. Zika virus sexual transmission is known, but detection of the virus in different parts of the female reproductive tract is not well established. In this case report, we describe prolonged detection of ZIKV RNA in the vaginal secretion and endocervical mucosa from a Brazilian woman convalescent to ZIKV infection. A viral load of 2 x 10(2) copies/mL was detected up to 31 days after symptom onset in both samples. Other biological fluids, including whole blood, plasma, serum, urine, and saliva samples, were negative for ZIKV RNA. These findings advance the understanding of ZIKV infection and provide data for additional testing strategies.
C1 [da Cruz, Tais E.; Souza, Raquel P.; Morelli, Fabricio; Suehiro, Tamy T.; Damke, Edilson; Bonfim-Mendonca, Patricia de S.; da Silva, Vania R. S.; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Ave Colombo,5790 Zona 7, BR-87020900 Maringa, Parana, Brazil.
   [Pelloso, Sandra M.] Univ Estadual Maringa, Dept Nursing, Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Clin Anal & Biomed, Ave Colombo,5790 Zona 7, BR-87020900 Maringa, Parana, Brazil.
EM taiselisangela07@gmail.com; raquelpantarotto@gmail.com.br;
   smpelloso@gmail.com; fahmorelli@gmail.com; tamysuehiro89@gmail.com;
   edilsondamke@gmail.com; patbonfim.09@gmail.com; vaniasela@gmail.com;
   melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU CAPES/Brazilian GovernmentCAPES [88881.130822/2016-01]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico/CNPqNational
   Council for Scientific and Technological Development (CNPq)
   [440521/2016-5]; Departamento de Ciencia e Tecnologia da Secretaria de
   Ciencia, Tecnologia e Insumos Estrategicos do Ministerio da Saude
   (Decit/SCTIE/MS)
FX This work was supported by grants from CAPES/Brazilian Government
   (88881.130822/2016-01); Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico/CNPq (440521/2016-5); and Departamento de Ciencia e
   Tecnologia da Secretaria de Ciencia, Tecnologia e Insumos Estrategicos
   do Ministerio da Saude (Decit/SCTIE/MS).
CR Atkinson B, 2017, EMERG INFECT DIS, V23, P611, DOI 10.3201/eid2304.161692
   Azevedo RSS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17765-5
   Azevedo RSS, 2016, J CLIN VIROL, V85, P56, DOI 10.1016/j.jcv.2016.10.024
   Barzon L., 2016, EUROSURVEILLANCE, V21, P2016, DOI DOI 10.2807/1560-7917.ES.2016.21.32.30316
   Barzon L, 2017, LANCET INFECT DIS, V17, P1107, DOI 10.1016/S1473-3099(17)30495-4
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3
   Durbin AP, 2016, SEMIN REPROD MED, V34, P299, DOI 10.1055/s-0036-1592070
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Gaskell KM, 2017, EMERG INFECT DIS, V23, P137, DOI 10.3201/eid2301.161300
   Harrower J, 2016, EMERG INFECT DIS, V22, P1855, DOI 10.3201/eid2210.160951
   Matheron S, 2016, CLIN INFECT DIS, V63, DOI 10.1093/cid/ciw509
   Moreira J, 2017, CLIN MICROBIOL INFEC, V23, P296, DOI 10.1016/j.cmi.2016.12.027
   Murray KO, 2017, EMERG INFECT DIS, V23, P99, DOI 10.3201/eid2301.161394
   Nayar R, 2017, ACTA CYTOL, V61, P359, DOI 10.1159/000477556
   Nicastri E, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.32.30314
   Nicastri E, 2016, LANCET INFECT DIS, V16, P771, DOI 10.1016/S1473-3099(16)30074-3
   Penot P, 2017, EUROSURVEILLANCE, V22, P8, DOI 10.2807/1560-7917.ES.2017.22.3.30444
   Perez S, 2016, EUROSURVEILLANCE, V21, P1, DOI 10.2807/1560-7917.ES.2016.21.24.30261
   Prisant N, 2016, LANCET INFECT DIS, V16, P1000, DOI 10.1016/S1473-3099(16)30193-1
   Russell K, 2017, CLIN INFECT DIS, V64, P211, DOI 10.1093/cid/ciw692
   Yun SI, 2017, J MICROBIOL, V55, P204, DOI 10.1007/s12275-017-7063-6
NR 22
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2019
VL 100
IS 1
BP 183
EP 186
DI 10.4269/ajtmh.18-0623
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA HG7WU
UT WOS:000455207700039
PM 30398145
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Damke, E
   Kurscheidt, FA
   Irie, MMT
   Gimenes, F
   Consolaro, MEL
AF Damke, Edilson
   Kurscheidt, Fabio A.
   Irie, Mary M. T.
   Gimenes, Fabricia
   Consolaro, Marcia E. L.
TI Male Partners of Infertile Couples With Seminal Positivity for Markers
   of Bacterial Vaginosis Have Impaired Fertility
SO AMERICAN JOURNAL OF MENS HEALTH
LA English
DT Article
DE semen; infertile couples; bacterial vaginosis markers; seminal
   parameters
ID POLYMERASE-CHAIN-REACTION; SEXUALLY-TRANSMITTED PATHOGENS; MALE
   GENITAL-TRACT; UREAPLASMA-UREALYTICUM; REPRODUCTIVE-TRACT;
   GARDNERELLA-VAGINALIS; CHLAMYDIA-TRACHOMATIS; CHROMATIN INTEGRITY;
   MYCOPLASMA-HOMINIS; MEDICAL-TREATMENT
AB To access the possibility that key markers of bacterial vaginosis (KM-BV) could affect seminal parameters and thus fertility a prospective cohort study was designed (a) to develop rapid and sensitive multiplex polymerase chain reaction (M-PCR) assays to screen 13 key markers of bacterial vaginosis (KM-BV) in semen specimens, (b) to determine the prevalence of KM-BV in semen from randomized male partners of couples seeking fertility evaluation. A total of 229 semen samples were included in the study from males who visited the Sperm Analysis Section of Brazil between October 2015 and March 2016. Eligible men were 18 years or older and had a semen analysis due fertility evaluation (after failing to conceive with their partner after 1 year of unprotected intercourse). Basic seminal parameters were analyzed, and KM-BV was detected by M-PCR assays. M-PCR assays clearly distinguished 13 KM-BV in 146 semen samples (63.8%), mainly Gardnerella vaginalis (50.7%). Some important associations occurred between the presence of KM-BV in semen and changes in seminal parameters. KM-BV is commonly present in the semen of males seeking fertility evaluation and could potentially play significant roles in male subfertility and/or infertility.
C1 [Damke, Edilson; Irie, Mary M. T.; Gimenes, Fabricia; Consolaro, Marcia E. L.] Univ Estadual Maringa, Maringa, Parana, Brazil.
   [Kurscheidt, Fabio A.] Sao Camilo Lab, Sperm Anal Sect, Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin & Biomed, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Brazilian GovernmentCAPES
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was supported by grants from the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Brazilian Government.
CR Abusarah EA, 2013, DIAGN MICR INFEC DIS, V77, P283, DOI 10.1016/j.diagmicrobio.2013.05.018
   Al-Sweih NA, 2012, J ANDROL, V33, P1323, DOI 10.2164/jandrol.111.013821
   Althani AA, 2016, J CELL PHYSIOL, V231, P1688, DOI 10.1002/jcp.25284
   Andrade-Rocha FT, 2009, GYNECOL OBSTET INVES, V68, P134, DOI 10.1159/000228583
   Bautista CT, 2016, MILITARY MED RES, V3, DOI 10.1186/s40779-016-0074-5
   Benway BM, 2008, UROL CLIN N AM, V35, P23, DOI 10.1016/j.ucl.2007.09.008
   Boivin J, 2007, HUM REPROD, V22, P1506, DOI 10.1093/humrep/dem046
   Braundmeier AG, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00097
   BUKOVSKY A, 1991, FERTIL STERIL, V55, P595
   Carr BR, 2013, SEMIN REPROD MED, V31, P231, DOI 10.1055/s-0033-1345267
   Chandra Anjani, 2013, Natl Health Stat Report, P1
   De Francesco MA, 2011, EUR J CONTRACEP REPR, V16, P47, DOI 10.3109/13625187.2010.533219
   Ferris MJ, 2004, J CLIN MICROBIOL, V42, P5892, DOI [10.1128/JCM.42.12.5892-5894.2004, 10.1128/jcm.42.12.5892-5894.2004]
   Fethers K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030633
   Foxman B, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.10.003
   Franasiak JM, 2015, FERTIL STERIL, V104, P1364, DOI 10.1016/j.fertnstert.2015.10.012
   Fredricks DN, 2009, J CLIN MICROBIOL, V47, P721, DOI 10.1128/JCM.01384-08
   Fredricks DN, 1999, CLIN INFECT DIS, V29, P475, DOI 10.1086/598618
   Gdoura R, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-129
   Gimenes F, 2014, NAT REV UROL, V11, P672, DOI 10.1038/nrurol.2014.285
   Gonzales GF, 2001, ASIAN J ANDROL, V3, P251
   Hay P., 2014, MEDICINE, V42, P359, DOI DOI 10.1016/J.MPMED.2014.04.011
   Ingianni A, 1997, FEMS IMMUNOL MED MIC, V18, P61, DOI 10.1016/S0928-8244(97)00024-2
   Isaiah IN, 2011, N AM J MED SCI, V3, P562, DOI 10.4297/najms.2011.3559
   Mandar R, 2013, PHARMACOL RES, V69, P32, DOI 10.1016/j.phrs.2012.10.019
   Malaguti N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/645853
   Manhart LE, 2013, SEX TRANSM DIS, V40, P944, DOI 10.1097/OLQ.0000000000000054
   McIver CJ, 2009, J CLIN MICROBIOL, V47, P1358, DOI 10.1128/JCM.01873-08
   Monteiro C, 2018, AM J REPROD IMMUNOL, V79, DOI 10.1111/aji.12838
   Morgan XC, 2013, TRENDS GENET, V29, P51, DOI 10.1016/j.tig.2012.09.005
   Muvunyi CM, 2011, DIAGN MICR INFEC DIS, V71, P29, DOI 10.1016/j.diagmicrobio.2011.06.005
   Nassar FA, 2008, ADV MED SCI-POLAND, V53, P80, DOI 10.2478/v10039-008-0020-1
   Obata-Yasuoka M, 2002, OBSTET GYNECOL, V100, P759, DOI 10.1016/S0029-7844(02)02201-9
   Pajovic B, 2013, ANDROLOGIA, V45, P266, DOI 10.1111/and.12004
   Peipert JF, 2001, AM J OBSTET GYNECOL, V184, P856, DOI 10.1067/mob.2001.113847
   Potts JM, 2000, J UROLOGY, V163, P1775, DOI 10.1016/S0022-5347(05)67540-4
   Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107
   Reichart M, 2000, BIOL REPROD, V63, P1041, DOI 10.1095/biolreprod63.4.1041
   RILEY DE, 1991, J CLIN MICROBIOL, V29, P2746, DOI 10.1128/JCM.29.12.2746-2751.1991
   Rittenberg V, 2010, HUM FERTIL, V13, P208, DOI 10.3109/14647273.2010.534833
   Robert M, 1995, MOL HUM REPROD, V1, P292, DOI 10.1093/molehr/1.6.292
   Rowe PJ, 2000, WHO MANUAL STANDARDI
   Rybar R, 2012, ANDROLOGIA, V44, P410, DOI 10.1111/j.1439-0272.2011.01198.x
   Shipitsyna E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060670
   Srinivasan S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037818
   Tiveljung A, 1996, INT J SYST BACTERIOL, V46, P332, DOI 10.1099/00207713-46-1-332
   Villegas J, 2005, APOPTOSIS, V10, P105, DOI 10.1007/s10495-005-6065-8
   Virecoulon F, 2005, ANDROLOGIA, V37, P160, DOI 10.1111/j.1439-0272.2005.00673.x
   Weng SL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110152
   World Health Organization, 2010, WHO LAB MAN EX PROC
NR 50
TC 1
Z9 1
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1557-9883
EI 1557-9891
J9 AM J MENS HEALTH
JI Am. J. Mens Health
PD NOV
PY 2018
VL 12
IS 6
BP 2104
EP 2115
DI 10.1177/1557988318794522
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA GX8ZL
UT WOS:000448085200029
PM 30132409
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Kaplum, V
   Ramos, AC
   Consolaro, MEL
   Fernandez, MA
   Ueda-Nakamura, T
   Dias, BP
   Silva, SD
   de Mello, JCP
   Nakamura, CV
AF Kaplum, Vanessa
   Ramos, Anelise C.
   Consolaro, Marcia E. L.
   Fernandez, Maria A.
   Ueda-Nakamura, Tania
   Dias-Filho, Benedito P.
   Silva, Sueli de Oliveira
   de Mello, Joao C. P.
   Nakamura, Celso V.
TI Proanthocyanidin Polymer-Rich Fraction of Stryphnodendron adstringens
   Promotes in Vitro and in Vivo Cancer Cell Death via Oxidative Stress
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE proanthocyanidins; cervical cancer cells; oxidative stress; apoptosis;
   in vivo activity
ID HUMAN-PAPILLOMAVIRUS; LIPID-PEROXIDATION; APOPTOSIS; THIOLS; TUMOR;
   QUANTIFICATION; GLUTATHIONE; PROGRESSION; METABOLISM; ACTIVATION
AB Cervical cancer is the fourth most common cancer that affects women, mainly through human papilloma virus (HPV) infection with high-risk HPV16 and HPV18. The present study investigated the in vitro anticancer activity and mechanism of action of a proanthocyanidin polymer-rich fraction of Stryphnodendron adstringens (F2) in cervical cancer cell lines, including HeLa (HPV18-positive), SiHa (HPV16-positive), and C33A (HPV-negative) cells, and also evaluated in vivo anticancer activity. In vitro, cell viability was determined by the MTT assay. Cell migration was determined by the wound healing assay. The mechanism of action was investigated by performing ultrastructural analysis and evaluating reactive oxygen species (ROS) production, mitochondrial metabolism, lipoperoxidation, BCL-2 family expression, caspase expression, and DNA and cell membrane integrity. In vivo activity was evaluated using the murine Ehrlich solid tumor model. F2 time-and dose-dependently reduced cell viability and significantly inhibited the migration of cervical cancer cells. HeLa and SiHa cells treated with F2 (IC50) exhibited intense oxidative stress (i.e., increase in ROS and decrease in antioxidant species) and mitochondrial damage (i.e., mitochondrial membrane potential depolarization and a reduction of intracellular levels of adenosine triphosphate). Increases in the Bax/BCL-2 ratio and caspase 9 and caspase 3 expression, were observed, with DNA damage that was sufficient to trigger mitochondria-dependent apoptosis. Cell membrane disruption was observed in C33A cells (IC50 and IC90) and HeLa and SiHa cells (IC90), indicating progress to late apoptosis/necrosis. The inhibition of ROS production by N-acetylcysteine significantly suppressed oxidative stress in all three cell lines. In vivo, F2 significantly reduced tumor volume and weight of the Ehrlich solid tumor, and significantly increased lipoperoxidation, indicating that F2 also induces oxidative stress in the in vivo model. These findings indicate that the proanthocyanidin polymer-rich fraction of S. adstringens may be a potential chemotherapeutic candidate for cancer treatment.
C1 [Kaplum, Vanessa; Ueda-Nakamura, Tania; Dias-Filho, Benedito P.; Silva, Sueli de Oliveira; de Mello, Joao C. P.; Nakamura, Celso V.] Univ Estadual Maringa, Programa Posgrad Ciencias Farmaceut, Maringa, Parana, Brazil.
   [Ramos, Anelise C.; Fernandez, Maria A.] Univ Estadual Maringa, Programa Posgrad Ciencias Biol, Maringa, Parana, Brazil.
   [Consolaro, Marcia E. L.] Univ Estadual Maringa, Programa Posgrad Biociencias & Fisiopatol, Maringa, Parana, Brazil.
RP Nakamura, CV (corresponding author), Univ Estadual Maringa, Programa Posgrad Ciencias Farmaceut, Maringa, Parana, Brazil.
EM cvnakamura@uem.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; de Mello, Joao Carlos
   P/B-9418-2013; Lautenschlager, Sueli OS/P-2164-2017; Fernandez,
   Maria/AAK-7652-2020; Nakamura, Celso Vataru/AAA-5620-2019
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; de Mello, Joao
   Carlos P/0000-0002-7532-3395; Lautenschlager, Sueli
   OS/0000-0001-9303-0804; Fernandez, Maria Aparecida/0000-0002-7696-5680
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [401100/2013-8]; Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES)CAPES; Financiadora de Estudos e Projetos
   (FINEP)Ciencia Tecnologia e Inovacao (FINEP); Pronex/Fundacao
   AraucariaFundacao Araucaria; COMCAP Complexo de Centrais de Apoio a
   Pesquisa - UEM; Programa de Pos-Graduacao em Ciencias Farmaceuticas
FX This work was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) [401100/2013-8], Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Financiadora de
   Estudos e Projetos (FINEP), Pronex/Fundacao Araucaria, COMCAP Complexo
   de Centrais de Apoio a Pesquisa - UEM, and Programa de Pos-Graduacao em
   Ciencias Farmaceuticas.
CR Ashkenazi A, 2017, NAT REV DRUG DISCOV, V16, P273, DOI 10.1038/nrd.2016.253
   Biswas S, 2016, BIOMED PHARMACOTHER, V84, P1419, DOI 10.1016/j.biopha.2016.10.005
   Chang HW, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00634
   Chen Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107045
   Chen W, 2008, J PHARMACEUT BIOMED, V48, P1375, DOI 10.1016/j.jpba.2008.08.033
   Clark AG, 2015, CURR OPIN CELL BIOL, V36, P13, DOI 10.1016/j.ceb.2015.06.004
   Costa MA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/841580
   Costa MA, 2010, REGUL TOXICOL PHARM, V58, P330, DOI 10.1016/j.yrtph.2010.07.006
   Crosbie EJ, 2013, LANCET, V382, P889, DOI 10.1016/S0140-6736(13)60022-7
   de Albuquerque UP, 2007, J ETHNOPHARMACOL, V110, P76, DOI 10.1016/j.jep.2006.09.010
   de Mello JCP, 1999, PHYTOCHEMISTRY, V51, P1105, DOI 10.1016/S0031-9422(98)00715-8
   Debski D, 2016, FREE RADICAL BIO MED, V95, P323, DOI 10.1016/j.freeradbiomed.2016.03.027
   deMello JP, 1996, PHYTOCHEMISTRY, V42, P857
   deMello JP, 1996, PHYTOCHEMISTRY, V41, P807, DOI 10.1016/0031-9422(95)00686-9
   Dickinson DA, 2002, BIOCHEM PHARMACOL, V64, P1019, DOI 10.1016/S0006-2952(02)01172-3
   Ding B, 2007, J CELL SCI, V120, P2284, DOI 10.1242/jcs.002345
   de Freitas ALD, 2018, J ETHNOPHARMACOL, V216, P184, DOI 10.1016/j.jep.2018.01.008
   Elsherbiny NM, 2016, PATHOL RES PRACT, V212, P767, DOI 10.1016/j.prp.2016.06.004
   Filippova M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/574659
   Fulda Simone, 2010, Int J Cell Biol, V2010, P214074, DOI 10.1155/2010/214074
   Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002
   Graham SV, 2017, CLIN SCI, V131, P2201, DOI 10.1042/CS20160786
   Hajrezaie M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09097
   Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011
   Henriques BO, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/9872598
   Higuchi Y, 2004, J CELL MOL MED, V8, P455, DOI 10.1111/j.1582-4934.2004.tb00470.x
   Holetz FB, 2005, MEM I OSWALDO CRUZ, V100, P397, DOI 10.1590/S0074-02762005000400010
   Ishida K, 2006, J ANTIMICROB CHEMOTH, V58, P942, DOI 10.1093/jac/dkl377
   Jung J, 2014, TOX RESEARCH, V30, P1, DOI 10.5487/TR.2014.30.1.001
   Kudryavtseva AV, 2016, ONCOTARGET, V7, P44879, DOI 10.18632/oncotarget.9821
   Larsen BD, 2017, FEBS J, V284, P1160, DOI 10.1111/febs.13970
   Leon-Gonzalez AJ, 2015, BIOCHEM PHARMACOL, V98, P371, DOI 10.1016/j.bcp.2015.07.017
   Mao XB, 2017, ONCOTARGET, V8, P81649, DOI 10.18632/oncotarget.20887
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   Mileo AM, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6475624
   Moloney JN, 2018, SEMIN CELL DEV BIOL, V80, P50, DOI 10.1016/j.semcdb.2017.05.023
   Nandakumar V, 2008, CANCER LETT, V269, P378, DOI 10.1016/j.canlet.2008.03.049
   Ng KB, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-41
   Noaman E, 2008, CANCER LETT, V268, P348, DOI 10.1016/j.canlet.2008.04.012
   Okimoto Y, 2000, FEBS LETT, V474, P137, DOI 10.1016/S0014-5793(00)01587-8
   Ozaslan M, 2011, AFR J BIOTECHNOL, V10, P2375
   Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105
   Pizzino G, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6341671
   POMPELLA A, 1987, LIPIDS, V22, P206, DOI 10.1007/BF02537304
   Prokhorova EA, 2015, CELL MOL LIFE SCI, V72, P4593, DOI 10.1007/s00018-015-2031-y
   Rasola A, 2011, CELL CALCIUM, V50, P222, DOI 10.1016/j.ceca.2011.04.007
   Rebecca MA, 2003, TOXICOL LETT, V143, P55, DOI 10.1016/S0378-4274(03)00065-1
   Redondo-Blanco S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00109
   Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI 10.1016/j.bbamcr.2016.09.012
   Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P49, DOI 10.1089/ars.2007.9.49
   Sabino APL, 2018, APPL BIOCHEM BIOTECH, V184, P1375, DOI 10.1007/s12010-017-2632-z
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shiau JY, 2017, ONCOTARGET, V8, P56942, DOI 10.18632/oncotarget.18183
   Sinha K, 2013, ARCH TOXICOL, V87, P1157, DOI 10.1007/s00204-013-1034-4
   Sosa V, 2013, AGEING RES REV, V12, P376, DOI 10.1016/j.arr.2012.10.004
   Souza RC, 2017, INT J CORROS, V2017, DOI 10.1155/2017/4927210
   Srivastava S, 2016, SCI REP-UK, V6, DOI 10.1038/srep24049
   Sznarkowska A, 2017, ONCOTARGET, V8, P15996, DOI 10.18632/oncotarget.13723
   Vanden Berghe T, 2013, METHODS, V61, P117, DOI 10.1016/j.ymeth.2013.02.011
   Walsh DWM, 2017, SCI REP-UK, V7, DOI 10.1038/srep46684
   Winther JR, 2014, BBA-GEN SUBJECTS, V1840, P838, DOI 10.1016/j.bbagen.2013.03.031
   Yazdani M, 2015, TOXICOL IN VITRO, V30, P578, DOI 10.1016/j.tiv.2015.08.010
   Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001
   Zhou Y, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080515
NR 64
TC 4
Z9 4
U1 0
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUL 3
PY 2018
VL 9
AR 694
DI 10.3389/fphar.2018.00694
PG 18
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA GL5EP
UT WOS:000437186800001
PM 30018550
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Catarino, CM
   Pedrosa, TD
   Pennacchi, PC
   de Assis, SR
   Gimenes, F
   Consolaro, MEL
   Barros, SBD
   Maria-Engler, SS
AF Catarino, Carolina Motter
   Pedrosa, Tatiana do Nascimento
   Pennacchi, Paula Comune
   de Assis, Silvia Romano
   Gimenes, Fabricia
   Lopes Consolaro, Marcia Edilaine
   de Moraes Barros, Silvia Berlanga
   Maria-Engler, Silvya Stuchi
TI Skin corrosion test: a comparison between reconstructed human epidermis
   and full thickness skin models
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Reconstructed human epidermis; Full thickness skin; Risk assessment;
   Skin corrosion
ID IN-VITRO; FIBROBLASTS; DIFFERENTIATION; REGENERATION; KERATINOCYTE
AB Currently, there is a strong global trend towards the development of in vitro models to replace the use of animals in safety evaluation tests. Reconstructed Human Epidermis (RHE) models have been employed as an alternative method to animal testing of skin corrosion and irritation potential of chemical compounds. However, the consequences of an absence of the dermal compartment in these models should be considered since the cross-talk between fibroblasts and keratinocytes is fundamental for promoting proper epidermal stratification, homeostasis, inflammatory response and wound healing. In this study, we compare in-house developed models of Reconstructed Human Epidermis (i.e. USP-RHE) and full thickness skin (i.e. USP-FTS) regarding their response when submitted to skin corrosion assays, based on Guideline 431 (OECD). The results show that both models correctly classified the four substances tested (2-phenylethyl bromide, benzylacetone, lactic acid, octanoic acid) as corrosive or non-corrosive, Furthermore, we have demonstrated higher cell viability of the USP-FTS model compared to the USP-RHE model, a sign of its improved barrier function, following the exposure to the substances test on the corrosion assay. This emphasizes the importance of employing in vitro models that are more physiologically relevant and that better mimic the in vivo situation for the toxicological screening of substances.
C1 [Catarino, Carolina Motter] Rensselaer Polytech Inst, Ctr Biotechnol & Interdisciplinary Studies, Dept Chem & Biol Engineer, 110,8th St, Troy, NY 12180 USA.
   [Catarino, Carolina Motter; Pedrosa, Tatiana do Nascimento; Pennacchi, Paula Comune; de Assis, Silvia Romano; de Moraes Barros, Silvia Berlanga; Maria-Engler, Silvya Stuchi] Univ Sao Paulo, Sch Pharmaceut Sci, Clin & Toxicol Anal Dept, Av Prof Lineu Prestes 580,Bloco 17, BR-05508000 Sao Paulo, SP, Brazil.
   [Gimenes, Fabricia; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Clin Anal & Biomed, Ave Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
RP Maria-Engler, SS (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Av Prof Lineu Prestes 580,Bloco 17, BR-05508900 Sao Paulo, SP, Brazil.
EM silvya@usp.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Engler, Silvya Stuchi
   Maria/K-5936-2016; Barros, Silvia B M/K-6856-2014; Barros, Silvia B
   M/H-1090-2012; Maria-Engler, Silvya/ABC-2016-2020
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Engler, Silvya
   Stuchi Maria/0000-0003-4771-6041; Maria-Engler,
   Silvya/0000-0003-4771-6041
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2011/14327-6, 2011/07441-7, 2011/22812-1, 2013/00735-0, 2013/12682-9,
   2014-24000-0]; CNPq - RENAMA [403252/2012-0]; INCT-if
FX We thank the Histological Techniques Sector of ICB I-USP for the
   technical support. We thank Professors Maria Beatriz Puzzi, Luciana
   Biagini Lopes and Pankaj Karande for our scientific discussions.
   Financial support was provided by FAPESP (Grants # 2011/14327-6;
   2011/07441-7; 2011/22812-1; 2013/00735-0 2013/12682-9 and 2014-24000-0),
   CNPq - RENAMA (403252/2012-0) and INCT-if.
CR Alepee N, 2014, TOXICOL IN VITRO, V28, P131, DOI 10.1016/j.tiv.2013.10.016
   Alepee N, 2014, TOXICOL IN VITRO, V28, P616, DOI 10.1016/j.tiv.2013.12.013
   ASSELINEAU D, 1986, J INVEST DERMATOL, V86, P181, DOI 10.1111/1523-1747.ep12284237
   Batheja P, 2009, PHARM RES-DORDR, V26, P1689, DOI 10.1007/s11095-009-9879-1
   Boehnke K, 2007, EUR J CELL BIOL, V86, P731, DOI 10.1016/j.ejcb.2006.12.005
   Boelsma E, 2000, ACTA DERM-VENEREOL, V80, P82
   Desprez B, 2015, TOXICOL IN VITRO, V29, P2055, DOI 10.1016/j.tiv.2015.08.015
   ECKERT RL, 1989, ENVIRON HEALTH PERSP, V80, P109, DOI 10.2307/3430736
   El Ghalbzouri A, 2008, TOXICOL IN VITRO, V22, P1311, DOI 10.1016/j.tiv.2008.03.012
   EL Ghalbzouri A, 2004, WOUND REPAIR REGEN, V12, P359, DOI 10.1111/j.1067-1927.2004.012306.x
   El-Ghalbzouri A, 2002, BRIT J DERMATOL, V147, P230, DOI 10.1046/j.1365-2133.2002.04871.x
   FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X
   FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807
   Green KJ, 2007, J INVEST DERMATOL, V127, P2499, DOI 10.1038/sj.jid.5701015
   HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779
   Luu-The V, 2009, J STEROID BIOCHEM, V116, P178, DOI 10.1016/j.jsbmb.2009.05.011
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   OECD, 2013, TEST 431 IN VITR SKI, DOI 10.1787/9789264203822-en
   OECD, 2016, TEST 431 IN VITR SKI, DOI 10.1787/9789264203822-en
   Pedrosa TD, 2017, TOXICOL IN VITRO, V42, P31, DOI 10.1016/j.tiv.2017.03.010
   Pennacchi PC, 2015, TISSUE ENG PT A, V21, P2417, DOI [10.1089/ten.tea.2015.0009, 10.1089/ten.TEA.2015.0009]
   Planz V, 2016, J CONTROL RELEASE, V242, P89, DOI 10.1016/j.jconrel.2016.09.002
   Ponec M, 2001, SKIN PHARMACOL APPL, V14, P63, DOI 10.1159/000056392
   Qiu J, 2016, INT J COSMETIC SCI, V38, P60, DOI 10.1111/ics.12249
   Reijnders CMA, 2015, TISSUE ENG PT A, V21, P2448, DOI [10.1089/ten.TEA.2015.0139, 10.1089/ten.tea.2015.0139]
   Schafer-Korting M, 2008, ATLA-ALTERN LAB ANIM, V36, P161, DOI 10.1177/026119290803600207
   Spiekstra SW, 2005, EXP DERMATOL, V14, P109, DOI 10.1111/j.0906-6705.2005.00226.x
   Thalcoersing V. S., 2012, TISSUE ENG PART C-ME, V18, P1, DOI 10.1089/ten.tec.2011.0175
   Wojtowicz AM, 2014, WOUND REPAIR REGEN, V22, P246, DOI 10.1111/wrr.12154
   Worth A, 2014, ALTERNATIVE METHODS
   Zhang Zheng, 2012, Pharmaceutics, V4, P26, DOI 10.3390/pharmaceutics4010026
NR 31
TC 5
Z9 5
U1 1
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD APR
PY 2018
VL 125
BP 51
EP 57
DI 10.1016/j.ejpb.2018.01.002
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA GB9MO
UT WOS:000429398100006
PM 29317274
DA 2020-12-08
ER

PT J
AU Kurscheidt, FA
   Damke, E
   Bento, JC
   Balani, VA
   Takeda, KI
   Piva, S
   Piva, JP
   Irie, MMT
   Gimenes, F
   Consolaro, MEL
AF Kurscheidt, Fabio A.
   Damke, Edilson
   Bento, Jaqueline C.
   Balani, Valerio A.
   Takeda, Karen I.
   Piva, Sergio
   Piva, Joao P.
   Irie, Mary M. T.
   Gimenes, Fabricia
   Consolaro, Marcia E. L.
TI Effects of Herpes Simplex Virus Infections on Seminal Parameters in Male
   Partners of Infertile Couples
SO UROLOGY
LA English
DT Article
ID GENITAL HERPES; MEDICAL-TREATMENT; TYPE-1 INFECTION; SEMEN PARAMETERS;
   IMPACT; MEN; LEUKOCYTOSPERMIA; CYTOMEGALOVIRUS; PREVALENCE; PATHOGENS
AB OBJECTIVE To assess the possibility that herpes simplex virus (HSV) infection could affect seminal parameters, we (1) standardize and validate a multiplex polymerase chain reaction (M-PCR) assay to detect HSV-1 and HSV-2 in semen, and (2) determine the prevalence of HSV-1/-2 in the semen of randomized male partners of couples seeking fertility evaluation.
   MATERIALS AND METHODS A total of 279 semen samples were included in the study from men who visited the Sperm Analysis Section of Sao Camilo Laboratory of Maringa, Brazil, between November 2014 and July 2015. Eligible men were 18 years or older and had a semen analysis due fertility evaluation (after failing to conceive with their partner after 1 year of unprotected intercourse). Basic seminal parameters were analyzed, and HSV-1 and HSV-2 were detected by M-PCR.
   RESULTS The M-PCR assay clearly distinguished and identified 2 HSV types in semen samples. HSV in total was detected in 10.7% of samples, of which 7.5% had HSV-1 exclusively and 3.2% had HSV-2 exclusively. We detected a significant association of HSV-2 infection with hematospermia and with a lower mean seminal volume, and between HSV-1 infection and a lower mean sperm count.
   CONCLUSION These findings suggest that the male partners of infertile couples with HSV infections may have changes on the 2 equally important components of semen, spermatozoa and seminal fluid, which may influence fertility. Further studies enrolling a larger number of patients are necessary to confirm these data and to elucidate the clinical relevance of HSV presence in semen. (C) 2017 Elsevier Inc.
C1 Univ Estadual Maringa, Dept Anal Clin & Biomed, Programa Posgrad Biociencias & Fisiopatol, Maringa, Parana, Brazil.
   Sao Camilo Lab, Sperm Anal Sect, Maringa, Parana, Brazil.
   [Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Anal Clin & Biomed, Av Colombo 5790, BR-87025210 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin & Biomed, Av Colombo 5790, BR-87025210 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Kurscheidt,
   Fabio/0000-0002-0863-7765
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)/Brazilian GovernmentCAPES; Division of Biotechnology/Sao Camilo
   Laboratory/Maringa/PR/Brazil
FX We greatly acknowledge the full financial support from the Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)/Brazilian
   Government and Division of Biotechnology/Sao Camilo
   Laboratory/Maringa/PR/Brazil.
CR Abdulmedzhidova A. G., 2007, Urologiya (Moscow), P56
   Bezold G, 2007, FERTIL STERIL, V87, P1087, DOI 10.1016/j.fertnstert.2006.08.109
   Bocharova E N, 2007, Dokl Biol Sci, V412, P82, DOI 10.1134/S0012496607010279
   Brookings C, 2013, KOREAN J UROL, V54, P149, DOI 10.4111/kju.2013.54.3.149
   Carr BR, 2013, SEMIN REPROD MED, V31, P231, DOI 10.1055/s-0033-1345267
   CHAN PJ, 1994, FERTIL STERIL, V61, P986
   COMHAIRE FH, 1989, J ANDROL, V10, P50
   Conrady CD, 2011, J BIOMED RES, V25, P111, DOI 10.1016/S1674-8301(11)60014-6
   Dejucq N, 2001, MICROBIOL MOL BIOL R, V65, P208, DOI 10.1128/MMBR.65.2.208-231.2001
   Engelberg R, 2003, SEX TRANSM DIS, V30, P174, DOI 10.1097/00007435-200302000-00015
   Fromentin M, 2016, IDCases, V6, P26, DOI 10.1016/j.idcr.2016.09.004
   Garolla A, 2013, J REPROD IMMUNOL, V100, P20, DOI 10.1016/j.jri.2013.03.004
   Gimenes F, 2014, NAT REV UROL, V11, P672, DOI 10.1038/nrurol.2014.285
   Gimenes F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098862
   Kalendar R, 2011, GENOMICS, V98, P137, DOI 10.1016/j.ygeno.2011.04.009
   Kalichman SC, 2008, SEX TRANSM DIS, V35, P55, DOI 10.1097/OLQ.0b013e318141fe9b
   Kapranos N, 2003, FERTIL STERIL, V79, P1566, DOI 10.1016/S0015-0282(03)00370-4
   Klimova R. R., 2010, Voprosy Virusologii, V55, P27
   Lafferty WE, 2000, J INFECT DIS, V181, P1454, DOI 10.1086/315395
   Lorusso F, 2010, ANDROLOGIA, V42, P121, DOI 10.1111/j.1439-0272.2009.00970.x
   Monavari SH, 2013, J BIOMED RES, V27, P56, DOI 10.7555/JBR.27.20110139
   Neofytou E, 2009, FERTIL STERIL, V91, P2487, DOI 10.1016/j.fertnstert.2008.03.074
   Ochsendorf FR, 2008, ANDROLOGIA, V40, P72, DOI 10.1111/j.1439-0272.2007.00825.x
   Rittenberg V, 2010, HUM FERTIL, V13, P208, DOI 10.3109/14647273.2010.534833
   Souza RP, 2013, AM J TROP MED HYG, V89, P1199, DOI 10.4269/ajtmh.13-0315
   Wald A, 2000, NEW ENGL J MED, V342, P844, DOI 10.1056/NEJM200003233421203
   WOLFF H, 1990, FERTIL STERIL, V53, P528
   World Health Organization, 2000, WHO MAN STAND VEST D
   World Health Organization, 2010, WHO LAB MAN EX PROC
   Wu Kun-He, 2007, Zhonghua Nan Ke Xue, V13, P1075
   Zuckerman RA, 2009, AIDS, V23, P479, DOI 10.1097/QAD.0b013e328326ca62
NR 31
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
EI 1527-9995
J9 UROLOGY
JI Urology
PD MAR
PY 2018
VL 113
BP 52
EP 58
DI 10.1016/j.urology.2017.11.050
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA GA0WL
UT WOS:000428035200020
PM 29287977
DA 2020-12-08
ER

PT J
AU de Lima, NCA
   Ratti, BA
   Mendonca, PDB
   Murata, G
   Pereira, RRA
   Nakamura, CV
   Consolaro, MEL
   Svidzinski, TIE
   Hatanaka, E
   Bruschi, ML
   Silva, SD
AF Alves de Lima, Nayara Cristina
   Ratti, Bianca Altrao
   Bonfim Mendonca, Patricia de Souza
   Murata, Gilson
   Araujo Pereira, Raphaela Regina
   Nakamura, Celso Vataru
   Lopes Consolaro, Marcia Edilaine
   Estivalet Svidzinski, Terezinha Inez
   Hatanaka, Elaine
   Bruschi, Marcos Luciano
   Silva, Sueli de Oliveira
TI Propolis increases neutrophils response against Candida albicans through
   the increase of reactive oxygen species
SO FUTURE MICROBIOLOGY
LA English
DT Article
DE neutrophils; propolis; vulvovaginal candidiasis
ID RECURRENT; EXTRACTS; CELLS
AB Aim: To investigate whether Brazilian green propolis improves the immune response against recurrent form isolate recurrent vulvovaginal candidiasis (RVVC) caused by Candida albicans by increasing neutrophil oxidative burst. Materials & methods: We evaluated oxidant species production, oxygen consumption, microbicidal activity and myeloperoxidase activity in neutrophils previously treated with propolis and activated with different isolates of C. albicans (RVVC), vulvovaginal candidiasis, asymptomatic isolates and the reference strain. Results: Propolis significantly increased oxidant species production, oxygen consumption, microbicidal activity and myeloperoxidase activity of neutrophils against different isolates of C. albicans including RVVC isolate that are considered resistant to the microbicidal activity of neutrophils. Conclusion: Brazilian green propolis may increase neutrophil burst oxidative response to RVVC leading to an efficient removal of C. albicans.
   [GRAPHICS]
   .
C1 [Alves de Lima, Nayara Cristina; Ratti, Bianca Altrao; Lopes Consolaro, Marcia Edilaine; Estivalet Svidzinski, Terezinha Inez; Silva, Sueli de Oliveira] Univ Estadual Maringa, Biosci & Physiopathol Grad Program, Av Colombo 5790, BR-87025210 Maringa, PR, Brazil.
   [Bonfim Mendonca, Patricia de Souza] Univ Estadual Maringa, Hlth Sci Grad Program, Av Colombo 5790, BR-87025210 Maringa, PR, Brazil.
   [Murata, Gilson; Hatanaka, Elaine] Univ Cruzeiro Sul, Inst Phys Act & Sport Sci, Sao Paulo, SP, Brazil.
   [Araujo Pereira, Raphaela Regina; Nakamura, Celso Vataru; Bruschi, Marcos Luciano; Silva, Sueli de Oliveira] Univ Estadual Maringa, Pharmaceut Sci Grad Program, Av Colombo 5790, BR-87025210 Maringa, PR, Brazil.
RP Silva, SD (corresponding author), Univ Estadual Maringa, Biosci & Physiopathol Grad Program, Av Colombo 5790, BR-87025210 Maringa, PR, Brazil.; Silva, SD (corresponding author), Univ Estadual Maringa, Pharmaceut Sci Grad Program, Av Colombo 5790, BR-87025210 Maringa, PR, Brazil.
EM lautenschlager@uem.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Nakamura, Celso
   Vataru/AAA-5620-2019; Lautenschlager, Sueli OS/P-2164-2017; Hatanaka,
   Elaine/D-6337-2012; Bruschi, Marcos Luciano/J-1871-2012
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Lautenschlager,
   Sueli OS/0000-0001-9303-0804; Bruschi, Marcos
   Luciano/0000-0002-4838-5742
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel superior
   (CAPES)CAPES; Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq); FINEPCiencia Tecnologia e Inovacao (FINEP); Fundacao
   AraucariaFundacao Araucaria
FX This work was supported by grants from Coordenacao de Aperfeicoamento de
   Pessoal de Nivel superior (CAPES), Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, FINEP and Fundacao Araucaria. The authors have
   no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Banskota AH, 2001, PHYTOTHER RES, V15, P561, DOI 10.1002/ptr.1029
   BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
   Bruschi ML, 2007, J PHARM SCI-US, V96, P2074, DOI 10.1002/jps.20843
   Bruschi ML, 2003, INT J PHARM, V264, P45, DOI 10.1016/S0378-5173(03)00386-7
   Coffer PJ, 1997, IMMUNOL LETT, V57, P27, DOI 10.1016/S0165-2478(97)00067-9
   Dota KFD, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq029
   Dypbukt JM, 2005, FREE RADICAL BIO MED, V39, P1468, DOI 10.1016/j.freeradbiomed.2005.07.008
   EDWARDS SW, 1987, J GEN MICROBIOL, V133, P3591
   Estabrook RW, 1967, METHOD ENZYMOL, V10, P41, DOI 10.1016/0076-6879(67)10010-4
   Fidel PL, 1996, CLIN MICROBIOL REV, V9, P335, DOI 10.1128/CMR.9.3.335
   Jaeger M, 2013, CURR INFECT DIS REP, V15, P136, DOI 10.1007/s11908-013-0319-3
   Longhini Renata, 2007, Rev. bras. farmacogn., V17, P388, DOI 10.1590/S0102-695X2007000300015
   Marcucci MC, 2001, J ETHNOPHARMACOL, V74, P105, DOI 10.1016/S0378-8741(00)00326-3
   Marcucci MC, 2000, 01054716 INPI PI BRA
   Orsatti CL, 2010, PHYTOTHER RES, V24, P1141, DOI 10.1002/ptr.3086
   Orsi R. O., 2000, Journal of Venomous Animals and Toxins including Tropical Diseases, V6, P205, DOI 10.1590/S0104-79302000000200006
   Orsolic N, 2003, J ETHNOPHARMACOL, V84, P265, DOI 10.1016/S0378-8741(02)00329-X
   Ratti BA, 2015, CELL IMMUNOL, V293, P22, DOI 10.1016/j.cellimm.2014.11.004
   Rebecchi IMM, 2000, CELL BIOCHEM FUNCT, V18, P127, DOI 10.1002/(SICI)1099-0844(200006)18:2<127::AID-CBF865>3.0.CO;2-V
   Rimoin LP, 2013, DERMATOL THER, V26, P157, DOI 10.1111/dth.12034
   Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653
   Sobel JD, 2004, NEW ENGL J MED, V351, P876, DOI 10.1056/NEJMoa033114
   STEVENS P, 1984, MICROCHEM J, V30, P135, DOI 10.1016/0026-265X(84)90034-1
   Strober W., 2001, CURR PROTOC IMMUNOL, V59, P18
   Sy LB, 2006, INT IMMUNOPHARMACOL, V6, P1053, DOI 10.1016/j.intimp.2006.01.015
   Szliszka E, 2011, INT J ONCOL, V38, P941, DOI 10.3892/ijo.2011.930
   Teixeira EW, 2010, EVID-BASED COMPL ALT, V7, P307, DOI 10.1093/ecam/nem177
   US pharmacopeial convention usp, 2016, USP US PHARM CONV 39
   Volpert R, 1996, ARZNEIMITTELFORSCH, V46, P47
   Walrand S, 2003, CLIN CHIM ACTA, V331, P103, DOI 10.1016/S0009-8981(03)00086-X
NR 30
TC 4
Z9 4
U1 0
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0913
EI 1746-0921
J9 FUTURE MICROBIOL
JI Future Microbiol.
PD FEB
PY 2018
VL 13
IS 2
BP 221
EP 230
DI 10.2217/fmb-2017-0112
PG 10
WC Microbiology
SC Microbiology
GA FZ0PR
UT WOS:000427273500008
PM 29302986
DA 2020-12-08
ER

PT J
AU Souza, RP
   Bonfim-Mcndonca, PS
   Damke, GMZF
   Carva-Iho, ARBDA
   Rattia, BA
   Dembogurski, DSO
   da-Silva, VRS
   Silva, SO
   Da-Silva, DB
   Bruschi, ML
   Maria-Engler, SS
   Consolaroa, MEL
AF Souza, Raquel P.
   Bonfim-Mcndonca, Patricia S.
   Damke, Gabrielle M. Z. F.
   de-Assis Carva-Iho, Analinc R. B.
   Rattia, Bianca A.
   Dembogurski, Djaccli S. O.
   da-Silva, Vania R. S.
   Silva, Sueli O.
   Da-Silva, Denise B.
   Bruschi, Marcos L.
   Maria-Engler, Silvya S.
   Consolaroa, Marcia E. L.
TI Artepillin C Induces Selective Oxidative Stress and Inhibits Migration
   and Invasion in a Comprehensive Panel of Human Cervical Cancer Cell
   Lines
SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Artepillin C; propolis; cervical cancer; apoptosis; cell migration and
   invasion; oxidative stress
ID BRAZILIAN GREEN PROPOLIS; CINNAMIC ACID-DERIVATIVES; IN-VITRO; FERRIC
   NITRILOTRIACETATE; HUMAN-PAPILLOMAVIRUS; ETHANOLIC EXTRACT;
   NATURAL-PRODUCTS; MAJOR COMPONENT; GROWTH; APOPTOSIS
AB Background: Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) is the main bioactive component of Brazilian green propolis, and possesses, among other things, anticancer properties. However, to the best of our knowledge, there are no studies of artepillin C in cervical cancer.
   Method: To explore a new therapeutic candidate for cervical cancer, we have evaluated the effects of artepillin C on cellular viability in a comprehensive panel of human cervical cancer-derived cell lines including HeLa (human papillomavirus/HPV 18-positive), SiHa (HPV 16-positive), CaSki (HPV 16- and 18-positive) and C33A (HPV-negative) cells compared to a spontaneously immortalized human epithelial cell line (HaCaT).
   Results: Our results demonstrated that artepillin C had a selective effect on cellular viability and could induce apoptosis possibly by intrinsic pathway, likely a result of oxidative stress, in all cancer-derived cell lines but not in HaCaT. Additionally, artepillin C was able to inhibit the migration and invasion of cancer cells.
   Conclusion: Thus, artepillin C appears to be a promising new candidate as an anticancer drug for cervical cancer induced by different HPV types.
C1 [Souza, Raquel P.; Bonfim-Mcndonca, Patricia S.; Damke, Gabrielle M. Z. F.; de-Assis Carva-Iho, Analinc R. B.; Rattia, Bianca A.; da-Silva, Vania R. S.; Silva, Sueli O.; Consolaroa, Marcia E. L.] State Univ Marine UEM, Dept Clin Anal & Biomed, Postgrad Program Biosci & Pathophysiol, Maringa, Parana, Brazil.
   [Dembogurski, Djaccli S. O.; Da-Silva, Denise B.] Univ Fed Mato Grosso do Sul, Lab Nat Prod & Mass Spectrometry LAPNEM, Campo Grande, RS, Brazil.
   [Bruschi, Marcos L.] State Univ Marine UEM, Dept Pharm, Postgrad Program Pharmaceut Sci, Maringa, Parana, Brazil.
   [Maria-Engler, Silvya S.] Univ Sao Paulo, Fac Pharm, Postgrad Program Pharm Physiopathol & Toxicol, Sao Paulo, SP, Brazil.
RP Souza, RP (corresponding author), State Univ Marina UEM, Av Colombo 5790, BR-87025210 Maringa, Parana, Brazil.
EM raquelpantarotto@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; da Silva, Denise
   Brentan/G-1460-2012; Bruschi, Marcos Luciano/J-1871-2012; Engler, Silvya
   Stuchi Maria/K-5936-2016; Maria-Engler, Silvya/ABC-2016-2020;
   Dembogurski, Djaceli/S-4270-2019; Lautenschlager, Sueli OS/P-2164-2017
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; da Silva, Denise
   Brentan/0000-0003-0872-2756; Bruschi, Marcos
   Luciano/0000-0002-4838-5742; Engler, Silvya Stuchi
   Maria/0000-0003-4771-6041; Maria-Engler, Silvya/0000-0003-4771-6041;
   Dembogurski, Djaceli/0000-0002-7422-7238; Lautenschlager, Sueli
   OS/0000-0001-9303-0804
FU Brazilian Government [PROCAD 88881.068413/2014-01]
FX This work was supported by grants from Brazilian Government (PROCAD
   88881.068413/2014-01).
CR Ahn MR, 2007, CANCER LETT, V252, P235, DOI 10.1016/j.canlet.2006.12.039
   Ahn MR, 2009, MOL NUTR FOOD RES, V53, P643, DOI 10.1002/mnfr.200800021
   Akao Y, 2003, BIOL PHARM BULL, V26, P1057, DOI 10.1248/bpb.26.1057
   Arya M, 2006, SURG ONCOL, V15, P117, DOI 10.1016/j.suronc.2006.10.002
   Chakrabarti A., 2012, LIFE SCI, V16, P403
   Cheung KW, 2011, J ETHNOPHARMACOL, V138, P463, DOI 10.1016/j.jep.2011.09.031
   Chou ST, 2011, ANTICANCER RES, V31, P1667
   Cragg GM, 2013, BBA-GEN SUBJECTS, V1830, P3670, DOI 10.1016/j.bbagen.2013.02.008
   de Oliveira PF, 2014, PLANTA MED, V80, P490, DOI 10.1055/s-0034-1368298
   Defamie N, 2014, FEBS LETT, V588, P1331, DOI 10.1016/j.febslet.2014.01.012
   Di Meo S, 2016, OXID MED CELL LONGEV
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Freshney RI, 2011, CULTURE ANIMAL CELLS
   Gordaliza M, 2007, CLIN TRANSL ONCOL, V9, P767, DOI 10.1007/s12094-007-0138-9
   Gupta S, 2001, BIOCHEM BIOPH RES CO, V287, P914, DOI 10.1006/bbrc.2001.5672
   Hayashi K, 1999, CHEM PHARM BULL, V47, P1521, DOI 10.1248/cpb.47.1521
   Hwang HJ, 2006, J NUTR BIOCHEM, V17, P356, DOI 10.1016/j.jnutbio.2005.08.009
   INCA, 2011, GEN COORD STRAT ACT
   Iqbal B, 2016, J CLIN DIAGN RES, V10, pXC1, DOI 10.7860/JCDR/2016/18507.7579
   Jagetia GC, 2005, LIFE SCI, V77, P780, DOI 10.1016/j.lfs.2005.01.015
   Kimoto T, 1996, Gan To Kagaku Ryoho, V23, P1855
   Kimoto T, 2001, ANTICANCER RES, V21, P221
   Kimoto T, 2001, VIRCHOWS ARCH, V438, P259, DOI 10.1007/s004280000350
   Kimoto T, 1998, CANCER DETECT PREV, V22, P506, DOI 10.1046/j.1525-1500.1998.00020.x
   Kimoto T, 2000, PATHOL INT, V50, P679, DOI 10.1046/j.1440-1827.2000.01097.x
   Kjaer SK, 2010, JNCI-J NATL CANCER I, V102, P1478, DOI 10.1093/jnci/djq356
   Koh WJ, 2015, J NATL COMPR CANC NE, V13, P1321, DOI 10.6004/jnccn.2015.0162
   Kumazaki M, 2014, PHYTOMEDICINE, V21, P1070, DOI 10.1016/j.phymed.2014.04.006
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Lim CB, 2010, INTEGR CANCER THER, V9, P36, DOI 10.1177/1534735409359773
   Marvibaigi M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158942
   Matsuno T, 1997, ANTICANCER RES, V17, P3565
   Messerli SM, 2009, PHYTOTHER RES, V23, P423, DOI 10.1002/ptr.2658
   Middleton E, 2000, PHARMACOL REV, V52, P673
   Morita M, 2016, REDOX BIOL, V8, P127, DOI 10.1016/j.redox.2016.01.005
   Nakanishi I, 2003, ORG BIOMOL CHEM, V1, P1452, DOI 10.1039/b302098c
   Park H, 2015, J SCI FOOD AGR, V95, P1697, DOI 10.1002/jsfa.6874
   Paulino N, 2008, EUR J PHARMACOL, V587, P296, DOI 10.1016/j.ejphar.2008.02.067
   Sawicka D, 2012, FOLIA HISTOCHEM CYTO, V50, P25, DOI [10.5603/FHC.2012.0004, 10.2478/18693]
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Sforcin JM, 2007, J ETHNOPHARMACOL, V113, P1, DOI 10.1016/j.jep.2007.05.012
   Sforcin JM, 2011, J ETHNOPHARMACOL, V133, P253, DOI 10.1016/j.jep.2010.10.032
   Shimizu K, 2005, MOL CARCINOGEN, V44, P293, DOI 10.1002/mc.20148
   Shukla AK, 2012, EUR J MED CHEM, V54, P49, DOI 10.1016/j.ejmech.2012.04.034
   Simoes LMC, 2004, J ETHNOPHARMACOL, V94, P59, DOI 10.1016/j.jep.2004.04.026
   Machado BAS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134489
   Spano D, 2012, SEMIN CANCER BIOL, V22, P234, DOI 10.1016/j.semcancer.2012.03.006
   Szliszka E, 2011, EVID-BASED COMPL ALT, V8, P1
   Szliszka E, 2009, MOLECULES, V14, P738, DOI [10.3390/molecules, 10.3390/molecules14020738]
   Szliszka E, 2012, INT J ONCOL, V41, P818, DOI 10.3892/ijo.2012.1527
   Szliszka E, 2011, INT J ONCOL, V38, P941, DOI 10.3892/ijo.2011.930
   Tan G, 2006, CURR DRUG TARGETS, V7, P265, DOI 10.2174/138945006776054942
   Tavares LC, 2010, QUIM NOVA, V33, P2051, DOI 10.1590/S0100-40422010001000009
   Tomin K, 2016, METHODS MOL BIOL, V1441, P65, DOI 10.1007/978-1-4939-3684-7_6
   TWENTYMAN PR, 1987, BRIT J CANCER, V56, P279, DOI 10.1038/bjc.1987.190
   WHO, 2012, GLOBOCAN 2012 EST CA
   Xu JM, 2013, MICROSC RES TECHNIQ, V76, P612, DOI 10.1002/jemt.22207
   Younes RN, 2007, CLINICS, V62, P763, DOI 10.1590/S1807-59322007000600017
NR 58
TC 1
Z9 1
U1 1
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5206
EI 1875-5992
J9 ANTI-CANCER AGENT ME
JI Anti-Cancer Agents Med. Chem.
PY 2018
VL 18
IS 12
BP 1750
EP 1760
DI 10.2174/1871520618666180604092930
PG 11
WC Oncology; Chemistry, Medicinal
SC Oncology; Pharmacology & Pharmacy
GA HJ0RH
UT WOS:000456869200011
PM 29866020
DA 2020-12-08
ER

PT J
AU Kienen, N
   Bittencourt, L
   Pelloso, SM
   Consolaro, MEL
   Castle, PE
   Partridge, EE
   Silva, VRS
   Scarinci, IC
AF Kienen, Nadia
   Bittencourt, Lorna
   Pelloso, Sandra M.
   Consolaro, Marcia E. L.
   Castle, Philip E.
   Partridge, Edward E.
   Silva, Vania R. S.
   Scarinci, Isabel C.
TI Cervical Cancer Screening among Underscreened and Unscreened Brazilian
   Women: Training Community Health Workers to be Agents of Change
SO PROGRESS IN COMMUNITY HEALTH PARTNERSHIPS-RESEARCH EDUCATION AND ACTION
LA English
DT Article
DE Cervical cancer; capacity building; women's health; community health
   workers; behavior change
ID INTERVENTION; AMERICAN; LITERACY; ADVISERS; LATINA; PERFORMANCE;
   CURRICULUM; EDUCATION; OUTREACH; BREAST
AB Background: Despite the availability of cervical cancer screening programs in Brazil, some women do not participate in these programs owing to structural and/or interpersonal/intrapersonal barriers, resulting in high cervical cancer incidence and mortality. Integrating community health workers (CHWs) into the delivery of cervical cancer screening interventions is potentially a feasible strategy to address these barriers.
   Objectives: This study aimed to implement and evaluate a CHW training to deliver a brief intervention to promote cervical cancer screening among underscreened and unscreened women in Brazil.
   Methods: The curriculum addressed cervical cancer and screening, behavioral intervention strategies, and protection of human subjects in research. Pretest and post-test questionnaires assessed changes in CHW objective and perceived knowledge as well as perceived skills and confidence (N = 15).
   Results: There was a significant increase in objective and perceived knowledge about cervical cancer, behavior change strategies, and protection of human subjects in research between pretest and post-test, but not in self-perception about skills and confidence to motivate women to engage in cervical cancer screening.
   Conclusions: Improvements in CHW knowledge about cervical cancer screening and behavior change represents a step forward toward successful interventions, but adaptations are needed to boost their self-confidence and perceived skills with regard to their ability to promote behavior change at the community level.
C1 [Kienen, Nadia; Silva, Vania R. S.] Univ Estadual Londrina, Londrina, Brazil.
   [Bittencourt, Lorna; Partridge, Edward E.; Scarinci, Isabel C.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Pelloso, Sandra M.; Consolaro, Marcia E. L.] Univ Estadual Maringa, Maringa, Parana, Brazil.
   [Castle, Philip E.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
RP Kienen, N (corresponding author), Univ Estadual Londrina, Londrina, Brazil.
RI Castle, Philip/AAP-6395-2020; Consolaro, Marcia Edilaine
   Lopes/I-4932-2014
OI Castle, Philip/0000-0003-1082-6554; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865
FU National Cancer Institute-USAUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30CA013148-43S2]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)-BrazilNational Council for Scientific
   and Technological Development (CNPq) [470040/2014-9]; CNPqNational
   Council for Scientific and Technological Development (CNPq); NATIONAL
   CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148, P30CA013148, P30CA013148, P30CA013148,
   P30CA013148, P30CA013148] Funding Source: NIH RePORTER
FX This work was supported through a research grant from the National
   Cancer Institute-USA (P30CA013148-43S2) and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)-Brazil (470040/2014-9).
   Dr. Kienen also received a scholarship from CNPq.
CR Albuquerque JC, 2014, SAO PAULO MED J, V132, P48, DOI 10.1590/1516-3180.2014.1321575
   ALBUQUERQUE P.M, 2003, THESIS
   Amorim VMSL, 2006, CAD SAUDE PUBLICA, V22, P9
   [Anonymous], 2009, TRAB AG COM SAUD, P1
   Baker DW, 2002, AGING MENT HEALTH, V6, P22, DOI 10.1080/13607860120101121
   Bittencourt L, 2017, HLTH PROMOT INT
   Bruni L, 2016, HUMAN PAPILLOMAVIRUS, P4
   Chacko Shiny, 2014, Nurs J India, V105, P221
   Cherrington A, 2010, ETHNIC DIS, V20, P189
   Christopher S, 2008, HEALTH EDUC BEHAV, V35, P821, DOI 10.1177/1090198107309457
   Department of Medical Services Ministry of Public Health, 2004, PUBL HLTH INT OCC B
   Dumbauld J, 2014, HEALTH PROMOT PRACT, V15, P79, DOI 10.1177/1524839913504416
   Florindo AA, 2014, J PHYS ACT HEALTH, V11, P1531, DOI 10.1123/jpah.2012-0260
   Ford S, 2014, HEALTH EDUC RES, V29, P158, DOI 10.1093/her/cyt100
   Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115
   Levinthal BR, 2008, J GEN INTERN MED, V23, P1172, DOI 10.1007/s11606-008-0612-2
   Luque JS, 2011, AM J PUBLIC HEALTH, V101, P2233, DOI 10.2105/AJPH.2011.300324
   Martinez-Donate Ana P, 2009, WMJ, V108, P259
   Ministerio de Salud y Proteccion Social Instituto Nacional de Cancerologia E.S.E, 2012, PROP STAT R IN PRESS, P1
   Mock J, 2007, AM J PUBLIC HEALTH, V97, P1693, DOI 10.2105/AJPH.2006.086470
   Morrow D, 2006, GERONTOLOGIST, V46, P669, DOI 10.1093/geront/46.5.669
   National Center for Professional & Research Ethics (NCPRE), ETH COR COLL ONL RES
   Paskett ED, 2011, CANCER EPIDEM BIOMAR, V20, P835, DOI 10.1158/1055-9965.EPI-10-0880
   Prochaska JO, 2015, HLTH BEHAV THEORY RE, P125
   Queirós Agleildes Arichele Leal de, 2012, Trab. educ. saúde, V10, P257, DOI 10.1590/S1981-77462012000200005
   Brischiliari SCR, 2012, CAD SAUDE PUBLICA, V28, P1976, DOI 10.1590/S0102-311X2012001000015
   Scarinci IC, 2016, J HEALTH CARE POOR U, V27, P1779, DOI 10.1353/hpu.2016.0162
   Skinner CS, 2015, HLTH BEHAV THEORY RE, P75
   Smith JL, 2013, J WOMENS HEALTH, V22, P718, DOI 10.1089/jwh.2013.4467
   Studts CR, 2012, PREV MED, V54, P408, DOI 10.1016/j.ypmed.2012.03.019
   SWELLER J, 1988, COGNITIVE SCI, V12, P257, DOI 10.1016/0364-0213(88)90023-7
   Swider SM, 2002, PUBLIC HEALTH NURS, V19, P11, DOI 10.1046/j.1525-1446.2002.19003.x
   Taylor VM, 2010, AM J PUBLIC HEALTH, V100, P1924, DOI 10.2105/AJPH.2009.190348
   Thompson B, 2014, J RURAL HEALTH, V30, P196, DOI 10.1111/jrh.12044
   VELLA J, 1994, LEARNING LISTEN LEAR
   Wasserman Melanie R, 2006, J Immigr Minor Health, V8, P67, DOI 10.1007/s10903-006-6343-0
   Watson-Johnson LC, 2012, J HEALTH CARE POOR U, V23, P1704, DOI 10.1353/hpu.2012.0150
   Wiggins N, 2013, J COMMUNITY PRACT, V21, P186, DOI 10.1080/10705422.2013.811622
   Williams KP, 2009, J CANCER EDUC, V24, P257, DOI 10.1080/08858190902972939
   Woodruff SI, 2010, J COMMUN HEALTH, V35, P124, DOI 10.1007/s10900-009-9207-z
   Yuan NP, 2012, HEALTH EDUC BEHAV, V39, P544, DOI 10.1177/1090198111421622
NR 41
TC 4
Z9 4
U1 0
U2 1
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
   21218-4363 USA
SN 1557-0541
EI 1557-055X
J9 PROG COMM HLTH PARTN
JI Prog. Community Health Partnersh.
PY 2018
VL 12
SI SI
BP 111
EP 119
DI 10.1353/cpr.2018.0026
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA GV1CM
UT WOS:000445805400011
PM 29755054
OA Bronze
DA 2020-12-08
ER

PT J
AU Venancio, PA
   Maria-Engler, SS
   Consolaro, MEL
   Villa, LL
   Derchain, SF
   Campa, A
   Discacciati, MG
AF Venancio, Paloma Almeida
   Maria-Engler, Silvya Stuchi
   Lopes Consolaro, Marcia Edilaine
   Villa, Luisa Lina
   Derchain, Sophie Francoise
   Campa, Ana
   Discacciati, Michelle Garcia
TI Upregulation of IDO in bacterial vaginosis: Role in HPV coinfection.
SO CLINICAL CANCER RESEARCH
LA English
DT Meeting Abstract
CT AACR International Conference on Translational Cancer Medicine held in
   Cooperation with the Latin-American-Cooperative-Oncology-Group
CY MAY 04-06, 2017
CL Sao Paulo, BRAZIL
SP Amer Assoc Canc Res, Latin Amer Cooperat Oncol Grp
C1 [Venancio, Paloma Almeida; Maria-Engler, Silvya Stuchi; Villa, Luisa Lina; Campa, Ana; Discacciati, Michelle Garcia] Univ Sao Paulo, Sao Paulo, SP, Brazil.
   [Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Maringa, Parana, Brazil.
   [Derchain, Sophie Francoise] Univ Estadual Campinas, Sao Paulo, SP, Brazil.
RI Derchain, Sophie FM/I-9500-2014; Maria-Engler, Silvya/ABC-2016-2020;
   Engler, Silvya Stuchi Maria/K-5936-2016; VILLA, LUISA/AAH-4761-2019
OI Derchain, Sophie FM/0000-0003-1029-9993; Maria-Engler,
   Silvya/0000-0003-4771-6041; Engler, Silvya Stuchi
   Maria/0000-0003-4771-6041; VILLA, LUISA/0000-0003-4074-2335
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JAN
PY 2018
VL 24
IS 1
SU S
MA A46
BP 43
EP 44
PG 2
WC Oncology
SC Oncology
GA FR6MK
UT WOS:000419180000062
DA 2020-12-08
ER

PT J
AU Lima, NA
   Santana, NDS
   de Lima, NCA
   Lazarin-Bidoia, D
   Bonfim-Mendonca, PD
   Nakamura, TU
   Nakamura, CV
   Consolaro, MEL
   Ximenes, VF
   Silva, SD
AF Lima, Natalia Alves
   Scharf Santana, Natalia de Carvalho
   Alves de Lima, Nayara Cristina
   Lazarin-Bidoia, Danielle
   Bonfim-Mendonca, Patricia de Souza
   Nakamura, Tania Ueda
   Nakamura, Celso Vataru
   Lopes Consolaro, Marcia Edilaine
   Ximenes, Valdecir Farias
   Silva, Sueli de Oliveira
TI Antiproliferative effect of apocynin in cervical epithelial cells
   infected by HPV 16 involves change of ROS production and cell cycle
SO MEDICINAL CHEMISTRY RESEARCH
LA English
DT Article
DE SiHa; HPV 16; Apocynin; Reactive oxygen species
ID NADPH OXIDASE INHIBITOR; CANCER; APOPTOSIS; PROTEINS; PREVALENCE;
   EXPRESSION; DEATH; E6
AB The cervical cancer is characterized as a public health problem. The human papillomavirus, especially the high-risk types 16 and 18, is present in 99.7% of cases of invasive cervical cancers. Due to high prevalence, the search for new drugs for the treatment is continuous. The apocynin, compound belonging to the class of catechol-methoxy acetophenone, has been used as an effective and non-toxic inhibitor of the NADPH oxidase complex, in many experimental models. Some early studies have indicated that apocynin also exerts antiproliferative activity inducing cell death by apoptosis. Thus, we evaluated the effect of apocynin in cervical epithelial cells infected by human papillomavirus 16 (SiHa cells) by analyzing oxygen species production, cell cycle, cell morphology, cell volume, membrane integrity and mitochondria membrane potential. Our data showed that apocynin induces antiproliferative effects by decreasing reactive oxygen species production and inducing cell cycle arrest, activating pathways that induce apoptosis cell death.
C1 [Lima, Natalia Alves; Scharf Santana, Natalia de Carvalho; Alves de Lima, Nayara Cristina] Univ Estadual Maringa, Programa Posgrad Biociencias Aplicadas Farm, Av Colombo 5-790, BR-87020900 Maringa, Parana, Brazil.
   [Lazarin-Bidoia, Danielle] Univ Estadual Maringa, Programa Posgrad Ciencias Farmaceut, Av Colombo 5-790, BR-87020900 Maringa, Parana, Brazil.
   [Bonfim-Mendonca, Patricia de Souza] Univ Estadual Maringa, Programa Posgrad Ciencias Saude, Av Colombo 5-790, BR-87020900 Maringa, Parana, Brazil.
   [Nakamura, Tania Ueda; Nakamura, Celso Vataru; Silva, Sueli de Oliveira] Univ Estadual Maringa, Dept Ciencias Basicas Saude, Av Colombo 5-790, BR-87020900 Maringa, Parana, Brazil.
   [Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Anal Clin & Biomed, Av Colombo 5-790, BR-87020900 Maringa, Parana, Brazil.
   [Ximenes, Valdecir Farias] Univ Estadual Paulista, Dept Quim, Fac Ciencias, Av Eng Luiz Edmundo Carrijo Coube S-N, BR-17033360 Baum, SP, Brazil.
RP Silva, SD (corresponding author), Univ Estadual Maringa, Dept Ciencias Basicas Saude, Av Colombo 5-790, BR-87020900 Maringa, Parana, Brazil.
EM lautenschlager@uem.br
RI Nakamura, Celso Vataru/AAA-5620-2019; Bidoia, Danielle
   Lazarin/AAQ-2024-2020; Consolaro, Marcia Edilaine Lopes/I-4932-2014;
   Ximenes, Valdecir/A-5323-2008; Lautenschlager, Sueli OS/P-2164-2017
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Ximenes,
   Valdecir/0000-0003-2636-3080; Lautenschlager, Sueli
   OS/0000-0001-9303-0804
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (Capes)CAPES; Fundacao AraucariaFundacao Araucaria
FX This study was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (Capes), Fundacao Araucaria. Programa de Pos
   Graduacao em Biociencias Aplicadas a Farmacia da Universidade Estadual
   de Maringa.
CR Barbieri SS, 2004, FREE RADICAL BIO MED, V37, P156, DOI 10.1016/j.freeradbiomed.2004.04.020
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Benedyk M, 2007, J INVEST DERMATOL, V127, P2001, DOI 10.1038/sj.jid.5700820
   DeFilippis RA, 2003, J VIROL, V77, P1551, DOI 10.1128/JVI.77.2.1551-1563.2003
   Dunne EF, 2007, JAMA-J AM MED ASSOC, V297, P813, DOI 10.1001/jama.297.8.813
   Freinbichler W, 2011, CELL MOL LIFE SCI, V68, P2067, DOI 10.1007/s00018-011-0682-x
   Hopfl R, 2000, LANCET, V356, P1985, DOI 10.1016/S0140-6736(00)03315-8
   INCA, 2012, INC CANC BRAS
   Koeppen BM, 2007, RENAL PHYSL, V24, P3263
   Kuznetsov AV, 2011, BBA-MOL CELL RES, V1813, P1144, DOI 10.1016/j.bbamcr.2011.03.002
   Lee YJ, 2006, J CELL PHYSIOL, V209, P802, DOI 10.1002/jcp.20763
   Liu Z, 2015, J BIOMED MAT RES A
   MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20
   Mejia EM, 2016, J BIOENERG BIOMEMBR, V48, P99, DOI 10.1007/s10863-015-9601-4
   Mohan S, 2010, J ETHNOPHARMACOL, V131, P592, DOI 10.1016/j.jep.2010.07.043
   Munoz N, 2004, J INFECT DIS, V190, P2077, DOI 10.1086/425907
   Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412
   Pilch H, 2001, Zentralbl Gynakol, V123, P91, DOI 10.1055/s-2001-12411
   Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571
   Qin Y, 2011, CHEM-BIOL INTERACT, V193, P246, DOI 10.1016/j.cbi.2011.07.004
   Spangle JM, 2010, J VIROL, V84, P9398, DOI 10.1128/JVI.00974-10
   Stefanska J, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/106507
   Suzuki S, 2013, CANCER SCI, V104, P1711, DOI 10.1111/cas.12292
   Suzuki S, 2013, EXP TOXICOL PATHOL, V65, P1035, DOI 10.1016/j.etp.2013.03.002
   Yu SP, 2000, P NATL ACAD SCI USA, V97, P9360, DOI 10.1073/pnas.97.17.9360
   Zhang Y, 2002, CANCER RES, V62, P1205
NR 26
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER BIRKHAUSER
PI NEW YORK
PA 233 SPRING STREET, 6TH FLOOR, NEW YORK, NY 10013 USA
SN 1054-2523
EI 1554-8120
J9 MED CHEM RES
JI Med. Chem. Res.
PD NOV
PY 2017
VL 26
IS 11
BP 2853
EP 2860
DI 10.1007/s00044-017-1984-9
PG 8
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA FK8MT
UT WOS:000413763600016
OA Green Published
DA 2020-12-08
ER

PT J
AU Nakamura-Vasconcelos, SS
   Fiorini, A
   Zanni, PD
   Bonfim-Mendonca, PD
   Godoy, JR
   Almeida-Apolonio, AA
   Consolaro, MEL
   Svidzinski, TIE
AF Nakamura-Vasconcelos, Sandra Sayuri
   Fiorini, Adriana
   Zanni, Pamela Delvas
   Bonfim-Mendonca, Patricia de Souza
   Godoy, Janine Ribeiro
   Almeida-Apolonio, Adriana Araujo
   Lopes Consolaro, Marcia Edilaine
   Estivalet Svidzinski, Terezinha Inez
TI Emergence of Candida glabrata in vulvovaginal candidiasis should be
   attributed to selective pressure or virulence ability?
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Candida glabrata; Fluconazole; Drug resistance; Adherence; Biofilm
ID ANTIFUNGAL SUSCEPTIBILITY; SPECIES DISTRIBUTION; SOUTHERN CHINA;
   ADHERENCE; FLUCONAZOLE; INFECTIONS; ALBICANS; YEASTS; SPP.
AB Vulvovaginal candidiasis (VVC) is one of the most frequent female genital disorders and Candida glabrata is the second most common agent. Current study was aimed to study the susceptibility to antifungal agents of C. glabrata isolated from vaginal samples and some virulence attributes in order to better understand why this species is emerging as the main VVC agents.
   A total of 60 C. glabrata vaginal isolates were included in this study. Firstly they were screened by susceptibility tests to antifungal agents. The isolates that showed sensitivity or resistance to fluconazole were evaluated for their virulence potential, including ability to adhere to polystyrene and vaginal ring, cell surface hydrophobicity (CSH) and capacity to form biofilm.
   Candida glabrata isolates varied significantly in adherence capacity, biofilm formation and CSH. However, it was possible to observe that isolates resistant to fluconazole adhered more efficiently to the vaginal ring and were statistically more able to form biofilm.
   These results allow hypothesizing that C. glabrata is an emergent agent in VVC probably because the treatment with fluconazole selects this species. But once adhered, yeasts remain on biotic or abiotic surfaces causing colonization or VVC symptomatology.
C1 [Nakamura-Vasconcelos, Sandra Sayuri; Bonfim-Mendonca, Patricia de Souza; Godoy, Janine Ribeiro; Estivalet Svidzinski, Terezinha Inez] Univ Estadual Maringa, Div Med Mycol, Dept Clin Anal, Teaching & Res Lab Clin Anal, Ave Colombo 5790,Bloco T20 Sala 203, BR-87020900 Maringa, Parana, Brazil.
   [Fiorini, Adriana] Fed Univ Parana UFPR, Palotina, Parana, Brazil.
   [Zanni, Pamela Delvas; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol Lab, Maringa, Parana, Brazil.
   [Almeida-Apolonio, Adriana Araujo] Fed Univ Grande Dourados, Dourados, Mato Grosso Do, Brazil.
RP Svidzinski, TIE (corresponding author), Univ Estadual Maringa, Div Med Mycol, Dept Clin Anal, Teaching & Res Lab Clin Anal, Ave Colombo 5790,Bloco T20 Sala 203, BR-87020900 Maringa, Parana, Brazil.
EM terezinha.svidzinski@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Araujo de Almeida
   Apolonio, Adriana/V-2007-2017
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Araujo de Almeida
   Apolonio, Adriana/0000-0002-3836-8519
FU Programa Nacional de Cooperacao Academica (CAPES/PNPD); Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (Cnpq).National
   Council for Scientific and Technological Development (CNPq)
FX This study was funded by Programa Nacional de Cooperacao Academica
   (CAPES/PNPD) and Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (Cnpq).
CR Gunther LSA, 2014, SAO PAULO MED J, V132, P116, DOI 10.1590/1516-3180.2014.1322640
   Alfouzan W, 2015, J MYCOL MED, V25, P23, DOI 10.1016/j.mycmed.2014.10.021
   Babin D, 2013, INT J RES BIOL SCI, V3, P55
   Bonfim-Mendonca PD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107805
   Camacho DP, 2007, MYCOPATHOLOGIA, V163, P261, DOI 10.1007/s11046-007-9007-x
   Carnacho DP, 2007, CONTRACEPTION, V76, P439, DOI 10.1016/j.contraception.2007.07.012
   Dalben-Dota KF, 2010, J ALTERN COMPLEM MED, V16, P285, DOI 10.1089/acm.2009.0281
   Alczuk SDD, 2015, REV INST MED TROP SP, V57, P169, DOI 10.1590/S0036-46652015000200012
   dos Santos ER, 2014, REV INST MED TROP SP, V56, P477, DOI 10.1590/S0036-46652014000600004
   Doyle RJ, 2000, MICROBES INFECT, V2, P391, DOI 10.1016/S1286-4579(00)00328-2
   El-Kirat-Chatel S, 2015, ACS NANO, V9, P1648, DOI 10.1021/nn506370f
   European Committee on Antimicrobial Susceptibility, 2010, T EUC CLIN BREAKP VE
   Fan SR, 2008, J OBSTET GYNAECOL RE, V34, P561, DOI 10.1111/j.1447-0756.2008.00817.x
   Paiva LCF, 2010, MICROSC MICROANAL, V16, P537, DOI 10.1017/S1431927610093773
   Gomez-Molero E, 2015, FEMS YEAST RES, V15, DOI 10.1093/femsyr/fov098
   Goncalves B, 2016, CRIT REV MICROBIOL, V42, P905, DOI 10.3109/1040841X.2015.1091805
   Goswami D, 2006, J INFECTION, V52, P111, DOI 10.1016/j.jinf.2005.03.005
   Hamad M, 2014, MYCOSES, V57, P184, DOI 10.1111/myc.12141
   Institute CaLS, 2008, REF METH BROTH DIL A
   Kennedy Melissa A, 2010, Curr Infect Dis Rep, V12, P465, DOI 10.1007/s11908-010-0137-9
   Kumari V, 2013, INDIAN J PATHOL MICR, V56, P144, DOI 10.4103/0377-4929.118703
   Liu XP, 2014, J MYCOL MED, V24, P106, DOI 10.1016/j.mycmed.2014.01.060
   Lopes Consolaro Marcia Edilaine, 2004, Rev Iberoam Micol, V21, P202
   Maria Cheraghi, 2013, Glob J Health Sci, V6, P201, DOI 10.5539/gjhs.v6n1p201
   Negri M, 2010, BRIT J BIOMED SCI, V67, P120
   Ogouyemi-Hounto A, 2014, J MYCOL MED, V24, P100, DOI 10.1016/j.mycmed.2014.01.003
   Paiva LCF, 2012, MICRON, V43, P497, DOI 10.1016/j.micron.2011.09.013
   Payne MS, 2016, AUST NZ J OBSTET GYN, V56, P179, DOI 10.1111/ajo.12409
   Ragunathan L, 2014, J CLIN DIAGN RES, V8, pDC1, DOI 10.7860/JCDR/2014/7434.4311
   Raut Jayant, 2010, Nihon Ishinkin Gakkai Zasshi, V51, P131, DOI 10.3314/jjmm.51.131
   Rodrigues CF, 2014, EUR J CLIN MICROBIOL, V33, P673, DOI 10.1007/s10096-013-2009-3
   Martins HPR, 2012, ACTA DERM-VENEREOL, V92, P78, DOI 10.2340/00015555-1194
   Samaranayake LP, 2002, ORAL DIS, V8, P151, DOI 10.1034/j.1601-0825.8.s2.6.x
   Santander MP, 2016, QUIMIOTERAPIA, V29, P151
   Seneviratne CJ, 2008, ANTIMICROB AGENTS CH, V52, P3259, DOI 10.1128/AAC.00541-08
   Irie MMT, 2006, J CLIN LAB ANAL, V20, P195, DOI 10.1002/jcla.20132
   Vitali A, 2017, J CHEMOTHERAPY, V29, P164, DOI 10.1080/1120009X.2016.1199507
   Wang FJ, 2016, CHINESE MED J-PEKING, V129, P1161, DOI 10.4103/0366-6999.181964
NR 38
TC 5
Z9 5
U1 0
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD SEP
PY 2017
VL 296
IS 3
BP 519
EP 526
DI 10.1007/s00404-017-4465-y
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA FD2LQ
UT WOS:000407366800016
PM 28730269
DA 2020-12-08
ER

PT J
AU Bahls, L
   Yamakawa, R
   Zanao, K
   Alfieri, D
   Flauzino, T
   Delongui, F
   de Abreu, A
   Souza, R
   Gimenes, F
   Reiche, E
   Borelli, S
   Consolaro, M
AF Bahls, Larissa
   Yamakawa, Roger
   Zanao, Karina
   Alfieri, Daniela
   Flauzino, Tamires
   Delongui, Francieli
   de Abreu, Andre
   Souza, Raquel
   Gimenes, Fabricia
   Reiche, Edna
   Borelli, Sueli
   Consolaro, Marcia
TI Human Leukocyte Antigen Class I and Class II Polymorphisms and Serum
   Cytokine Profiles in Cervical Cancer
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE genes; major histocompatibility complex class I; genes; major
   histocompatibility complex class II; serum cytokines; papillomavirus
   infections; uterine cervical dysplasia; uterine cervical neoplasms
ID HUMAN-PAPILLOMAVIRUS INFECTION; GENOME-WIDE ASSOCIATION; INTRAEPITHELIAL
   NEOPLASIA; COMPREHENSIVE ANALYSIS; SUSCEPTIBILITY LOCI; NATURAL-HISTORY;
   TUMOR-GROWTH; HLA-A; RISK; ALLELES
AB Only a small proportion of women who are exposed to infection with high-risk human papillomavirus (HR-HPV) progress to persistent infection and develop cervical cancer (CC). The immune response and genetic background of the host may affect the risk of progression from a HR-HPV infection to lesions and cancer. However, to our knowledge, no studies has been conducted to evaluate the relationship between variability of human leukocyte antigens (HLA) genes and serum cytokine expression in this pathology. In the current study, we examined the associations of HLA alleles and haplotypes including Class I (HLA-A, -B and -C) and II (HLA-DRB1, -DQA1 and -DQB1) with serum levels of cytokines interleukin (IL)-6, tumor necrosis factor- (TNF-), IL-10 and IL-17 as well as risks of HPV infections, lesions and CC among admixed Brazilian women. HLA polymorphisms were associated with an increased risk or protection from HPV, lesions and CC. Additionally, we demonstrated a potential association of a HLA class I haplotype (HLA-B*14-C*08) with higher IL-10 cytokine serum levels in cervical disease, suggesting an association between HLA class I and specific cytokines in cervical carcinogenesis. However, larger studies with detailed HPV types coupled with genetic data are needed to further evaluate the effects of HLA and CC by HPV genotype.
C1 [Bahls, Larissa; Yamakawa, Roger; Zanao, Karina; Borelli, Sueli] State Univ Maringa UEM, Dept Basic Hlth Sci, Immunogenet Lab, BR-87020900 Maringa, PR, Brazil.
   [Bahls, Larissa; de Abreu, Andre; Souza, Raquel; Gimenes, Fabricia; Consolaro, Marcia] State Univ Maringa UEM, Dept Clin Anal & Biomed, Lab Clin Cytol, BR-87020900 Maringa, PR, Brazil.
   [Bahls, Larissa; Souza, Raquel; Consolaro, Marcia] State Univ Maringa UEM, Post Grad Program Biosci & Physiopathol, Clin Anal & Biomed Dept, BR-87020900 Maringa, PR, Brazil.
   [Alfieri, Daniela; Flauzino, Tamires; Delongui, Francieli; Reiche, Edna] State Univ Londrina UEL, Dept Pathol, Lab Clin & Toxicol Anal, BR-86057970 Londrina, PR, Brazil.
RP Consolaro, M (corresponding author), State Univ Maringa UEM, Dept Clin Anal & Biomed, Lab Clin Cytol, BR-87020900 Maringa, PR, Brazil.; Consolaro, M (corresponding author), State Univ Maringa UEM, Post Grad Program Biosci & Physiopathol, Clin Anal & Biomed Dept, BR-87020900 Maringa, PR, Brazil.
EM laribahls@gmail.com; spruem2011@gmail.com; karinazanao6@gmail.com;
   frizon.alfieri@gmail.com; t.flauzino@hotmail.com;
   frandelongui@hotmail.com; andreluelsdorf@gmail.com;
   raquelpantarotto@gmail.com; fabricia.gimenes@gmail.com;
   reiche@sercomtel.com.br; sueliborelli@gmail.com; melconsolaro@uem.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Reiche, EDNa/AAD-4186-2020
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Reiche,
   EDNa/0000-0001-6507-2839
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Brazilian Government; Laboratory of Immunogenetics
   [00639/99-DEG-UEM]
FX This study was supported by grants from the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazilian
   Government, and Laboratory of Immunogenetics (Proc. No.
   00639/99-DEG-UEM).
CR [Anonymous], 2017, WKLY EPIDEMIOL REC, V92, P241, DOI DOI 10.1016/j.vaccine.2017.05.069
   Ayres M., 2007, BIOESTAT 5 0 APLICAC, V1, P364
   Bailey SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00276
   Beskow AH, 2002, INT J CANCER, V101, P526, DOI 10.1002/ijc.90010
   Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321
   Castrilli G, 1997, BRIT J CANCER, V75, P855, DOI 10.1038/bjc.1997.152
   Chan DPC, 2005, J INFECT DIS, V192, P1749, DOI 10.1086/497342
   Chan PKS, 2007, GYNECOL ONCOL, V105, P736, DOI 10.1016/j.ygyno.2007.02.013
   Chen D, 2013, JNCI-J NATL CANCER I, V105, P624, DOI 10.1093/jnci/djt051
   Chen LH, 2013, J MED VIROL, V85, P1229, DOI 10.1002/jmv.23582
   Chuang LC, 2012, CANCER-AM CANCER SOC, V118, P223, DOI 10.1002/cncr.26227
   Cuzick J, 2000, BRIT J CANCER, V82, P1348, DOI 10.1054/bjoc.1999.1103
   Davidson EJ, 2003, CANCER RES, V63, P400
   de Abreu ALP, 2016, AM J CANCER RES, V6, P1371
   Souza PSD, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-246
   Souza PSD, 2009, FUTURE ONCOL, V5, P359, DOI [10.2217/fon.09.8, 10.2217/FON.09.8]
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Franco EL, 1999, J INFECT DIS, V180, P1415, DOI 10.1086/315086
   Gimenes F, 2014, BBA-REV CANCER, V1846, P576, DOI 10.1016/j.bbcan.2014.10.004
   Hildesheim A, 1998, CANCER EPIDEM BIOMAR, V7, P1035
   Hildesheim A, 2002, VIRUS RES, V89, P229, DOI 10.1016/S0168-1702(02)00191-0
   Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703
   Hong JH, 2010, INT J GYNECOL CANCER, V20, P1011, DOI 10.1111/IGC.0b013e3181e513e5
   Hosono S, 2010, J EPIDEMIOL, V20, P295, DOI 10.2188/jea.JE20090155
   Ivansson EL, 2008, GENES IMMUN, V9, P613, DOI 10.1038/gene.2008.58
   Katz Leticia Maria C., 2016, J. Bras. Patol. Med. Lab., V52, P210, DOI 10.5935/1676-2444.20160034
   Klein J, 2000, NEW ENGL J MED, V343, P702, DOI 10.1056/NEJM200009073431006
   Kohno T, 2003, CANCER RES, V63, P5091
   Liang JX, 2008, CANCER GENET CYTOGEN, V187, P95, DOI 10.1016/j.cancergencyto.2008.07.011
   Lin P, 2001, CANCER EPIDEM BIOMAR, V10, P1037
   Maciag PC, 2002, J INFECT DIS, V186, P164, DOI 10.1086/341080
   Maciag PC, 2000, CANCER EPIDEM BIOMAR, V9, P1183
   Madeleine MM, 2008, CANCER RES, V68, P3532, DOI 10.1158/0008-5472.CAN-07-6471
   Madeleine MM, 2002, J INFECT DIS, V186, P1565, DOI 10.1086/345285
   Marangon AV, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/146079
   Mege JL, 2006, LANCET INFECT DIS, V6, P557, DOI 10.1016/S1473-3099(06)70577-1
   Mota F, 1999, CLIN EXP IMMUNOL, V116, P33
   Paradkar PH, 2014, ASIAN PAC J CANCER P, V15, P3851, DOI 10.7314/APJCP.2014.15.9.3851
   Probst CM, 2000, HUM BIOL, V72, P597
   Punt S., 2015, ONCOIMMUNOLOGY, V3, DOI 10.4161/2162402X.2014.98453925949866
   Qiu XP, 2011, ASIAN PAC J CANCER P, V12, P2597
   Rodriguez AC, 2008, JNCI-J NATL CANCER I, V100, P513, DOI 10.1093/jnci/djn044
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
   Santin AD, 2000, J VIROL, V74, P4729, DOI 10.1128/JVI.74.10.4729-4737.2000
   Serrano B, 2015, EUR J CANCER, V51, P1732, DOI 10.1016/j.ejca.2015.06.001
   Shi YY, 2013, NAT GENET, V45, P918, DOI 10.1038/ng.2687
   SOBIN LH, 1981, B WORLD HEALTH ORGAN, V59, P813
   Souza PSD, 2003, MUTAT RES-REV MUTAT, V544, P375, DOI 10.1016/j.mrrev.2003.06.013
   Sullivan KM, 2009, PUBLIC HEALTH REP, V124, P471, DOI 10.1177/003335490912400320
   Tota JE, 2011, PREV MED, V53, pS12, DOI 10.1016/j.ypmed.2011.08.017
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Wang SS, 2002, CANCER EPIDEM BIOMAR, V11, P419
   Wang SS, 2002, J INFECT DIS, V186, P598, DOI 10.1086/342295
   Wang SS, 2001, J INFECT DIS, V184, P1310, DOI 10.1086/324209
   Wang SS, 2003, J NATL CANC I MONOGR, P35, DOI DOI 10.1093/OXFORDJOURNALS.JNCIMONOGRAPHS.A003480
   Wang Y, 2013, BIOMED REP, V1, P347, DOI 10.3892/br.2013.69
   Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226
   WU TC, 1994, CURR OPIN IMMUNOL, V6, P746, DOI 10.1016/0952-7915(94)90079-5
   Wu YP, 2006, INT J CANCER, V118, P3006, DOI 10.1002/ijc.21746
   Zhang X, 2014, BJOG-INT J OBSTET GY, V121, P664, DOI 10.1111/1471-0528.12638
   Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212
   Zijlmans HJMAA, 2012, BRIT J CANCER, V107, P1956, DOI 10.1038/bjc.2012.488
   zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798
NR 63
TC 8
Z9 8
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2017
VL 18
IS 9
AR 1478
DI 10.3390/ijms18091478
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA FI4RW
UT WOS:000411963800001
PM 28858203
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Pedrosa, TD
   Catarino, CM
   Pennacchi, PC
   de Assis, SR
   Gimenes, F
   Consolaro, MEL
   Barros, SBD
   Maria-Engler, SS
AF Pedrosa, Tatiana do Nascimento
   Catarino, Carolina Motter
   Pennacchi, Paula Comune
   de Assis, Silvia Romano
   Gimenes, Fabricia
   Lopes Consolaro, Marcia Edilaine
   de Moraes Barros, Silvia Berlanga
   Maria-Engler, Silvya Stuchi
TI A new reconstructed human epidermis for in vitro skin irritation testing
SO TOXICOLOGY IN VITRO
LA English
DT Article
DE Irritation assays; RHE; OECD; New skin models
ID MODEL; CULTIVATION; CHEMICALS; EXPOSURE; RELEASE
AB Different models of reconstructed human epidermis (RHE) are currently validated to assess skin irritation in vitro and ultimately to the animal replacement of the Draize test. The development of a new RHE model is a challenge for many laboratories, representing a potential gain of autonomy and improvement of technological knowledge. The Organization for Economic Co-operation and Development (OECD) encourages the development of new models and, for this purpose, offers a thorough guideline on quality control parameters (OECD TG 439 performance standards). This work aimed to develop an RHE model (i.e. USP-RHE) for in vitro skin irritation assays, following the OECD TG 439. The developed model presents a well-differentiated epidermis similar to the Validated Reference Methods (VRM) and to native human epidermis. Quality parameters, i.e. optical density of negative control, tissue integrity and barrier function, were similar to VRM and in accordance with OECD TG 439. Moreover, the USP-RHE model was shown to have 85,7% of specificity (6/7), 100% of sensitivity (6/6) and 92,3% of accuracy (12/13) when compared to in vivo UN GHS classification. The within-laboratory reproducibility was 92.3% (12/13). Thus, we demonstrated that USP-RHE model attends to all OECD TG 439 performance standards and is ready to be used by private and public laboratories and companies for future validation studies.
C1 [Pedrosa, Tatiana do Nascimento; Catarino, Carolina Motter; Pennacchi, Paula Comune; de Assis, Silvia Romano; de Moraes Barros, Silvia Berlanga; Maria-Engler, Silvya Stuchi] Univ Sao Paulo, Sch Pharmaceut Sci, Clin Chem & Toxicol Dept, Ave Prof Lineu Prestes,580,Bloco 17, BR-05508000 Sao Paulo, SP, Brazil.
   [Gimenes, Fabricia; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Clin Anal & Biomed, Ave Colombo,5790, BR-87020900 Maringa, Parana, Brazil.
RP Maria-Engler, SS (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Chem & Toxicol, Skin Biol & Melanoma Grp, Ave Prof Lineu Prestes,580,Bl 17,Room 114, BR-05508000 Sao Paulo, SP, Brazil.
EM silvya@usp.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Barros, Silvia B
   M/K-6856-2014; Maria-Engler, Silvya/ABC-2016-2020; Barros, Silvia B
   M/H-1090-2012; Engler, Silvya Stuchi Maria/K-5936-2016; Pennacchi,
   Paula/L-2220-2015; do Nascimento Pedrosa, Tatiana/K-6813-2017
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Maria-Engler,
   Silvya/0000-0003-4771-6041; Engler, Silvya Stuchi
   Maria/0000-0003-4771-6041; Pennacchi, Paula/0000-0003-0875-0263; do
   Nascimento Pedrosa, Tatiana/0000-0003-0009-1013
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2013/12682-9, 2011/07441-7, 2011/14327-6, 2011/22812-1, 2013/00735-0,
   2014/24400-0]; CAPESCAPES; CNPq-INCT-if/RENAMA [403452/2012-0]
FX The authors thank the Histological Techniques Sector of ICB-USP for the
   technical support. Financial support was provided by FAPESP (Grants #
   2013/12682-9, 2011/07441-7, 2011/14327-6; 2011/22812-1; 2013/00735-0;
   2014/24400-0), CAPES, CNPq-INCT-if/RENAMA (403452/2012-0).
CR Abdel-Aziz Abdel-Hamid M, 2005, EGYPT DERMATOL J, V1, P1
   Alepee N, 2010, TOXICOL IN VITRO, V24, P257, DOI 10.1016/j.tiv.2009.08.024
   Chatterjee A, 2006, TOXICOL LETT, V167, P85, DOI 10.1016/j.toxlet.2006.08.017
   Coquette A, 1999, TOXICOL IN VITRO, V13, P867, DOI 10.1016/S0887-2333(99)00076-4
   De Vuyst E, 2014, METHODS MOL BIOL, V1195, P191, DOI 10.1007/7651_2013_40
   Frankart A, 2012, ARCH DERMATOL RES, V304, P289, DOI 10.1007/s00403-012-1209-5
   Gimenes F., 2014, PLOS ONE, V9
   Groeber F, 2016, TOXICOL IN VITRO, V36, P254, DOI 10.1016/j.tiv.2016.07.008
   Hoffmann J, 2005, TOXICOL IN VITRO, V19, P925, DOI 10.1016/j.tiv.2005.06.010
   Jung KM, 2014, TOXICOL IN VITRO, V28, P742, DOI 10.1016/j.tiv.2014.02.014
   Kojima H, 2014, J APPL TOXICOL, V34, P766, DOI 10.1002/jat.2937
   Lamb R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052494
   Lemper M, 2014, SKIN PHARMACOL PHYS, V27, P106, DOI 10.1159/000351814
   Mewes K.R., 2016, TOXICOL IN VITRO
   Molinari J, 2013, TOXICOL IN VITRO, V27, P441, DOI 10.1016/j.tiv.2012.08.002
   Norton J.P., 2015, OECD GUID TEST CHEM, P1
   OECD, 2015, PERF STAND ASS PROP, P22
   Pennacchi PC, 2015, TISSUE ENG PT A, V21, P2417, DOI [10.1089/ten.tea.2015.0009, 10.1089/ten.TEA.2015.0009]
   Portes P, 2002, TOXICOL IN VITRO, V16, P765, DOI 10.1016/S0887-2333(02)00090-5
   Poumay Y, 2004, ARCH DERMATOL RES, V296, P203, DOI 10.1007/s00403-004-0507-y
   PRUNIERAS M, 1983, J INVEST DERMATOL, V81, pS28, DOI 10.1111/1523-1747.ep12540324
   RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8
   Sarafian V, 2006, ARCH DERMATOL RES, V298, P73, DOI 10.1007/s00403-006-0662-4
   Vinardell MP, 2008, J PHARM SCI-US, V97, P46, DOI 10.1002/jps.21088
   Wever B De, 2015, APPL VITR TOXICOL, V1, P5, DOI DOI 10.1089/AIVT.2014.0011
NR 25
TC 10
Z9 10
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-2333
J9 TOXICOL IN VITRO
JI Toxicol. Vitro
PD AUG
PY 2017
VL 42
BP 31
EP 37
DI 10.1016/j.tiv.2017.03.010
PG 7
WC Toxicology
SC Toxicology
GA EY9FQ
UT WOS:000404304900004
PM 28344105
OA Bronze
DA 2020-12-08
ER

PT J
AU Montanha, MC
   Silva, LL
   Pangoni, FBB
   Cesar, GB
   Goncalves, RS
   Caetano, W
   Hioka, N
   Tominaga, TT
   Consolaro, MEL
   Diniz, A
   Kimura, E
AF Montanha, Maiara Camotti
   Silva, Larissa Lachi
   Borghi Pangoni, Fernanda Belincanta
   Cesar, Gabriel Batista
   Goncalves, Renato Sonchini
   Caetano, Wilker
   Hioka, Noboru
   Tominaga, Tania Toyomi
   Lopes Consolaro, Marcia Edilaine
   Diniz, Andrea
   Kimura, Elza
TI Response surface method optimization of a novel Hypericin formulation in
   P123 micelles for colorectal cancer and antimicrobial photodynamic
   therapy
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE Hypericin; Pluronics P123; Nanoencapsulation; Photodynamic therapy;
   Intestinal bacteria; Cytotoxicity activity
ID IN-VITRO; COPOLYMERS; CELLS; PHOTOSENSITIZER; SOLUBILIZATION;
   APPLICABILITY; LOCALIZATION; AGGREGATION; REGRESSION; POLYMER
AB The photodynamic properties of Hypericin (Hyp) may be used as an alternative treatment for malignancies of the lower gastrointestinal tract and for the prevention of surgical-site infection; however, its use in photodynamic therapy has been limited because of its poor hydrosolubility. Therefore, in order to improve its water solubility and its photodynamic effect, Hyp was encapsulated in Pluronic P123 (P123) and the photodynamic effects against intestinal and epidermal bacteria and against two lineages of intestinal colon carcinoma cells were investigated. Two response surface methods (RSM) were used to achieve the best in vitro photodynamic activity against Enterococcus faecalis, Escherichia coil and Staphylococcus nitrous: in the first (full 2(3) RSM), Hyp concentration (HC*), incubation time (IT*) and LED-light time (LT*) were considered as the independent variables and E. faecalis inhibition as the dependent variable. In the second (full 3(2) RSM), Hyp concentration (HC*) and P123 concentration (CC*) were considered as independent variables and E. faecalis, E. coli and S. aureus inhibition as dependent variables. The optimized experimental conditions achieved were: Hyp concentration = 37.5 mu mol/L; P123 concentration = 21.5 mu mol/L and 6.3 J/cm(2), which resulted in 2.86 +/- 0.12 and 2.30 +/- 0.31 CFU log-reductions of E. faecalis and S. aureus. No effect was seen against E. coli. The cytotoxic effects of Hyp/P123 were also investigated for Caco-2 and HT-29 intestinal colon carcinoma cells at Hyp/P123 concentrations of 1, 0.5, 0.25 and 0.1 mu mol/L for Caco-2 cells and 4, 3, 2 and 1 mu mol/L for HT 29 cells. The cytotoxic concentrations for 50% (CC50) and 90% (CC90) of Hyp/P123 were 0.443 and 0.870 mu mol/L for Caco-2 cells and 1.4 and 2.84 mu mol/L for HT-29 cells. The P123 nanocarrier played a significant role in the permeation of Hyp through the cell membrane leading to significant cell death, and showed itself to be a promising photosensitizer for PDT that could be suitable for the treatment of colonic diseases since it is effective against positive Gram bacteria and intestinal colon carcinoma cells.
C1 [Montanha, Maiara Camotti; Silva, Larissa Lachi; Borghi Pangoni, Fernanda Belincanta; Diniz, Andrea; Kimura, Elza] Univ Estadual Maringa, Dept Pharm, Maringa, Parana, Brazil.
   [Cesar, Gabriel Batista; Goncalves, Renato Sonchini; Caetano, Wilker; Hioka, Noboru] Univ Estadual Maringa, Dept Chem, Maringa, Parana, Brazil.
   [Tominaga, Tania Toyomi] Univ Estadual Centro Oeste, Dept Phys, Guarapuava, Parana, Brazil.
   [Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Clin Anal & Biomed, Maringa, Parana, Brazil.
RP Kimura, E (corresponding author), Hosp Univ, Ave Mandacaru,1590, BR-87083240 Maringa, Parana, Brazil.
EM ekimura@uem.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Kimura, Elza/B-4690-2015
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Hioka,
   Noboru/0000-0003-0775-5839; Batista, Gabriel/0000-0003-2536-5236;
   Camotti Montanha, Maiara/0000-0002-2078-360X
FU National Council of Technological and Scientific Development Foundation,
   Brazil [CNPq - 477272/2012-6]; Parana State Science and Technology
   Secretariat, Brazil [UGF-SETI-PR - TC75/2012]
FX This work was supported by the National Council of Technological and
   Scientific Development Foundation (CNPq - 477272/2012-6) and Parana
   State Science and Technology Secretariat (UGF-SETI-PR - TC75/2012),
   Brazil.
CR Alalchov V., 1999, COLLOID SURFACE B, V16, P113
   Apaydin EA, 2016, SYST REV, V5, DOI 10.1186/s13643-016-0325-2
   Batista G. Cesar, 2014, THESIS, P27
   Borghi-Pangoni FB, 2016, LAT AM J PHARM, V35, P2125
   Box G. P., 1960, TECHNOMETRICS, V2, P456, DOI DOI 10.1080/00401706.1960.10489912
   BOX GE, 1961, TECHNOMETRICS, V3, P311, DOI 10.2307/1266725
   Delcanale P, 2015, SCI REP-UK, V5, DOI 10.1038/srep15564
   Feinweber D, 2014, PHOTOCH PHOTOBIO SCI, V13, P1607, DOI 10.1039/c4pp00251b
   Gu QR, 2013, J BIOMATER APPL, V28, P298, DOI 10.1177/0885328212446822
   Huang LF, 2014, CHIN J NAT MEDICINES, V12, P81, DOI 10.1016/S1875-5364(14)60014-5
   Kadam Y, 2011, COLLOID SURFACE B, V83, P49, DOI 10.1016/j.colsurfb.2010.10.041
   Kadam Y, 2009, COLLOID SURFACE B, V72, P141, DOI 10.1016/j.colsurfb.2009.03.027
   Kawczyk-Krupka A, 2015, PHOTODIAGN PHOTODYN, V12, P545, DOI 10.1016/j.pdpdt.2015.04.004
   Kleban J, 2006, J PHOTOCH PHOTOBIO B, V84, P79, DOI 10.1016/j.jphotobiol.2006.02.003
   Leonhartsberger JG, 2002, MONATSH CHEM, V133, P167, DOI 10.1007/s706-002-8246-x
   Lima AM, 2013, J PHOTOCH PHOTOBIO B, V125, P146, DOI 10.1016/j.jphotobiol.2013.05.010
   Liu XJ, 2015, J PHARM SCI-US, V104, P215, DOI 10.1002/jps.24230
   de Melo WDMA, 2013, PHOTODIAGN PHOTODYN, V10, P647, DOI 10.1016/j.pdpdt.2013.08.001
   Nafee N, 2013, INT J PHARMACEUT, V454, P249, DOI 10.1016/j.ijpharm.2013.06.067
   Nelson H, 2001, JNCI-J NATL CANCER I, V93, P583, DOI 10.1093/jnci/93.8.583
   Penjweini R, 2015, J CONTROL RELEASE, V218, P82, DOI 10.1016/j.jconrel.2015.09.064
   Penjweini R, 2013, PHOTODIAGN PHOTODYN, V10, P591, DOI 10.1016/j.pdpdt.2013.06.005
   Sanovic R, 2011, PHOTODIAGN PHOTODYN, V8, P291, DOI 10.1016/j.pdpdt.2011.04.003
   Sperandio Felipe F, 2013, Recent Pat Antiinfect Drug Discov, V8, P108
   Suloglu AK, 2015, CYTOTECHNOLOGY, V67, P311, DOI 10.1007/s10616-013-9688-6
   Van de Putte M, 2005, BRIT J CANCER, V92, P1406, DOI 10.1038/sj.bjc.6602512
   WANKA G, 1994, MACROMOLECULES, V27, P4145, DOI 10.1021/ma00093a016
   Yow CMN, 2012, PHOTOCHEM PHOTOBIOL, V88, P626, DOI 10.1111/j.1751-1097.2012.01085.x
   Zhang W, 2013, CARBOHYD POLYM, V95, P366, DOI 10.1016/j.carbpol.2013.03.020
   Zhang XC, 1996, INT J PHARM, V132, P195, DOI 10.1016/0378-5173(95)04386-1
   Zhu TC, 2008, MED PHYS, V35, P3127, DOI 10.1118/1.2937440
NR 31
TC 22
Z9 22
U1 1
U2 21
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD MAY
PY 2017
VL 170
BP 247
EP 255
DI 10.1016/j.jphotobiol.2017.04.008
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA EX8OW
UT WOS:000403511100030
PM 28454049
DA 2020-12-08
ER

PT J
AU Damke, E
   Kurscheidt, FA
   Balani, VA
   Takeda, KI
   Irie, MMT
   Gimenes, F
   Consolaro, MEL
AF Damke, Edilson
   Kurscheidt, Fabio A.
   Balani, Valerio A.
   Takeda, Karen I.
   Irie, Mary M. T.
   Gimenes, Fabricia
   Consolaro, Marcia E. L.
TI Male Partners of Infertile Couples with Seminal Infections of Human
   Papillomavirus Have Impaired Fertility Parameters
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID SPERM INFECTION; HPV-DNA; SEMEN; PREVALENCE; VIRUS; RISK; MEN;
   GENOTYPES; DETECT
AB Several studies have addressed the impact of viral infections on male infertility. However, it is still unknown whether human papillomavirus (HPV) can alter seminal parameters. The aim of this study was to determine the prevalence of HPV in the semen of male partners of couples seeking fertility evaluation. Additionally, we assessed the possibility that HPV infections affect seminal parameters. A total of 229 semen samples were collected from men in the Sperm Analysis Section of Sao Camilo Laboratory of Maringa, Brazil, between October 2015 and March 2016. Basic seminal parameters were analyzed, and HPV was detected and genotyped by polymerase chain reaction. HPV DNA was detected in 16.6% of samples. Of these, 10.5% had single type HPV infections, 6.1% had multiple HPV infections, 5.7% had exclusively high-risk HPV, and 6.1% had exclusively low-risk HPV. Samples positive for single and multiple types of HPV were associated with abnormal viscosity, and samples positive for multiple HPV types were also associated with hypospermia, higher pH, and increased leukocyte numbers. These findings suggest that the male partners of infertile couples with seminal HPV infections may have prostate disturbances indicative of glandular dysfunction, which may influence fertility.
C1 [Damke, Edilson; Kurscheidt, Fabio A.; Irie, Mary M. T.; Gimenes, Fabricia; Consolaro, Marcia E. L.] Univ Estadual Maringa, Clin Cytol & STD Lab, Dept Clin Anal & Biomed, Maringa, PR, Brazil.
   [Kurscheidt, Fabio A.; Balani, Valerio A.; Takeda, Karen I.] Sao Camilo Lab, Sperm Anal Sect, Maringa, PR, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Clin Cytol & STD Lab, Dept Clin Anal & Biomed, Maringa, PR, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Kurscheidt,
   Fabio/0000-0002-0863-7765
CR BARCHAMA N, 1994, UROL CLIN N AM, V21, P469
   Bayasgalan G, 2004, ASIAN J ANDROL, V6, P305
   Bezold G, 2007, FERTIL STERIL, V87, P1087, DOI 10.1016/j.fertnstert.2006.08.109
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   BUKOVSKY A, 1991, FERTIL STERIL, V55, P595
   Capra G, 2015, EUR REV MED PHARMACO, V19, P4153
   Chen LH, 2013, J MED VIROL, V85, P1229, DOI 10.1002/jmv.23582
   COMHAIRE FH, 1989, J ANDROL, V10, P50
   Dunne EF, 2006, J INFECT DIS, V194, P1044, DOI 10.1086/507432
   Faridi R, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-269
   Foresta C, 2015, ANDROLOGY-US, V3, P163, DOI 10.1111/andr.284
   Foresta C, 2010, FERTIL STERIL, V93, P802, DOI 10.1016/j.fertnstert.2008.10.050
   Garolla A, 2016, FERTIL STERIL, V105, P65, DOI 10.1016/j.fertnstert.2015.09.018
   Gimenes F, 2014, NAT REV UROL, V11, P672, DOI 10.1038/nrurol.2014.285
   Gimenes F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098862
   Gizzo S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/230263
   Golob B, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/956901
   GONZALES GF, 1993, ARCH ANDROLOGY, V30, P63, DOI 10.3109/01485019308988370
   Gonzales GF, 2001, ASIAN J ANDROL, V3, P251
   Kapranos N, 2003, FERTIL STERIL, V79, P1566, DOI 10.1016/S0015-0282(03)00370-4
   Kaspersen MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018095
   Lai YM, 1997, FERTIL STERIL, V67, P1152, DOI 10.1016/S0015-0282(97)81454-9
   Laprise C, 2014, HUM REPROD, V29, P640, DOI 10.1093/humrep/det453
   Luttmer R, 2016, HUM REPROD, V31, P280, DOI 10.1093/humrep/dev317
   MANOS MM, 1994, J INFECT DIS, V170, P1096, DOI 10.1093/infdis/170.5.1096
   Monsonego J, 2015, GYNECOL ONCOL, V137, P47, DOI 10.1016/j.ygyno.2015.01.551
   Pekler VA, 2003, J CLIN LAB ANAL, V17, P264, DOI 10.1002/jcla.10107
   Perino A, 2011, FERTIL STERIL, V95, P1845, DOI 10.1016/j.fertnstert.2010.11.047
   Rintala MAM, 2004, INT J STD AIDS, V15, P740, DOI 10.1258/0956462042395122
   Robert M, 1995, MOL HUM REPROD, V1, P292, DOI 10.1093/molehr/1.6.292
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
   Schillaci R, 2013, FERTIL STERIL, V100, P1236, DOI 10.1016/j.fertnstert.2013.06.042
   WHO, 2010, WHO LAB MAN EXAM PRO
   Wortley PM, 1998, OBSTET GYNECOL, V91, P515, DOI 10.1016/S0029-7844(98)00040-4
   Yang Y, 2013, ASIAN J ANDROL, V15, P529, DOI 10.1038/aja.2013.36
NR 35
TC 6
Z9 6
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2017
VL 2017
AR 4684629
DI 10.1155/2017/4684629
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA FC2ZJ
UT WOS:000406707500001
PM 28835893
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Francisco, LMB
   Costa, YTC
   Outuki, PM
   Souza, RP
   Mendonca, PDB
   Novello, CR
   Consolaro, MEL
   Bruschi, ML
AF Belloto de Francisco, Lizziane Maria
   Caner Costa, Yeda Thamiris
   Outuki, Priscila Miyuki
   Souza, Raquel Pantarotto
   Bonfim Mendonca, Patricia de Souza
   Novello, Claudio Roberto
   Lopes Consolaro, Marcia Edilaine
   Bruschi, Marcos Luciano
TI Nanoparticles of Waste Material of Propolis and Gelatin as a Novel
   System for Delivery of L-Ascorbic Acid
SO CURRENT DRUG DELIVERY
LA English
DT Article
DE Antioxidant activity; drug release; gelatin; L-ascorbic acid;
   nanoparticles; physicochemical properties; propolis byproduct
ID IN-VITRO; ENCAPSULATION EFFICIENCY; ANTIOXIDANT ACTIVITY; RELEASE;
   EXTRACTS; MICROPARTICLES; COMPOSITES; CHEMISTRY; CARRIERS; THERAPY
AB Background: The waste material from the preparation of propolis extracts is a potential natural compound for application in pharmaceutical and medicine nanostructured products. Ascorbic acid is an excellent antioxidant and an important cofactor of several physiological and biochemical processes.
   Objective: The aim of this study was to develop and characterize nanoparticles containing L-ascorbic acid prepared with propolis byproduct.
   Method: Nanoparticle's physicochemical characteristics (surface morphology, particle size, zeta potential, and entrapment efficiency), antioxidant activity, in vitro release profile, and in vitro cytotoxicity were evaluated.
   Results: Nanoparticles showed to be spherical, with agglomeration, mean diameter between 110.93 and 480.59 nm, zeta potential near zero and good entrapment efficiency. Antioxidant activity of L-ascorbic acid increased when nanoencapsulated and the drug release was prolonged, controlled mainly by the phenomenon of relaxation of polymer chains and dependent of propolis residue concentration. The application of technology provided a reduction in the level of cytotoxicity of L-ascorbic acid, and the nanoparticles showed a protective effect on macrophages.
C1 [Belloto de Francisco, Lizziane Maria; Caner Costa, Yeda Thamiris; Novello, Claudio Roberto; Bruschi, Marcos Luciano] Univ Estadual Maringa, Dept Pharm, Lab Res & Dev Drug Delivery Syst, Postgrad Program Pharmaceut Sci, Maringa, Parana, Brazil.
   [Outuki, Priscila Miyuki] Univ Estadual Maringa, Dept Pharm, Lab Qual Control & Dev Phytotherap, Postgrad Program Pharmaceut Sci, Maringa, Parana, Brazil.
   [Souza, Raquel Pantarotto; Bonfim Mendonca, Patricia de Souza; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Clin Anal & Biomed, Lab Clin Cytol & STDs, Maringa, Parana, Brazil.
   Univ Estadual Maringa, Dept Clin Anal & Biomed, Lab Med Mycol, Maringa, Parana, Brazil.
RP Bruschi, ML (corresponding author), Univ Estadual Maringa, Dept Pharm, Colombo Ave 5790,K68,S05, BR-87020900 Maringa, Parana, Brazil.
EM mlbruschi@uem.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Bruschi, Marcos
   Luciano/J-1871-2012
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Bruschi, Marcos
   Luciano/0000-0002-4838-5742
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico/National Council of Scientific and Technological
   Development) [470965-2013-4]; CAPES (Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior/Coordination for the Improvement of Higher
   Education)CAPES; FINEP (Financiadora de Estudos e Projetos/Financier of
   Studies and Projects)
FX The authors are grateful to CNPq (Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico/National Council of Scientific and
   Technological Development; Grants no 470965-2013-4), CAPES (Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior/Coordination for the
   Improvement of Higher Education), and FINEP (Financiadora de Estudos e
   Projetos/Financier of Studies and Projects) for their financial support.
CR Alhnan MA, 2011, EUR J PHARM BIOPHARM, V79, P432, DOI 10.1016/j.ejpb.2011.03.015
   Ashori A, 2008, BIORESOURCE TECHNOL, V99, P4661, DOI 10.1016/j.biortech.2007.09.043
   Avanco G. B., 2008, Revista de Ciencias Farmaceuticas Basica e Aplicada, V29, P129
   Balata G, 2014, DRUG DELIV, V21, P55, DOI 10.3109/10717544.2013.847032
   Bankova VS, 2000, APIDOLOGIE, V31, P3, DOI 10.1051/apido:2000102
   Aguero MB, 2014, IND CROP PROD, V57, P166, DOI 10.1016/j.indcrop.2014.03.009
   Bruschi M. L., 2004, J BASIC APPL SCI, V25, P79
   Bruschi M. L., 2002, J BASIC APP PHARM SC, V23, P289
   Bruschi ML, 2007, J PHARM SCI-US, V96, P2074, DOI 10.1002/jps.20843
   Bruschi Marcos L, 2015, Recent Pat Drug Deliv Formul, V9, P79
   Bruschi ML, 2003, INT J PHARM, V264, P45, DOI 10.1016/S0378-5173(03)00386-7
   Burdock GA, 1998, FOOD CHEM TOXICOL, V36, P347, DOI 10.1016/S0278-6915(97)00145-2
   Comunian TA, 2014, FOOD CHEM, V152, P271, DOI 10.1016/j.foodchem.2013.11.149
   Cortesi R, 2002, BIOMATERIALS, V23, P2283, DOI 10.1016/S0142-9612(01)00362-3
   COUVREUR P, 1995, EUR J PHARM BIOPHARM, V41, P2
   de Francisco LMB, 2013, DRUG DEV IND PHARM, V39, P1644, DOI 10.3109/03639045.2012.728610
   dos Santos RM, 2013, IND CROP PROD, V50, P707, DOI 10.1016/j.indcrop.2013.08.049
   Dota KF, 2011, EVID-BASED COMPL ALT, V2011
   Duymus HG, 2014, FOOD CHEM, V155, P112, DOI 10.1016/j.foodchem.2014.01.028
   Farahnaky A, 2003, FOOD HYDROCOLLOID, V17, P321, DOI 10.1016/S0268-005X(02)00093-0
   Florence A.T., 2006, PHYSICOCHEMICAL PRIN
   Gregoris E, 2011, INT J PHARMACEUT, V405, P97, DOI 10.1016/j.ijpharm.2010.11.052
   Gugulothu D, 2014, J PHARM SCI-US, V103, P687, DOI 10.1002/jps.23828
   Hasirci V., 2011, COMPREHENSIVE BIOMAT
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Hill S. E., 1998, MAILLARD REACTION FO
   ICH, 2005, VAL AN PROC TEXT MET
   Isla MI, 2001, J ETHNOPHARMACOL, V76, P165, DOI 10.1016/S0378-8741(01)00231-8
   Istenic K, 2015, J FOOD ENG, V167, P196, DOI 10.1016/j.jfoodeng.2015.04.007
   Jyothi NVN, 2010, J MICROENCAPSUL, V27, P187, DOI 10.3109/02652040903131301
   Kabir F, 2015, FOOD CHEM, V167, P358, DOI 10.1016/j.foodchem.2014.06.099
   Lee JB, 2004, BIOSCI BIOTECH BIOCH, V68, P495, DOI 10.1271/bbb.68.495
   Lenardao EJ, 2003, QUIM NOVA, V26, P123, DOI 10.1590/S0100-40422003000100020
   List P. H., 1989, PHYTOPHARMACEUTICAL
   Lopes Carla Martins, 2005, Rev. Bras. Cienc. Farm., V41, P143, DOI 10.1590/S1516-93322005000200003
   LYKLEMA J, 2000, FUNDAMENTALS INTERFA, V1
   Machado JL, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/157652
   Maia AM, 2007, TALANTA, V71, P639, DOI 10.1016/j.talanta.2006.05.006
   Marcucci MC, 2001, J ETHNOPHARMACOL, V74, P105, DOI 10.1016/S0378-8741(00)00326-3
   Metaxa AF, 2014, MATER LETT, V132, P432, DOI 10.1016/j.matlet.2014.06.134
   MILLER NJ, 1993, CLIN SCI, V84, P407, DOI 10.1042/cs0840407
   Ng SM, 2010, INT J PHARMACEUT, V384, P120, DOI 10.1016/j.ijpharm.2009.10.005
   Pathak Y, 2009, DRUG DELIVERY NANOPA
   Pereira RRA, 2013, LAT AM J PHARM, V32, P719
   Phillips KM, 2010, J FOOD COMPOS ANAL, V23, P253, DOI 10.1016/j.jfca.2009.08.018
   Piao HY, 2011, INT J PHARMACEUT, V420, P156, DOI 10.1016/j.ijpharm.2011.08.025
   Pierucci APTR, 2006, J MICROENCAPSUL, V23, P654, DOI 10.1080/02652040600776523
   Campos EVR, 2013, J PHARM SCI-US, V102, P215, DOI 10.1002/jps.23350
   Reis CP, 2006, NANOMED-NANOTECHNOL, V2, P8, DOI 10.1016/j.nano.2005.12.003
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168-3659(87)90035-6
   Pereira HVR, 2009, FOOD RES INT, V42, P115, DOI 10.1016/j.foodres.2008.10.008
   Rowe C. R., 2012, HDB PHARM EXCIPIENTS, P1033
   Rufino M.D.S.M., 2007, SCI METHODOLOGY DETE
   de Toledo LDS, 2016, CURR DRUG DELIV, V13, P1152, DOI 10.2174/1567201813666151113121827
   de Funari CS, 2007, J ETHNOPHARMACOL, V111, P206, DOI 10.1016/j.jep.2006.11.032
   Sosnik A, 2014, ADV DRUG DELIVER REV, V73, P140, DOI 10.1016/j.addr.2014.05.004
   Sulaiman GM, 2011, FOOD CHEM TOXICOL, V49, P2415, DOI 10.1016/j.fct.2011.06.060
   Tanaka A, 2014, J VASC SURG, V60, P749, DOI 10.1016/j.jvs.2013.07.013
   Rego MMT, 2010, REV BRAS ZOOTECN, V39, P2281, DOI 10.1590/S1516-35982010001000026
   Thaipong K, 2006, J FOOD COMPOS ANAL, V19, P669, DOI 10.1016/j.jfca.2006.01.003
   Thakur VK, 2014, CARBOHYD POLYM, V109, P102, DOI 10.1016/j.carbpol.2014.03.039
   Uddin MS, 2001, J MICROENCAPSUL, V18, P199
   Victor VV, 2000, IMMUNOPHARMACOLOGY, V46, P89, DOI 10.1016/S0162-3109(99)00162-9
   Villa Nova M., 2013, DRUG DEV IND PHARM, P1
   Zhang ZP, 2006, BIOMATERIALS, V27, P4025, DOI 10.1016/j.biomaterials.2006.03.006
NR 65
TC 7
Z9 7
U1 1
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2018
EI 1875-5704
J9 CURR DRUG DELIV
JI Curr. Drug Deliv.
PY 2017
VL 14
IS 7
BP 1028
EP 1039
DI 10.2174/1570159X14666160322144315
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA FQ1IP
UT WOS:000418111000013
PM 27067407
DA 2020-12-08
ER

PT J
AU Souza, RP
   Bonfim-Mendonca, PD
   Gimenes, F
   Ratti, BA
   Kaplum, V
   Bruschi, ML
   Nakamura, CV
   Silva, SO
   Maria-Engler, SS
   Consolaro, MEL
AF Souza, Raquel P.
   Bonfim-Mendonca, Patricia de S.
   Gimenes, Fabricia
   Ratti, Bianca A.
   Kaplum, Vanessa
   Bruschi, Marcos L.
   Nakamura, Celso V.
   Silva, Sueli O.
   Maria-Engler, Silvya S.
   Consolaro, Marcia E. L.
TI Oxidative Stress Triggered by Apigenin Induces Apoptosis in a
   Comprehensive Panel of Human Cervical Cancer-Derived Cell Lines
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID HUMAN LUNG-CANCER; GROWTH-FACTOR; IN-VITRO; HUMAN-PAPILLOMAVIRUS; CYCLE
   ARREST; FLAVONOIDS; CARCINOMA; INHIBITION; ACTIVATION; ADENOCARCINOMA
AB Recently, the cytotoxic effects of apigenin (4',5,7-trihydroxyflavone), particularly its marked inhibition of cancer cell viability both in vitro and in vivo, have attracted the attention of the anticancer drug discovery field. Despite this, there are few studies of apigenin in cervical cancer, and these studies have mostly been conducted using HeLa cells. To evaluate the possibility of apigenin as a new therapeutic candidate for cervical cancer, we evaluated its cytotoxic effects in a comprehensive panel of human cervical cancer-derived cell lines including HeLa (human papillomavirus/HPV 18-positive), SiHa (HPV 16-positive), CaSki (HPV 16 and HPV 18-positive), and C33A (HPV-negative) cells in comparison to a nontumorigenic spontaneously immortalized human epithelial cell line (HaCaT). Our results demonstrated that apigenin had a selective cytotoxic effect and could induce apoptosis in all cervical cancer cell lines which were positively marked with Annexin V, but not in HaCaT (control cells). Additionally, apigenin was able to induce mitochondrial redox impairment, once it increased ROS levels and H2O2, decreased the Delta psi m, and increased LPO. Still, apigenin was able to inhibit migration and invasion of cancer cells. Thus, apigenin appears to be a promising new candidate as an anticancer drug for cervical cancer induced by different HPV genotypes.
C1 [Souza, Raquel P.; Gimenes, Fabricia; Ratti, Bianca A.; Silva, Sueli O.; Consolaro, Marcia E. L.] Univ Estadual Maringa, Postgrad Program Bioscience & Physiopathol, Av Colombo 5790, BR-87025210 Maringa, Parana, Brazil.
   [Souza, Raquel P.; Bonfim-Mendonca, Patricia de S.; Gimenes, Fabricia; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol & STD Lab, Av Colombo 5790, BR-87025210 Maringa, Parana, Brazil.
   [Kaplum, Vanessa; Bruschi, Marcos L.; Nakamura, Celso V.; Silva, Sueli O.] Univ Estadual Maringa, Postgrad Program Pharmaceut Sci, Lab Res & Dev Drug Delivery Syst, Av Colombo 5790, BR-87025210 Maringa, Parana, Brazil.
   [Maria-Engler, Silvya S.; Consolaro, Marcia E. L.] Univ Sao Paulo, Postgrad Program Pharmaceut Sci, Clin Anal Area, Av Lineu Prestes 580, BR-05508900 Sao Paulo, SP, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Postgrad Program Bioscience & Physiopathol, Av Colombo 5790, BR-87025210 Maringa, Parana, Brazil.; Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol & STD Lab, Av Colombo 5790, BR-87025210 Maringa, Parana, Brazil.; Consolaro, MEL (corresponding author), Univ Sao Paulo, Postgrad Program Pharmaceut Sci, Clin Anal Area, Av Lineu Prestes 580, BR-05508900 Sao Paulo, SP, Brazil.
EM melconsolaro@gmail.com
RI Bruschi, Marcos Luciano/J-1871-2012; Maria-Engler, Silvya/ABC-2016-2020;
   Lautenschlager, Sueli OS/P-2164-2017; Nakamura, Celso
   Vataru/AAA-5620-2019; Engler, Silvya Stuchi Maria/K-5936-2016;
   Consolaro, Marcia Edilaine Lopes/I-4932-2014; Bonfim-Mendonca,
   Patricia/C-1658-2019
OI Bruschi, Marcos Luciano/0000-0002-4838-5742; Maria-Engler,
   Silvya/0000-0003-4771-6041; Lautenschlager, Sueli
   OS/0000-0001-9303-0804; Engler, Silvya Stuchi Maria/0000-0003-4771-6041;
   Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Bonfim-Mendonca,
   Patricia/0000-0002-0116-2189
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel superior
   (CAPES)CAPES; Brazilian Government [PVE A109/2013, PROCAD
   88881.068413/2014-01]; Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq) [CNPq 470040/2014-9]
FX This work was supported by grants from Coordenacao de Aperfeicoamento de
   Pessoal de Nivel superior (CAPES), Brazilian Government (PVE A109/2013
   and PROCAD 88881.068413/2014-01) and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq 470040/2014-9).
CR Agati G, 2012, PLANT SCI, V196, P67, DOI 10.1016/j.plantsci.2012.07.014
   Banerjee K, 2015, REDOX BIOL, V5, P153, DOI 10.1016/j.redox.2015.04.009
   Beckenkamp A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134305
   Birt DF, 2001, PHARMACOL THERAPEUT, V90, P157, DOI 10.1016/S0163-7258(01)00137-1
   Britta EA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041440
   Budavari S, 1997, MERCK INDEX
   BUENING MK, 1981, CANCER RES, V41, P67
   Buer CS, 2010, J INTEGR PLANT BIOL, V52, P98, DOI 10.1111/j.1744-7909.2010.00905.x
   Chakrabarti A., 2012, LIFE SCI, V16, P403
   Cragg GM, 2013, BBA-GEN SUBJECTS, V1830, P3670, DOI 10.1016/j.bbagen.2013.02.008
   CZECZOT H, 1990, MUTAT RES, V240, P209, DOI 10.1016/0165-1218(90)90060-F
   Czyz J, 2005, INT J CANCER, V114, P12, DOI 10.1002/ijc.20620
   Das S, 2012, EXP BIOL MED, V237, P1433, DOI 10.1258/ebm.2012.012148
   Avelino-Flores MD, 2015, J MED FOOD, V18, P299, DOI 10.1089/jmf.2013.0055
   DIMEO S, 2016, OXID MED CELL LONGEV, V2016, DOI DOI 10.1155/2016/1245049
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Garcia FP, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/940531
   Gary RK, 2005, ANAL BIOCHEM, V343, P329, DOI 10.1016/j.ab.2005.06.003
   Gupta S, 2001, BIOCHEM BIOPH RES CO, V287, P914, DOI 10.1006/bbrc.2001.5672
   Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031-9422(00)00235-1
   Hernandez-Flores G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-483
   Horvathova K, 2004, NEOPLASMA, V51, P395
   Huang WY, 2010, NUTR CANCER, V62, P1, DOI 10.1080/01635580903191585
   IARC, 2012, GLOB 2012 EST INC MO
   Iqbal B, 2016, J CLIN DIAGN RES, V10, pXC1, DOI 10.7860/JCDR/2016/18507.7579
   Jagetia GC, 2005, LIFE SCI, V77, P780, DOI 10.1016/j.lfs.2005.01.015
   Jayasooriya RGPT, 2012, FOOD CHEM TOXICOL, V50, P2605, DOI 10.1016/j.fct.2012.05.024
   Jeyabal PVS, 2005, MOL CARCINOGEN, V44, P11, DOI 10.1002/mc.20115
   Ju SM, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/186436
   Khalil J, 2015, Gynecol Oncol Res Pract, V2, P7, DOI 10.1186/s40661-015-0011-4
   Kim JS, 2015, ONCOTARGET, V6, P16746, DOI 10.18632/oncotarget.3796
   Kjaer SK, 2010, JNCI-J NATL CANCER I, V102, P1478, DOI 10.1093/jnci/djq356
   Kobayashi T, 2002, CANCER LETT, V176, P17, DOI 10.1016/S0304-3835(01)00738-8
   Koh WJ, 2015, J NATL COMPR CANC NE, V13, P1321, DOI 10.6004/jnccn.2015.0162
   Kumar S, 2013, SCI WORLD J, DOI 10.1155/2013/162750
   Laberge RM, 2007, BIOCHEM PHARMACOL, V73, P1727, DOI 10.1016/j.bcp.2007.02.005
   Lepiniec L, 2006, ANNU REV PLANT BIOL, V57, P405, DOI 10.1146/annurev.arplant.57.032905.105252
   Li CH, 2013, J NUTR BIOCHEM, V24, P1766, DOI 10.1016/j.jnutbio.2013.03.006
   Li HL, 2002, WORLD J GASTROENTERO, V8, P431, DOI 10.3748/wjg.v8.i3.431
   Li SW, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0334-1
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Lim W, 2016, J CELL PHYSIOL, V231, P2690, DOI 10.1002/jcp.25372
   Lindenmeyer F, 2001, NUTR CANCER, V39, P139, DOI 10.1207/S15327914nc391_19
   Liu J, 2015, MOL MED REP, V11, P665, DOI 10.3892/mmr.2014.2720
   Liu LZ, 2005, MOL PHARMACOL, V68, P635, DOI 10.1124/mol.105.011254
   Llorens F, 2004, EXP CELL RES, V299, P15, DOI 10.1016/j.yexcr.2004.05.006
   Lorusso D, 2014, GYNECOL ONCOL, V133, P117, DOI 10.1016/j.ygyno.2014.01.042
   Louis KS, 2011, METHODS MOL BIOL, V740, P7, DOI 10.1007/978-1-61779-108-6_2
   Lu HF, 2011, HUM EXP TOXICOL, V30, P1053, DOI 10.1177/0960327110386258
   Macville M, 1999, CANCER RES, V59, P141
   Maggioni D, 2013, INT J ONCOL, V43, P1675, DOI 10.3892/ijo.2013.2072
   Middleton E, 2000, PHARMACOL REV, V52, P673
   Morita M, 2016, REDOX BIOL, V8, P127, DOI 10.1016/j.redox.2016.01.005
   Nabavi SM, 2015, ANTI-CANCER AGENT ME, V15, P728, DOI 10.2174/1871520615666150304120643
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Nishikawa M, 2005, J CONTROL RELEASE, V109, P101, DOI 10.1016/j.jconrel.2005.09.017
   Noh HJ, 2010, ONCOL REP, V24, P277, DOI 10.3892/or_00000857
   Pani G, 2009, INT J BIOCHEM CELL B, V41, P1002, DOI 10.1016/j.biocel.2008.10.011
   Patel D, 2007, INT J ONCOL, V30, P233
   Ribeiro DA, 2005, INT J EXP PATHOL, V86, P375, DOI 10.1111/j.0959-9673.2005.00444.x
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Shi XF, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1249-z
   Shukla AK, 2012, EUR J MED CHEM, V54, P49, DOI 10.1016/j.ejmech.2012.04.034
   Shukla S, 2005, FASEB J, V19, P2042, DOI 10.1096/fj.05-3740fje
   Shukla S, 2012, PHARM RES-DORDR, V29, P1506, DOI 10.1007/s11095-011-0625-0
   SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x
   Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006/gyno.2000.5826
   Sun YM, 2014, J CHROMATOGR B, V962, P59, DOI 10.1016/j.jchromb.2014.05.027
   Szliszka E, 2009, MOLECULES, V14, P738, DOI [10.3390/molecules, 10.3390/molecules14020738]
   Tomin K, 2016, METHODS MOL BIOL, V1441, P65, DOI 10.1007/978-1-4939-3684-7_6
   Tong X, 2013, ANTI-CANCER AGENT ME, V13, P971, DOI 10.2174/18715206113139990119
   Urani C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/949514
   Valdameri G, 2011, CHEM-BIOL INTERACT, V193, P180, DOI 10.1016/j.cbi.2011.06.009
   Vizcaino AP, 1998, INT J CANCER, V75, P536, DOI 10.1002/(SICI)1097-0215(19980209)75:4<536::AID-IJC8>3.0.CO;2-U
   Wang WQ, 2000, MOL CARCINOGEN, V28, P102
   Way TD, 2004, J BIOL CHEM, V279, P4479, DOI 10.1074/jbc.M305529200
   Wright TC, 2007, AM J OBSTET GYNECOL, V197, P346, DOI 10.1016/j.ajog.2007.07.047
   Wu DG, 2014, TOXICOL LETT, V224, P157, DOI 10.1016/j.toxlet.2013.10.007
   Xiao ZP, 2011, MINI-REV MED CHEM, V11, P169, DOI 10.2174/138955711794519546
   Xu JM, 2013, MICROSC RES TECHNIQ, V76, P612, DOI 10.1002/jemt.22207
   Xu YM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029169
   Yao LH, 2004, PLANT FOOD HUM NUTR, V59, P113, DOI 10.1007/s11130-004-0049-7
   Yee SB, 2003, ARCH PHARM RES, V26, P151, DOI 10.1007/BF02976662
   Zheng PW, 2005, LIFE SCI, V76, P1367, DOI 10.1016/j.lfs.2004.08.023
   Zhu Y, 2015, MOL MED REP, V11, P1004, DOI 10.3892/mmr.2014.2801
NR 85
TC 16
Z9 16
U1 0
U2 11
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2017
VL 2017
AR 1512745
DI 10.1155/2017/1512745
PG 18
WC Cell Biology
SC Cell Biology
GA EK7PJ
UT WOS:000394117400001
PM 28191273
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Zanni, PCMD
   Bonfim-Mendonca, PD
   Negri, M
   Nakamura, SS
   Donatti, L
   Svidzinski, TIE
   Consolaro, MEL
AF Mastellaro Delvas Zanni, Pamela Cristina
   Bonfim-Mendonca, Patricia de Souza
   Negri, Melyssa
   Nakamura, Sandra Sayuri
   Donatti, Lucelia
   Estivalet Svidzinski, Terezinha Inez
   Lopes Consolaro, Marcia Edilaine
TI Virulence factors and genetic variability of vaginal Candida albicans
   isolates from HIV-infected women in the post-highly active
   antiretroviral era
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE Vulvovaginal candidiasis; Candida albicans; HIV; Virulence; Genetic
   variability
ID SECRETED ASPARTYL PROTEINASES; PATHOGENICITY; PROTEASE
AB Vulvovaginal candidiasis (VVC) in HIV-infected (HIV+) women is a serious public health problem. However, little is known about the virulence mechanisms of vaginal Candida albicans from HIV+ women in the post-highly active antiretroviral therapy (HAART) era. Here, we report a comparative analysis of the expression of key virulence factors and genetic variability of 26 vaginal C. albicans strains isolated from HIV+ women undergoing HAART and 18 from HIV-uninfected (HIV-) women. In general, we observed that C. albicans from HIV+ women receiving HAART showed lower expression of virulence factors compared with C. albicans from HIV-women, except for the proteinase activity which is highly expressed. The results in HIV-women further suggest that virulence factors appear to be expressed in response to the yeast stress, in the presence of an adequate immune response. Furthermore, the RAPD results showed a high heterogeneity among isolates from both groups of women. These findings in HIV+ women using HAART will help to improve the monitoring of vaginal yeast infections and the quality of life of patients.
C1 [Mastellaro Delvas Zanni, Pamela Cristina; Bonfim-Mendonca, Patricia de Souza; Negri, Melyssa; Nakamura, Sandra Sayuri; Estivalet Svidzinski, Terezinha Inez] Univ Estadual Maringa, Dept Anal Clin & Biomed, Lab Micol Med, Maringa, Parana, Brazil.
   [Donatti, Lucelia] Univ Fed Parana, Dept Biol Celular, Curitiba, Parana, Brazil.
   [Mastellaro Delvas Zanni, Pamela Cristina; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Anal Clin & Biomed, Lab Citol Clin, Av Colombo 5790,Zona 7, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin & Biomed, Lab Citol Clin, Av Colombo 5790,Zona 7, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Donatti,
   Lucelia/E-1930-2013
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Donatti,
   Lucelia/0000-0002-9023-2483
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Brazilian GovernmentCAPES [AUX-PE-PRODOC 2571/2010]
FX This work was supported by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES), Brazilian Government Grant [AUX-PE-PRODOC
   2571/2010].
CR Apalata T, 2014, ANN MED HEALTH SCI R, V4, P410, DOI 10.4103/2141-9248.133470
   Bonfim-Mendonca PD, 2013, REV INST MED TROP SP, V55, P385, DOI 10.1590/S0036-46652013000600003
   Brown AJP, 2014, J EXP BIOL, V217, P144, DOI 10.1242/jeb.088930
   da Costa KRC, 2012, MYCOSES, V55, pe97, DOI 10.1111/j.1439-0507.2011.02125.x
   Chong PP, 2003, J MED MICROBIOL, V52, P657, DOI 10.1099/jmm.0.04973-0
   Alczuk SDD, 2015, REV INST MED TROP SP, V57, P169, DOI 10.1590/S0036-46652015000200012
   DeBernardis F, 1996, INFECT IMMUN, V64, P466, DOI 10.1128/IAI.64.2.466-471.1996
   Enger L, 2001, J CLIN MICROBIOL, V39, P658, DOI 10.1128/JCM.39.2.658-669.2001
   Paiva LCF, 2010, MICROSC MICROANAL, V16, P537, DOI 10.1017/S1431927610093773
   Gruber A, 1999, IMMUNOPHARMACOLOGY, V41, P227, DOI 10.1016/S0162-3109(99)00035-1
   Hamad M, 2014, MYCOSES, V57, P184, DOI 10.1111/myc.12141
   Hammer KA, 2000, MED MYCOL, V38, P355, DOI 10.1080/mmy.38.5.354.361
   KLOTZ SA, 1985, INFECT IMMUN, V50, P97, DOI 10.1128/IAI.50.1.97-101.1985
   Korting HC, 1999, ANTIMICROB AGENTS CH, V43, P2038, DOI 10.1128/AAC.43.8.2038
   Kuriyama T, 2003, ORAL MICROBIOL IMMUN, V18, P405, DOI 10.1046/j.0902-0055.2002.00100.x
   Larone DH, 2011, MED IMPORTANT FUNGI
   Lederman MM, 2013, ADV IMMUNOL, V119, P51, DOI 10.1016/B978-0-12-407707-2.00002-3
   Lian C, 2004, MYCOSES, V47, P495, DOI 10.1111/j.1439-0507.2004.01049.x
   Lockhart SR, 1996, J CLIN MICROBIOL, V34, P767, DOI 10.1128/JCM.34.4.767-777.1996
   Lopes Consolaro Marcia Edilaine, 2004, Rev Iberoam Micol, V21, P202
   Mane A, 2013, MYCOSES, V56, P182, DOI 10.1111/myc.12002
   Mayer FL, 2013, VIRULENCE, V4, P119, DOI 10.4161/viru.22913
   Merenstein D, 2013, AIDS RES HUM RETROV, V29, P30, DOI [10.1089/aid.2012.0269, 10.1089/AID.2012.0269]
   Naglik JR, 2003, MICROBIOL MOL BIOL R, V67, P400, DOI 10.1128/MMBR.67.3.400-428.2003
   Naglik JR, 2003, J INFECT DIS, V188, P469, DOI 10.1086/376536
   Negri M, 2010, BRIT J BIOMED SCI, V67, P120
   Pascon Renata C, 2011, Enzyme Res, V2011, P679624, DOI 10.4061/2011/679624
   Ramage G, 2005, EUKARYOT CELL, V4, P633, DOI 10.1128/EC.4.4.633-638.2005
   Raut Jayant, 2010, Nihon Ishinkin Gakkai Zasshi, V51, P131, DOI 10.3314/jjmm.51.131
   Ray A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008739.pub2
   Richardson JP, 2015, VIRULENCE, V6, P327, DOI 10.1080/21505594.2015.1004977
   Samaranayake L. P., 1990, ORAL CANDIDOSIS
   Skrbec D, 2002, BIOCHEM BIOPH RES CO, V297, P1350, DOI 10.1016/S0006-291X(02)02372-0
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Sobel JD, 2002, INT J STD AIDS, V13, P358, DOI 10.1258/095646202760029741
   Spanu T, 2012, J CLIN MICROBIOL, V50, P176, DOI 10.1128/JCM.05742-11
   Van Tornout M, 2013, J CLIN PERIODONTOL, V40, P180, DOI 10.1111/jcpe.12031
   Zhao X, 2005, MICROBIOL-SGM, V151, P1619, DOI 10.1099/mic.0.27763-0
NR 38
TC 0
Z9 0
U1 0
U2 0
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PY 2017
VL 59
AR e44
DI 10.1590/S1678-9946201759044
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FD3IV
UT WOS:000407427600001
PM 28793015
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Santana, NDS
   Lima, NA
   Desoti, VC
   Bidoia, DL
   Mendonca, PDB
   Ratti, BA
   Nakamura, TU
   Nakamura, CV
   Consolaro, MEL
   Ximenes, VF
   Silva, SD
AF Scharf Santana, Natalia de Carvalho
   Lima, Natalia Alves
   Desoti, Vania Cristina
   Bidoia, Danielle Lazarin
   Bonfim Mendonca, Patricia de Souza
   Ratti, Bianca Altrao
   Nakamura, Tania Ueda
   Nakamura, Celso Vataru
   Lopes Consolaro, Marcia Edilaine
   Ximenes, Valdecir Farias
   Silva, Sueli de Oliveira
TI Vitamin K3 induces antiproliferative effect in cervical epithelial cells
   transformed by HPV 16 (SiHa cells) through the increase in reactive
   oxygen species production
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Human Papillomavirus; Vitamin K3; Apoptosis SiHa cells
ID UBIQUITIN-PROTEASOME SYSTEM; CANCER; DEGRADATION; METABOLISM; APOPTOSIS;
   ONCOPROTEIN; DYSFUNCTION; WARBURG
AB Cervical cancer is characterized as an important public health problem. According to latest estimates, cancer of the cervix is the fourth most common cancer among women. Due to its high prevalence, the search for new and efficient drugs to treat this infection is continuous. The progression of HPV-associated cervical cancer involves the expression of two viral proteins, E6 and E7, which are rapidly degraded by the ubiquitin-proteasome system through the increase in reactive oxygen species generation. Vitamins are essential to human substances, participate in the regulation of metabolism, and facilitate the process of energy transfer.
   Some early studies have indicated that vitamin K3 exerts antitumor activity by inducing cell death by apoptosis through an increase in the generation of reactive oxygen species. Thus, we evaluated the antiproliferative effect and a likely mechanism of action of vitamin K3 against cervical epithelial cells transformed by HPV 16 (SiHa cells) assessing the production of total ROS, the mitochondrial membrane potential, the cell morphology, the cell volume, and the cell membrane integrity.
   Our results show that vitamin K3 induces an increase in ROS production in SiHa cells, triggering biochemical and morphological events, such as depolarization of mitochondrial membrane potential and decreasing cell volume.
   Our data showed that vitamin K3 generates an oxidative imbalance in SiHa cells, leading to mechanisms that induce cell death by apoptosis.
C1 [Scharf Santana, Natalia de Carvalho; Lima, Natalia Alves; Ratti, Bianca Altrao] Univ Estadual Maringa, Programa Posgrad Biociencias Aplicadas Farm, Ave Colombo 5-790, BR-87020900 Maringa, Parana, Brazil.
   [Bonfim Mendonca, Patricia de Souza] Univ Estadual Maringa, Programa Posgrad Ciencias Saude, Ave Colombo 5-790, BR-87020900 Maringa, Parana, Brazil.
   [Desoti, Vania Cristina; Bidoia, Danielle Lazarin] Univ Estadual Maringa, Programa Posgrad Ciencias Farmaceut, Ave Colombo 5-790, BR-87020900 Maringa, Parana, Brazil.
   [Nakamura, Tania Ueda; Nakamura, Celso Vataru; Silva, Sueli de Oliveira] Univ Estadual Maringa, Dept Ciencias Basicas Saude, Ave Colombo 5-790,Bloco I-90, BR-87020900 Maringa, Parana, Brazil.
   [Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Anal Clin & Biomed, Ave Colombo 5-790, BR-87020900 Maringa, Parana, Brazil.
   [Ximenes, Valdecir Farias] Univ Estadual Paulista, Fac Ciencias, Dept Quim, Av Eng Luiz Edmundo Carrijo Coube S-N, BR-17033360 Bauru, SP, Brazil.
RP Silva, SD (corresponding author), Univ Estadual Maringa, Dept Ciencias Basicas Saude, Ave Colombo 5-790,Bloco I-90, BR-87020900 Maringa, Parana, Brazil.
EM lautenschlager@uem.br
RI Bidoia, Danielle Lazarin/AAQ-2024-2020; Desoti, Vania/AAC-6414-2020;
   Consolaro, Marcia Edilaine Lopes/I-4932-2014; Ximenes,
   Valdecir/A-5323-2008; Lautenschlager, Sueli OS/P-2164-2017; Nakamura,
   Celso Vataru/AAA-5620-2019
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Ximenes,
   Valdecir/0000-0003-2636-3080; Lautenschlager, Sueli
   OS/0000-0001-9303-0804; DESOTI, VANIA/0000-0002-2087-5248
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (Capes) e Fundacao Araucaria
FX This study was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (Capes) e Fundacao Araucaria.
CR Akiyoshi T, 2009, CANCER CHEMOTH PHARM, V65, P143, DOI 10.1007/s00280-009-1016-7
   Barbour JA, 2014, INT J CELL BIOL, V2014, P12, DOI DOI 10.1155/2014/156020
   Bonilla-Porras AR, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-19
   Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731
   Busk M, 2008, INT J CANCER, V122, P2726, DOI 10.1002/ijc.23449
   Chao A, 2014, CURR TREAT OPTION ON, V15, P1, DOI 10.1007/s11864-013-0273-1
   Chaturvedi AK, 2007, JNCI-J NATL CANCER I, V99, P1634, DOI 10.1093/jnci/djm201
   Franco R, 2009, CELL DEATH DIFFER, V16, P1303, DOI 10.1038/cdd.2009.107
   Held NM, 2015, BIOESSAYS, V37, P867, DOI 10.1002/bies.201500013
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Jing K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.477
   Khan AM, 2008, FUTURE ONCOL, V4, P515, DOI 10.2217/14796694.4.4.515
   Khan S, 2007, INT J INFECT DIS, V11, P313, DOI 10.1016/j.ijid.2006.06.007
   Kitano T, 2012, BIOL PHARM BULL, V35, P617, DOI 10.1248/bpb.35.617
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Lim HY, 2011, MITOCHONDRION, V11, P437, DOI 10.1016/j.mito.2010.12.015
   Matzno S, 2008, BIOL PHARM BULL, V31, P1270, DOI 10.1248/bpb.31.1270
   Monteiro JP, 2013, BBA-BIOMEMBRANES, V1828, P1899, DOI 10.1016/j.bbamem.2013.04.006
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Paul A, 2013, J INTEGR MED-JIM, V11, P405, DOI 10.3736/jintegrmed2013057
   Perera RM, 2011, NATURE, V475, P43, DOI 10.1038/475043a
   Ralph SJ, 2006, RECENT PAT ANTI-CANC, V1, P327, DOI 10.2174/157489206778776952
   Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989
   Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046
   Spangle JM, 2010, J VIROL, V84, P9398, DOI 10.1128/JVI.00974-10
   Stewart D, 2004, J GEN VIROL, V85, P1419, DOI 10.1099/vir.0.19679-0
   Yang CR, 2013, TOXICOL APPL PHARM, V273, P611, DOI 10.1016/j.taap.2013.10.007
   Ye JJ, 2015, ONCOTARGETS THER, V8, P1211, DOI 10.2147/OTT.S79899
   Yee GPC, 2013, CURR CANCER DRUG TAR, V13, P205
NR 31
TC 3
Z9 3
U1 0
U2 11
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD OCT
PY 2016
VL 294
IS 4
BP 797
EP 804
DI 10.1007/s00404-016-4097-7
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DV4UJ
UT WOS:000382920400017
PM 27091196
OA Green Published
DA 2020-12-08
ER

PT J
AU Akimoto-Gunther, L
   Bonfim-Mendonca, PD
   Takahachi, G
   Irie, MMT
   Miyamoto, S
   Consolaro, MEL
   Svidzinsk, TIE
AF Akimoto-Gunther, Luciene
   Bonfim-Mendonca, Patricia de Souza
   Takahachi, Gisele
   Irie, Mary Mayumi T.
   Miyamoto, Sonia
   Lopes Consolaro, Marcia Edilaine
   Estivalet Svidzinsk, Terezinha I.
TI Highlights Regarding Host Predisposing Factors to Recurrent Vulvovaginal
   Candidiasis: Chronic Stress and Reduced Antioxidant Capacity
SO PLOS ONE
LA English
DT Article
ID ALBICANS; WOMEN; COLONIZATION; INFECTIONS; SYMPTOMS; IMMUNITY; GLUCOSE;
   DEFENSE
AB We studied host factors that could predispose women to develop recurrent vulvovaginal candidiasis (RVVC), including glycemia, insulin resistance, chronic stress, antioxidant capacity, overall immune status, local inflammation and vaginal microbiota. The presence of yeasts in vaginal culture was screened in 277 women, with or without signs and symptoms of VVC and RVVC. The presence of an inflammatory process and microbiota were analyzed through vaginal bacterioscopy and cervical-vaginal cytology, respectively. Fasting-blood samples were collected by standard venipuncture for biochemical analyses. Flow cytometry was employed to obtain the T helper/T cytotoxic lymphocyte ratio, and insulin resistance was assessed by the HOMA index (HI). Yeasts were isolated from 71 (26%) women: 23 (32.4%) with a positive culture but without symptoms (COL), 22 (31%) in an acute episode (VVC), and 26 (36.6%) with RVVC. C. albicans was the main yeast isolated in all clinical profiles. The control group (negative culture) comprised 206 women. Diabetes mellitus and insulin resistance were more associated with the positive-culture groups (COL, VVC and RVVC) than with negative ones. The RVVC group showed lower mean levels of cortisol than the control group and lower antioxidant capacity than all other groups. The T Helper/T cytotoxic lymphocyte ratio was similar in all groups. The RVVC group showed a similar level of vaginal inflammation to the control group, and lower than in the COL and VVC groups. Only the CVV group showed a reduction in vaginal lactobacillus microbiota. Our data suggest that both chronic stress (decreased early-morning cortisol levels) and reduced antioxidant capacity can be host predisposing factors to RVVC.
C1 [Akimoto-Gunther, Luciene; Bonfim-Mendonca, Patricia de Souza; Lopes Consolaro, Marcia Edilaine; Estivalet Svidzinsk, Terezinha I.] Univ Estadual Maringa, Postgrad Program Hlth Sci, Maringa, Parana, Brazil.
   [Akimoto-Gunther, Luciene; Bonfim-Mendonca, Patricia de Souza; Takahachi, Gisele; Irie, Mary Mayumi T.; Miyamoto, Sonia; Lopes Consolaro, Marcia Edilaine; Estivalet Svidzinsk, Terezinha I.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Maringa, Parana, Brazil.
RP Svidzinsk, TIE (corresponding author), Univ Estadual Maringa, Postgrad Program Hlth Sci, Maringa, Parana, Brazil.; Svidzinsk, TIE (corresponding author), Univ Estadual Maringa, Dept Clin Anal & Biomed, Maringa, Parana, Brazil.
EM terezinha.svidzinski@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   Brazilian GovernmentNational Council for Scientific and Technological
   Development (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   superior (CAPES), Brazilian GovernmentCAPES; Fundacao Araucaria de Apoio
   ao Desenvolvimento Tecnologico e Cientifico do Parana, Brazilian
   GovernmentFundacao Araucaria
FX This study was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao de
   Aperfeicoamento de Pessoal de Nivel superior (CAPES) and Fundacao
   Araucaria de Apoio ao Desenvolvimento Tecnologico e Cientifico do
   Parana, Brazilian Government.
CR Gunther LSA, 2014, SAO PAULO MED J, V132, P116, DOI 10.1590/1516-3180.2014.1322640
   Amouri I, 2013, ANN BIOL CLIN-PARIS, V71, P151, DOI 10.1684/abc.2013.0797
   [Anonymous], 2015, DIABETES CARE, V38, pS4, DOI 10.2337/dc15-S003
   Bassyouni RH, 2015, J MICROBIOL BIOTECHN, V25, P1734, DOI 10.4014/jmb.1504.04009
   Bonfim-Mendonca PD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107805
   Buchta V, 2013, Ceska Gynekol, V78, P537
   Carrara MA, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.011
   Cassone A, 2015, BJOG-INT J OBSTET GY, V122, P785, DOI 10.1111/1471-0528.12994
   Donders GGG, 2002, AM J OBSTET GYNECOL, V187, P989, DOI 10.1067/mob.2002.126285
   Ehrstrom SM, 2005, AM J OBSTET GYNECOL, V193, P1376, DOI 10.1016/j.ajog.2005.03.068
   Fidel PL, 2007, AM J REPROD IMMUNOL, V57, P2, DOI 10.1111/j.1600-0897.2006.00450.x
   FIDEL PL, 1995, INFECT IMMUN, V63, P2403, DOI 10.1128/IAI.63.7.2403-2408.1995
   Jonsson P, 2015, PHYSIOL BEHAV, V15, P30034
   Kurtzman C.P., 1998, YEAST TAXONOMIC STUD
   Liu MB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079812
   Meyer H, 2006, MYCOSES, V49, P202, DOI 10.1111/j.1439-0507.2006.01235.x
   Muzny CA, 2015, CLIN INFECT DIS, V61, P601, DOI 10.1093/cid/civ353
   Nayar R, 2015, BETHESDA SYSTEM REPO
   Nyirjesy P, 2013, POSTGRAD MED, V125, DOI 10.3810/pgm.2013.05.2650
   Nyirjesy P, 2012, CURR MED RES OPIN, V28, P1173, DOI 10.1185/03007995.2012.697053
   ODDS FC, 1988, J MED VET MYCOL, V26, P277
   Ratti BA, 2015, CELL IMMUNOL, V293, P22, DOI 10.1016/j.cellimm.2014.11.004
   Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3
   Richardson M, 2009, FRONT BIOSCI-LANDMRK, V14, P4363, DOI 10.2741/3533
   Sandini S, 2011, FEMS IMMUNOL MED MIC, V62, P215, DOI 10.1111/j.1574-695X.2011.00802.x
   Smith RAJ, 2008, ANN NY ACAD SCI, V1147, P105, DOI 10.1196/annals.1427.003
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Sobel JD, 2015, AM J OBSTET GYNECOL, V15, P716
   Straub RH, 2011, Z RHEUMATOL, V70, P767, DOI 10.1007/s00393-011-0784-8
   Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487
   Zhou X, 2009, INFECT IMMUN, V77, P4130, DOI 10.1128/IAI.00436-09
NR 31
TC 10
Z9 11
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 14
PY 2016
VL 11
IS 7
AR e0158870
DI 10.1371/journal.pone.0158870
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DR0DZ
UT WOS:000379579500046
PM 27415762
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Rocha, RM
   Zanni, PCMD
   Bonfim-Mendonca, PD
   Gimenes, F
   Alczuk, SSD
   Svidzinski, TIE
   Consolaro, MEL
AF Rocha, Rodrigo M.
   Delvas Zanni, Pamela C. M.
   Bonfim-Mendonca, Patricia de Souza
   Gimenes, Fabricia
   Dantas Alczuk, Silvia S.
   Estivalet Svidzinski, Terezinha I.
   Lopes Consolaro, Marcia E.
TI Effect of norfloxacin therapy for acute, uncomplicated lower urinary
   tract infection on vaginal Candida prevalence
SO INTERNATIONAL UROGYNECOLOGY JOURNAL
LA English
DT Article
DE Urinary tract infection; Norfloxacin; Treatment; Vulvovaginal
   candidiasis; Vaginal Candida colonization; Vaginal microbiota
ID RISK-FACTORS; WOMEN; ANTIBIOTICS; PIVMECILLINAM; ALBICANS; FLORA
AB Acute uncomplicated lower urinary tract infections (UTI) and vulvovaginal candidiasis (VVC) both occur frequently in women. Although VVC is believed to commonly occur after antibiotic therapy, few studies have demonstrated this association. Thus, the aim of the study was to estimate the prevalence of colonization by Candida spp. and VVC after norfloxacin (NOR) use for UTI and the effects on the vaginal microbiota and inflammatory process.
   This was a prospective cohort study of women with culture-proven UTI who were treated with NOR (antibiotic group). The control group consisted of women with noninfectious diseases or in preventive care. Candida vaginal infections were monitored both clinically and mycologically at baseline and at the follow-up evaluation.
   All women showed UTI remission after NOR treatment, and no woman in either group, antibiotic and control, showed symptoms of VVC. Both groups showed similar ratios of a positive Candida culture at baseline (6.7 % and 12.8 %, respectively) and at follow-up (3.3 % and 8.5 %, respectively) (p = 0.2768 and p = 0.5035, respectively). The antibiotic group showed no increased risk of Candida colonization or VVC after NOR treatment compared with the control group [odds ratio (OR) 0.556, 95 % confidence interval (CI) 0.2407-10.05].
   NOR was effective for UTI treatment, did not increase the risk of vaginal colonization by Candida or VVC, and did not lead to major disturbances of the vaginal microbiota.
C1 [Rocha, Rodrigo M.; Delvas Zanni, Pamela C. M.; Bonfim-Mendonca, Patricia de Souza; Gimenes, Fabricia; Dantas Alczuk, Silvia S.; Lopes Consolaro, Marcia E.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol Lab, Maringa, Parana, Brazil.
   [Delvas Zanni, Pamela C. M.; Bonfim-Mendonca, Patricia de Souza; Dantas Alczuk, Silvia S.; Estivalet Svidzinski, Terezinha I.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Med Mycol Lab, Maringa, Parana, Brazil.
   [Lopes Consolaro, Marcia E.] Univ Estadual Maringa, Dept Anal Clin & Biomed, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol Lab, Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Rocha,
   Rodrigo/AAN-6428-2020
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Rocha,
   Rodrigo/0000-0002-1456-3483
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel superior (CAPES),
   Brazilian Government (PROAP)
FX This study was funded by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel superior (CAPES), Brazilian Government (PROAP-2013).
CR Aydin A, 2015, INT UROGYNECOL J, V26, P795, DOI 10.1007/s00192-014-2569-5
   Baron EJ, 2007, MANUAL OF CLINICAL MICROBIOLOGY, 9TH ED, P1
   Cassone A, 2015, BJOG-INT J OBSTET GY, V122, P785, DOI 10.1111/1471-0528.12994
   Consolaro Marcia Edilaine Lopes, 2004, Revista Iberoamericana de Micologia, V21, P202
   Fihn SD, 2003, NEW ENGL J MED, V349, P259, DOI 10.1056/NEJMcp030027
   Glover Douglas D, 2003, Infect Dis Obstet Gynecol, V11, P157, DOI 10.1080/10647440300025514
   GRABE M, 2009, GUIDELINES UROLOGICA
   Griebling TL, 2005, J UROLOGY, V173, P128
   Hamad M, 2014, MYCOSES, V57, P184, DOI 10.1111/myc.12141
   Holland J, 2003, SEX TRANSM INFECT, V79, P249, DOI 10.1136/sti.79.3.249
   Larone DH, 2011, MED IMPORTANT FUNGI
   McClelland RS, 2009, J INFECT DIS, V199, P1883, DOI 10.1086/599213
   Menday AP, 2002, INT J ANTIMICROB AG, V20, P297, DOI 10.1016/S0924-8579(02)00171-1
   Mendling W, 2015, MYCOSES, V58, P1, DOI 10.1111/myc.12292
   Nayar R, 2015, BETHESDA SYSTEM REPO
   NEU HC, 1992, INFECTION, V20, pS266, DOI 10.1007/BF01710012
   Norinder BS, 2006, ANTIMICROB AGENTS CH, V50, P1528, DOI 10.1128/AAC.50.4.1528-1530.2006
   Pascon RC, 2011, ENZYME RES, P1
   Ribeiro RM, 2002, INT UROGYNECOL J PEL, V13, P190, DOI 10.1007/s192-002-8352-0
   SCHAEFFER AJ, 1985, J UROLOGY, V133, P628, DOI 10.1016/S0022-5347(17)49118-X
   Scholes D, 2000, J INFECT DIS, V182, P1177, DOI 10.1086/315827
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Sobel JD, 1998, AM J OBSTET GYNECOL, V178, P203, DOI 10.1016/S0002-9378(98)80001-X
   Spanu T, 2012, J CLIN MICROBIOL, V50, P176, DOI 10.1128/JCM.05742-11
   Tabrizi SN, 2006, MYCOSES, V49, P523, DOI 10.1111/j.1439-0507.2006.01312.x
   Wilton LV, 2003, DRUG SAFETY, V26, P589, DOI 10.2165/00002018-200326080-00005
   Xu JP, 2008, J AM BOARD FAM MED, V21, P261, DOI 10.3122/jabfm.2008.04.070169
   Xu Jinping, 2003, Curr Infect Dis Rep, V5, P481, DOI 10.1007/s11908-003-0091-x
NR 28
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-3462
EI 1433-3023
J9 INT UROGYNECOL J
JI Int. Urogynecol. J.
PD MAY
PY 2016
VL 27
IS 5
BP 773
EP 780
DI 10.1007/s00192-015-2884-5
PG 8
WC Obstetrics & Gynecology; Urology & Nephrology
SC Obstetrics & Gynecology; Urology & Nephrology
GA DJ9ZU
UT WOS:000374572900012
PM 26564224
DA 2020-12-08
ER

PT J
AU Gimenes, F
   Souza, RP
   de Abreu, ALP
   Pereira, MW
   Consolaro, MEL
   da Silva, VRS
AF Gimenes, Fabricia
   Souza, Raquel Pantarotto
   Pimenta de Abreu, Andre Luelsdorf
   Pereira, Monalisa Wolski
   Lopes Consolaro, Marcia Edilaine
   Sela da Silva, Vania Ramos
TI Simultaneous detection of human papillomavirus integration and c-MYC
   gene amplification in cervical lesions: an emerging marker for the risk
   to progression
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Human papillomavirus; Cervical cancer; Integration; c-MYC; Biomarkers
ID IN-SITU HYBRIDIZATION; HPV INTEGRATION; NATURAL-HISTORY; GRADE; CANCER;
   CELLS; NEOPLASIA; INFECTION; PATTERNS; CYTOLOGY
AB The persistence of high-risk oncogenic human papillomavirus (HR-HPV) infection and its integration into the host genome are key steps in the induction of malignant alterations. c-MYC chromosome region is a frequent localization for HPV insertion that has been observed in chromosome band 8q24 by fluorescence in situ hybridization (FISH). We report the HPV viral integration and amplification patterns of the c-MYC gene in cytological smears with FISH as a potential biomarker for the progression of squamous intraepithelial lesions (SIL).
   HPV detection and genotyping by polymerase chain reaction (PCR) and FISH analysis by "Vysis Cervical FISH Probe" kit (ABBOTT Molecular Inc.) were performed in 37 cervical samples including 8 NILM, 7 ASC-US, 7 LSIL, 3 ASC-H, 7 HSIL and 5 SCC.
   The results show concordance between FISH and PCR techniques for HPV detection. The majority of the samples contained HR-HPV, the majority being -16 and -18 genotypes. HPV integration as determined by FISH was most frequent in high-risk lesions. The c-MYC gene amplification was found only in HPV-positive samples and was detected primarily in high-risk lesions and in cells with an integrated form of HPV.
   HPV integration and c-MYC gene amplification detected by FISH could be an important biomarker for use in clinical practice to determine SIL with a risk of progression.
C1 [Gimenes, Fabricia; Souza, Raquel Pantarotto; Pimenta de Abreu, Andre Luelsdorf; Pereira, Monalisa Wolski; Lopes Consolaro, Marcia Edilaine; Sela da Silva, Vania Ramos] Univ Estadual Maringa, Dept Clin Anal & Biomed, Lab Clin Cytol & Semen Anal, BR-87020900 Maringa, PR, Brazil.
RP da Silva, VRS (corresponding author), Univ Estadual Maringa, Dept Clin Anal & Biomed, Lab Clin Cytol & Semen Anal, BR-87020900 Maringa, PR, Brazil.
EM vaniasela@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel superior (CAPES),
   Brazilian GovernmentCAPES [PVE A109/2013, AUX/PE-PRODOC 2571/2010]
FX The author acknowledgements go to Abbott Company for providing the kits
   for realization of this research and Ph.D. Marcelo Gialluisi Bonini at
   College of Medicine, Departments of Medicine, Pharmacology and
   Pathology, University of Illinois at Chicago, for invaluable partnership
   and collaborations. This work was supported by grants from Coordenacao
   de Aperfeicoamento de Pessoal de Nivel superior (CAPES), Brazilian
   Government (PVE A109/2013 and AUX/PE-PRODOC 2571/2010).
CR Garcia DA, 2011, COLOMB MEDICA, V42, P144
   Akagi K, 2014, GENOME RES, V24, P185, DOI 10.1101/gr.164806.113
   Annunziata C, 2012, PATHOL ONCOL RES, V18, P803, DOI 10.1007/s12253-012-9507-y
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Cai Q, 2013, ARCH GYNECOL OBSTET, V287, P541, DOI 10.1007/s00404-012-2665-z
   Canadas MP, 2010, J CLIN VIROL, V48, P198, DOI 10.1016/j.jcv.2010.03.023
   Chen SM, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-40
   Chow LT, 2010, APMIS, V118, P422, DOI 10.1111/j.1600-0463.2010.02625.x
   Consolaro MEL, 2012, CITOLOGIA CLIN CERVI
   Das P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041012
   Dong DD, 2010, REPROD SCI, V17, P718, DOI 10.1177/1933719110369183
   Evans MF, 2004, J PATHOL, V202, P1, DOI 10.1002/path.1519
   Evans MF, 2002, MODERN PATHOL, V15, P1339, DOI 10.1038/modpathol.3880698
   Ferber MJ, 2003, ONCOGENE, V22, P7233, DOI 10.1038/sj.onc.1207006
   Gao G, 2014, J CLIN VIROL, V59, P195, DOI 10.1016/j.jcv.2013.12.006
   Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653
   Ho CM, 2011, VIRUS RES, V161, P124, DOI 10.1016/j.virusres.2011.06.012
   Hopman AHN, 2004, J PATHOL, V202, P23, DOI 10.1002/path.1490
   IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2009, REV HUM CARC B
   Kubler K, 2015, ONCOTARGET, V6, P825
   MANOS MM, 1994, J INFECT DIS, V170, P1096, DOI 10.1093/infdis/170.5.1096
   Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869
   Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886
   Moukova L, 2012, EUR ONCOL HAEMATOL, V8, P92
   Munoz N, 2000, J CLIN VIROL, V19, P1, DOI 10.1016/S1386-6532(00)00125-6
   Obermann EC, 2013, CANCER CYTOPATHOL, V121, P423, DOI 10.1002/cncy.21280
   Parkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111
   Peter M, 2006, ONCOGENE, V25, P5985, DOI 10.1038/sj.onc.1209625
   Pett M, 2007, J PATHOL, V212, P356, DOI 10.1002/path.2192
   Policht FA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-432
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
   Scarpini CG, 2014, J PATHOL, V233, P281, DOI 10.1002/path.4358
   Sokolova I, 2007, J MOL DIAGN, V9, P604, DOI 10.2353/jmoldx.2007.070007
   Solomon D, 2005, SISTEMA BETHESDA CIT
   Song M, 2010, DIAGN CYTOPATHOL, V38, P28, DOI 10.1002/dc.21142
   Termini L, 2008, J BRAS DOENCAS SEX T, V20, P125
   Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Wentzensen N, 2004, CANCER RES, V64, P3878, DOI 10.1158/0008-5472.CAN-04-0009
   Wentzensen N, 2009, PATHOBIOLOGY, V76, P82, DOI 10.1159/000201676
   Woodman CBJ, 2007, NAT REV CANCER, V7, P11, DOI 10.1038/nrc2050
   Xu B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066693
   Yu TX, 2005, CANCER GENET CYTOGEN, V158, P27, DOI 10.1016/j.cancergencyto.2004.08.021
NR 43
TC 6
Z9 8
U1 0
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD APR
PY 2016
VL 293
IS 4
BP 857
EP 863
DI 10.1007/s00404-015-3870-3
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DH2FP
UT WOS:000372599900023
PM 26315473
DA 2020-12-08
ER

PT J
AU Wohlmeister, D
   Vianna, DRB
   Helfer, VE
   Gimenes, F
   Consolaro, MEL
   Barcellos, RB
   Rossetti, ML
   Calil, LN
   Buffon, A
   Pilger, DA
AF Wohlmeister, Denise
   Barreto Vianna, Debora Renz
   Helfer, Virginia Etges
   Gimenes, Fabricia
   Lopes Consolaro, Marcia Edilaine
   Barcellos, Regina Bones
   Rossetti, Maria Lucia
   Calil, Luciane Noal
   Buffon, Andreia
   Pilger, Diogo Andre
TI Association of human papillomavirus and Chlamydia trachomatis with
   intraepithelial alterations in cervix samples
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE HPV; C. trachomatis; intraepithelial lesions; sexually transmitted
   diseases
ID GENOTYPE DISTRIBUTION; INFECTION; WOMEN; HPV; PREVALENCE; CYTOLOGY;
   LESIONS; CANCER; SOUTH; ASSAY
AB The influence of different infectious agents and their association with human papillomavirus (HPV) in cervical carcinogenesis have not been completely elucidated. This study describes the association between cytological changes in cervical epithelium and the detection of the most relevant aetiological agents of sexually transmitted diseases. Samples collected from 169 patients were evaluated by conventional cytology followed by molecular analysis to detect HPV DNA, Chlamydia trachomatis, herpes simplex virus 1 and 2, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis, and Treponema pallidum, besides genotyping for most common high-risk HPV. An association between cytological lesions and different behavioural habits such as smoking and sedentariness was observed. Intraepithelial lesions were also associated with HPV and C. trachomatis detection. An association was also found between both simple and multiple genotype infection and cytological changes. The investigation of HPV and C. trachomatis proved its importance and may be considered in the future for including in screening programs, since these factors are linked to the early diagnosis of patients with precursor lesions of cervical cancer.
C1 [Wohlmeister, Denise; Buffon, Andreia; Pilger, Diogo Andre] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Farmaceut, Porto Alegre, RS, Brazil.
   [Wohlmeister, Denise; Barreto Vianna, Debora Renz; Calil, Luciane Noal; Buffon, Andreia; Pilger, Diogo Andre] Univ Fed Rio Grande do Sul, Fac Farm, Dept Anal, Lab Anal Bioquim & Citol, Porto Alegre, RS, Brazil.
   [Barreto Vianna, Debora Renz; Helfer, Virginia Etges] Univ Fed Rio Grande do Sul, Fac Farm, Porto Alegre, RS, Brazil.
   [Gimenes, Fabricia; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Lab Citol Clin, Maringa, PR, Brazil.
   [Barcellos, Regina Bones; Rossetti, Maria Lucia] Fundacao Estadual Prod & Pesquisa Saude, Ctr Desenvolvimento Cient & Tecnol, Porto Alegre, RS, Brazil.
RP Pilger, DA (corresponding author), Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Farmaceut, Porto Alegre, RS, Brazil.; Pilger, DA (corresponding author), Univ Fed Rio Grande do Sul, Fac Farm, Dept Anal, Lab Anal Bioquim & Citol, Porto Alegre, RS, Brazil.
EM diogo.pilger@ufrgs.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Pilger, Diogo
   Andre/S-5299-2019
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Pilger, Diogo
   Andre/0000-0002-6773-6480
FU CNPq/MCTI [442790/2014-7]; PPGCF/UFRGS; PROPESQ/UFRGS; FAPERGSFoundation
   for Research Support of the State of Rio Grande do Sul (FAPERGS)
   [13/1154-1]
FX Financial support: CNPq/MCTI (442790/2014-7), PPGCF/UFRGS,
   PROPESQ/UFRGS, FAPERGS (13/1154-1)
CR Abreu ALP, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-262
   Al-Daraji WI, 2009, INT J CLIN EXP PATHO, V2, P48
   Barcellos RB, 2011, J VIROL METHODS, V177, P38, DOI 10.1016/j.jviromet.2011.06.010
   Batista JE, 2014, REV PESQ SAUDE, V15, P218
   Bellaminutti S, 2014, J MED VIROL, V86, P1920, DOI 10.1002/jmv.24041
   Bringhenti MEZ, 2010, J BRAS DOENCAS SEX T, V22, P135
   Bruge F, 2011, J BIOTECHNOL, V156, P153, DOI 10.1016/j.jbiotec.2011.09.018
   Campos ACC, 2008, SAO PAULO MED J, V126, P333, DOI 10.1590/S1516-31802008000600008
   Clifford GM, 2005, CANCER EPIDEM BIOMAR, V14, P1157, DOI 10.1158/1055-9965.EPI-04-0812
   Consolaro MEL, 2012, CITOLOGIA CLIN CERVI, P31
   Correa MD, 2012, CAD SAUDE PUBLICA, V28, P2257, DOI 10.1590/S0102-311X2012001400005
   Deluca GD, 2011, BRAZ J INFECT DIS, V15, P567, DOI [10.1590/S1413-86702011000600011, 10.1016/S1413-8670(11)70252-5]
   de Abreu ALP, 2012, AM J TROP MED HYG, V87, P1149, DOI 10.4269/ajtmh.2012.12-0287
   Melo Simone Cristina Castanho Sabaini de, 2009, Rev. Gaúcha Enferm., V30, P602, DOI 10.1590/S1983-14472009000400004
   de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5
   Entiauspe LG, 2010, REV SOC BRAS MED TRO, V43, P260, DOI 10.1590/S0037-86822010000300009
   Falcao GB, 2014, CAD SAUDE COLET, V22, P165
   Gimenes F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098862
   Instituto Nacional do Cancer (INCA), 2014, EST 2014
   Kaderli R, 2014, INT J COLORECTAL DIS, V29, P899, DOI 10.1007/s00384-014-1922-y
   Kraus I, 2006, J CLIN MICROBIOL, V44, P1310, DOI 10.1128/JCM.44.4.1310-1317.2006
   MARTINS MCL, 2007, REV BRAS ANAL CLIN, V39, P217
   Munoz N, 2000, J CLIN VIROL, V19, P1, DOI 10.1016/S1386-6532(00)00125-6
   Murta EFC, 2001, REV BRAS GINECOL OBS, V23, P217
   Muvunyi CM, 2011, DIAGN MICR INFEC DIS, V71, P29, DOI 10.1016/j.diagmicrobio.2011.06.005
   Nakagawa JTT, 2010, REV BRAS ENFERM, V63, P307, DOI 10.1590/S0034-71672010000200021
   Og A, 2010, N AM J MED SCI, V2, P97, DOI 10.4297/najms.2010.297
   Oliveira-Silva M, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-4
   Parkin DM, 2008, VACCINE, V26, pL1, DOI 10.1016/j.vaccine.2008.05.043
   Pinheiro MM, 2013, REV CIENC SAUDE, V15, P19
   Rodrigues Adriana Dalpicolli, 2009, J. Bras. Patol. Med. Lab., V45, P457, DOI 10.1590/S1676-24442009000600004
   Rodriguez-Cerdeira C, 2012, ISRN Obstet Gynecol, V2012, P240190, DOI 10.5402/2012/240190
   Schiffman M, 2013, NEW ENGL J MED, V369, P2324, DOI 10.1056/NEJMcp1210379
   Schmitt M, 2014, J INFECTION, V69, P123, DOI 10.1016/j.jinf.2014.04.006
   Schmitt M, 2013, J CLIN MICROBIOL, V51, P1458, DOI 10.1128/JCM.00087-13
   Shen-Gunther J, 2011, GYNECOL ONCOL, V123, P263, DOI 10.1016/j.ygyno.2011.07.017
   Solomon D, 2005, SISTEMA BETHESDA CIT
   Souza RP, 2013, AM J TROP MED HYG, V89, P1199, DOI 10.4269/ajtmh.13-0315
   Urbina María Teresa, 2010, Rev Obstet Ginecol Venez, V70, P90
NR 39
TC 12
Z9 15
U1 0
U2 8
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD FEB
PY 2016
VL 111
IS 2
BP 106
EP 113
DI 10.1590/0074-02760150330
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA DE3IW
UT WOS:000370522900004
PM 26841046
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Abreu, ALP
   Malaguti, N
   Souza, RP
   Uchimura, NS
   Ferreira, EC
   Pereira, MW
   Carvalho, MDB
   Pelloso, SM
   Bonini, MG
   Gimenes, F
   Consolaro, MEL
AF de Abreu, Andre L. P.
   Malaguti, Natalia
   Souza, Raquel P.
   Uchimura, Nelson S.
   Ferreira, Erika C.
   Pereira, Monalisa W.
   Carvalho, Maria D. B.
   Pelloso, Sandra M.
   Bonini, Marcelo G.
   Gimenes, Fabricia
   Consolaro, Marcia E. L.
TI Association of human papillomavirus, Neisseria gonorrhoeae and Chlamydia
   trachomatis co-infections on the risk of high-grade squamous
   intraepithelial cervical lesion
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Cervical cancer; HPV; co-factors; sexually transmitted diseases;
   progression risk; HSIL
ID HPV INFECTION; CANCER; WOMEN; NEOPLASIA; PREVALENCE; DISEASE
AB The link between high-risk human Papillomavirus (HR-HPV) and other sexually transmitted diseases (STDs) in the risk of developing cervical cancer still unclear. Thus, in this report we investigated the rates of co-infections between HPV and other important non-HPV STDs in different cervical findings using a multiplex polymerase chain reaction (M-PCR) to simultaneously detect Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis, HSV-1 and -2, and Treponema pallidum. A total of 838 women aged 18 to 68 years were screened using Papanicolaou smears for cervical abnormalities, HPV and non-HPV STDs using PCR and M-PCR methods. A total of 614 (73.3%) of the women had normal cytology (NILM) and 224 (26.7%) women exhibited abnormal cytology (>= ASC-US). HPV-DNA prevalence was 33.9%, and HPV-16 was the most prevalent genotype in women with NILM and >= ASC-US cytology. Non-HPV STDs were detected in 30.4% women and T. vaginalis was the most prevalent one (11.6%). A higher increased risk of >= ASC-US and HSIL occurred in co-infections of HR-HPV with C. trachomatis and N. gonorrhoeae. Co-infections of HPV-DNA and HR-HPV with HSV-2 exhibited a similar increased risk but only with >= ASC-US. Co-infections of HPV-DNA and HR-HPV with T. vaginalis demonstrated a similar increased risk of >= ASC-US and HSIL. We found that C. trachomatis and N. gonorrhoeae were the primary pathogens associated with HR-HPV for the increased risk for all grades of cervical abnormalities but mainly for HSIL, suggesting a possible synergistic action in cervical lesions progression. Our results reinforce the hypothesis that some non-HPV STDs might play a role as co-factors in HPV-mediated cervical carcinogenesis. These data improve our understanding of the etiology of SCC and may also be useful for disease prevention.
C1 [de Abreu, Andre L. P.; Malaguti, Natalia; Souza, Raquel P.; Pereira, Monalisa W.; Gimenes, Fabricia; Consolaro, Marcia E. L.] State Univ Maringa UEM, Clin Cytol Lab, Maringa, Parana, Brazil.
   [Uchimura, Nelson S.; Carvalho, Maria D. B.] Univ Estadual Maringa, Dept Med, Maringa, Parana, Brazil.
   [Ferreira, Erika C.] Univ Estadual Maringa, Dept Stat, Maringa, Parana, Brazil.
   [Pelloso, Sandra M.] Univ Estadual Maringa, Dept Nursing, Maringa, Parana, Brazil.
   [de Abreu, Andre L. P.; Bonini, Marcelo G.] Univ Illinois, Dept Pharmacol, Chicago, IL USA.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol Lab, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico,
   Parana State Government [37635/2013]; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel superior (CAPES), Brazilian Government Project [PVE
   A109-2013]
FX This work was supported by grants from the from Fundacao Araucaria de
   Apoio ao Desenvolvimento Cientifico e Tecnologico, Parana State
   Government, Project no 37635/2013, and Coordenacao de Aperfeicoamento de
   Pessoal de Nivel superior (CAPES), Brazilian Government Project PVE
   A109-2013.
CR Biernat-Sudolska M, 2011, ADV MED SCI-POLAND, V56, P299, DOI 10.2478/v10039-011-0028-9
   Bodily J, 2011, TRENDS MICROBIOL, V19, P33, DOI 10.1016/j.tim.2010.10.002
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Carrillo-Garcia A, 2014, GYNECOL ONCOL, V134, P534, DOI 10.1016/j.ygyno.2014.06.018
   Castle PE, 2001, CANCER EPIDEM BIOMAR, V10, P1021
   Castle Philip E, 2003, J Natl Cancer Inst Monogr, P29
   Chen LH, 2013, J MED VIROL, V85, P1229, DOI 10.1002/jmv.23582
   Creatsas G, 2012, J MED MICROBIOL, V61, P1347, DOI 10.1099/jmm.0.042507-0
   de Abreu ALP, 2012, AM J TROP MED HYG, V87, P1149, DOI 10.4269/ajtmh.2012.12-0287
   Discacciati MG, 2015, CANCER EPIDEM BIOMAR, V24, P1539, DOI 10.1158/1055-9965.EPI-15-0420
   Donders GGG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0086266
   GALLOWAY DA, 1983, NATURE, V302, P21, DOI 10.1038/302021a0
   Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703
   Kjaer SK, 2010, JNCI-J NATL CANCER I, V102, P1478, DOI 10.1093/jnci/djq356
   Koh WJ, 2015, J NATL COMPR CANC NE, V13, P395, DOI 10.6004/jnccn.2015.0055
   Lazenby GB, 2014, CLIN THER, V36, P38, DOI 10.1016/j.clinthera.2013.11.009
   Lehtinen M, 2011, SEX TRANSM INFECT, V87, P372, DOI 10.1136/sti.2010.044354
   Lizano M, 2009, ARCH MED RES, V40, P428, DOI 10.1016/j.arcmed.2009.06.001
   Magana-Contreras M, 2015, J MED VIROL, V87, P2098, DOI 10.1002/jmv.24278
   Malaguti N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/645853
   Marrazzo JM, 2007, CLIN INFECT DIS, V44, pS102, DOI 10.1086/511423
   Monsonego J, 2015, GYNECOL ONCOL, V137, P47, DOI 10.1016/j.ygyno.2015.01.551
   Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3
   Muvunyi CM, 2011, DIAGN MICR INFEC DIS, V71, P29, DOI 10.1016/j.diagmicrobio.2011.06.005
   Paba P, 2008, INTERVIROLOGY, V51, P230, DOI 10.1159/000156481
   Rajkumar T, 2006, INT J CANCER, V118, P1481
   Raju K, 2015, BIOMED RES THER, V2, P220, DOI 10.7603/s40730-015-0007-z
   Samoff E, 2005, AM J EPIDEMIOL, V162, P668, DOI 10.1093/aje/kwi262
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
   SCHMAUZ R, 1989, INT J CANCER, V43, P805, DOI 10.1002/ijc.2910430511
   Shew ML, 2006, ARCH PEDIAT ADOL MED, V160, P151, DOI 10.1001/archpedi.160.2.151
   Solomon D, 2015, ANTICANCER RES, V35, P5708
   Souza RP, 2013, AM J TROP MED HYG, V89, P1199, DOI 10.4269/ajtmh.13-0315
   Tota JE, 2011, PREV MED, V53, pS12, DOI 10.1016/j.ypmed.2011.08.017
   Tran-Thanh D, 2003, AM J OBSTET GYNECOL, V188, P129, DOI 10.1067/mob.2003.66
   Verteramo R, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-16
   Zereu M, 2007, GYNECOL ONCOL, V105, P172, DOI 10.1016/j.ygyno.2006.11.006
   Zhao YY, 2012, J MED VIROL, V84, P1920, DOI 10.1002/jmv.23353
NR 38
TC 22
Z9 22
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2016
VL 6
IS 6
BP 1371
EP 1383
PG 13
WC Oncology
SC Oncology
GA DQ8GX
UT WOS:000379448200013
PM 27429850
DA 2020-12-08
ER

PT J
AU Discacciati, MG
   Gimenes, F
   Pennacchi, PC
   Faiao-Flores, F
   Zeferino, LC
   Derchain, SM
   Teixeira, JC
   Costa, MC
   Zonta, M
   Termini, L
   Boccardo, E
   Longatto, A
   Consolaro, MEL
   Villa, LL
   Maria-Engler, SS
AF Discacciati, Michelle G.
   Gimenes, Fabrcia
   Pennacchi, Paula C.
   Faiao-Flores, Fernanda
   Zeferino, Luiz C.
   Derchain, Sophie M.
   Teixeira, Julio C.
   Costa, Maria C.
   Zonta, Marco
   Termini, Lara
   Boccardo, Enrique
   Longatto-Filho, Adhemar
   Consolaro, Marcia E. L.
   Villa, Luisa L.
   Maria-Engler, Silvya S.
TI MMP-9/RECK Imbalance: A Mechanism Associated with High-Grade Cervical
   Lesions and Genital Infection by Human Papillomavirus and Chlamydia
   trachomatis
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID MATRIX METALLOPROTEINASES; INTRAEPITHELIAL NEOPLASIA; BACTERIAL
   VAGINOSIS; HPV INFECTION; KAZAL MOTIFS; IN-VITRO; CANCER; RISK;
   EXPRESSION; WOMEN
AB Background: Matrix metalloproteinases (MMP) are important enzymes in the tumor microenvironment associated with progression of cervical intraepithelial neoplasia (CIN) toward squamous cell carcinoma (SCC) of the cervix. However, the role of MMPs in the inflammatory process associated with Chlamydia trachomatis infection concomitant with the carcinogenic process driven by HPV has not yet been addressed. In the present study, we analyzed the state of the MMP-9-RECK axis in cervical carcinogenesis.
   Methods: The levels of MMP-9 and RECK expression were analyzed by immunocytochemistry in liquid-based cytology samples from 136 women with high-grade cervical lesions (CIN2/CIN3) and cervical SCC diagnosed by LLETZ, and in 196 women without cervical neoplasia or CIN1. Real-time qPCR was performed to analyze expression of MMP-9 and RECK in 15 cervical samples. The presence of HPV-DNA and other genital pathogens was evaluated by PCR.
   Results: We found a higher expression of MMP-9 [OR, 4.2; 95% confidence interval (CI), 2.2-7.8] and lower expression of RECK (OR, 0.4; 95% CI, 0.2-0.7) in women with CIN2/CIN3/SCC when compared with women from the control group (no neoplasia/CIN1). A statistically significant association was also found between MMP-9/RECK imbalance and infection by alpha-9 HPV and C. trachomatis. The prevalence of C. trachomatis infection was significantly higher in women with high-grade cervical disease (OR, 3.7; 95% CI, 1.3-11.3).
   Conclusions: MMP-9/RECK imbalance in cervical smears is significantly associated with high-grade cervical diseases and infection by alpha-9 HPV and C. trachomatis.
   Impact: MMP-9/RECK imbalance during cervical inflammation induced by C. trachomatis might play a role in HPV-mediated cervical carcinogenesis. (C) 2015 AACR.
C1 [Discacciati, Michelle G.; Pennacchi, Paula C.; Faiao-Flores, Fernanda; Maria-Engler, Silvya S.] Univ Sao Paulo, Sch Pharmaceut Sci, Lab Clin Cytopathol, BR-05508900 Sao Paulo, Brazil.
   [Gimenes, Fabrcia; Consolaro, Marcia E. L.] State Univ Maringa UEM, Clin Cytol Lab, Maringa, Parana, Brazil.
   [Zeferino, Luiz C.; Derchain, Sophie M.; Teixeira, Julio C.] State Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynecol, Campinas, SP, Brazil.
   [Costa, Maria C.; Termini, Lara; Villa, Luisa L.] INCT HPV Santa Casa Res Inst, Santa Casa Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Zonta, Marco] Univ Fed Sao Paulo, Discipline Infectol, LEMC Lab, Sao Paulo, Brazil.
   [Zonta, Marco] Univ Santo Amaro, Dept Pathol, Sao Paulo, Brazil.
   [Boccardo, Enrique] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, BR-05508900 Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Univ Sao Paulo, Sch Med, Dept Pathol, Lab Med Invest LIM, BR-05508900 Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst, Braga, Portugal.
   [Longatto-Filho, Adhemar] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal.
   [Longatto-Filho, Adhemar] Pio XII Fdn, Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil.
   [Villa, Luisa L.] Univ Sao Paulo, Sch Med, Dept Radiol & Oncol, BR-05508900 Sao Paulo, Brazil.
RP Maria-Engler, SS (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci, 580 Lineu Prestes Ave,17 Bldg, BR-05508900 Sao Paulo, Brazil.
EM silvya@usp.br
RI Zonta, Marco/AAL-4749-2020; Termini, Lara/P-2387-2015; Filho, Adhemar
   Longatto/A-2889-2016; Zeferino, Luiz Carlos/AAQ-2140-2020; Teixeira,
   Julio Cesar/H-3151-2013; Maria-Engler, Silvya/ABC-2016-2020;
   Faiao-Flores, Fernanda/F-7111-2012; Longatto-Filho, Adhemar/N-3397-2019;
   VILLA, LUISA/AAH-4761-2019; Derchain, Sophie FM/I-9500-2014; Boccardo,
   Enrique/A-3960-2012; longatto-filho, adhemar/D-7039-2013; Consolaro,
   Marcia Edilaine Lopes/I-4932-2014; Engler, Silvya Stuchi
   Maria/K-5936-2016; Discacciati, Michelle Garcia/B-4608-2014
OI Zonta, Marco/0000-0002-9280-4270; Termini, Lara/0000-0002-3588-8877;
   Teixeira, Julio Cesar/0000-0002-0979-376X; Maria-Engler,
   Silvya/0000-0003-4771-6041; Faiao-Flores, Fernanda/0000-0003-3449-9930;
   Longatto-Filho, Adhemar/0000-0002-5779-9752; VILLA,
   LUISA/0000-0003-4074-2335; Derchain, Sophie FM/0000-0003-1029-9993;
   Boccardo, Enrique/0000-0003-1900-0273; longatto-filho,
   adhemar/0000-0002-5779-9752; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865; Engler, Silvya Stuchi
   Maria/0000-0003-4771-6041; Discacciati, Michelle
   Garcia/0000-0003-3660-3826
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2008/03232-1,
   2012/09746-2]; National Counsel of Technological and Scientific
   Development pharmaceutical innovation (CNPQ-INCT-if)
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP), numbers 2008/03232-1 (to L.L. Villa) and
   2012/09746-2 (to M.G. Discacciati and S.S. Maria-Engler) and National
   Counsel of Technological and Scientific Development pharmaceutical
   innovation (CNPQ-INCT-if; to S.S. Maria-Engler).
CR Ault KA, 2002, AM J OBSTET GYNECOL, V187, P1377, DOI 10.1067/mob.2002.126850
   Bahmanyar ER, 2012, GYNECOL ONCOL, V127, P440, DOI 10.1016/j.ygyno.2012.08.033
   Boccardo E, 2010, CARCINOGENESIS, V31, P1905, DOI 10.1093/carcin/bgq176
   Bulkmans NWJ, 2005, INT J CANCER, V117, P177, DOI 10.1002/ijc.21210
   Castellsague X, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0551-y
   Chang CK, 2008, J CELL MOL MED, V12, P2781, DOI 10.1111/j.1582-4934.2008.00215.x
   Chumduri C, 2013, CELL HOST MICROBE, V13, P746, DOI 10.1016/j.chom.2013.05.010
   Cardeal LBD, 2006, BIOCHEM CELL BIOL, V84, P713, DOI 10.1139/O06-084
   Cardeal LBD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033585
   Discacciati MG, 2014, BIOMARK INSIGHTS, V9, P15, DOI [10.4137/BMIMI.S14296, 10.4137/BMI.S14296]
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Ghosh A, 2014, J CANCER RES CLIN, V140, P1585, DOI 10.1007/s00432-014-1695-2
   Hu VH, 2012, INFECT IMMUN, V80, P121, DOI 10.1128/IAI.05965-11
   Jacomasso T, 2014, MELANOMA RES, V24, P32, DOI 10.1097/CMR.0000000000000039
   Jensen KE, 2014, SEX TRANSM INFECT, V90, P550, DOI 10.1136/sextrans-2013-051431
   Kang YB, 2013, CANCER CELL, V23, P573, DOI 10.1016/j.ccr.2013.04.017
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Kurman RJCM, 2014, WHO CLASSIFICATION T
   Li Y, 2012, MED ONCOL, V29, P3394, DOI 10.1007/s12032-012-0283-z
   Libra M, 2009, INT J ONCOL, V34, P897, DOI 10.3892/ijo_00000215
   Luostarinen T, 2013, INT J CANCER, V133, P1756, DOI 10.1002/ijc.28173
   Ma YT, 2011, BRIT J CANCER, V104, P1500, DOI 10.1038/bjc.2011.113
   Marconi C, 2014, J LOW GENIT TRACT DI, V18, P261, DOI 10.1097/LGT.0000000000000003
   Matheus ER, 2014, DIAGN CYTOPATHOL, V42, P827, DOI 10.1002/dc.23124
   McIver CJ, 2009, J CLIN MICROBIOL, V47, P1358, DOI 10.1128/JCM.01873-08
   No JH, 2009, ANN NY ACAD SCI, V1171, P100, DOI 10.1111/j.1749-6632.2009.04898.x
   NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991
   Oh HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104374
   Paba P, 2008, INTERVIROLOGY, V51, P230, DOI 10.1159/000156481
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418
   Reis ST, 2011, INT J BIOL MARKER, V26, P255, DOI 10.5301/JBM.2011.8831
   Roura E, 2014, INT J CANCER, V135, P453, DOI 10.1002/ijc.28666
   Silins I, 2005, INT J CANCER, V116, P110, DOI 10.1002/ijc.20970
   Silva J, 2014, ARCH GYNECOL OBSTET, V289, P1157, DOI 10.1007/s00404-014-3215-7
   Snijders PJF, 2006, J PATHOL, V208, P152, DOI 10.1002/path.1866
   Souza RP, 2013, AM J TROP MED HYG, V89, P1199, DOI 10.4269/ajtmh.13-0315
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Wang L, 2013, ASIAN PAC J CANCER P, V14, P2113, DOI 10.7314/APJCP.2013.14.3.2113
   Zeferino LC, 2006, BEST PRACT RES CL OB, V20, P339, DOI 10.1016/j.bpobgyn.2006.01.018
NR 40
TC 14
Z9 15
U1 0
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD OCT
PY 2015
VL 24
IS 10
BP 1539
EP 1547
DI 10.1158/1055-9965.EPI-15-0420
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA CU3CR
UT WOS:000363401800012
PM 26261088
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Baig, MS
   Zaichick, SV
   Mao, M
   de Abreu, AL
   Bakhshi, FR
   Hart, PC
   Saqib, U
   Deng, J
   Chatterjee, S
   Block, ML
   Vogel, SM
   Malik, AB
   Consolaro, MEL
   Christman, JW
   Minshall, RD
   Gantner, BN
   Bonini, MG
AF Baig, Mirza Saqib
   Zaichick, Sofia V.
   Mao, Mao
   de Abreu, Andre L.
   Bakhshi, Farnaz R.
   Hart, Peter C.
   Saqib, Uzma
   Deng, Jing
   Chatterjee, Saurabh
   Block, Michelle L.
   Vogel, Stephen M.
   Malik, Asrar B.
   Consolaro, Marcia E. L.
   Christman, John W.
   Minshall, Richard D.
   Gantner, Benjamin N.
   Bonini, Marcelo G.
TI NOS1-derived nitric oxide promotes NF-kappa B transcriptional activity
   through inhibition of suppressor of cytokine signaling-1
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID SYNTHASE-DEFICIENT MICE; S-NITROSYLATION; MOLECULAR-MECHANISMS;
   INFLAMMATION; EXPRESSION; P65; ACTIVATION; PROTEIN; MOUSE; SOCS
AB The NF-kappa B pathway is central to the regulation of inflammation. Here, we demonstrate that the low-output nitric oxide (NO) synthase 1 (NOS1 or nNOS) plays a critical role in the inflammatory response by promoting the activity of NF-kappa B. Specifically, NOS1-derived NO production in macrophages leads to proteolysis of suppressor of cytokine signaling 1 (SOCS1), alleviating its repression of NF-kappa B transcriptional activity. As a result, NOS1(-/-) mice demonstrate reduced cytokine production, lung injury, and mortality when subjected to two different models of sepsis. Isolated NOS1(-/-) macrophages demonstrate similar defects in proinflammatory transcription on challenge with Gram-negative bacterial LPS. Consistently, we found that activated NOS1(-/-) macrophages contain increased SOCS1 protein and decreased levels of p65 protein compared with wild-type cells. NOS1-dependent S-nitrosation of SOCS1 impairs its binding to p65 and targets SOCS1 for proteolysis. Treatment of NOS1(-/-) cells with exogenous NO rescues both SOCS1 degradation and stabilization of p65 protein. Point mutation analysis demonstrated that both Cys147 and Cys179 on SOCS1 are required for its NO-dependent degradation. These findings demonstrate a fundamental role for NOS1-derived NO in regulating TLR4-mediated inflammatory gene transcription, as well as the intensity and duration of the resulting host immune response.
C1 [Baig, Mirza Saqib; Zaichick, Sofia V.; Mao, Mao; de Abreu, Andre L.; Hart, Peter C.; Deng, Jing; Christman, John W.; Bonini, Marcelo G.] Univ Illinois, Coll Med, Dept Med, Chicago, IL 60607 USA.
   [Baig, Mirza Saqib; Zaichick, Sofia V.; Mao, Mao; de Abreu, Andre L.; Bakhshi, Farnaz R.; Saqib, Uzma; Vogel, Stephen M.; Malik, Asrar B.; Minshall, Richard D.; Gantner, Benjamin N.; Bonini, Marcelo G.] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60607 USA.
   [Chatterjee, Saurabh] Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60607 USA.
   [Block, Michelle L.] Univ Illinois, Coll Med, Dept Pathol, Chicago, IL 60607 USA.
   [Minshall, Richard D.] Univ S Carolina, Dept Environm Hlth Sci, Columbia, SC 29208 USA.
   [Hart, Peter C.; Bonini, Marcelo G.] Indiana Univ, Stark Neurosci Res Inst, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Consolaro, Marcia E. L.] Univ Estadual Maringa, Programa Biociencias Aplicadas Farm PBF, BR-87020900 Maringa, Parana, Brazil.
RP Bonini, MG (corresponding author), Univ Illinois, Coll Med, Dept Med, Chicago, IL 60607 USA.
EM bgantner@uic.edu; mbonini@uic.edu
RI Mao, Mao/E-3783-2013; Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Mao, Mao/0000-0003-1524-8853; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865; Hart, Peter/0000-0003-1843-9102; Block,
   Michelle/0000-0001-8303-7914
FU American Heart Association, Scientist Development GrantsAmerican Heart
   Association [09SDG2250933, 13GRNT16400010]; Department of DefenseUnited
   States Department of Defense [W911NF-12-1-0493/61758-LS]; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [P01HL077806, P01HL077806,
   P01HL077806, P01HL077806, P01HL077806, P01HL077806, R01HL125356,
   P01HL077806, R01HL125350, P01HL077806, R01HL125350, P01HL077806,
   P01HL077806, R01HL125356, P01HL077806, P01HL077806, P01HL077806,
   P01HL077806, P01HL077806, P01HL077806, P01HL077806, P01HL077806,
   R01HL125350, P01HL077806, P01HL077806, R01HL125350, P01HL077806,
   R01HL075557, R01HL075557, P01HL077806, P01HL077806, P01HL077806,
   P01HL077806, P01HL077806, P01HL077806, P01HL077806, P01HL077806,
   P01HL077806, P01HL077806, P01HL077806, P01HL077806, P01HL077806,
   R01HL125356, R01HL075557, P01HL077806, P01HL077806, P01HL077806,
   P01HL077806, P01HL077806, R01HL075557, P01HL077806, P01HL077806,
   P01HL077806, P01HL077806, R01HL075557, P01HL077806, R01HL075557,
   P01HL077806, P01HL077806, P01HL077806, P01HL077806, P01HL077806,
   P01HL077806, P01HL077806, R01HL075557, P01HL077806, R01HL075557,
   P01HL077806, P01HL077806, P01HL077806, P01HL077806, P01HL077806,
   P01HL077806, P01HL077806, P01HL077806, P01HL077806, P01HL077806,
   R01HL125350, P01HL077806, P01HL077806, P01HL077806, R01HL125356,
   P01HL077806, P01HL077806, P01HL077806, P01HL077806, R01HL075557,
   P01HL077806, P01HL077806, R01HL075557, P01HL077806, P01HL077806,
   R01HL075557, P01HL077806, P01HL077806, P01HL077806, P01HL077806,
   P01HL077806, P01HL077806, P01HL077806, P01HL077806, P01HL077806,
   R01HL125356, P01HL077806, P01HL077806, P01HL077806, P01HL077806,
   P01HL077806, P01HL077806, P01HL077806, P01HL077806, P01HL077806,
   P01HL077806, P01HL077806, P01HL077806, P01HL077806, P01HL077806,
   P01HL077806, P01HL077806, P01HL077806, P01HL077806, P01HL077806,
   P01HL077806, R01HL125356, P01HL077806, P01HL077806, P01HL077806,
   P01HL077806, P01HL077806, P01HL077806, P01HL077806, P01HL077806] Funding
   Source: NIH RePORTER
FX This work was sponsored by the American Heart Association, Scientist
   Development Grants nos. 09SDG2250933 and 13GRNT16400010; and Department
   of Defense grant W911NF-12-1-0493/61758-LS to M.G. Bonini.
CR Aktan F, 2004, LIFE SCI, V75, P639, DOI 10.1016/j.lfs.2003.10.042
   Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592
   Badrichani AZ, 1999, J CLIN INVEST, V103, P543, DOI 10.1172/JCI2517
   Baetz A, 2004, J BIOL CHEM, V279, P54708, DOI 10.1074/jbc.M410992200
   Baltimore D, 2011, NAT IMMUNOL, V12, P683, DOI 10.1038/ni.2072
   Basak S, 2007, CELL, V128, P369, DOI 10.1016/j.cell.2006.12.033
   Ben-Neriah Y, 2003, MOL CELL, V12, P1344, DOI 10.1016/S1097-2765(03)00493-3
   Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004
   Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8
   Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936
   delaTorre A, 1999, J IMMUNOL, V162, P4101
   deLuca LS, 2012, NAT REV IMMUNOL, V12, P339, DOI 10.1038/nri3193
   Dixon B, 2004, ANAESTH INTENS CARE, V32, P619, DOI 10.1177/0310057X0403200502
   Dombrovskiy VY, 2007, CRIT CARE MED, V35, P1244, DOI 10.1097/01.CCM.0000261890.41311.E9
   Driessler F, 2004, CLIN EXP IMMUNOL, V135, P64, DOI 10.1111/j.1365-2249.2004.02342.x
   Duma D, 2011, EUR J PHARMACOL, V668, P285, DOI 10.1016/j.ejphar.2011.05.065
   Edgley AJ, 2012, CARDIOVASC THER, V30, pe30, DOI 10.1111/j.1755-5922.2010.00228.x
   Fieren MWJA, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/976241
   Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787
   Geng H, 2009, EMBO REP, V10, P381, DOI 10.1038/embor.2009.10
   Gingras S, 2004, J BIOL CHEM, V279, P54702, DOI 10.1074/jbc.M411043200
   Green LS, 2012, BIOCHEMISTRY-US, V51, P2157, DOI 10.1021/bi201785u
   GROLLMAN AP, 1968, J BIOL CHEM, V243, P4089
   Han S, 2008, BIOCHEM BIOPH RES CO, V377, P612, DOI 10.1016/j.bbrc.2008.10.017
   HANDY RLC, 1995, BRIT J PHARMACOL, V116, P2349, DOI 10.1111/j.1476-5381.1995.tb15078.x
   Hickey MJ, 1997, FASEB J, V11, P955
   Huang Z, 2012, J BIOL CHEM, V287, P4492, DOI 10.1074/jbc.M111.315598
   Hume D A, 2001, BMC Immunol, V2, P11, DOI 10.1186/1471-2172-2-11
   Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0
   Jacobson JR, 2009, TRANSL RES, V154, P219, DOI 10.1016/j.trsl.2009.07.012
   Javaid K, 2003, CIRC RES, V92, P1089, DOI 10.1161/01.RES.0000072971.88704.CB
   Jeon YJ, 1999, TOXICOL LETT, V104, P195, DOI 10.1016/S0378-4274(98)00372-5
   Kanwar JR, 2009, CURR MED CHEM, V16, P2373, DOI 10.2174/092986709788682155
   Kelleher ZT, 2007, J BIOL CHEM, V282, P30667, DOI 10.1074/jbc.M705929200
   Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6
   KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249
   Koelink PJ, 2012, PHARMACOL THERAPEUT, V133, P1, DOI 10.1016/j.pharmthera.2011.06.008
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Lange M, 2010, BIOCHEM BIOPH RES CO, V399, P286, DOI 10.1016/j.bbrc.2010.07.071
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Li N, 2011, CANCER CELL, V19, P429, DOI 10.1016/j.ccr.2011.03.018
   Lin YC, 2012, FREE RADICAL BIO MED, V52, P1844, DOI 10.1016/j.freeradbiomed.2012.02.028
   Linossi EM, 2012, IUBMB LIFE, V64, P316, DOI 10.1002/iub.1011
   Liu YH, 2011, NAT REV NEPHROL, V7, P684, DOI 10.1038/nrneph.2011.149
   Ma A, 2012, NAT REV IMMUNOL, V12, P774, DOI 10.1038/nri3313
   MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323
   Marshall HE, 2004, P NATL ACAD SCI USA, V101, P8841, DOI 10.1073/pnas.0403034101
   Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236
   Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200
   Miki S, 2005, CRIT CARE MED, V33, P716, DOI 10.1097/01.CCM.0000159200.69314.3A
   Nacher Maria, 2011, Front Biosci (Schol Ed), V3, P1089
   Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1
   Nicholas C, 2007, J IMMUNOL, V179, P7121, DOI 10.4049/jimmunol.179.10.7121
   Panettieri RA, 2008, AM J RESP CRIT CARE, V177, P248, DOI 10.1164/rccm.200708-1217PP
   Park SH, 2003, DNA CELL BIOL, V22, P131, DOI 10.1089/104454903321515931
   Parsons PE, 2005, CRIT CARE MED, V33, P1, DOI 10.1097/01.CCM.0000149854.61192.DC
   PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214
   Pittet LA, 2011, AM J RESP CELL MOL, V45, P573, DOI 10.1165/rcmb.2010-0210OC
   Porras M, 2006, AM J PHYSIOL-GASTR L, V290, pG423, DOI 10.1152/ajpgi.00323.2005
   Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101
   de Souza KPR, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-267
   Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214
   Rossi B, 2011, J LEUKOCYTE BIOL, V89, P539, DOI 10.1189/jlb.0710432
   Ruland J, 2011, NAT IMMUNOL, V12, P709, DOI 10.1038/ni.2055
   Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8
   Sabatel H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038246
   Sadik CD, 2011, TRENDS IMMUNOL, V32, P452, DOI 10.1016/j.it.2011.06.008
   Sadikot RT, 2001, AM J RESP CRIT CARE, V164, P873, DOI 10.1164/ajrccm.164.5.2008059
   Saluja R, 2010, CELL TISSUE RES, V340, P381, DOI 10.1007/s00441-010-0947-y
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schodel J, 2009, ATHEROSCLEROSIS, V206, P383, DOI 10.1016/j.atherosclerosis.2009.02.033
   Shi LB, 2003, P NATL ACAD SCI USA, V100, P241, DOI 10.1073/pnas.0136863100
   Strebovsky J, 2011, FASEB J, V25, P863, DOI 10.1096/fj.10-170597
   Sun BC, 2012, J HEPATOL, V56, P704, DOI 10.1016/j.jhep.2011.09.020
   Sun XC, 2011, ACS MED CHEM LETT, V2, P402, DOI 10.1021/ml200045s
   Takizawa H, 2012, BLOOD, V119, P2991, DOI 10.1182/blood-2011-12-380113
   Tiruppathi C, 2008, J BIOL CHEM, V283, P4210, DOI 10.1074/jbc.M703153200
   Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091
   Villanueva C, 2010, FREE RADICAL BIO MED, V49, P307, DOI 10.1016/j.freeradbiomed.2010.04.004
   Vogel SM, 2000, PHYSIOL GENOMICS, V4, P137
   Wang W, 2004, AM J PHYSIOL-RENAL, V287, pF1044, DOI 10.1152/ajprenal.00136.2004
   Xia YY, 1997, AM J PATHOL, V151, P375
   Yuan ZR, 2004, LIFE SCI, V74, P3199, DOI 10.1016/j.lfs.2003.10.037
NR 87
TC 50
Z9 51
U1 1
U2 5
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD SEP 21
PY 2015
VL 212
IS 10
BP 1725
EP 1738
DI 10.1084/jem.20140654
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA CW6VB
UT WOS:000365135200019
PM 26324446
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Alczuk, SDD
   Bonfim-Mendonca, PD
   Rocha-Brischiliari, SC
   Shinobu-Mesquita, CS
   Martins, HPR
   Gimenes, F
   de Abreu, ALP
   Carvalho, MDD
   Pelloso, SM
   Svidzinski, TIE
   Consolaro, MEL
AF Dantas Alczuk, Silvia de Souza
   Bonfim-Mendonca, Patricia de Souza
   Rocha-Brischiliari, Sheila Cristina
   Shinobu-Mesquita, Cristiane Suemi
   Rodrigues Martins, Helen Priscilla
   Gimenes, Fabricia
   Pimenta de Abreu, Andre Luelsdorf
   de Barros Carvalho, Maria Dalva
   Pelloso, Sandra Marisa
   Estivalet Svidzinski, Terezinha Inez
   Lopes Consolaro, Marcia Edilaine
TI EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON VAGINAL Candida spp.
   ISOLATION IN HIV-INFECTED COMPARED TO HIV-UNINFECTED WOMEN
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE HIV; Vulvovaginal candidiasis; Candida spp.; Antiretroviral therapy
ID COLONIZATION; FLUCONAZOLE; RESISTANCE; MUCOSA; YEASTS
AB Vulvovaginal candidiasis (VVC) in HIV-infected women contributed to the impairment of their quality of life. The aim of this study was to evaluate the effect of highly active antiretroviral therapy (HAART) use on the vaginal Candida spp. isolation in HIV-infected compared to HIV-uninfected women. This cross-sectional study included 178 HIV-infected (HIV group) and 200 HIV-uninfected women (control) that were studied at the Specialized Assistance Service (SAE) for sexually transmitted diseases (STD)/AIDS of the city of Maringa, Brazil, from April 1 to October 30, 2011. The yeasts were isolated and identified by phenotypic and molecular methods. The in vitro antifungal susceptibility to fluconazole, itraconazole, nystatin and amphotericin B was tested by the reference microdilution method. Higher frequencies of total vaginal Candida spp. isolation were found in the HIV-infected group than in the control group. However, both groups showed a similar frequency of colonization and VVC. Although C. albicans was the most frequent and sensitive to azolics and polyenes in both HIV-infected and uninfected women, the emerging resistance of C. glabrata to amphotericin B in the HIV-infected women was observed. Although higher frequency of vaginal Candida spp. isolation had been observed in the HIV-infected than in HIV-uninfected women, colonization and VVC showed similar frequency in both groups, indicating that HAART appears to protect against vaginal colonization and VVC.
C1 [Dantas Alczuk, Silvia de Souza; Bonfim-Mendonca, Patricia de Souza; Shinobu-Mesquita, Cristiane Suemi; Rodrigues Martins, Helen Priscilla; Gimenes, Fabricia; Pimenta de Abreu, Andre Luelsdorf; Estivalet Svidzinski, Terezinha Inez; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Anal Clin & Biomed, BR-87020900 Maringa, Parana, Brazil.
   [Rocha-Brischiliari, Sheila Cristina; Pelloso, Sandra Marisa] Univ Estadual Maringa, Dept Nursing, BR-87020900 Maringa, Parana, Brazil.
   [de Barros Carvalho, Maria Dalva] Univ Estadual Maringa, Dept Med, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin & Biomed, Av Colombro 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Shinobu Mesquita,
   Cristiane/0000-0002-1089-9246
FU Fundacao Araucaria Apoio ao Desenvolvimento Cientifico e Tecnologico do
   ParanaFundacao Araucaria; Ministerio da Saude do Brasil [EFP
   00002873-SISCT]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES), Brazilian GovernmentCAPES [AUX-PE-PRODOC 2571/2010]
FX This study was supported by grants from the Fundacao Araucaria Apoio ao
   Desenvolvimento Cientifico e Tecnologico do Parana, the Ministerio da
   Saude do Brasil, (Grant number EFP 00002873-SISCT) and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES, AUX-PE-PRODOC
   2571/2010), Brazilian Government.
CR Beltrame A, 2006, INT J STD AIDS, V17, P260, DOI 10.1258/095646206776253435
   Brasil. Ministerio da Saude, 2012, B EPIDEMIOL AIDS, V8, P9
   Clinical and Laboratory Standards Institute, 2008, M27A3 CLSI
   Cortese Margaret M., 2009, Morbidity and Mortality Weekly Report, V58, P1
   Dalben-Dota KF, 2010, J ALTERN COMPLEM MED, V16, P285, DOI 10.1089/acm.2009.0281
   Dota KFD, 2008, ACTA BIOQUIM CLIN L, V110, P66
   Duerr A, 2003, OBSTET GYNECOL, V101, P548, DOI 10.1016/S0029-7844(02)02729-1
   Ghannoum MA, 1999, CLIN MICROBIOL REV, V12, P501, DOI 10.1128/CMR.12.4.501
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Holland J, 2003, SEX TRANSM INFECT, V79, P249, DOI 10.1136/sti.79.3.249
   Kurtzman C, 1998, YEASTS TAXONOMIC STU
   Lopes Consolaro Marcia Edilaine, 2004, Rev Iberoam Micol, V21, P202
   Merenstein D, 2013, AIDS RES HUM RETROV, V29, P30, DOI [10.1089/aid.2012.0269, 10.1089/AID.2012.0269]
   Moragues MD, 2003, INFECT IMMUN, V71, P5273, DOI 10.1128/IAI.71.9.5273-5279.2003
   Mumtaz G, 2011, SEX TRANSM INFECT, V87, P101, DOI 10.1136/sti.2010.043711
   Nardin M. E., 2000, Revista Argentina de Micologia, V22, P13
   Oliveira PM, 2011, BRAZ J INFECT DIS, V15, P239, DOI [10.1590/S1413-86702011000300010, 10.1016/S1413-8670(11)70182-9]
   Pascon Renata C, 2011, Enzyme Res, V2011, P679624, DOI 10.4061/2011/679624
   Ray A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008739.pub2
   REESE RE, 1991, PRACTICAL APPROACH I
   Ribeiro MA, 2005, MED MYCOL, V43, P647, DOI 10.1080/13693780500093838
   Ribeiro MA, 2004, MYCOPATHOLOGIA, V157, P255, DOI 10.1023/B:MYCO.0000024173.02010.a5
   Martins HPR, 2012, ACTA DERM-VENEREOL, V92, P78, DOI 10.2340/00015555-1194
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Sobel JD, 1998, AM J OBSTET GYNECOL, V178, P203, DOI 10.1016/S0002-9378(98)80001-X
   Spanu T, 2012, J CLIN MICROBIOL, V50, P176, DOI 10.1128/JCM.05742-11
   van de Wijgert DHHM, 2008, JAIDS-J ACQ IMM DEF, V48, P203, DOI 10.1097/QAI.0b013e3181743936
   Wei YP, 2010, INT J GYNECOL OBSTET, V110, P227, DOI 10.1016/j.ijgo.2010.04.026
NR 28
TC 2
Z9 5
U1 0
U2 3
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD MAR-APR
PY 2015
VL 57
IS 2
BP 169
EP 174
DI 10.1590/S0036-46652015000200012
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CH0JQ
UT WOS:000353706200012
PM 25923898
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Hart, PC
   Mao, M
   de Abreu, ALP
   Ansenberger-Fricano, K
   Ekoue, DN
   Ganini, D
   Kajdacsy-Balla, A
   Diamond, AM
   Minshall, RD
   Consolaro, MEL
   Santos, JH
   Bonini, MG
AF Hart, Peter C.
   Mao, Mao
   de Abreu, Andre Luelsdorf P.
   Ansenberger-Fricano, Kristine
   Ekoue, Dede N.
   Ganini, Douglas
   Kajdacsy-Balla, Andre
   Diamond, Alan M.
   Minshall, Richard D.
   Consolaro, Marcia E. L.
   Santos, Janine H.
   Bonini, Marcelo G.
TI MnSOD upregulation sustains the Warburg effect via mitochondrial ROS and
   AMPK-dependent signalling in cancer
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MANGANESE SUPEROXIDE-DISMUTASE; ACTIVATED PROTEIN-KINASE;
   HYPOXIA-INDUCIBLE FACTOR; CELL-CYCLE PROGRESSION; INHIBIT APOPTOSIS;
   OXIDATIVE STRESS; EPITHELIAL-CELLS; LIFE-SPAN; C-MYC; BREAST
AB Manganese superoxide dismutase (MnSOD/SOD2) is a mitochondria-resident enzyme that governs the types of reactive oxygen species egressing from the organelle to affect cellular signalling. Here we demonstrate that MnSOD upregulation in cancer cells establishes a steady flow of H2O2 originating from mitochondria that sustains AMP-activated kinase (AMPK) activation and the metabolic shift to glycolysis. Restricting MnSOD expression or inhibiting AMPK suppresses the metabolic switch and dampens the viability of transformed cells indicating that the MnSOD/AMPK axis is critical to support cancer cell bioenergetics. Recapitulating in vitro findings, clinical and epidemiologic analyses of MnSOD expression and AMPK activation indicated that the MnSOD/AMPK pathway is most active in advanced stage and aggressive breast cancer subtypes. Taken together, our results indicate that MnSOD serves as a biomarker of cancer progression and acts as critical regulator of tumour cell metabolism.
C1 [Hart, Peter C.; Mao, Mao; de Abreu, Andre Luelsdorf P.; Ansenberger-Fricano, Kristine; Bonini, Marcelo G.] Univ Illinois, Dept Med, Chicago, IL 60612 USA.
   [Hart, Peter C.; Ekoue, Dede N.; Kajdacsy-Balla, Andre; Diamond, Alan M.; Bonini, Marcelo G.] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA.
   [Mao, Mao; de Abreu, Andre Luelsdorf P.; Ansenberger-Fricano, Kristine; Minshall, Richard D.; Bonini, Marcelo G.] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA.
   [de Abreu, Andre Luelsdorf P.; Consolaro, Marcia E. L.] Univ Estadual Maringa, BR-87020900 Maringa, Parana, Brazil.
   [Ganini, Douglas] NIEHS, Free Radical Metabolite Sect, Lab Toxicol & Pharmacol, NIH, Res Triangle Pk, NC 27709 USA.
   [Minshall, Richard D.] Univ Illinois, Dept Anesthesiol, Chicago, IL 60612 USA.
   [Santos, Janine H.] Univ Med & Dent New Jersey, Dept Physiol & Pharmacol, Newark, NJ 07103 USA.
RP Bonini, MG (corresponding author), Univ Illinois, Dept Med, 909 South Wolcott Ave,COMRB 1131, Chicago, IL 60612 USA.
EM mbonini@uic.edu
RI Mao, Mao/E-3783-2013; Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Mao, Mao/0000-0003-1524-8853; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865; Hart, Peter/0000-0003-1843-9102
FU US Department of Defense (ARO)United States Department of Defense
   [61758-LS]; NCRR/NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [S10RR027848]; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [HL072742, P01 HL60678]; CAPES-Coordenacao de Aperfeicoamento Pessoal,
   Ministerio da Ciencia e Tecnologia/Brazil [RO1 CA101053, A109/2013]; 
   [1R21CA182103-01]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R21CA182103, R01CA101053, R01CA101053,
   R21CA182103, R01CA101053, R01CA101053, R21CA182103, R21CA182103] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Research Resources (NCRR)
   [S10RR027848] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, T32HL072742, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   T32HL072742, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   T32HL072742, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, T32HL072742,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, T32HL072742, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, T32HL072742, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, T32HL072742, P01HL060678, P01HL060678, P01HL060678,
   T32HL072742, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, T32HL072742, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, P01HL060678,
   P01HL060678, P01HL060678, P01HL060678, P01HL060678, T32HL072742] Funding
   Source: NIH RePORTER
FX We are indebted to Drs Larry W. Oberley (in memoriam) and Frederick
   Domann (University of Iowa) for the generous gift of cell lines stably
   overexpressing MnSOD, Dr Kevin P. Claffey (University of Connecticut)
   for the generous gift of MCF-7-AMPKa1 -/- cells, Dr Kevin Struhl
   (Harvard University) for the gift of the MCF10A lines expressing v-Src
   under ER induction, Patricia Mavrogianis, Andrew Hall and Emily Ionetz
   at the Research Histology Core at the University of Illinois at Chicago
   for providing histology services, Dr Soumen Bera, Emmanuel Ansong, Paula
   Green, Alyssa Master and M. Saqib Baig for technical assistance, and for
   funding provided by the US Department of Defense (ARO no. 61758-LS) to
   M.G.B, the NCRR/NIH (S10RR027848) to M.G.B., 1R21CA182103-01 to A.M.D.
   and M.G.B. K.A.-F. and P.C.H. were supported by NIH T32 (HL072742). We
   also acknowledge gifts from RO1 CA101053 to A.M.D., NIH P01 HL60678 to
   R.D.M., CAPES-Coordenacao de Aperfeicoamento Pessoal, Ministerio da
   Ciencia e Tecnologia/Brazil-A109/2013 to M.G.B. and M.E.L.C.
CR Ansenberger-Fricano K, 2013, FREE RADICAL BIO MED, V54, P116, DOI 10.1016/j.freeradbiomed.2012.08.573
   Bell EL, 2008, ANTIOXID REDOX SIGN, V10, P635, DOI 10.1089/ars.2007.1655
   Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536
   Britschgi A, 2013, P NATL ACAD SCI USA, V110, pE1026, DOI 10.1073/pnas.1217072110
   Brunelle JK, 2004, J BIOL CHEM, V279, P4305, DOI 10.1074/jbc.M312241200
   Bryson JM, 2002, J BIOL CHEM, V277, P11392, DOI 10.1074/jbc.M110927200
   Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107
   Cai Y, 2007, FREE RADICAL BIO MED, V42, P64, DOI 10.1016/j.freeradbiomed.2006.09.018
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Chaiswing L, 2014, FREE RADICAL BIO MED, V67, P342, DOI 10.1016/j.freeradbiomed.2013.11.006
   Chen CH, 2008, SHOCK, V29, P300, DOI 10.1097/shk.0b013e3181454295
   Chetboun M, 2012, J CELL BIOCHEM, V113, P1966, DOI 10.1002/jcb.24065
   Damelin LH, 2007, J CELL BIOCHEM, V101, P723, DOI 10.1002/jcb.21229
   DAWSON DM, 1964, SCIENCE, V143, P929, DOI 10.1126/science.143.3609.929
   Dhar SK, 2011, CANCER RES, V71, P6684, DOI 10.1158/0008-5472.CAN-11-1233
   Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101
   Eldridge A, 2012, FREE RADICAL BIO MED, V53, P1838, DOI 10.1016/j.freeradbiomed.2012.08.589
   Ennen M, 2011, FREE RADICAL BIO MED, V50, P1771, DOI 10.1016/j.freeradbiomed.2011.03.013
   Erickson JR, 2008, CELL, V133, P462, DOI 10.1016/j.cell.2008.02.048
   Glick D, 2012, MOL CELL BIOL, V32, P2570, DOI 10.1128/MCB.00167-12
   Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006
   Guo HL, 2013, CARDIOVASC DRUG THER, V27, P189, DOI 10.1007/s10557-013-6442-4
   Hamanaka RB, 2012, J EXP MED, V209, P211, DOI 10.1084/jem.20120162
   Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110
   Holley AK, 2010, MITOCHONDRION, V10, P649, DOI 10.1016/j.mito.2010.06.003
   Holley AK, 2010, ANN NY ACAD SCI, V1201, P72, DOI 10.1111/j.1749-6632.2010.05612.x
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066
   Kang MC, 2013, FOOD CHEM TOXICOL, V53, P294, DOI 10.1016/j.fct.2012.12.012
   Kao KJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-143
   Kelly PN, 2011, CELL DEATH DIFFER, V18, P1414, DOI 10.1038/cdd.2011.17
   Knight JA, 2004, CANCER EPIDEM BIOMAR, V13, P146, DOI 10.1158/1055-9965.EPI-03-0164
   KOCH OR, 1994, BIOCHEM BIOPH RES CO, V201, P1356, DOI 10.1006/bbrc.1994.1853
   Kulawiec M, 2008, CANCER BIOL THER, V7, P1732, DOI 10.4161/cbt.7.11.6729
   Lawler JM, 2009, AM J PHYSIOL-REG I, V296, pR1496, DOI 10.1152/ajpregu.90314.2008
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Lim YC, 2012, MOL CANCER THER, V11, P1863, DOI 10.1158/1535-7163.MCT-11-1044
   Luczak ED, 2014, J MOL CELL CARDIOL, V73, P112, DOI 10.1016/j.yjmcc.2014.02.004
   Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014
   Marin-Valencia I, 2012, CELL METAB, V15, P827, DOI 10.1016/j.cmet.2012.05.001
   Marosi K, 2012, NEUROSCIENCE, V226, P21, DOI 10.1016/j.neuroscience.2012.09.001
   Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9
   McDuff FKE, 2011, CELL SIGNAL, V23, P6, DOI 10.1016/j.cellsig.2010.07.004
   Meng ZP, 2013, MOL CANCER THER, V12, P2067, DOI 10.1158/1535-7163.MCT-13-0314
   Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642
   Na HK, 2008, ARCH BIOCHEM BIOPHYS, V476, P171, DOI 10.1016/j.abb.2008.04.003
   Negoro S, 2001, CIRCULATION, V104, P979, DOI 10.1161/hc3401.095947
   Qing GL, 2010, CANCER RES, V70, P10351, DOI 10.1158/0008-5472.CAN-10-0740
   Quiros I, 2009, INT J CANCER, V125, P1497, DOI 10.1002/ijc.24501
   Reddi AR, 2013, CELL, V152, P224, DOI 10.1016/j.cell.2012.11.046
   Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543
   Robey RB, 2009, SEMIN CANCER BIOL, V19, P25, DOI 10.1016/j.semcancer.2008.11.010
   Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351
   Sarsour EH, 2012, CANCER RES, V72, P3807, DOI 10.1158/0008-5472.CAN-11-1063
   Sgambato A, 2009, CANCER SCI, V100, P1026, DOI 10.1111/j.1349-7006.2009.01141.x
   Solomon H, 2011, J PATHOL, V225, P475, DOI 10.1002/path.2988
   Sullivan LB, 2014, CELL CYCLE, V13, P347, DOI 10.4161/cc.27513
   Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108
   Tormos KV, 2011, CELL METAB, V14, P537, DOI 10.1016/j.cmet.2011.08.007
   Vrailas-Mortimer A, 2011, DEV CELL, V21, P783, DOI 10.1016/j.devcel.2011.09.002
   WARBURG O, 1956, SCIENCE, V124, P269
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
   Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.3.CO;2-V
   Wheaton WW, 2011, AM J PHYSIOL-CELL PH, V300, pC385, DOI 10.1152/ajpcell.00485.2010
   Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1
   Woo DK, 2012, AM J PATHOL, V180, P24, DOI 10.1016/j.ajpath.2011.10.003
   Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006
   Zarse K, 2012, CELL METAB, V15, P451, DOI 10.1016/j.cmet.2012.02.013
   Zhang M, 2008, CIRC RES, V102, P328, DOI 10.1161/CIRCRESAHA.107.163253
   Zhao F, 2010, ONCOGENE, V29, P2962, DOI 10.1038/onc.2010.67
NR 70
TC 119
Z9 126
U1 1
U2 36
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB
PY 2015
VL 6
AR 6053
DI 10.1038/ncomms7053
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC0OO
UT WOS:000350035500001
PM 25651975
OA DOAJ Gold, Green Accepted
DA 2020-12-08
ER

PT J
AU Malaguti, N
   Bahls, LD
   Uchimura, NS
   Gimenes, F
   Consolaro, MEL
AF Malaguti, Natalia
   Bahls, Larissa Danielle
   Uchimura, Nelson Shozo
   Gimenes, Fabricia
   Lopes Consolaro, Marcia Edilaine
TI Sensitive Detection of Thirteen Bacterial Vaginosis-Associated Agents
   Using Multiplex Polymerase Chain Reaction
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID GARDNERELLA-VAGINALIS; UREAPLASMA-UREALYTICUM; ATOPOBIUM-VAGINAE;
   RISK-FACTOR; PCR; MYCOPLASMA; INFECTIONS; DIAGNOSIS; WOMEN;
   QUANTIFICATION
AB Bacterial vaginosis (BV) is characterized by a polymicrobial proliferation of anaerobic bacteria and depletion of lactobacilli, which are components of natural vaginal microbiota. Currently, there are limited conventional methods for BV diagnosis, and these methods are time-consuming, expensive, and rarely allow for the detection of more than one agent simultaneously. Therefore, we conceived and validated a multiplex polymerase chain reaction (M-PCR) assay for the simultaneous screening of thirteen bacterial vaginosis-associated agents (BV-AAs) related to symptomatic BV: Gardnerella vaginalis, Mobiluncus curtisii, Mobiluncus mulieris, Bacteroides fragilis, Mycoplasma hominis, Atopobium vaginae, Ureaplasma urealyticum, Megasphaera type I, Clostridia-like bacteria vaginosis-associated bacteria (BVABs) 1, 2, and 3, Sneathia sanguinegens, and Mycoplasma genitalium. The overall validation parameters of M-PCR compared to single PCR(sPCR) were extremely high, including agreement of 99.1% and sensitivity, specificity, and positive predictive values of 100.0%, negative predictive value of 97.0%, accuracy of 99.3%, and agreement with Nugent results of 100.0%. The prevalence of BV-AAs was very high (72.6%), and simultaneous agents were detected in 53.0%, which demonstrates the effectiveness of the M-PCR assay. Therefore, the M-PCR assay has great potential to impact BV diagnostic methods in vaginal samples and diminish associated complications in the near future.
C1 [Malaguti, Natalia; Bahls, Larissa Danielle; Gimenes, Fabricia; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol & STD Lab, BR-87020900 Maringa, Parana, Brazil.
   [Uchimura, Nelson Shozo] Univ Estadual Maringa, Dept Med, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol & STD Lab, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@uem.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Brazilian GovernmentCAPES [AUX-PE-PRODOC 2571/2010, PVE A109/2013]
FX This work was supported by grants from Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), AUX-PE-PRODOC 2571/2010 and PVE
   A109/2013, Brazilian Government.
CR AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9
   Bahar H, 2005, INT J ANTIMICROB AG, V25, P268, DOI 10.1016/j.ijantimicag.2004.09.019
   Brotman RM, 2008, CLIN INFECT DIS, V47, P44, DOI 10.1086/588662
   Cartwright CP, 2012, J CLIN MICROBIOL, V50, P2321, DOI 10.1128/JCM.00506-12
   Chawla R, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/365194
   Cohen C. R., 2012, INFECT DIS OBSTET GY, V2012
   Ferris MJ, 2004, J CLIN MICROBIOL, V42, P5892, DOI [10.1128/JCM.42.12.5892-5894.2004, 10.1128/jcm.42.12.5892-5894.2004]
   Fethers K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030633
   Foxman B, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.10.003
   Fredricks DN, 2007, J CLIN MICROBIOL, V45, P3270, DOI 10.1128/JCM.01272-07
   Fredricks DN, 2009, J CLIN MICROBIOL, V47, P721, DOI 10.1128/JCM.01384-08
   Fredricks DN, 2005, NEW ENGL J MED, V353, P1899, DOI 10.1056/NEJMoa043802
   Fredricks DN, 1999, CLIN INFECT DIS, V29, P475, DOI 10.1086/598618
   Gergova RT, 2013, BRAZ J INFECT DIS, V17, P313, DOI 10.1016/j.bjid.2012.10.026
   Gillet E, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-10
   Gimenes F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098862
   Haggerty CL, 2009, SEX TRANSM INFECT, V85, P242, DOI 10.1136/sti.2008.032821
   Haggerty CL, 2004, CLIN INFECT DIS, V39, P990, DOI 10.1086/423963
   Harwich MD, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-375
   Hay P., 2014, MEDICINE, V42, P359, DOI DOI 10.1016/J.MPMED.2014.04.011
   HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503
   Huppert JS, 2013, J PEDIATR ADOL GYNEC, V26, P36, DOI 10.1016/j.jpag.2012.09.005
   Ingianni A, 1997, FEMS IMMUNOL MED MIC, V18, P61, DOI 10.1016/S0928-8244(97)00024-2
   Klebanoff MA, 2005, AM J OBSTET GYNECOL, V192, P470, DOI 10.1016/j.ajog.2004.07.017
   Klebanoff MA, 2004, OBSTET GYNECOL, V104, P267, DOI 10.1097/01.AOG.0000134783.98382.b0
   Leitich H, 2003, AM J OBSTET GYNECOL, V189, P139, DOI 10.1067/mob.2003.339
   Ling ZX, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-488
   Livengood Charles H, 2009, Rev Obstet Gynecol, V2, P28
   Mallard K, 2005, J MICROBIOL METH, V60, P13, DOI 10.1016/j.mimet.2004.08.005
   Marrazzo JM, 2011, ANAEROBE, V17, P186, DOI 10.1016/j.anaerobe.2011.03.016
   McIver CJ, 2009, J CLIN MICROBIOL, V47, P1358, DOI 10.1128/JCM.01873-08
   McKechnie ML, 2009, J CLIN MICROBIOL, V47, P1871, DOI 10.1128/JCM.00120-09
   Menard JP, 2008, CLIN INFECT DIS, V47, P33, DOI 10.1086/588661
   Muvunyi CM, 2011, DIAGN MICR INFEC DIS, V71, P29, DOI 10.1016/j.diagmicrobio.2011.06.005
   Nassar FA, 2008, ADV MED SCI-POLAND, V53, P80, DOI 10.2478/v10039-008-0020-1
   NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991
   Obata-Yasuoka M, 2002, OBSTET GYNECOL, V100, P759, DOI 10.1016/S0029-7844(02)02201-9
   Peipert JF, 2001, AM J OBSTET GYNECOL, V184, P856, DOI 10.1067/mob.2001.113847
   Pepin J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025082
   Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107
   RILEY DE, 1991, J CLIN MICROBIOL, V29, P2746, DOI 10.1128/JCM.29.12.2746-2751.1991
   Schwebke Jane R, 2009, Curr Infect Dis Rep, V11, P143, DOI 10.1007/s11908-009-0021-7
   Shipitsyna E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060670
   SILVER HM, 1989, AM J OBSTET GYNECOL, V161, P808, DOI 10.1016/0002-9378(89)90406-7
   Souza RP, 2013, AM J TROP MED HYG, V89, P1199, DOI 10.4269/ajtmh.13-0315
   Srinivasan S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037818
   Sweet R L, 2000, Infect Dis Obstet Gynecol, V8, P184, DOI 10.1155/S1064744900000260
   Swidsinski A, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.06.039
   Tiveljung A, 1996, INT J SYST BACTERIOL, V46, P332, DOI 10.1099/00207713-46-1-332
   Turovskiy Y, 2011, J APPL MICROBIOL, V110, P1105, DOI 10.1111/j.1365-2672.2011.04977.x
   Twin J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076892
   Ugwumadu AHN, 2002, CURR OPIN OBSTET GYN, V14, P115, DOI 10.1097/00001703-200204000-00003
   Waites KB, 2012, J MOL DIAGN, V14, P437, DOI 10.1016/j.jmoldx.2012.06.001
NR 53
TC 13
Z9 13
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
VL 2015
AR 645853
DI 10.1155/2015/645853
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CJ4GC
UT WOS:000355441800001
PM 26078959
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Ratti, BA
   Godoy, JSR
   Mendonca, PDB
   Bidoia, DL
   Nakamura, TU
   Nakamura, CV
   Consolaro, MEL
   Svidzinski, TIE
   Silva, SD
AF Ratti, Bianca Altrao
   Ribeiro Godoy, Janine Silva
   Bonfim Mendonca, Patricia de Souza
   Bidoia, Danielle Lazarin
   Nakamura, Tania Ueda
   Nakamura, Celso Vataru
   Lopes Consolaro, Marcia Edilaine
   Estivalet Svidzinski, Terezinha Inez
   Silva, Sueli de Oliveira
TI Microbicidal activity of neutrophils is inhibited by isolates from
   recurrent vaginal candidiasis (RVVC) caused by Candida albicans through
   fungal thioredoxin reductase
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE Candida albicans; Neutrophils; Oxidants species; Thioredoxin reductase
ID MYELOPEROXIDASE; ACTIVATION; ASSAY; IMMUNOPATHOGENESIS; INFECTIONS;
   CHALLENGE; BLOOD; WOMEN
AB Vulvovaginal candidiasis (WC) is characterized by an infection of the vulva and vagina, mainly caused by Candida albicans, a commensal microorganism that inhabits the vaginal, digestive, and respiratory mucosae. Vulvovaginal candidiasis affects approximately 75% of women, and 5% develop the recurrent form (RVVC). The aim of the present study was to evaluate whether neutrophils microbicidal response is triggered when activated With RVVC isolates caused by C. albicans. Our results showed that RVVC isolates induced neutrophil migration but significantly decrease the microbicidal activity of neutrophils, compared with WC and ASS isolates. The microbicidal activity of neutrophils is highly dependent on the production of reactive oxygen species/reactive nitrogen species (ROS/RNS). However, this isolate induced detoxification of ROS/RNS produced by neutrophils, reflected by the high level of thiol groups and by the oxygen consumption. Therefore, RVVC isolates induced biochemical changes in the inflammatory response triggered by neutrophils, and these effects were mainly related to the detoxification of ROS/RNS through the thioredoxin reductase (TR), a key antioxidant enzyme in fungi. This might be one of the resistance mechanisms triggered by RVVC caused by C. albicans. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Ratti, Bianca Altrao; Ribeiro Godoy, Janine Silva] Univ Estadual Maringa, Programa Posgrad Biociencias Aplicadas Farm, BR-87020900 Maringa, PR, Brazil.
   [Bonfim Mendonca, Patricia de Souza] Univ Estadual Maringa, Programa Posgrad Ciencias Saude, BR-87020900 Maringa, PR, Brazil.
   [Bidoia, Danielle Lazarin] Univ Estadual Maringa, Programa Posgrad Ciencias Farmaceut, BR-87020900 Maringa, PR, Brazil.
   [Nakamura, Tania Ueda; Nakamura, Celso Vataru; Silva, Sueli de Oliveira] Univ Estadual Maringa, Dept Ciencias Basicas Saude, BR-87020900 Maringa, PR, Brazil.
   [Lopes Consolaro, Marcia Edilaine; Estivalet Svidzinski, Terezinha Inez] Univ Estadual Maringa, Dept Anal Clin & Biomed, BR-87020900 Maringa, PR, Brazil.
RP Silva, SD (corresponding author), Univ Estadual Maringa, Av Colombo 5-790,Bloco 1-90, BR-87020900 Maringa, PR, Brazil.
EM lautenschlager@uem.br
RI Nakamura, Celso Vataru/AAA-5620-2019; Consolaro, Marcia Edilaine
   Lopes/I-4932-2014; Lautenschlager, Sueli OS/P-2164-2017; Bidoia,
   Danielle Lazarin/AAQ-2024-2020
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Lautenschlager,
   Sueli OS/0000-0001-9303-0804; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Financiadora de Estudos e Projetos, Fundacao Araucaria
FX This study was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Financiadora de Estudos e Projetos,
   Fundacao Araucaria. Programa de Pos Graduacao em Biociencias Aplicadas a
   Farmacia da Universidade Estadual de Maringa, and Complexo de Centrais
   de Apoio a Pesquisa - UEM.
CR Abadio AKR, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-75
   Amouri I, 2013, ANN BIOL CLIN-PARIS, V71, P151, DOI 10.1684/abc.2013.0797
   Amouri I, 2012, J MED MICROBIOL, V61, P1091, DOI 10.1099/jmm.0.043992-0
   Arner ESJ, 1999, METHOD ENZYMOL, V300, P226
   Ayres-Sander CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060025
   BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
   Braga PC, 2007, MYCOSES, V50, P502, DOI 10.1111/j.1439-0507.2007.01412.x
   Butterfield TA, 2006, J ATHL TRAINING, V41, P457
   Dale DC, 2008, BLOOD, V112, P935, DOI 10.1182/blood-2007-12-077917
   Dunst CJ, 2012, J INTELLECT DEV DIS, V37, P89, DOI 10.3109/13668250.2012.673575
   Dypbukt JM, 2005, FREE RADICAL BIO MED, V39, P1468, DOI 10.1016/j.freeradbiomed.2005.07.008
   EDWARDS SW, 1987, J GEN MICROBIOL, V133, P3591
   Estabrook RW, 1967, METHOD ENZYMOL, V10, P41, DOI 10.1016/0076-6879(67)10010-4
   Fidel PL, 2004, INFECT IMMUN, V72, P2939, DOI 10.1128/IAI.72.5.2939-2946.2004
   Fidel PL, 2003, MED MYCOL, V41, P97, DOI 10.1080/714043904
   Fidel PL, 1996, CLIN MICROBIOL REV, V9, P335, DOI 10.1128/CMR.9.3.335
   Foxman B., 2013, J LOW GENIT TRACT DI, V12, P1
   Houle TT, 2005, HEADACHE, V45, P414, DOI 10.1111/j.1526-4610.2005.05092.x
   Jaeger M, 2013, CURR INFECT DIS REP, V15, P136, DOI 10.1007/s11908-013-0319-3
   Johnson SR, 2010, J LOW GENIT TRACT DI, V14, P287, DOI 10.1097/LGT.0b013e3181d85bb7
   Kalkanci A, 2013, J OBSTET GYNAECOL, V33, P378, DOI 10.3109/01443615.2013.767323
   Kemmelmeier E. G., 2011, Revista de Ciencias Farmaceuticas Basica e Aplicada, V32, P253
   Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697
   Liu L, 2013, APPL MICROBIOL BIOT, V97, P2551, DOI 10.1007/s00253-012-4368-6
   Lopes Consolaro Marcia Edilaine, 2004, Rev Iberoam Micol, V21, P202
   McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421
   PARRY MF, 1981, ANN INTERN MED, V95, P293, DOI 10.7326/0003-4819-95-3-293
   Pascon Renata C, 2011, Enzyme Res, V2011, P679624, DOI 10.4061/2011/679624
   Pattison DI, 2012, FREE RADICAL RES, V46, P975, DOI 10.3109/10715762.2012.667566
   Petry A, 2010, ANTIOXID REDOX SIGN, V13, P467, DOI 10.1089/ars.2009.3026
   Raska M, 2007, FOLIA MICROBIOL, V52, P297, DOI 10.1007/BF02931313
   Rimoin LP, 2013, DERMATOL THER, V26, P157, DOI 10.1111/dth.12034
   Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653
   Sheary Belinda, 2005, Aust Fam Physician, V34, P147
   Shukla AK, 2012, EUR J MED CHEM, V54, P49, DOI 10.1016/j.ejmech.2012.04.034
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Spanu T, 2012, J CLIN MICROBIOL, V50, P176, DOI 10.1128/JCM.05742-11
   Tasic Suzana, 2009, Med Pregl, V62, P427
   Tavanti A, 2006, MICROBES INFECT, V8, P791, DOI 10.1016/j.micinf.2005.09.016
   Walrand S, 2003, CLIN CHIM ACTA, V331, P103, DOI 10.1016/S0009-8981(03)00086-X
   Witkin S.S., 2000, IT J GYNECOL OBSTET, V3, P114
   Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287
NR 42
TC 9
Z9 10
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
EI 1090-2163
J9 CELL IMMUNOL
JI Cell. Immunol.
PD JAN
PY 2015
VL 293
IS 1
BP 22
EP 29
DI 10.1016/j.cellimm.2014.11.004
PG 8
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA AZ5GW
UT WOS:000348249200005
PM 25497972
DA 2020-12-08
ER

PT J
AU Capoci, IRG
   Bonfim-Mendonca, PD
   Arita, GS
   Pereira, RRD
   Consolaro, MEL
   Bruschi, ML
   Negri, M
   Svidzinski, TIE
AF Grenier Capoci, Isis Regina
   Bonfim-Mendonca, Patricia de Souza
   Arita, Glaucia Sayuri
   de Araujo Pereira, Raphaela Regina
   Lopes Consolaro, Marcia Edilaine
   Bruschi, Marcos Luciano
   Negri, Melyssa
   Estivalet Svidzinski, Terezinha Inez
TI Propolis Is an Efficient Fungicide and Inhibitor of Biofilm Production
   by Vaginal Candida albicans
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID CHEMICAL-COMPOSITION; ANTIMICROBIAL ACTIVITY; ANTIFUNGAL ACTIVITY;
   AMPHOTERICIN-B; BEE PROPOLIS; SUSCEPTIBILITY; ANTIOXIDANT; FLUCONAZOLE;
   TROPICALIS; EXTRACT
AB Vulvovaginal candidiasis (VVC) is one of the most common genital infections in women. The therapeutic arsenal remains restricted, and some alternatives to VVC treatment are being studied. The present study evaluated the influence of a propolis extractive solution (PES) on biofilm production by Candida albicans isolated from patients with VVC. Susceptibility testing was used to verify the minimum inhibitory concentration (MIC) of PES, with fluconazole and nystatin as controls. The biofilm formation of 29 vaginal isolates of C. albicans and a reference strain that were exposed to PES was evaluated using crystal violet staining. Colony-forming units were evaluated, proteins and carbohydrates of the matrix biofilm were quantified, and scanning electron microscopy was performed. The MIC of PES ranged from 68.35 to 546.87 mu g/mL of total phenol content in gallic acid. A concentration of 546.87 mu g/mL was able to cause the death of 75.8% of the isolates. PES inhibited biofilm formation by C. albicans from VVC. Besides antifungal activity, PES appears to present important antibiofilm activity on abiotic surfaces, indicating that it may have an additional beneficial effect in the treatment of VVC.
C1 [Grenier Capoci, Isis Regina; Bonfim-Mendonca, Patricia de Souza; Arita, Glaucia Sayuri; Negri, Melyssa; Estivalet Svidzinski, Terezinha Inez] Univ Estadual Maringa, Div Med Mycol, Teaching & Res Lab Clin Anal, Dept Clin Anal, BR-87020900 Maringa, Parana, Brazil.
   [de Araujo Pereira, Raphaela Regina; Bruschi, Marcos Luciano] Univ Estadual Maringa, Dept Pharm, Lab Res & Dev Drug Delivery Syst, BR-87020900 Maringa, Parana, Brazil.
   [Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol Lab, BR-87020900 Maringa, Parana, Brazil.
RP Svidzinski, TIE (corresponding author), Univ Estadual Maringa, Div Med Mycol, Teaching & Res Lab Clin Anal, Dept Clin Anal, Ave Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM terezinha.svidzinski@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Bruschi, Marcos
   Luciano/J-1871-2012
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Bruschi, Marcos
   Luciano/0000-0002-4838-5742; Negri, Melyssa/0000-0003-2071-8872
FU Fundacao AraucariaFundacao Araucaria; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
FX This study was supported by grants from the Fundacao Araucaria, Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), and
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES).
CR Agarwal G, 2012, CONTEMP CLIN DENT, V3, P256, DOI 10.4103/0976-237X.103614
   Al-Fattani MA, 2006, J MED MICROBIOL, V55, P999, DOI 10.1099/jmm.0.46569-0
   Almeida E. C. de, 2002, J. Venom. Anim. Toxins, V8, P191, DOI 10.1590/S0104-79302002000200002
   [Anonymous], 2010, FARMACOPEIA BRASILEI, V1-2
   [Anonymous], 1988, FARMACOPEIA BRASILEI
   Bankova V., 2009, Journal of ApiProduct and ApiMedical Science, V1, P23, DOI 10.3896/IBRA.4.01.2.01
   Barbaric M, 2011, J ETHNOPHARMACOL, V135, P772, DOI 10.1016/j.jep.2011.04.015
   Basma Abu Arra, 2011, Asian Pacific Journal of Tropical Biomedicine, V1, P20, DOI 10.1016/S2221-1691(11)60062-2
   Berretta AA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/641480
   Bruschi ML, 2007, J PHARM SCI-US, V96, P2074, DOI 10.1002/jps.20843
   Bruschi Marcos Luciano, 2002, Revista de Ciencias Farmaceuticas, V23, P289
   Burdock GA, 1998, FOOD CHEM TOXICOL, V36, P347, DOI 10.1016/S0278-6915(97)00145-2
   Calderone RA, 2001, TRENDS MICROBIOL, V9, P327, DOI 10.1016/S0966-842X(01)02094-7
   Carnacho DP, 2007, CONTRACEPTION, V76, P439, DOI 10.1016/j.contraception.2007.07.012
   Clinical and Laboratory Standards Institute (CLSI), 2008, M27S3 CLSI
   CLSI, 2008, M27A3 CLSI
   Coogan M M, 2006, Adv Dent Res, V19, P130
   Cushnie TPT, 2005, INT J ANTIMICROB AG, V26, P343, DOI 10.1016/j.ijantimicag.2005.09.002
   Frozza COD, 2013, FOOD CHEM TOXICOL, V52, P137, DOI 10.1016/j.fct.2012.11.013
   Dalben-Dota KF, 2010, J ALTERN COMPLEM MED, V16, P285, DOI 10.1089/acm.2009.0281
   Pereira RRD, 2013, J PHARM SCI-US, V102, P1222, DOI 10.1002/jps.23451
   de Castro PA, 2013, FUNGAL GENET BIOL, V60, P74, DOI 10.1016/j.fgb.2013.07.001
   Diskin CJ, 2007, NEPHRON CLIN PRACT, V107, pC128, DOI 10.1159/000110032
   Douglas L. Julia, 2002, Revista Iberoamericana de Micologia, V19, P139
   Douglas LJ, 2003, TRENDS MICROBIOL, V11, P30, DOI 10.1016/S0966-842X(02)00002-1
   Fan SR, 2011, MYCOSES, V54, P501, DOI 10.1111/j.1439-0507.2010.01887.x
   Fidel Paul L Jr, 2011, Curr Infect Dis Rep, V13, P102, DOI 10.1007/s11908-010-0143-y
   Imhof M, 2005, INT J GYNECOL OBSTET, V89, P127, DOI 10.1016/j.ijgo.2005.01.033
   Jin Y, 2003, J CLIN MICROBIOL, V41, P2961, DOI 10.1128/JCM.41.7.2961-2967.2003
   Khan MSA, 2012, J ETHNOPHARMACOL, V140, P416, DOI 10.1016/j.jep.2012.01.045
   Khodavandi A, 2010, MYCOPATHOLOGIA, V169, P287, DOI 10.1007/s11046-009-9251-3
   Kontoyiannis DP, 2001, MYCOSES, V44, P125, DOI 10.1046/j.1439-0507.2001.00649.x
   Lee Jeong Ah, 2010, Mycobiology, V38, P328, DOI 10.4489/MYCO.2010.38.4.328
   Lima Igara de Oliveira, 2006, Rev. bras. farmacogn., V16, P197, DOI 10.1590/S0102-695X2006000200011
   Liu XP, 2014, J MYCOL MED, V24, P106, DOI 10.1016/j.mycmed.2014.01.060
   Malich G, 1997, TOXICOLOGY, V124, P179, DOI 10.1016/S0300-483X(97)00151-0
   Mello J. C. P., 2003, FARMACOGNOSIA PLANTA
   Negri M, 2010, BRIT J BIOMED SCI, V67, P120
   Negri M, 2011, MED MYCOL, V49, P739, DOI 10.3109/13693786.2011.560619
   ODDS FC, 1994, J AM ACAD DERMATOL, V31, pS2, DOI 10.1016/S0190-9622(08)81257-1
   Park YK, 2002, J AGR FOOD CHEM, V50, P2502, DOI 10.1021/jf011432b
   Pereira RRA, 2013, LAT AM J PHARM, V32, P719
   Queiroz V. C. P. P., 2010, THESIS U ESTADUAL CA
   Rankovic B, 2010, MICROBIOLOGY+, V79, P809, DOI 10.1134/S0026261710060135
   Shin JH, 2002, J CLIN MICROBIOL, V40, P1244, DOI 10.1128/JCM.40.4.1244-1248.2002
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Sonmez S, 2005, J ETHNOPHARMACOL, V102, P371, DOI 10.1016/j.jep.2005.06.035
   Valentin Amparo, 2007, Revista Iberoamericana de Micologia, V24, P272
   Zhang JD, 2006, J ETHNOPHARMACOL, V103, P76, DOI 10.1016/j.jep.2005.07.006
NR 49
TC 24
Z9 24
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2015
VL 2015
AR 287693
DI 10.1155/2015/287693
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA CF2WT
UT WOS:000352409200001
PM 25815029
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Gimenes, F
   Teixeira, JJV
   de Abreu, ALP
   Souza, RP
   Pereira, MW
   da Silva, VRS
   Boer, CG
   Maria-Engler, SS
   Bonini, MG
   Borelli, SD
   Consolaro, MEL
AF Gimenes, Fabricia
   Vieira Teixeira, Jorge Juarez
   Pimenta de Abreu, Andre Luelsdorf
   Souza, Raquel Pantarotto
   Pereira, Monalisa Wolski
   Sela da Silva, Vania Ramos
   Boer, Cinthia Gandolfi
   Maria-Engler, Silvya Stuchi
   Bonini, Marcelo Gialluisi
   Borelli, Sueli Donizete
   Lopes Consolaro, Marcia Edilaine
TI Human leukocyte antigen (HLA)-G and cervical cancer immunoediting: A
   candidate molecule for therapeutic intervention and prognostic
   biomarker?
SO BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
LA English
DT Review
DE Cervical cancer; HLA-G; HPV; Cancer immunoediting; Therapeutic
   intervention; Prognostic biomarker
ID HLA-G EXPRESSION; 3' UNTRANSLATED REGION; TUMOR IMMUNE ESCAPE; CLASS-I
   MOLECULES; G GENE; HUMAN-PAPILLOMAVIRUS; G POLYMORPHISMS; INTERLEUKIN-10
   EXPRESSION; HEPATOCELLULAR-CARCINOMA; ALTERED EXPRESSION
AB While persistent infection with oncogenic types of human Papillomavirus (HPV) is required for cervical epithelial cell transformation and cervical carcinogenesis, HPV infection alone is not sufficient to induce tumorigenesis. Only a minor fraction of HPV infections produce high-grade lesions and cervical cancer, suggesting complex host virus interactions. Based on its pronounced immunoinhibitory properties, human leukocyte antigen (HLA)-G has been proposed as a possible prognostic biomarker and therapeutic target relevant in a wide variety of cancers and viral infections, but to date remains underexplored in cervical cancer. Given the possible influence of HLA-G on the clinical course of HPV infection, cervical lesions and cancer progression, a better understanding of HLA-G involvement in cervical carcinogenesis might contribute to two aspects of fundamental importance: I. Characterization of a novel diagnostic/prognostic biomarker to identify cervical cancer and to monitor disease stage, critical for patient screening; 2. Identification of HLA-G-driven immune mechanisms involved in lesion development and cancer progression, leading to the development of strategies for modulating HLA-G expression for treatment purposes. Thus, this systematic review explores the potential involvement of HLA-G protein expression and polymorphisms in cervical carcinogenesis. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Gimenes, Fabricia; Vieira Teixeira, Jorge Juarez; Pimenta de Abreu, Andre Luelsdorf; Souza, Raquel Pantarotto; Pereira, Monalisa Wolski; Sela da Silva, Vania Ramos; Boer, Cinthia Gandolfi; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Clin Anal & Biomed, Lab Clin Cytol, BR-87020900 Maringa, Parana, Brazil.
   [Maria-Engler, Silvya Stuchi] Univ Sao Paulo, Sch Pharmaceut Sci, Clin Chem & Toxicol Dept, BR-05508000 Sao Paulo, Brazil.
   [Bonini, Marcelo Gialluisi] Univ Illinois, Dept Med, Coll Med, Chicago, IL 60612 USA.
   [Bonini, Marcelo Gialluisi] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA.
   [Bonini, Marcelo Gialluisi] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA.
   [Borelli, Sueli Donizete] Univ Estadual Maringa, Dept Basic Hlth Sci, Immunogenet Lab, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin & Biomed, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Engler, Silvya Stuchi
   Maria/K-5936-2016; Maria-Engler, Silvya/ABC-2016-2020
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Engler, Silvya
   Stuchi Maria/0000-0003-4771-6041; Maria-Engler,
   Silvya/0000-0003-4771-6041
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) of
   Brazilian GovernmentCAPES [PRODOC 2571/2010, PVE A109/2013]
FX The authors wish to acknowledge financial support from the Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) of Brazilian
   Government (PRODOC 2571/2010 and PVE A109/2013).
CR Algarra I, 2004, CANCER IMMUNOL IMMUN, V53, P904, DOI 10.1007/s00262-004-0517-9
   Amiot L, 2011, CELL MOL LIFE SCI, V68, P417, DOI 10.1007/s00018-010-0583-4
   Amodio G., 2012, HISTOCOMPATIBILITY
   Rodriguez JA, 2012, PATHOBIOLOGY, V79, P72, DOI 10.1159/000334089
   Basta P, 2011, AM J REPROD IMMUNOL, V65, P164, DOI 10.1111/j.1600-0897.2010.00897.x
   Beller EM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001419
   Bortolotti D, 2014, TISSUE ANTIGENS, V83, P113, DOI 10.1111/tan.12281
   Burkholder B, 2014, BBA-REV CANCER, V1845, P182, DOI 10.1016/j.bbcan.2014.01.004
   Carosella ED, 1999, IMMUNOL TODAY, V20, P60, DOI 10.1016/S0167-5699(98)01387-5
   Carosella ED, 2008, BLOOD, V111, P4862, DOI 10.1182/blood-2007-12-127662
   Carosella ED, 2003, ADV IMMUNOL, V81, P199, DOI 10.1016/S0065-2776(03)81006-4
   Carosella ED, 2011, IMMUNOL LETT, V138, P22, DOI 10.1016/j.imlet.2011.02.011
   Castelli EC, 2010, GENES IMMUN, V11, P134, DOI 10.1038/gene.2009.74
   Castelli EC, 2009, HUM IMMUNOL, V70, P1020, DOI 10.1016/j.humimm.2009.07.028
   Chang CC, 2004, CURR OPIN IMMUNOL, V16, P644, DOI 10.1016/j.coi.2004.07.015
   Chattopadhyay Koushik, 2011, Indian J Hum Genet, V17, P132, DOI 10.4103/0971-6866.92087
   Chen HX, 2010, HUM IMMUNOL, V71, P892, DOI 10.1016/j.humimm.2010.06.009
   Chen XY, 2008, TISSUE ANTIGENS, V72, P335, DOI 10.1111/j.1399-0039.2008.01107.x
   Creput C, 2003, HUM IMMUNOL, V64, P1033, DOI 10.1016/j.humimm.2003.08.356
   Creput C, 2003, J HEPATOL, V39, P587, DOI 10.1016/S0168-8278(03)00354-4
   da Silva GK, 2014, INFECT GENET EVOL, V21, P418, DOI 10.1016/j.meegid.2013.12.013
   Davidson B, 2005, GYNECOL ONCOL, V96, P42, DOI 10.1016/j.ygyno.2004.09.049
   Souza PSD, 2009, FUTURE ONCOL, V5, P359, DOI [10.2217/fon.09.8, 10.2217/FON.09.8]
   de Kruijf EM, 2010, J IMMUNOL, V185, P7452, DOI 10.4049/jimmunol.1002629
   Donadi EA, 2011, CELL MOL LIFE SCI, V68, P369, DOI 10.1007/s00018-010-0580-7
   Dong DD, 2010, REPROD SCI, V17, P718, DOI 10.1177/1933719110369183
   Du LT, 2011, CANCER SCI, V102, P1272, DOI 10.1111/j.1349-7006.2011.01951.x
   Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991
   Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803
   Favier B, 2007, TISSUE ANTIGENS, V69, P207, DOI 10.1111/j.1399-0039.2006.00757.x
   Ferguson R, 2012, INT J CANCER, V131, pE312, DOI 10.1002/ijc.27356
   Ferguson R, 2011, HUM IMMUNOL, V72, P337, DOI 10.1016/j.humimm.2011.01.010
   Franco EL, 1999, J INFECT DIS, V180, P1415, DOI 10.1086/315086
   FUJII T, 1994, J IMMUNOL, V153, P5516
   Goncalves MAG, 2008, EUR J OBSTET GYN R B, V141, P70, DOI 10.1016/j.ejogrb.2008.06.010
   Gillio-Tos A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-618
   Gonzales GF, 2004, ANDROLOGIA, V36, P1, DOI 10.1046/j.0303-4569.2003.00594.x
   Gregori S, 2010, BLOOD, V116, P935, DOI 10.1182/blood-2009-07-234872
   Gros F, 2006, NEOPLASIA, V8, P223, DOI 10.1593/neo.05703
   Guimaraes MCM, 2010, J HISTOCHEM CYTOCHEM, V58, P405, DOI 10.1369/jhc.2009.954131
   Hildesheim A, 2002, VIRUS RES, V89, P229, DOI 10.1016/S0168-1702(02)00191-0
   Hviid TVF, 2004, IMMUNOGENETICS, V56, P135, DOI 10.1007/s00251-004-0673-2
   ISHITANI A, 1992, P NATL ACAD SCI USA, V89, P3947, DOI 10.1073/pnas.89.9.3947
   Iversen AC, 2008, J REPROD IMMUNOL, V78, P158, DOI 10.1016/j.jri.2008.03.001
   Jasinski-Bergner S., 2013, J IMMUNOTHER CANC S1, V1, P174, DOI DOI 10.1186/2051-1426-1-S1-P174
   Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115
   Jiang YT, 2011, DNA CELL BIOL, V30, P1027, DOI 10.1089/dna.2011.1238
   Kanai T, 2001, MOL HUM REPROD, V7, P195, DOI 10.1093/molehr/7.2.195
   Kanai T, 2001, AM J REPROD IMMUNOL, V45, P94, DOI 10.1111/j.8755-8920.2001.450205.x
   Klein J, 2000, NEW ENGL J MED, V343, P702, DOI 10.1056/NEJM200009073431006
   Klein J, 2000, NEW ENGL J MED, V343, P782, DOI 10.1056/NEJM200009143431106
   Kleinberg L, 2006, VIRCHOWS ARCH, V449, P31, DOI 10.1007/s00428-005-0144-7
   Kren L, 2010, J NEUROIMMUNOL, V220, P131, DOI 10.1016/j.jneuroim.2010.01.014
   Larsen MH, 2010, TISSUE ANTIGENS, V75, P253, DOI 10.1111/j.1399-0039.2009.01435.x
   Larsen MH, 2013, J INFECT DIS, V207, P903, DOI 10.1093/infdis/jis924
   Le Rond S, 2004, EUR J IMMUNOL, V34, P649, DOI 10.1002/eji.200324266
   Le Rond S, 2006, J IMMUNOL, V176, P3266, DOI 10.4049/jimmunol.176.5.3266
   Lefebvre S, 2002, J PATHOL, V196, P266, DOI 10.1002/path.1039
   Leleu X, 2005, CLIN CANCER RES, V11, P7297, DOI 10.1158/1078-0432.CCR-05-0456
   LeMaoult J, 2005, FASEB J, V19, P662, DOI 10.1096/fj.04-1617fje
   Li XJ, 2012, HUM IMMUNOL, V73, P946, DOI 10.1016/j.humimm.2012.07.041
   Lila N, 2001, P NATL ACAD SCI USA, V98, P12150, DOI 10.1073/pnas.201407398
   Lin A, 2010, J CELL MOL MED, V14, P2318, DOI 10.1111/j.1582-4934.2009.00858.x
   Maki G, 2008, LEUKEMIA, V22, P998, DOI 10.1038/leu.2008.15
   Mendes CT, 2007, TISSUE ANTIGENS, V70, P330, DOI 10.1111/j.1399-0039.2007.00910.x
   Menier C., 2009, ATLAS GENET CYTOGENE, V6, P879
   Metcalfe S, 2013, HUM IMMUNOL, V74, P1610, DOI 10.1016/j.humimm.2013.08.279
   Morandi F, 2007, CANCER RES, V67, P6433, DOI 10.1158/0008-5472.CAN-06-4588
   Moreau P, 2009, J CELL MOL MED, V13, P2973, DOI 10.1111/j.1582-4934.2009.00800.x
   Munoz N, 2000, J CLIN VIROL, V19, P1, DOI 10.1016/S1386-6532(00)00125-6
   Pangault C, 2002, HUM IMMUNOL, V63, P83, DOI 10.1016/S0198-8859(01)00373-1
   Paul P, 1998, P NATL ACAD SCI USA, V95, P4510, DOI 10.1073/pnas.95.8.4510
   Pistoia V, 2007, SEMIN CANCER BIOL, V17, P469, DOI 10.1016/j.semcancer.2007.07.004
   Rebmann V, 2007, TISSUE ANTIGENS, V69, P143, DOI 10.1111/j.1399-0039.2006.763_5.x
   Rebmann V, 2003, SEMIN CANCER BIOL, V13, P371, DOI 10.1016/S1044-579X(03)00028-2
   Riteau B, 2001, J IMMUNOL, V166, P5018, DOI 10.4049/jimmunol.166.8.5018
   Riteau B, 2001, TRANSPLANT P, V33, P2360, DOI 10.1016/S0041-1345(01)02021-8
   Rouas-Freiss N, 2005, CANCER RES, V65, P10139, DOI 10.1158/0008-5472.CAN-05-0097
   Rouas-Freiss N, 2007, SEMIN CANCER BIOL, V17, P413, DOI 10.1016/j.semcancer.2007.07.003
   Rouas-Freiss N, 2007, TRANSPLANTATION, V84, pS21, DOI 10.1097/01.tp.0000269117.32179.1c
   RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P5249, DOI 10.1073/pnas.94.10.5249
   RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P11520, DOI 10.1073/pnas.94.21.11520
   Rousseau P, 2003, HUM IMMUNOL, V64, P1005, DOI 10.1016/j.humimm.2003.08.347
   Schutt P, 2010, HUM IMMUNOL, V71, P489, DOI 10.1016/j.humimm.2010.02.015
   Sebti Y, 2007, BRIT J HAEMATOL, V138, P202, DOI 10.1111/j.1365-2141.2007.06647.x
   Sheu J, 2010, J FORMOS MED ASSOC, V109, P248, DOI 10.1016/S0929-6646(10)60050-2
   Silva ID, 2013, HUM IMMUNOL, V74, P452, DOI 10.1016/j.humimm.2012.11.025
   Simoes RT, 2009, MODERN PATHOL, V22, P1075, DOI 10.1038/modpathol.2009.67
   Singer G, 2003, CLIN CANCER RES, V9, P4460
   Tan Z, 2007, AM J HUM GENET, V81, P829, DOI 10.1086/521200
   Teixeira AC, 2013, TISSUE ANTIGENS, V81, P408, DOI 10.1111/tan.12097
   Tota JE, 2011, PREV MED, V53, pS12, DOI 10.1016/j.ypmed.2011.08.017
   Tripathi P, 2006, CANCER INVEST, V24, P178, DOI 10.1080/07357900500524579
   Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054
   Ugurel S, 2001, CANCER, V92, P369, DOI 10.1002/1097-0142(20010715)92:2<369::AID-CNCR1332>3.0.CO;2-U
   Urosevic M, 2002, BLOOD, V99, P609, DOI 10.1182/blood.V99.2.609
   Urosevic M, 2008, CANCER RES, V68, P627, DOI 10.1158/0008-5472.CAN-07-2704
   Veit TD, 2009, TRANSPL IMMUNOL, V20, P229, DOI 10.1016/j.trim.2008.11.001
   Wiendl H, 2002, J IMMUNOL, V168, P4772, DOI 10.4049/jimmunol.168.9.4772
   WU TC, 1994, CURR OPIN IMMUNOL, V6, P746, DOI 10.1016/0952-7915(94)90079-5
   Yan WH, 2010, EXPERT REV HEMATOL, V3, P67, DOI [10.1586/ehm.09.72, 10.1586/EHM.09.72]
   Yan WH, 2005, CELL RES, V15, P176, DOI 10.1038/sj.cr.7290283
   Yang YC, 2014, EUR J CANCER, V50, P469, DOI 10.1016/j.ejca.2013.10.018
   Yie S.-M., 2012, ATLAS GENET CYTOGENE, V16, P406
   Yie SM, 2011, HISTOL HISTOPATHOL, V26, P409, DOI 10.14670/HH-26.409
   Yoon BS, 2007, INT J GYNECOL OBSTET, V98, P48, DOI 10.1016/j.ijgo.2007.03.041
   Zheng N, 2011, TISSUE ANTIGENS, V77, P218, DOI 10.1111/j.1399-0039.2010.01607.x
   Zhou JH, 2006, LIFE SCI, V78, P2643, DOI 10.1016/j.lfs.2005.10.039
   Zidi I, 2011, TUMOR BIOL, V32, P1071, DOI 10.1007/s13277-011-0213-2
NR 109
TC 20
Z9 21
U1 1
U2 46
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-419X
EI 1879-2561
J9 BBA-REV CANCER
JI Biochim. Biophys. Acta-Rev. Cancer
PD DEC
PY 2014
VL 1846
IS 2
BP 576
EP 589
DI 10.1016/j.bbcan.2014.10.004
PG 14
WC Biochemistry & Molecular Biology; Biophysics; Oncology
SC Biochemistry & Molecular Biology; Biophysics; Oncology
GA AY0BQ
UT WOS:000347263400025
PM 25453366
DA 2020-12-08
ER

PT J
AU Gimenes, F
   Souza, RP
   Bento, JC
   Teixeira, JJV
   Maria-Engler, SS
   Bonini, MG
   Consolaro, MEL
AF Gimenes, Fabricia
   Souza, Raquel P.
   Bento, Jaqueline C.
   Teixeira, Jorge J. V.
   Maria-Engler, Silvya S.
   Bonini, Marcelo G.
   Consolaro, Marcia E. L.
TI Male infertility: a public health issue caused by sexually transmitted
   pathogens
SO NATURE REVIEWS UROLOGY
LA English
DT Review
ID HEPATITIS-C-VIRUS; CHLAMYDIA-TRACHOMATIS INFECTION;
   HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX-VIRUS; MALE GENITAL-TRACT;
   HUMAN-PAPILLOMAVIRUS INFECTION; UREAPLASMA-UREALYTICUM INFECTION;
   ASYMPTOMATIC MALE PARTNERS; TRICHOMONAS-VAGINALIS; MYCOPLASMA-GENITALIUM
AB Sexually transmitted diseases (STDs) are caused by several pathogens, including bacteria, viruses and protozoa, and can induce male infertility through multiple pathophysiological mechanisms. Additionally, horizontal transmission of STD pathogens to sexual partners or vertical transmission to fetuses and neonates is possible. Chlamydia trachomatis, Ureaplasma spp., human papillomavirus, hepatitis B and hepatitis C viruses, HIV-1 and human cytomegalovirus have all been detected in semen from symptomatic and asymptomatic men with testicular, accessory gland and urethral infections. These pathogens are associated with poor sperm quality and decreased sperm concentration and motility. However, the effects of these STD agents on semen quality are unclear, as are the effects of herpes simplex virus type-1 and type-2, Neisseria gonorrhoeae, Mycoplasma spp., Treponema pallidum and Trichomonas vaginalis, because few studies have evaluated the influence of these pathogens on male infertility. Chronic or inadequately treated infections seem to be more relevant to infertility than acute infections are, although in many cases the exact aetiological agents remain unknown.
C1 [Gimenes, Fabricia; Souza, Raquel P.; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Lab Clin Cytol & Semen Anal, BR-87020900 Maringa, Parana, Brazil.
   [Teixeira, Jorge J. V.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Div Epidemiol, BR-87020900 Maringa, Parana, Brazil.
   [Bento, Jaqueline C.] Sao Camilo Clin Anal Lab, Div Semen Anal, BR-87013050 Maringa, Parana, Brazil.
   [Maria-Engler, Silvya S.] Univ Sao Paulo, Sch Pharmaceut Sci, Clin Chem & Toxicol Dept, BR-05508900 Sao Paulo, Brazil.
   [Bonini, Marcelo G.] Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA.
   [Bonini, Marcelo G.] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA.
   [Bonini, Marcelo G.] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Clin Anal & Biomed, Lab Clin Cytol & Semen Anal, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Maria-Engler, Silvya/ABC-2016-2020; Engler, Silvya Stuchi
   Maria/K-5936-2016; Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Maria-Engler, Silvya/0000-0003-4771-6041; Engler, Silvya Stuchi
   Maria/0000-0003-4771-6041; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel superior
   (CAPES)CAPES; Instituto Nacional de Ciencia e Tecnologia para Inovacao
   terapeutica (INCT-if), Brazilian Government
FX This work was supported by grants from Coordenacao de Aperfeicoamento de
   Pessoal de Nivel superior (CAPES) and Instituto Nacional de Ciencia e
   Tecnologia para Inovacao terapeutica (INCT-if), Brazilian Government.
CR Abdulmedzhidova A. G., 2007, Urologiya (Moscow), P56
   Abou-Setta AM, 2004, HUM REPROD, V19, P2711, DOI 10.1093/humrep/deh509
   Abusarah EA, 2013, DIAGN MICR INFEC DIS, V77, P283, DOI 10.1016/j.diagmicrobio.2013.05.018
   AITKEN RJ, 1993, MOL REPROD DEV, V35, P302, DOI 10.1002/mrd.1080350313
   Akande V, 2010, HUM FERTIL, V13, P115, DOI 10.3109/14647273.2010.513893
   Akre O, 1999, FERTIL STERIL, V71, P1066, DOI 10.1016/S0015-0282(99)00115-6
   Al-Daghistani HI, 2010, BIOCHEM RES INT, V2010, DOI 10.1155/2010/409640
   Al-Mously N, 2007, J MED MICROBIOL, V56, P1025, DOI 10.1099/jmm.0.47241-0
   Al-Mously N, 2009, FERTIL STERIL, V92, P1606, DOI 10.1016/j.fertnstert.2008.08.128
   Al-Sweih NA, 2012, J ANDROL, V33, P1323, DOI 10.2164/jandrol.111.013821
   Alderete JF, 2002, PARASITOL INT, V51, P285, DOI 10.1016/S1383-5769(02)00015-6
   Ali BA, 2006, ASIAN J ANDROL, V8, P273, DOI 10.1111/j.1745-7262.2006.00141.x
   Ali BA, 2005, MOL REPROD DEV, V70, P30, DOI 10.1002/mrd.20185
   ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201
   Anderson JA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001053
   Andrade-Rocha FT, 2003, UROL INT, V71, P377, DOI 10.1159/000074089
   Association of Biomedical Andrologists, 2008, Hum Fertil (Camb), V11, P201, DOI 10.1080/14647270802563816
   Aydin S., 1996, International Urology and Nephrology, V28, P117, DOI 10.1007/BF02550148
   Badalyan RR, 2003, ANDROLOGIA, V35, P263, DOI 10.1046/j.1439-0272.2003.00582.x
   BAGASRA O, 1994, AIDS, V8, P1669, DOI 10.1097/00002030-199412000-00005
   BAGASRA O, 1988, J ACQ IMMUN DEF SYND, V1, P431
   Barboza JM, 2004, ARCH ANDROLOGY, V50, P121, DOI 10.1080/01485010490269524
   Barzon L, 2012, J CLIN VIROL, V55, P256, DOI 10.1016/j.jcv.2012.07.013
   Bayasgalan G, 2004, ASIAN J ANDROL, V6, P305
   Berlier W, 2006, J CLIN VIROL, V36, P204, DOI 10.1016/j.jcv.2006.04.004
   BERRY WR, 1987, JAMA-J AM MED ASSOC, V257, P1079, DOI 10.1001/jama.257.8.1079
   Bezold G, 2007, FERTIL STERIL, V87, P1087, DOI 10.1016/j.fertnstert.2006.08.109
   Bocharova E N, 2007, Dokl Biol Sci, V412, P82, DOI 10.1134/S0012496607010279
   BORNMAN MS, 1990, ANDROLOGIA, V22, P118
   Bourlet T, 2002, J CLIN MICROBIOL, V40, P3252, DOI 10.1128/JCM.40.9.3252-3255.2002
   Bourlet T, 2009, HUM REPROD, V24, P530, DOI 10.1093/humrep/den414
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Briat A, 2005, AIDS, V19, P1827, DOI 10.1097/01.aids.0000189847.98569.2d
   Brookings C, 2013, KOREAN J UROL, V54, P149, DOI 10.4111/kju.2013.54.3.149
   Bujan L, 2007, J ANDROL, V28, P444, DOI 10.2164/jandrol.106.001529
   Cai LY, 2009, REPROD TOXICOL, V27, P14, DOI 10.1016/j.reprotox.2008.11.052
   Cardona-Maya W, 2006, AM J REPROD IMMUNOL, V55, P241, DOI 10.1111/j.1600-0897.2005.00340.x
   Carlton JM, 2007, SCIENCE, V315, P207, DOI 10.1126/science.1132894
   Carter JJ, 2000, J INFECT DIS, V181, P1911, DOI 10.1086/315498
   Cassuto NG, 2002, HUM REPROD, V17, P3153, DOI 10.1093/humrep/17.12.3153
   Ceballos A, 2009, J EXP MED, V206, P2717, DOI 10.1084/jem.20091579
   Centers for Disease Control and Prevention, 2010, SEX TRANSM DIS TREAT
   Cheng L, 2011, ESSENTIALS ANATOMIC
   Colon-Lopez V, 2010, P R HEALTH SCI J, V29, P232
   Comar M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042880
   Conrady CD, 2011, J BIOMED RES, V25, P111, DOI 10.1016/S1674-8301(11)60014-6
   Cowan MJ, 2006, J APPL PHYSIOL, V101, P1127, DOI 10.1152/japplphysiol.01287.2005
   Cox DL, 2010, INFECT IMMUN, V78, P5178, DOI 10.1128/IAI.00834-10
   Crouch ML, 2001, MICROB PATHOGENESIS, V31, P131, DOI 10.1006/mpat.2001.0455
   Cunningham KA, 2008, BIOL REPROD, V79, P180, DOI 10.1095/biolreprod.108.067835
   Dale AWS, 2001, INT J STD AIDS, V12, P342, DOI 10.1258/0956462011923066
   DALTON ADA, 1991, J PATHOL, V163, P47, DOI 10.1002/path.1711630109
   Dana A, 2009, OBSTET GYNECOL, V114, P1170, DOI 10.1097/AOG.0b013e3181c2a122
   DANAHER RJ, 1995, J BACTERIOL, V177, P7275, DOI 10.1128/jb.177.24.7275-7279.1995
   Motrich RD, 2006, J INFECTION, V53, P175, DOI 10.1016/j.jinf.2005.11.007
   de Barbeyrac B, 2006, EUR J OBSTET GYN R B, V129, P46, DOI 10.1016/j.ejogrb.2006.02.014
   Deguchi T, 2002, J UROLOGY, V167, P1210, DOI 10.1016/S0022-5347(05)65268-8
   Dejucq N, 2001, MICROBIOL MOL BIOL R, V65, P208, DOI 10.1128/MMBR.65.2.208-231.2001
   DeTure F A, 1976, Urology, V7, P541, DOI 10.1016/0090-4295(76)90204-1
   Devaux A, 2003, HUM REPROD, V18, P2342, DOI 10.1093/humrep/deg431
   Diafouka F, 2007, EUR J CLIN MICROBIOL, V26, P295, DOI 10.1007/s10096-007-0271-y
   Dohle GR, 2003, ANDROLOGIA, V35, P321, DOI 10.1046/j.1439-0272.2003.00577.x
   Dondero F, 1996, HUM REPROD, V11, P765
   Dulioust E, 2002, HUM REPROD, V17, P2112, DOI 10.1093/humrep/17.8.2112
   Dunne EF, 2006, J INFECT DIS, V194, P1044, DOI 10.1086/507432
   Durazzo M, 2006, WORLD J GASTROENTERO, V12, P3073, DOI 10.3748/wjg.v12.i19.3073
   Edwards JL, 2004, CLIN MICROBIOL REV, V17, P965, DOI 10.1128/CMR.17.4.965-981.2004
   Eggert-Kruse W, 2003, FERTIL STERIL, V80, P660, DOI 10.1016/S0015-0282(03)00761-1
   Eggert-Kruse W, 2009, FERTIL STERIL, V91, P67, DOI 10.1016/j.fertnstert.2007.11.014
   Ehrhardt A. A, 1999, SEXUALLY TRANSMITTED, P117
   el Borai N, 1997, J Obstet Gynaecol Res, V23, P17
   Eley A, 2005, LANCET INFECT DIS, V5, P53, DOI 10.1016/S1473-3099(04)01254-X
   Englert Y, 2004, HUM REPROD UPDATE, V10, P149, DOI 10.1093/humupd/dmh013
   ERBENGI T, 1993, HUM REPROD, V8, P416, DOI 10.1093/oxfordjournals.humrep.a138063
   Erles K, 2001, HUM REPROD, V16, P2333, DOI 10.1093/humrep/16.11.2333
   Fang L, 2010, SEX TRANSM DIS, V37, P18, DOI 10.1097/OLQ.0b013e3181b617dc
   Faridi R, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-269
   Fichorova RN, 2009, J REPROD IMMUNOL, V83, P185, DOI 10.1016/j.jri.2009.08.007
   Filippini P, 2001, SEX TRANSM DIS, V28, P725, DOI 10.1097/00007435-200112000-00010
   Fitzpatrick JM, 2006, BJU INT, V97, P3, DOI 10.1111/j.1464-410X.2006.06097.x
   Flesch FM, 2000, BBA-REV BIOMEMBRANES, V1469, P197, DOI 10.1016/S0304-4157(00)00018-6
   Foresta C, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-593
   Foresta C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015036
   Foresta C, 2010, FERTIL STERIL, V94, P1723, DOI 10.1016/j.fertnstert.2009.11.012
   Foresta C, 2010, FERTIL STERIL, V93, P802, DOI 10.1016/j.fertnstert.2008.10.050
   Foster GR, 2004, SEMIN LIVER DIS, V24, P97, DOI 10.1055/s-2004-832934
   Fox KK, 1999, AM J EPIDEMIOL, V149, P353, DOI 10.1093/oxfordjournals.aje.a009820
   Furuya R, 2004, J UROLOGY, V171, P1550, DOI 10.1097/01.ju.0000116288.59223.e9
   Gallegos-Avila G, 2009, HISTOPATHOLOGY, V55, P232, DOI 10.1111/j.1365-2559.2009.03341.x
   Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794
   Gantner F, 2003, EUR J IMMUNOL, V33, P1576, DOI 10.1002/eji.200323444
   Garcia AF, 2005, INFECT IMMUN, V73, P2602, DOI 10.1128/IAI.73.5.2602-2610.2005
   GARDNER WA, 1986, ARCH PATHOL LAB MED, V110, P430
   Garolla A, 2013, J REPROD IMMUNOL, V100, P20, DOI 10.1016/j.jri.2013.03.004
   Garolla A, 2012, HUM REPROD, V27, P967, DOI 10.1093/humrep/des009
   Gdoura R, 2008, J ANDROL, V29, P198, DOI 10.2164/jandrol.107.003566
   Geisler WM, 2010, J INFECT DIS, V201, pS104, DOI 10.1086/652402
   Gimenes F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098862
   Goldberg-Bittman L, 2008, CANCER GENET CYTOGEN, V180, P20, DOI 10.1016/j.cancergencyto.2007.09.009
   Goldstone SE, 2013, VACCINE, V31, P3849, DOI 10.1016/j.vaccine.2013.06.057
   Gomez C, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/726045
   Gringhuis SI, 2007, IMMUNITY, V26, P605, DOI 10.1016/j.immuni.2007.03.012
   Grunewald S, 2005, FERTIL STERIL, V83, P1106, DOI 10.1016/j.fertnstert.2004.12.011
   Gupta P, 2000, J INFECT DIS, V182, P79, DOI 10.1086/315644
   Habermann B, 1999, J EUR ACAD DERMATOL, V12, P25, DOI 10.1016/S0926-9959(98)00092-0
   HADCHOUEL M, 1985, J MED VIROL, V16, P61, DOI 10.1002/jmv.1890160109
   Halfon P, 2006, AIDS, V20, P241, DOI 10.1097/01.aids.0000200532.56490.fe
   Hamdad-Daoudi F, 2004, J MED MICROBIOL, V53, P985, DOI 10.1099/jmm.0.45641-0
   Han IH, 2012, PARASITE IMMUNOL, V34, P8, DOI 10.1111/j.1365-3024.2011.01338.x
   Harp DF, 2011, EUR J OBSTET GYN R B, V157, P3, DOI 10.1016/j.ejogrb.2011.02.024
   Harvey HA, 2000, MOL MICROBIOL, V36, P1059, DOI 10.1046/j.1365-2958.2000.01938.x
   Henkel R, 2006, WORLD J UROL, V24, P39, DOI 10.1007/s00345-005-0038-y
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Hobbs M. M., 2008, SEXUALLY TRANSMITTED, P771
   Hofny ERM, 2011, FERTIL STERIL, V95, P2557, DOI 10.1016/j.fertnstert.2011.05.014
   Hosseinzadeh S, 2003, J MED MICROBIOL, V52, P193, DOI 10.1099/jmm.0.04836-0
   Hosseinzadeh S, 2001, HUM REPROD, V16, P293, DOI 10.1093/humrep/16.2.293
   Hosseinzadeh S, 2000, INFECT IMMUN, V68, P4872, DOI 10.1128/IAI.68.9.4872-4876.2000
   Huang JM, 2002, ASIAN J ANDROL, V4, P209
   HUTTNER KM, 1993, BIOL REPROD, V49, P251, DOI 10.1095/biolreprod49.2.251
   Ibrahim AIA, 1996, ANN SAUDI MED, V16, P171
   Idahl A, 2004, HUM REPROD, V19, P1121, DOI 10.1093/humrep/deh155
   Isaiah IN, 2011, N AM J MED SCI, V3, P562, DOI 10.4297/najms.2011.3559
   Jensen JS, 2004, J EUR ACAD DERMATOL, V18, P1, DOI 10.1111/j.1468-3083.2004.00923.x
   Joki-Korpela P, 2009, FERTIL STERIL, V91, P1448, DOI 10.1016/j.fertnstert.2008.06.051
   Jungwirth A, 2003, ANDROLOGIA, V35, P314, DOI 10.1046/j.1439-0272.2003.00583.x
   Kalichman SC, 2008, SEX TRANSM DIS, V35, P55, DOI 10.1097/OLQ.0b013e318141fe9b
   Kalwij S, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-802
   Kang XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033471
   Kapranos N, 2003, FERTIL STERIL, V79, P1566, DOI 10.1016/S0015-0282(03)00370-4
   Karinen L, 2004, EPIDEMIOL INFECT, V132, P977, DOI 10.1017/S0950268804002195
   Kaspersen MD, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-226
   Kaspersen MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018095
   Keck C, 1998, HUM REPROD UPDATE, V4, P891, DOI 10.1093/humupd/4.6.891
   Kehl S, 2011, ARCH GYNECOL OBSTET, V284, P229, DOI 10.1007/s00404-011-1898-6
   Kimura M, 1993, Rinsho Byori, V41, P1059
   Klimova R. R., 2010, Voprosy Virusologii, V55, P27
   Kline KA, 2003, MOL MICROBIOL, V50, P3, DOI 10.1046/j.1365-2958.2003.03679.x
   Knox CL, 2003, FERTIL STERIL, V80, P921, DOI 10.1016/S0015-0282(03)01125-7
   Koppers AJ, 2008, J CLIN ENDOCR METAB, V93, P3199, DOI 10.1210/jc.2007-2616
   Korenromp EL, 2002, INT J STD AIDS, V13, P91, DOI 10.1258/0956462021924712
   Krieger JN, 2002, INT J ANTIMICROB AG, V19, P475, DOI 10.1016/S0924-8579(02)00086-9
   KRIEGER JN, 1995, SEX TRANSM DIS, V22, P83, DOI 10.1097/00007435-199503000-00003
   Kucknoor AS, 2007, CELL MICROBIOL, V9, P2586, DOI 10.1111/j.1462-5822.2007.00979.x
   KYO S, 1994, J INFECT DIS, V170, P682, DOI 10.1093/infdis/170.3.682
   La Vignera S, 2012, EUR J INTERN MED, V23, pE19, DOI 10.1016/j.ejim.2011.08.011
   Lai YM, 1997, FERTIL STERIL, V67, P1152, DOI 10.1016/S0015-0282(97)81454-9
   Lai YM, 1996, FERTIL STERIL, V65, P1026, DOI 10.1016/S0015-0282(16)58281-8
   LaMontagne DS, 2004, SEX TRANSM INFECT, V80, P335, DOI 10.1136/sti.2004.012856
   Landau EY, 2012, MED HYPOTHESES, V79, P408, DOI 10.1016/j.mehy.2012.06.008
   LANG DJ, 1974, NEW ENGL J MED, V291, P121, DOI 10.1056/NEJM197407182910303
   Laprise C, 2014, HUM REPROD, V29, P640, DOI 10.1093/humrep/det453
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Lee JS, 2013, UROLOGY, V81, P1219, DOI 10.1016/j.urology.2013.02.044
   Lee VCY, 2010, REPROD BIOMED ONLINE, V21, P712, DOI 10.1016/j.rbmo.2010.06.036
   Levy R, 2000, HUM REPROD, V15, P810, DOI 10.1093/humrep/15.4.810
   Levy R, 1997, FERTIL STERIL, V68, P820, DOI 10.1016/S0015-0282(97)00340-3
   Levy R, 2002, HUM REPROD, V17, P2650, DOI 10.1093/humrep/17.10.2650
   Liu Y, 2014, MUCOSAL IMMUNOL, V7, P165, DOI 10.1038/mi.2013.36
   Lorusso F, 2010, ANDROLOGIA, V42, P121, DOI 10.1111/j.1439-0272.2009.00970.x
   Lubick KJ, 2004, INFECT IMMUN, V72, P1284, DOI 10.1128/IAI.72.3.1284-1290.2004
   Ludwig M, 2008, ANDROLOGIA, V40, P76, DOI 10.1111/j.1439-0272.2007.00823.x
   Oberti JPM, 2011, REPRODUCTION, V142, P427, DOI 10.1530/REP-11-0163
   Maeda SI, 2004, INT J UROL, V11, P750, DOI 10.1111/j.1442-2042.2004.00887.x
   Manhart LE, 2011, CLIN INFECT DIS, V53, pS129, DOI 10.1093/cid/cir702
   Mastroianni A, 1996, GENITOURIN MED, V72, P447
   Mazzoli S, 2010, EUR UROL, V57, P708, DOI 10.1016/j.eururo.2009.05.015
   McClelland RS, 2008, J INFECT DIS, V197, P487, DOI 10.1086/526498
   McGowan JP, 2000, J ANTIMICROB CHEMOTH, V46, P657, DOI 10.1093/jac/46.5.657
   MCGOWAN MP, 1983, INT J ANDROL, V6, P331, DOI 10.1111/j.1365-2605.1983.tb00547.x
   Melo MAB, 2008, FERTIL STERIL, V89, P141, DOI 10.1016/j.fertnstert.2007.02.004
   Mencaglia L, 2005, HUM REPROD, V20, P2242, DOI 10.1093/humrep/dei031
   Mitteregger D, 2012, MED MICROBIOL IMMUN, V201, P113, DOI 10.1007/s00430-011-0205-2
   Mlisana K, 2012, J INFECT DIS, V206, P6, DOI 10.1093/infdis/jis298
   Monavari SH, 2013, J BIOMED RES, V27, P56, DOI 10.7555/JBR.27.20110139
   MONTAGUT JM, 1991, HUM REPROD, V6, P727, DOI 10.1093/oxfordjournals.humrep.a137416
   MOORE DE, 1989, JAMA-J AM MED ASSOC, V261, P3441, DOI 10.1001/jama.261.23.3441
   Moretti E, 2008, ANDROLOGIA, V40, P286, DOI 10.1111/j.1439-0272.2008.00855.x
   Motrich RD, 2012, J UROLOGY, V187, P1911, DOI 10.1016/j.juro.2011.12.055
   Moustafa MH, 2004, HUM REPROD, V19, P129, DOI 10.1093/humrep/deh024
   Muciaccia B, 1998, J REPROD IMMUNOL, V41, P81, DOI 10.1016/S0165-0378(98)00050-3
   Muciaccia B, 2007, HUM REPROD, V22, P2868, DOI 10.1093/humrep/dem288
   Muciaccia B, 1998, FASEB J, V12, P151
   Muvunyi CM, 2011, AM J TROP MED HYG, V84, P923, DOI 10.4269/ajtmh.2011.11-0057
   Mylonas I, 2012, ARCH GYNECOL OBSTET, V285, P1271, DOI 10.1007/s00404-012-2240-7
   Nadala EC, 2009, BMJ-BRIT MED J, V339, P2655
   Naumenko V, 2014, ANDROLOGY-US, V2, P687, DOI 10.1111/j.2047-2927.2014.00232.x
   Naumenko Victor A, 2011, Herpesviridae, V2, P7, DOI 10.1186/2042-4280-2-7
   Neofytou E, 2009, FERTIL STERIL, V91, P2487, DOI 10.1016/j.fertnstert.2008.03.074
   Nguyen O, 2010, J CLIN VIROL, V49, P65, DOI 10.1016/j.jcv.2010.06.008
   Nicopoullos JDM, 2004, HUM REPROD, V19, P2289, DOI 10.1093/humrep/deh426
   NUOVO GJ, 1994, AM J PATHOL, V144, P1142
   Ochsendorf FR, 2008, ANDROLOGIA, V40, P72, DOI 10.1111/j.1439-0272.2007.00825.x
   Ochsendorf FR, 1999, HUM REPROD UPDATE, V5, P399, DOI 10.1093/humupd/5.5.399
   OSEGBE DN, 1991, EUR UROL, V19, P204
   Otedo AEO, 2003, SAMJ S AFR MED J, V93, P380
   Ouzounova-Raykova V, 2010, ANDROLOGIA, V42, P176, DOI 10.1111/j.1439-0272.2009.00973.x
   Mackern-Oberti JP, 2013, J REPROD IMMUNOL, V100, P37, DOI 10.1016/j.jri.2013.05.002
   Mackern-Oberti JP, 2011, J MED MICROBIOL, V60, P307, DOI 10.1099/jmm.0.024877-0
   Pajovic B, 2013, ANDROLOGIA, V45, P266, DOI 10.1111/and.12004
   Pallier C, 2002, HUM REPROD, V17, P1281, DOI 10.1093/humrep/17.5.1281
   Pannekoek Y, 2000, J MED MICROBIOL, V49, P697, DOI 10.1099/0022-1317-49-8-697
   Papaxanthos-Roche A, 2004, HUM REPROD, V19, P1170, DOI 10.1093/humrep/deh220
   Parti RR, 2013, RES MICROBIOL, V164, P406, DOI 10.1016/j.resmic.2013.02.002
   Pate MS, 2001, INFECT IMMUN, V69, P7178, DOI 10.1128/IAI.69.11.7178-7181.2001
   Pavili L, 2010, FERTIL STERIL, V94, P2151, DOI 10.1016/j.fertnstert.2009.12.080
   Pekler VA, 2003, J CLIN LAB ANAL, V17, P264, DOI 10.1002/jcla.10107
   Pellati D, 2008, EUR J OBSTET GYN R B, V140, P3, DOI 10.1016/j.ejogrb.2008.03.009
   Perez-Andino J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005847
   Perino A, 2011, FERTIL STERIL, V95, P1845, DOI 10.1016/j.fertnstert.2010.11.047
   Piazza M, 1997, ARCH INTERN MED, V157, P1537, DOI 10.1001/archinte.157.14.1537
   Pilcher CD, 2001, AIDS, V15, P837, DOI 10.1097/00002030-200105040-00004
   PILIKIAN S, 1993, CONTRACEPT FERTIL S, V21, P865
   Povlsen K, 1998, J CLIN MICROBIOL, V36, P3211, DOI 10.1128/JCM.36.11.3211-3216.1998
   Qian WP, 2005, WORLD J GASTROENTERO, V11, P5385, DOI 10.3748/wjg.v11.i34.5385
   RADOLF JD, 1989, P NATL ACAD SCI USA, V86, P2051, DOI 10.1073/pnas.86.6.2051
   Radolf JD, 2012, NAT REV MICROBIOL, V10, P87, DOI 10.1038/nrmicro2714
   Ram S, 1998, J EXP MED, V188, P671, DOI 10.1084/jem.188.4.671
   Reichart M, 2000, BIOL REPROD, V63, P1041, DOI 10.1095/biolreprod63.4.1041
   Reichart M, 2001, J ANDROL, V22, P404
   Ricci G, 2002, HUM REPROD, V17, P2665, DOI 10.1093/humrep/17.10.2665
   Rintala MAM, 2004, INT J STD AIDS, V15, P740, DOI 10.1258/0956462042395122
   Rintala MAM, 2002, J INFECT DIS, V185, P1664, DOI 10.1086/340421
   Roback JD, 2001, TRANSFUSION, V41, P1249, DOI 10.1046/j.1537-2995.2001.41101249.x
   Rodriguez-Cerdeira C, 2012, ACTAS DERMO-SIFILOGR, V103, P679, DOI 10.1016/j.adengl.2012.09.003
   Rodriguez-Tirado C, 2012, MICROBES INFECT, V14, P290, DOI 10.1016/j.micinf.2011.11.002
   Roperto S, 2011, J GEN VIROL, V92, P1787, DOI 10.1099/vir.0.031740-0
   Rowe PJ, 2000, WHO MANUAL STANDARDI
   Rusz A, 2012, WORLD J UROL, V30, P23, DOI 10.1007/s00345-011-0726-8
   Rybar R, 2012, ANDROLOGIA, V44, P410, DOI 10.1111/j.1439-0272.2011.01198.x
   Ryu JS, 2004, INFECT IMMUN, V72, P1326, DOI 10.1128/IAI.72.3.1326-1332.2004
   Sabatte J, 2011, J IMMUNOL, V187, P5299, DOI 10.4049/jimmunol.1101889
   Sadiq ST, 2005, SEX TRANSM INFECT, V81, P380, DOI 10.1136/sti.2004.012914
   Salari M H, 2003, East Mediterr Health J, V9, P291
   Satta A, 2006, HUM REPROD, V21, P134, DOI 10.1093/humrep/dei269
   Savasi V, 2010, EUR J OBSTET GYN R B, V151, P52, DOI 10.1016/j.ejogrb.2010.03.011
   Savasi V, 2013, EUR J OBSTET GYN R B, V167, P181, DOI 10.1016/j.ejogrb.2012.12.012
   Seema Sood, 2008, Indian Journal of Sexually Transmitted Diseases, V29, P7
   Segnini A, 2003, ASIAN J ANDROL, V5, P47
   Senior K, 2012, LANCET INFECT DIS, V12, P517, DOI 10.1016/S1473-3099(12)70161-5
   Shafer WM, 2002, J ENDOTOXIN RES, V8, P47, DOI 10.1179/096805102125000083
   Shang X J, 1999, Asian J Androl, V1, P127
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Shehu-Xhilaga M, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-7
   Shevchuk MM, 1998, J REPROD IMMUNOL, V41, P69, DOI 10.1016/S0165-0378(98)00049-7
   Sifer C, 2002, HUM REPROD, V17, P1773, DOI 10.1093/humrep/17.7.1773
   Singh BN, 2009, GLYCOCONJUGATE J, V26, P3, DOI 10.1007/s10719-008-9157-1
   Sleha R, 2013, EPIDEMIOL MIKROBI IM, V62, P26
   Sommer U, 2005, J BIOL CHEM, V280, P23853, DOI 10.1074/jbc.M501752200
   Soni S, 2010, SEX TRANSM INFECT, V86, P21, DOI 10.1136/sti.2009.038190
   Soper D, 2004, AM J OBSTET GYNECOL, V190, P281, DOI 10.1016/j.ajog.2003.08.023
   Souza RP, 2013, AM J TROP MED HYG, V89, P1199, DOI 10.4269/ajtmh.13-0315
   SPECTOR SA, 1992, J CLIN MICROBIOL, V30, P2359, DOI 10.1128/JCM.30.9.2359-2365.1992
   Spielmann N, 2010, SEX TRANSM INFECT, V86, P331, DOI 10.1136/sti.2009.040857
   Sutcliffe S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002801
   Svenstrup HF, 2003, HUM REPROD, V18, P2103, DOI 10.1093/humrep/deg392
   Tahan V, 2005, AM J GASTROENTEROL, V100, P821, DOI 10.1111/j.1572-0241.2005.40879.x
   Tan CHR, 2008, SINGAP MED J, V49, P780
   Taylor Brandie D, 2011, Infect Drug Resist, V4, P19, DOI 10.2147/IDR.S12715
   Terrault NA, 2002, HEPATOLOGY, V36, pS99, DOI 10.1053/jhep.2002.36797
   Trojian TH, 2009, AM FAM PHYSICIAN, V79, P583
   Uuskula A, 2002, INT J STD AIDS, V13, P79, DOI 10.1258/0956462021924695
   van Leeuwen E, 2008, AIDS, V22, P637, DOI 10.1097/QAD.0b013e3282f4de10
   van Vliet SJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000625
   Vandelli C, 2004, AM J GASTROENTEROL, V99, P855, DOI 10.1111/j.1572-0241.2004.04150.x
   Vandermaelen A, 2010, HUM REPROD, V25, P374, DOI 10.1093/humrep/dep412
   Veznik Z, 2004, ACTA OBSTET GYN SCAN, V83, P656, DOI 10.1111/j.0001-6349.2004.00542.x
   Vicari E, 2006, Minerva Med, V97, P65
   Vigil P, 2002, ANDROLOGIA, V34, P155, DOI 10.1046/j.1439-0272.2002.00472.x
   VILLEGAS H, 1991, ARCH ANDROLOGY, V27, P117, DOI 10.3109/01485019108987663
   Villegas J, 2005, APOPTOSIS, V10, P105, DOI 10.1007/s10495-005-6065-8
   Volgmann Thorsten, 2005, Archives of Gynecology and Obstetrics, V273, P133, DOI 10.1007/s00404-005-0030-1
   Wald A, 2000, NEW ENGL J MED, V342, P844, DOI 10.1056/NEJM200003233421203
   Wang X, 2003, FERTIL STERIL, V80, P844, DOI 10.1016/S0015-0282(03)00983-X
   Wang Yi, 2006, Zhonghua Nan Ke Xue, V12, P615
   Watson-Jones D, 2000, SEX TRANSM INFECT, V76, P355, DOI 10.1136/sti.76.5.355
   Westrop GD, 2006, J BIOL CHEM, V281, P25062, DOI 10.1074/jbc.M600688200
   Weyn C, 2011, J INFECT DIS, V203, P341, DOI 10.1093/infdis/jiq056
   Wikstrom A, 2006, SEX TRANSM INFECT, V82, P276, DOI 10.1136/sti.2005.018598
   World Health Organization, 2011, PREV INC SEL SEX TRA
   Wortley PM, 1998, OBSTET GYNECOL, V91, P515, DOI 10.1016/S0029-7844(98)00040-4
   Wu JN, 2008, J PHARMACOL SCI, V108, P32, DOI 10.1254/jphs.FP0072079
   Wu Kun-He, 2007, Zhonghua Nan Ke Xue, V13, P1075
   Xiong XY, 2005, WORLD J GASTROENTERO, V11, P6440, DOI 10.3748/wjg.v11.i41.6440
   Xu C, 1997, ANDROLOGIA, V29, P219
   Xu X, 1992, Zhonghua Liu Xing Bing Xue Za Zhi, V13, P337
   Yadav M, 2005, PARASITE IMMUNOL, V27, P461, DOI 10.1111/j.1365-3024.2005.00800.x
   Yang Y, 2013, ASIAN J ANDROL, V15, P529, DOI 10.1038/aja.2013.36
   Zea-Mazo JW, 2010, ACTAS UROL ESP, V34, P845, DOI 10.1016/j.acuro.2010.07.002
   Zeighami H, 2009, INT J STD AIDS, V20, P387, DOI 10.1258/ijsa.2008.008334
   Zhao H, 1998, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V12, P367
   Zhou XP, 2011, ASIAN J ANDROL, V13, P465, DOI 10.1038/aja.2010.164
   Zhu WY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041260
   Zinzendorf N. Y., 2008, J REPROD CONTRACEPTI, V19, P65
   Zuckerman RA, 2009, AIDS, V23, P479, DOI 10.1097/QAD.0b013e328326ca62
NR 295
TC 83
Z9 97
U1 2
U2 59
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4812
EI 1759-4820
J9 NAT REV UROL
JI Nat. Rev. Urol.
PD DEC
PY 2014
VL 11
IS 12
BP 672
EP 687
DI 10.1038/nrurol.2014.285
PG 16
WC Urology & Nephrology
SC Urology & Nephrology
GA AU9JO
UT WOS:000345908700005
PM 25330794
DA 2020-12-08
ER

PT J
AU Goncalves, AK
   Machado, PRL
   de Souza, LC
   Costa, APF
   Gimenes, F
   Consolaro, ML
   Crispim, JO
   Eleuterio, J
   Giraldo, PC
AF Goncalves, Ana Katherine
   Lima Machado, Paula Renata
   de Souza, Luanda Canario
   Ferreira Costa, Ana Paula
   Gimenes, Fabricia
   Consolaro, Marcia Lopes
   Crispim, Janaina Oliveira
   Eleuterio, Jose, Jr.
   Giraldo, Paulo Cesar
TI Detection of Immunoglobulin IgA and IgG Against Human Papilloma Virus
SO VIRAL IMMUNOLOGY
LA English
DT Article
ID CERVICAL-CANCER VACCINE; CONTROLLED-TRIAL; NATURAL-HISTORY; G RESPONSES;
   TYPE-16; WOMEN; PARTICLES; HPV; IMMUNOGENICITY; ANTIBODIES
AB The interest in human papilloma virus (HPV) seropositivity has increased considerably since HPV vaccines have become available worldwide. The aim of this study was to assess the performance of enzyme-linked immunosorbent assay (ELISA) in analyzing serum samples provided from women with and without genital DNA-HPV infection confirmed by polymerase chain reaction (PCR), for detection of specific antibodies of the isotypes IgG and IgA recognizing HPV-16 and -18, as well as virus-like particles (VLPs). From August to December 2013, 50 sexually active female patients between 18 and 35 years of age from the outpatient clinic at the university hospital were enrolled. In order to test them, positive controls were obtained from patients with HPV-induced lesions and who were DNA-HPV positive confirmed by PCR. A specific assay was used to identify antibodies to HPV VLPs by ELISA. The samples were divided into HPV positive and negative, and an ELISA detecting IgA and IgG anti-HPV-VLP was carried out. The effectiveness of ELISA and the kappa (k) index was obtained from the values entered in the receiver operating characteristic (ROC) curves for IgG and IgA. IgG-VLP-HPV-16 showed a good correlation between ELISA and PCR (k=0.75), and IgG-VLP-HPV-18 showed a very good correlation between ELISA and PCR (k=0.84). While the IgA antibody correlation was also positive, although weaker, IgA-VLP-HPV-16 was moderate (k=0.45) and IgA-VLP-HPV-18 good (k=0.66). The efficacy of the assay concerning IgG was: sensitivity, specificity, and accuracy were 82.3%, 92%, and 88% to IgG-VLP-HPV-16, and 100%, 92%, and 94% to IgG-VLP-HPV-18. The assay concerning IgA was: sensitivity, specificity, and accuracy were 64.7%, 80%, and 73.8% to IgA-VLP-HPV-16, and 100%, 80%, and 84.8% to IgA-VLP-HPV-18. IgG and IgA antibodies against HPV-16 and -18 can be detected in unvaccinated individuals by using the VLP that serve as the basis for bivalent HPV vaccine. The values for ELISA assays and the values found for IgG correlate good/very good with HPV-16/18 detected by PCR.
C1 [Goncalves, Ana Katherine] Univ Fed Rio Grande do Norte, Dept Obstet & Gynecol, BR-59012570 Natal, RN, Brazil.
   [Lima Machado, Paula Renata; de Souza, Luanda Canario; Ferreira Costa, Ana Paula; Crispim, Janaina Oliveira] Univ Fed Rio Grande do Norte, Dept Toxicol & Clin Anal, BR-59012570 Natal, RN, Brazil.
   [Gimenes, Fabricia; Consolaro, Marcia Lopes] Univ Estadual Maringa, Dept Clin Anal & Biomed, Sect Clin Cytol, Maringa, Parana, Brazil.
   [Eleuterio, Jose, Jr.] Univ Fed Ceara, Dept Obstet & Gynecol, Fortaleza, Ceara, Brazil.
   [Giraldo, Paulo Cesar] Univ Estadual Campinas, Dept Obstet & Gynecol, Campinas, SP, Brazil.
RP Goncalves, AK (corresponding author), Univ Fed Rio Grande do Norte, Dept Obstet & Gynecol, Rua Gen Cordeiro de Farias S-N Petropolis, BR-59012570 Natal, RN, Brazil.
EM anakatherine@ufrnet.br
RI Junior, Jose Eleuterio/K-5027-2019; GONCALVES, ANA
   KATHERINE/K-2300-2017; Costa, Ana Paula Ferreira/AAB-8256-2020;
   Consolaro, Marcia Edilaine Lopes/I-4932-2014; Goncalves,
   Ana/AAO-4019-2020; Eleuterio, Jose/H-2724-2012
OI Junior, Jose Eleuterio/0000-0003-4617-7269; GONCALVES, ANA
   KATHERINE/0000-0002-8351-5119; Costa, Ana Paula
   Ferreira/0000-0002-4511-4373; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865; Goncalves, Ana/0000-0002-8351-5119;
   Eleuterio, Jose/0000-0003-4617-7269; Machado, Paula/0000-0002-3085-9778
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/19960-9]
FX Financially supported by the FAPESP (Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo). Process number: 2011/19960-9.
CR Bharti AC, 2009, INDIAN J MED RES, V130, P296
   Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3
   Carter JJ, 2000, J INFECT DIS, V181, P1911, DOI 10.1086/315498
   CDC, FDA LIC QUADR HUM PA
   Cobucci RNO, 2013, CANC CAUSING VIRUSES, P137
   deGruijl TD, 1997, J NATL CANCER I, V89, P630, DOI 10.1093/jnci/89.9.630
   Ferguson M, 2006, INT J CANCER, V118, P1508, DOI 10.1002/ijc.21515
   Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055
   Giraldo Paulo C., 2006, Braz J Infect Dis, V10, P232, DOI 10.1590/S1413-86702006000400002
   Goncalves AKS, 2006, EUR J OBSTET GYN R B, V124, P227, DOI 10.1016/j.ejogrb.2005.06.028
   Hagensee ME, 2000, J INFECT DIS, V181, P1234, DOI 10.1086/315364
   Harro CD, 2001, JNCI-J NATL CANCER I, V93, P284, DOI 10.1093/jnci/93.4.284
   Ho GYF, 2004, CANCER EPIDEM BIOMAR, V13, P110, DOI 10.1158/1055-9965.EPI-03-0191
   HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057
   Khatun S, 2012, JPN J CLIN ONCOL, V42, P36, DOI 10.1093/jjco/hyr173
   Kim YJ, 2010, J KOREAN MED SCI, V25, P1197, DOI 10.3346/jkms.2010.25.8.1197
   Kuehn BM, 2006, JAMA-J AM MED ASSOC, V296, P640, DOI 10.1001/jama.296.6.640
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Medina DMR, 2010, J ADOLESCENT HEALTH, V46, P414, DOI 10.1016/j.jadohealth.2010.02.006
   Moscicki AB, 2006, VACCINE, V24, P42, DOI 10.1016/j.vaccine.2006.06.018
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   Onda T, 2003, VIROLOGY, V312, P213, DOI 10.1016/S0042-6822(03)00196-X
   Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5
   Pagliusi SR, 2007, DIS MARKERS, V23, P283, DOI 10.1155/2007/591826
   Sasagawa T, 1998, INT J CANCER, V75, P529, DOI 10.1002/(SICI)1097-0215(19980209)75:4&lt;529::AID-IJC7&gt;3.0.CO;2-V
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527
   Studentsov YY, 2002, J CLIN MICROBIOL, V40, P1755, DOI 10.1128/JCM.40.5.1755-1760.2002
   Szarewski A, 2012, INT J CANCER, V131, P106, DOI 10.1002/ijc.26362
   van Doornum G, 1998, SEX TRANSM INFECT, V74, P354, DOI 10.1136/sti.74.5.354
   Viera AJ, 2005, FAM MED, V37, P360
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   WIDEROFF L, 1995, J INFECT DIS, V172, P1425, DOI 10.1093/infdis/172.6.1425
NR 33
TC 3
Z9 3
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0882-8245
EI 1557-8976
J9 VIRAL IMMUNOL
JI Viral Immunol.
PD NOV 1
PY 2014
VL 27
IS 9
BP 471
EP 477
DI 10.1089/vim.2014.0033
PG 7
WC Immunology; Virology
SC Immunology; Virology
GA AR9MT
UT WOS:000343900100008
PM 25191973
DA 2020-12-08
ER

PT J
AU Bonfim-Mendonca, PD
   Ratti, BA
   Godoy, JDR
   Negri, M
   de Lima, NCA
   Fiorini, A
   Hatanaka, E
   Consolaro, MEL
   Silva, SD
   Svidzinski, TIE
AF Bonfim-Mendonca, Patricia de Souza
   Ratti, Bianca Altrao
   Ribeiro Godoy, Janine da Silva
   Negri, Melyssa
   Alves de Lima, Nayara Cristina
   Fiorini, Adriana
   Hatanaka, Elaine
   Lopes Consolaro, Marcia Edilaine
   Silva, Sueli de Oliveira
   Estivalet Svidzinski, Terezinha Inez
TI beta-Glucan Induces Reactive Oxygen Species Production in Human
   Neutrophils to Improve the Killing of Candida albicans and Candida
   glabrata Isolates from Vulvovaginal Candidiasis
SO PLOS ONE
LA English
DT Article
ID OXIDATIVE BURST; HUMAN MONOCYTES; FLOW-CYTOMETRY; MYELOPEROXIDASE;
   LAMINARIN; CELLS; SUPEROXIDE; PREVALENCE; PHAGOSOME; VAGINITIS
AB Vulvovaginal candidiasis (VVC) is among the most prevalent vaginal diseases. Candida albicans is still the most prevalent species associated with this pathology, however, the prevalence of other Candida species, such as C. glabrata, is increasing. The pathogenesis of these infections has been intensely studied, nevertheless, no consensus has been reached on the pathogenicity of VVC. In addition, inappropriate treatment or the presence of resistant strains can lead to RVVC (vulvovaginal candidiasis recurrent). Immunomodulation therapy studies have become increasingly promising, including with the beta-glucans. Thus, in the present study, we evaluated microbicidal activity, phagocytosis, intracellular oxidant species production, oxygen consumption, myeloperoxidase (MPO) activity, and the release of tumor necrosis factor alpha (TNF-alpha), interleukin-8 (IL-8), IL-1 beta, and IL-1Ra in neutrophils previously treated or not with beta-glucan. In all of the assays, human neutrophils were challenged with C. albicans and C. glabrata isolated from vulvovaginal candidiasis. beta-glucan significantly increased oxidant species production, suggesting that beta-glucan may be an efficient immunomodulator that triggers an increase in the microbicidal response of neutrophils for both of the species isolated from vulvovaginal candidiasis. The effects of beta-glucan appeared to be mainly related to the activation of reactive oxygen species and modulation of cytokine release.
C1 [Bonfim-Mendonca, Patricia de Souza; Ribeiro Godoy, Janine da Silva; Negri, Melyssa; Fiorini, Adriana; Lopes Consolaro, Marcia Edilaine; Estivalet Svidzinski, Terezinha Inez] Univ Estadual Maringa, Dept Anal Clin & Biomed, Maringa, Parana, Brazil.
   [Ratti, Bianca Altrao; Alves de Lima, Nayara Cristina; Silva, Sueli de Oliveira] Univ Estadual Maringa, Dept Ciencias Basicas Saude, Maringa, Parana, Brazil.
   [Hatanaka, Elaine] Univ Cruzeiro Sul, Inst Ciencias Atividade Fis & Esporte, Sao Paulo, Brazil.
RP Svidzinski, TIE (corresponding author), Univ Estadual Maringa, Dept Anal Clin & Biomed, Maringa, Parana, Brazil.
EM terezinha.svidzinski@gmail.com
RI Lautenschlager, Sueli OS/P-2164-2017; Consolaro, Marcia Edilaine
   Lopes/I-4932-2014; Hatanaka, Elaine/D-6337-2012
OI Lautenschlager, Sueli OS/0000-0001-9303-0804; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES [320]; Fundacao Araucaria, Programa de Pos Graduacao em
   Ciencias da Saude, Universidade Estadual de Maringa; Complexo de
   Centrais de Apoio a Pesquisa-UEM
FX This research is supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES) - gant number 320, Edital 10/2009,
   Fundacao Araucaria, Programa de Pos Graduacao em Ciencias da Saude,
   Universidade Estadual de Maringa and Complexo de Centrais de Apoio a
   Pesquisa-UEM. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Babic M, 2010, BOSNIAN J BASIC MED, V10, P89
   Barsanti L, 2011, NAT PROD REP, V28, P457, DOI 10.1039/c0np00018c
   BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
   Brown GD, 2003, IMMUNITY, V19, P311, DOI 10.1016/S1074-7613(03)00233-4
   Buitron-Garcia-Figueroa R, 2009, CIR CIR, V77, P423
   Chai LYA, 2009, MED MYCOL, V47, P227, DOI 10.1080/13693780802209082
   Colombo AL, 2013, BRAZ J INFECT DIS, V17, P283, DOI 10.1016/j.bjid.2013.02.001
   Dypbukt JM, 2005, FREE RADICAL BIO MED, V39, P1468, DOI 10.1016/j.freeradbiomed.2005.07.008
   EDWARDS SW, 1987, J GEN MICROBIOL, V133, P3591
   Estabrook R.W., 1967, METHOD ENZYMOL, P41, DOI DOI 10.1016/0076-6879(67)10010-4
   Fidel PL, 2007, AM J REPROD IMMUNOL, V57, P2, DOI 10.1111/j.1600-0897.2006.00450.x
   Fidel Paul L Jr, 2011, Curr Infect Dis Rep, V13, P102, DOI 10.1007/s11908-010-0143-y
   Fidel PL, 1999, INFECT IMMUN, V67, P3135, DOI 10.1128/IAI.67.6.3135-3140.1999
   Foxman B, 2000, SEX TRANSM DIS, V27, P230, DOI 10.1097/00007435-200004000-00009
   Foxman B, 2013, J LOW GENIT TRACT DI, V17, P340, DOI 10.1097/LGT.0b013e318273e8cf
   Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010
   Gow NAR, 2002, CURR OPIN MICROBIOL, V5, P366, DOI 10.1016/S1369-5274(02)00338-7
   Grigoriou O, 2006, EUR J OBSTET GYN R B, V126, P121, DOI 10.1016/j.ejogrb.2005.09.015
   Hong E, 2014, J LOW GENIT TRACT DI, V18, P31, DOI 10.1097/LGT.0b013e318287aced
   Jaeger M, 2013, CURR INFECT DIS REP, V15, P136, DOI 10.1007/s11908-013-0319-3
   Kaur R, 2005, CURR OPIN MICROBIOL, V8, P378, DOI 10.1016/j.mib.2005.06.012
   Kennedy Melissa A, 2010, Curr Infect Dis Rep, V12, P465, DOI 10.1007/s11908-010-0137-9
   Leal CAM, 2011, REDOX REP, V16, P230, DOI 10.1179/1351000211Y.0000000013
   Lee JY, 2012, MOLECULES, V17, P5404, DOI 10.3390/molecules17055404
   Lipinski T, 2013, J IMMUNOL, V190, P4116, DOI 10.4049/jimmunol.1202937
   Liu L, 2013, APPL MICROBIOL BIOT, V97, P2551, DOI 10.1007/s00253-012-4368-6
   Lopes Consolaro Marcia Edilaine, 2004, Rev Iberoam Micol, V21, P202
   Naglik JR, 2011, MICROBES INFECT, V13, P963, DOI 10.1016/j.micinf.2011.06.009
   Nakagawa Y, 2003, J INFECT DIS, V187, P710, DOI 10.1086/368334
   Neyrinck AM, 2007, INT IMMUNOPHARMACOL, V7, P1497, DOI 10.1016/j.intimp.2007.06.011
   Nordenfelt P, 2011, J LEUKOCYTE BIOL, V90, P271, DOI 10.1189/jlb.0810457
   Pang ZC, 2005, BIOSCI BIOTECH BIOCH, V69, P553, DOI 10.1271/bbb.69.553
   Pascon Renata C, 2011, Enzyme Res, V2011, P679624, DOI 10.4061/2011/679624
   Prokopowicz Z, 2012, ARCH IMMUNOL THER EX, V60, P43, DOI 10.1007/s00005-011-0156-8
   Rebecchi IMM, 2000, CELL BIOCHEM FUNCT, V18, P127, DOI 10.1002/(SICI)1099-0844(200006)18:2<127::AID-CBF865>3.0.CO;2-V
   Roetzer A, 2011, FEMS MICROBIOL LETT, V314, P1, DOI 10.1111/j.1574-6968.2010.02102.x
   Rosa MI, 2013, EUR J OBSTET GYN R B, V167, P132, DOI 10.1016/j.ejogrb.2012.12.001
   Shukla AK, 2012, EUR J MED CHEM, V54, P49, DOI 10.1016/j.ejmech.2012.04.034
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Spanu T, 2012, J CLIN MICROBIOL, V50, P176, DOI 10.1128/JCM.05742-11
   STEVENS P, 1984, MICROCHEM J, V30, P135, DOI 10.1016/0026-265X(84)90034-1
   Thompson DS, 2011, EUKARYOT CELL, V10, P1173, DOI 10.1128/EC.05085-11
   Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957
   Wakshull E, 1999, IMMUNOPHARMACOLOGY, V41, P89, DOI 10.1016/S0162-3109(98)00059-9
   Walrand S, 2003, CLIN CHIM ACTA, V331, P103, DOI 10.1016/S0009-8981(03)00086-X
   WHITEOWEN C, 1992, J CLIN MICROBIOL, V30, P2071, DOI 10.1128/JCM.30.8.2071-2076.1992
   Winterbourn CC, 2006, J BIOL CHEM, V281, P39860, DOI 10.1074/jbc.M605898200
NR 47
TC 18
Z9 19
U1 0
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 17
PY 2014
VL 9
IS 9
AR e107805
DI 10.1371/journal.pone.0107805
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AP5MS
UT WOS:000342123900076
PM 25229476
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Gimenes, F
   Medina, FS
   de Abreu, ALP
   Irie, MMT
   Esquicati, IB
   Malagutti, N
   Vasconcellos, VRB
   Discacciati, MG
   Bonini, MG
   Maria-Engler, SS
   Consolaro, MEL
AF Gimenes, Fabricia
   Medina, Fabiana Soares
   Pimenta de Abreu, Andre Luelsdorf
   Taguti Irie, Mary Mayumi
   Esquicati, Isis Baroni
   Malagutti, Natalia
   Bulla Vasconcellos, Vinicius Rodrigo
   Discacciati, Michele Garcia
   Bonini, Marcelo Gialluisi
   Maria-Engler, Silvya Stuchi
   Lopes Consolaro, Marcia Edilaine
TI Sensitive Simultaneous Detection of Seven Sexually Transmitted Agents in
   Semen by Multiplex-PCR and of HPV by Single PCR
SO PLOS ONE
LA English
DT Article
ID CHLAMYDIA-TRACHOMATIS INFECTION; MALE GENITAL-TRACT;
   MYCOPLASMA-GENITALIUM; UREAPLASMA-UREALYTICUM; TRICHOMONAS-VAGINALIS;
   RAPID DETECTION; MEN; DISEASE; IMPACT; URETHRITIS
AB Sexually transmitted diseases (STDs) may impair sperm parameters and functions thereby promoting male infertility. To date limited molecular studies were conducted to evaluate the frequency and type of such infections in semen Thus, we aimed at conceiving and validating a multiplex PCR (M-PCR) assay for the simultaneous detection of the following STD pathogens in semen: Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis, Herpes virus simplex (HSV) -1 and -2, and Treponema pallidum; We also investigated the potential usefulness of this M-PCR assay in screening programs for semen pathogens. In addition, we aimed: to detect human Papillomavirus (HPV) and genotypes by single PCR (sPCR) in the same semen samples; to determine the prevalence of the seven STDs, HPV and co-infections; to assess the possibility that these infections affect semen parameters and thus fertility. The overall validation parameters of M-PCR were extremely high including agreement (99.2%), sensitivity (100.00%), specificity (99.70%), positive (96.40%) and negative predictive values (100.00%) and accuracy (99.80%). The prevalence of STDs was very high (55.3%). Furthermore, associations were observed between STDs and changes in semen parameters, highlighting the importance of STD detection in semen. Thus, this M-PCR assay has great potential for application in semen screening programs for pathogens in infertility and STD clinics and in sperm banks.
C1 [Gimenes, Fabricia; Medina, Fabiana Soares; Pimenta de Abreu, Andre Luelsdorf; Taguti Irie, Mary Mayumi; Esquicati, Isis Baroni; Malagutti, Natalia; Bulla Vasconcellos, Vinicius Rodrigo; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Sect Clin Cytol, Dept Clin Anal & Biomed, Maringa, Parana, Brazil.
   [Discacciati, Michele Garcia; Maria-Engler, Silvya Stuchi] Univ Sao Paulo, Clin Chem & Toxicol Dept, Sch Pharmaceut Sci, Sao Paulo, Brazil.
   [Bonini, Marcelo Gialluisi] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL USA.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Sect Clin Cytol, Dept Clin Anal & Biomed, Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Engler, Silvya Stuchi Maria/K-5936-2016; Maria-Engler,
   Silvya/ABC-2016-2020; Consolaro, Marcia Edilaine Lopes/I-4932-2014;
   Discacciati, Michelle Garcia/B-4608-2014
OI Engler, Silvya Stuchi Maria/0000-0003-4771-6041; Maria-Engler,
   Silvya/0000-0003-4771-6041; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865; Discacciati, Michelle
   Garcia/0000-0003-3660-3826
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel superior (CAPES),
   Brazilian GovernmentCAPES [AUX-PE-PRODOC 2571/2010]
FX This work was supported by grants from Coordenacao de Aperfeicoamento de
   Pessoal de Nivel superior (CAPES), AUX-PE-PRODOC 2571/2010, Brazilian
   Government. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Al-Daghistani HI, 2010, MIDDLE EAST FERTIL S, V15, P29, DOI 10.1016/j.mefs.2010.03.003
   Bezold G, 2007, FERTIL STERIL, V87, P1087, DOI 10.1016/j.fertnstert.2006.08.109
   Bolan G., 1999, SEXUALLY TRANSMITTED, P117
   Brookings C, 2013, KOREAN J UROL, V54, P149, DOI 10.4111/kju.2013.54.3.149
   Chen LH, 2013, J MED VIROL, V85, P1229, DOI 10.1002/jmv.23582
   Cheng L, 2002, ESSENTIALS ANATOMIC
   Cunningham KA, 2008, BIOL REPROD, V79, P180, DOI 10.1095/biolreprod.108.067835
   Edwards JL, 2004, CLIN MICROBIOL REV, V17, P965, DOI 10.1128/CMR.17.4.965-981.2004
   Elder K, 2005, INFECTIONS, INFERTILITY, AND ASSISTED REPRODUCTION, P1
   Eley A, 2005, LANCET INFECT DIS, V5, P53, DOI 10.1016/S1473-3099(04)01254-X
   Foresta C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015036
   Foresta C, 2010, FERTIL STERIL, V94, P1723, DOI 10.1016/j.fertnstert.2009.11.012
   Furuya R, 2004, J UROLOGY, V171, P1550, DOI 10.1097/01.ju.0000116288.59223.e9
   Garolla A, 2013, J REPROD IMMUNOL, V100, P20, DOI 10.1016/j.jri.2013.03.004
   Gdoura R, 2008, ANDROLOGIA, V40, P209, DOI 10.1111/j.1439-0272.2008.00845.x
   Gonzales GF, 2004, ANDROLOGIA, V36, P1, DOI 10.1046/j.0303-4569.2003.00594.x
   Gore-Felton C, 2003, INT J STD AIDS, V14, P539, DOI 10.1258/095646203767869156
   Hobbs MM, 2006, J CLIN MICROBIOL, V44, P3994, DOI 10.1128/JCM.00952-06
   Hobbs MM, 1999, SEX TRANSM DIS, V26, P381, DOI 10.1097/00007435-199908000-00003
   HOOK EW, 1999, SEXUALLY TRANSMITTED, P451
   Jensen JS, 2004, J EUR ACAD DERMATOL, V18, P1, DOI 10.1111/j.1468-3083.2004.00923.x
   Kalwij S, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-802
   Kaspersen MD, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-226
   Kaspersen MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018095
   Kotronias D, 1998, IN VIVO, V12, P391
   Krieger JN, 2002, INT J ANTIMICROB AG, V19, P475, DOI 10.1016/S0924-8579(02)00086-9
   LaMontagne DS, 2004, SEX TRANSM INFECT, V80, P335, DOI 10.1136/sti.2004.012856
   Lee JS, 2013, UROLOGY, V81, P1219, DOI 10.1016/j.urology.2013.02.044
   MANOS MM, 1994, J INFECT DIS, V170, P1096, DOI 10.1093/infdis/170.5.1096
   McIver CJ, 2009, J CLIN MICROBIOL, V47, P1358, DOI 10.1128/JCM.01873-08
   McKechnie ML, 2009, J CLIN MICROBIOL, V47, P1871, DOI 10.1128/JCM.00120-09
   Monavari SH, 2013, J BIOMED RES, V27, P56, DOI 10.7555/JBR.27.20110139
   Muvunyi CM, 2011, DIAGN MICR INFEC DIS, V71, P29, DOI 10.1016/j.diagmicrobio.2011.06.005
   Nadala EC, 2009, BMJ-BRIT MED J, V339, P2655
   Neofytou E, 2009, FERTIL STERIL, V91, P2487, DOI 10.1016/j.fertnstert.2008.03.074
   Ochsendorf FR, 2008, ANDROLOGIA, V40, P72, DOI 10.1111/j.1439-0272.2007.00825.x
   Olatunbosun O A, 1998, West Afr J Med, V17, P19
   Mackern-Oberti JP, 2013, J REPROD IMMUNOL, V100, P37, DOI 10.1016/j.jri.2013.05.002
   Peeling Rw, 2005, Can J Infect Dis Med Microbiol, V16, P73
   Pellati D, 2008, EUR J OBSTET GYN R B, V140, P3, DOI 10.1016/j.ejogrb.2008.03.009
   REIN MF, 1990, SEXUALLY TRANSMITTED, P481
   Rusz A, 2012, WORLD J UROL, V30, P23, DOI 10.1007/s00345-011-0726-8
   Sankuntaw N, 2011, MOL CELL PROBE, V25, P114, DOI 10.1016/j.mcp.2011.03.004
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
   Simms I, 2003, SEX TRANSM INFECT, V79, P491, DOI 10.1136/sti.79.6.491
   Sleha R, 2013, EPIDEMIOL MIKROBI IM, V62, P26
   Souza RP, 2013, AM J TROP MED HYG, V89, P1199, DOI 10.4269/ajtmh.13-0315
   Svenstrup HF, 2003, HUM REPROD, V18, P2103, DOI 10.1093/humrep/deg392
   Uuskula A, 2002, INT J STD AIDS, V13, P79, DOI 10.1258/0956462021924695
   Van Der Pol B, 2008, J INFECT DIS, V197, P548, DOI 10.1086/526496
   Wang Y, 2006, ASIAN J ANDROL, V8, P562, DOI 10.1111/j.1745-7262.2006.00190.x
   Wikstrom A, 2006, SEX TRANSM INFECT, V82, P276, DOI 10.1136/sti.2005.018598
   World Health Organization, 1993, MAN STAND INV DIAGN
   World Health Organization, 2007, GLOB STRAT PREV CONT
   World Health Organization, 2010, WHO LAB MAN EX PROC
   Wu Kun-He, 2007, Zhonghua Nan Ke Xue, V13, P1075
   Yoshida T, 2003, J CLIN MICROBIOL, V41, P1850, DOI 10.1128/JCM.41.5.1850-1855.2003
   Zuckerman RA, 2009, AIDS, V23, P479, DOI 10.1097/QAD.0b013e328326ca62
NR 58
TC 27
Z9 28
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 12
PY 2014
VL 9
IS 6
AR e98862
DI 10.1371/journal.pone.0098862
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK8TP
UT WOS:000338701300018
PM 24921247
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Zanni, PCMD
   Negri, M
   Salci, TP
   Bonfim-Mendonca, PD
   Kioshima, ES
   Svidzinski, TIE
   Consolaro, MEL
AF Zanni, Pamela C. M. D.
   Negri, Melyssa
   Salci, Tania P.
   Bonfim-Mendonca, Patricia de S.
   Kioshima, Erika S.
   Svidzinski, Terezinha I. E.
   Consolaro, Marcia E. L.
TI Animal models for the effective development of atrophic vaginitis
   therapies: possibilities and limitations
SO EXPERT OPINION ON DRUG DISCOVERY
LA English
DT Review
DE animal models; drug discovery; limitations; menopausal; therapies;
   vaginal atrophy
ID ESTROGEN-SENSITIVE PARAMETERS; FOLLICLE-STIMULATING-HORMONE;
   4-VINYLCYCLOHEXENE DIEPOXIDE; CONJUGATED ESTROGENS; POSTMENOPAUSAL
   WOMEN; REPLACEMENT THERAPY; MENOPAUSAL SYMPTOMS; ANTIESTROGEN EM-800;
   VAGINAL LUBRICATION; UROGENITAL ATROPHY
AB Introduction: Vaginal atrophy (VA) is an inflammation of the vagina that develops when there is a significant decrease in levels of the estrogen. Prolonged periods of hypoestrogenism may induce severe VA and treatment is essential. This is a significant problem which requires more focused attention for the development of existing and future therapies.
   Areas covered: This review evaluates the suitable animal models of VA, including: mice, rodents and non-human primates. It focuses particularly on the possibilities and limitations of these in vivo models for the effective development of VA therapies.
   Expert opinion: Hormone replacement therapy (HRT) has been prescribed and successfully used for VA. However, some studies have shown that HRT may be linked to an increased risk of breast cancer, coronary heart diseases and others risks. Thus, there is a growing interest in effective and safe alternatives to VA symptoms. There are, however, a number of things that must be considered for future drug discovery efforts. One major consideration is what animal model should be used and whether the model is appropriate for the study aim. Similarly, research studies must also consider the influencing factors on these animal models, so that these models can effectively mimic the actual disease. The authors also highlight the need to standardize research parameters to produce more reliable and reproducible data.
C1 [Zanni, Pamela C. M. D.; Negri, Melyssa; Salci, Tania P.; Bonfim-Mendonca, Patricia de S.; Kioshima, Erika S.; Svidzinski, Terezinha I. E.] Univ Estadual Maringa, Dept Clin Anal & Biomed, BR-87020900 Maringa, Parana, Brazil.
   [Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Anal Clin, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@uem.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; KIOSHIMA, ERIKA
   S/L-9305-2018
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; KIOSHIMA, ERIKA
   S/0000-0003-3290-8577; Negri, Melyssa/0000-0003-2071-8872
FU Coordenacao de aperfeicoamento de Nivel Superior (CAPES), Brazil
FX The authors are supported by the Coordenacao de aperfeicoamento de Nivel
   Superior (CAPES), Brazil.
CR Abramov Y, 2013, BJOG-INT J OBSTET GY, V120, P251, DOI 10.1111/j.1471-0528.2012.03447.x
   Abramov Y, 2012, INT UROGYNECOL J, V23, P1763, DOI 10.1007/s00192-012-1793-0
   Acarturk F, 1996, PHARMACEUT RES, V13, P779, DOI 10.1023/A:1016016120392
   Acosta JI, 2009, ENDOCRINOLOGY, V150, P4248, DOI 10.1210/en.2008-1802
   Adaikan PG, 2009, FERTIL STERIL, V92, P2008, DOI 10.1016/j.fertnstert.2008.09.020
   Akrivis Ch, 2003, Clin Exp Obstet Gynecol, V30, P229
   Appt SE, 2008, MATURITAS, V60, P216, DOI 10.1016/j.maturitas.2008.06.003
   Appt SE, 2006, FERTIL STERIL, V86, P1210, DOI 10.1016/j.fertnstert.2006.05.004
   Appt SE, 2006, MATURITAS, V55, P187, DOI 10.1016/j.maturitas.2006.02.002
   Ateba SB, 2013, J ETHNOPHARMACOL, V150, P298, DOI 10.1016/j.jep.2013.08.050
   Bachmann G, 2008, OBSTET GYNECOL, V111, P67, DOI 10.1097/01.AOG.0000296714.12226.0f
   Bachmann G, 2009, MENOPAUSE, V16, P719, DOI 10.1097/gme.0b013e3181a48c4e
   Bachmann GA, 2010, MENOPAUSE, V17, P480, DOI 10.1097/gme.0b013e3181c1ac01
   Baeza I, 2010, J NEUROIMMUNOL, V219, P90, DOI 10.1016/j.jneuroim.2009.12.008
   Bahr JM, 2005, MENOPAUSE, V12, P165, DOI 10.1097/00042192-200512020-00011
   Bellino FL, 2000, MENOPAUSE, V7, P14, DOI 10.1097/00042192-200007010-00004
   Bellino FL, 2003, BIOL REPROD, V68, P10, DOI 10.1095/biolreprod.102.005215
   Berger L, 2005, J STEROID BIOCHEM, V96, P201, DOI 10.1016/j.jsbmb.2005.02.018
   Boerrigter PJ, 1996, MATURITAS, V24, P63, DOI 10.1016/0378-5122(95)01020-3
   Brinton RD, 2012, ENDOCRINOLOGY, V153, P3571, DOI 10.1210/en.2012-1340
   Cardozo L, 1998, OBSTET GYNECOL, V92, P722, DOI 10.1016/S0029-7844(98)00175-6
   Cherdshewasart W, 2007, J REPROD DEVELOP, V53, P385, DOI 10.1262/jrd.18065
   Clarkson TB, 2002, J NUTR, V132, p566S
   Cline JM, 1996, FERTIL STERIL, V65, P1031, DOI 10.1016/S0015-0282(16)58282-X
   Crandall C, 2004, MENOPAUSE, V11, P519, DOI 10.1097/01.GME.0000117061.40493.AB
   Danilovich N, 2000, ENDOCRINOLOGY, V141, P4295, DOI 10.1210/en.141.11.4295
   Davis BJ, 2001, TOXICOL PATHOL, V29, P77, DOI 10.1080/019262301301418874
   Deveci I, 2013, OTOLARYNG HEAD NECK, V148, P595, DOI 10.1177/0194599812473241
   Doren M, 2001, MATURITAS, V38, pS23, DOI 10.1016/S0378-5122(01)00201-8
   Fares E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074719
   Foth D, 2000, Zentralbl Gynakol, V122, P96
   Game X, 2013, J SEX MED, V10, P1452, DOI 10.1111/jsm.12127
   Ghumman S., 2013, J S ASIAN FEDER MENO, V1, P4
   Gilardi KVK, 1997, BIOL REPROD, V57, P335, DOI 10.1095/biolreprod57.2.335
   Goldman JM, 2007, BIRTH DEFECTS RES B, V80, P84, DOI 10.1002/bdrb.20106
   GRAHAM CE, 1979, AM J PHYS ANTHROPOL, V50, P291, DOI 10.1002/ajpa.1330500302
   Gupta P, 2008, MENOPAUSE, V15, P94, DOI 10.1097/gme.0b013e318148b98b
   HANDA VL, 1994, OBSTET GYNECOL, V84, P215
   Hascalik S, 2005, GYNECOL OBSTET INVES, V60, P186, DOI 10.1159/000086963
   Higgins EW, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.05.050
   Hofseth LJ, 1999, J CLIN ENDOCR METAB, V84, P4559, DOI 10.1210/jc.84.12.4559
   Hoyer PB, 2001, TOXICOL PATHOL, V29, P91, DOI 10.1080/019262301301418892
   Jacoby RO, 2002, LAB ANIMAL MED
   Johnson M., 2012, MAT METHODS
   Kagan R, 2010, MENOPAUSE, V17, P281, DOI [10.1097/gme.0b013e3181b7c65f, 10.1097/GME.0b013e3181b7c65f]
   Karp DR, 2012, FEMALE PELVIC MED RE, V18, P211, DOI 10.1097/SPV.0b013e31825e6401
   Kavanagh K, 2005, J MED PRIMATOL, V34, P171, DOI 10.1111/j.1600-0684.2005.00114.x
   Kim DI, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-227
   Komi J, 2005, MENOPAUSE, V12, P202, DOI 10.1097/00042192-200512020-00015
   Labrie F, 2010, GYNECOL ENDOCRINOL, V26, P524, DOI 10.3109/09513590903511547
   Laws SC, 2000, TOXICOL SCI, V54, P154, DOI 10.1093/toxsci/54.1.154
   Lilley KG, 1997, LAB ANIM SCI, V47, P632
   Lima SM, 2013, MATURITAS
   Lopez-Belmonte J, 2012, MATURITAS, V72, P353, DOI 10.1016/j.maturitas.2012.05.007
   Luo SQ, 1997, INT J CANCER, V73, P381
   Luo SQ, 1998, ENDOCRINOLOGY, V139, P2645, DOI 10.1210/en.139.5.2645
   Lynch C, 2009, J WOMENS HEALTH, V18, P1595, DOI 10.1089/jwh.2008.1281
   Mac Bride MB, 2010, MAYO CLIN PROC, V85, P87, DOI 10.4065/mcp.2009.0413
   Mainini G, 2005, Clin Exp Obstet Gynecol, V32, P111
   Manjanatha M, 2006, CARCINOGENESIS, V27, P1970, DOI 10.1093/carcin/bgl028
   Maximov PY, 2013, CURR CLIN PHARMACOL, V8, P135, DOI 10.2174/1574884711308020006
   Mayer LP, 2004, BIOL REPROD, V71, P130, DOI 10.1095/biolreprod.103.016113
   Min K, 2003, J SEX MARITAL THER, V29, P77, DOI 10.1080/713847131
   MOORE DH, 1983, STEROIDS, V41, P15, DOI 10.1016/0039-128X(83)90012-0
   Moraes AB, 2009, EUR J OBSTET GYN R B, V146, P188, DOI 10.1016/j.ejogrb.2009.04.007
   MOYER DL, 1993, FERTIL STERIL, V59, P992
   Muhammad FS, 2009, COMPARATIVE MED, V59, P46
   NELSON JF, 1990, ANN NY ACAD SCI, V592, P8
   North Amer Menopause Soc, 2013, MENOPAUSE, V20, P888, DOI [10.1097/GME.0b013e3182a122c2, 10.1097/gme.0b013e3182a122c2]
   Otto C, 2012, ENDOCRINOLOGY, V153, P1725, DOI 10.1210/en.2011-1801
   Packer C, 1998, NATURE, V392, P807, DOI 10.1038/33910
   Panjari M, 2011, MATURITAS, V70, P22, DOI 10.1016/j.maturitas.2011.06.005
   PHILLIPS A, 1984, MATURITAS, V5, P147, DOI 10.1016/0378-5122(84)90047-1
   Pickar JH, 2013, MATURITAS, V75, P3, DOI 10.1016/j.maturitas.2013.01.020
   Pinkerton JV, 2013, MENOPAUSE
   Quintela LA, 2009, REPROD DOMEST ANIM, V44, P829, DOI 10.1111/j.1439-0531.2008.01095.x
   Raymundo N, 2004, CLIMACTERIC, V7, P312, DOI 10.1080/13697130400003147
   Rimoldi G, 2007, ENVIRON HEALTH PERSP, V115, P62, DOI 10.1289/ehp.9367
   Robinson D, 1996, NEUROUROL URODYNAM, V15, P215, DOI 10.1002/(SICI)1520-6777(1996)15:3<215::AID-NAU6>3.0.CO;2-I
   Rozenberg S, 2009, HUM REPROD, V24, P1739, DOI 10.1093/humrep/dep067
   Schnatz PF, 2012, J WOMENS HEALTH, V21, P858, DOI 10.1089/jwh.2011.3244
   Shideler SE, 2001, BIOL REPROD, V65, P1718, DOI 10.1095/biolreprod65.6.1718
   Sourla A, 1997, ENDOCRINOLOGY, V138, P5605, DOI 10.1210/en.138.12.5605
   Sourla A, 1998, J STEROID BIOCHEM, V66, P137, DOI 10.1016/S0960-0760(98)00052-1
   Stovall DW, 2007, MENOPAUSE, V14, P510, DOI 10.1097/GME.0b013e318031a83d
   Suckling J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001500.pub2
   Suzuki O, 2003, MOL REPROD DEV, V64, P219, DOI 10.1002/mrd.10242
   Unkila M, 2013, J STEROID BIOCHEM, V138, P107, DOI 10.1016/j.jsbmb.2013.04.004
   Van Kempen TA, 2011, BRAIN RES, V1379, P176, DOI 10.1016/j.brainres.2010.12.064
   WADSWORTH PF, 1979, CONTRACEPTION, V20, P559
   WAGNER JD, 1991, J CLIN INVEST, V88, P1995, DOI 10.1172/JCI115526
   Walker DM, 2011, NAT REV ENDOCRINOL, V7, P197, DOI 10.1038/nrendo.2010.215
   Walker ML, 2008, BIOL REPROD, V79, P398, DOI 10.1095/biolreprod.108.068536
   Wang XN, 2006, MENOPAUSE, V13, P609, DOI 10.1097/01.gme.0000227337.73738.c9
   Willhite LA, 2001, PHARMACOTHERAPY, V21, P464, DOI 10.1592/phco.21.5.464.34486
   Winneker RC, 2011, CLIN PHARMACOL THER, V89, P129, DOI 10.1038/clpt.2010.161
   Wood CE, 2007, MENOPAUSE, V14, P639, DOI 10.1097/01.gme.0000247017.41007.80
   Wood CE, 2006, BIOL REPROD, V75, P477, DOI 10.1095/biolreprod.106.052142
   Wurz GT, 2013, MATURITAS
   Zern TL, 2003, J NUTR, V133, P2268
NR 100
TC 1
Z9 2
U1 0
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1746-0441
EI 1746-045X
J9 EXPERT OPIN DRUG DIS
JI Expert. Opin. Drug Discov.
PD MAR
PY 2014
VL 9
IS 3
BP 269
EP 281
DI 10.1517/17460441.2014.877883
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AC7ZA
UT WOS:000332751600005
PM 24397873
DA 2020-12-08
ER

PT J
AU Bonini, MG
   Consolaro, MEL
   Hart, PC
   Mao, M
   de Abreu, ALP
   Master, AM
AF Bonini, Marcelo G.
   Consolaro, Marcia E. L.
   Hart, Peter C.
   Mao, Mao
   Pimenta de Abreu, Andre Luelsdorf
   Master, Alyssa M.
TI Redox control of enzymatic functions: The electronics of life's
   circuitry
SO IUBMB LIFE
LA English
DT Review
DE peroxynitrite; protein function; redox; sulfenic acid; redox signaling;
   thiol; ysteine; oxidants; hydrogen peroxide
ID TYROSINE-PHOSPHATASE 1B; CARBONATE RADICAL-ANION; PTEN TUMOR-SUPPRESSOR;
   NITRIC-OXIDE SYNTHASE; OXIDATIVE STRESS; REACTIVE OXYGEN; SINGLET
   OXYGEN; GROWTH-FACTOR; CU,ZN-SUPEROXIDE DISMUTASE; IMMUNOLOGICAL
   DETECTION
AB The field of redox biology has changed tremendously over the past 20 years. Formerly regarded as bi-products of the aerobic metabolism exclusively involved in tissue damage, reactive oxygen species (ROS) are now recognized as active participants of cell signaling events in health and in disease. In this sense, ROS and the more recently defined reactive nitrogen species (RNS) are, just like hormones and second messengers, acting as fundamental orchestrators of cell signaling pathways. The chemical modification of enzymes by ROS and RNS (that result in functional enzymatic alterations) accounts for a considerable fraction of the transient and persistent perturbations imposed by variations in oxidant levels. Upregulation of ROS and RNS in response to stress is a common cellular response that foments adaptation to a variety of physiologic alterations (hypoxia, hyperoxia, starvation, and cytokine production). Frequently, these are beneficial and increase the organisms' resistance against subsequent acute stress (preconditioning). Differently, the sustained ROS/RNS-dependent rerouting of signaling produces irreversible alterations in cellular functioning, often leading to pathogenic events. Thus, the duration and reversibility of protein oxidations define whether complex organisms remain "electronically" healthy. Among the 20 essential amino acids, four are particularly susceptible to oxidation: cysteine, methionine, tyrosine, and tryptophan. Here, we will critically review the mechanisms, implications, and repair systems involved in the redox modifications of these residues in proteins while analyzing well-characterized prototypic examples. Occasionally, we will discuss potential consequences of amino acid oxidation and speculate on the biologic necessity for such events in the context of adaptative redox signaling. (c) 2014 IUBMB Life, 66(3):167-181, 2014
C1 [Bonini, Marcelo G.; Hart, Peter C.; Mao, Mao; Pimenta de Abreu, Andre Luelsdorf; Master, Alyssa M.] Univ Illinois, Dept Med, Coll Med, Chicago, IL 60612 USA.
   [Bonini, Marcelo G.; Mao, Mao; Pimenta de Abreu, Andre Luelsdorf; Master, Alyssa M.] Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612 USA.
   [Bonini, Marcelo G.; Hart, Peter C.; Mao, Mao; Pimenta de Abreu, Andre Luelsdorf; Master, Alyssa M.] Univ Illinois, Dept Pathol, Coll Med, Chicago, IL 60612 USA.
   [Bonini, Marcelo G.; Consolaro, Marcia E. L.; Pimenta de Abreu, Andre Luelsdorf] Univ Estadual Maringa, Programa Biociencias Aplicadas Farm PBF, Maringa, Parana, Brazil.
RP Bonini, MG (corresponding author), Univ Illinois, Dept Med, 909 S Wolcott Ave,COMRB 1131, Chicago, IL 60612 USA.
EM mbonini@uic.edu
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; mao, mao/E-3783-2013
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Hart,
   Peter/0000-0003-1843-9102; mao, mao/0000-0003-1524-8853
FU U.S. Department of DefenseUnited States Department of Defense
   [W911NF-07-R-0003-04]; American Heart AssociationAmerican Heart
   Association [13GRNT16400010]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA
   [5T32HL072742-09]
FX The Bonini lab is funded by grants from the U.S. Department of Defense
   (W911NF-07-R-0003-04) and American Heart Association (13GRNT16400010).
   PCH is supported by NIH grant (5T32HL072742-09).
CR Aggeli IKS, 2008, CELL SIGNAL, V20, P1292, DOI 10.1016/j.cellsig.2008.02.019
   Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8
   Angeloni C, 2011, AM J PHYSIOL-HEART C, V300, pH2196, DOI 10.1152/ajpheart.00934.2010
   Ansenberger-Fricano K. A., MNSOD SOD2 IN PRESS
   Ansley DM, 2013, J PATHOL, V229, P232, DOI 10.1002/path.4113
   Augusto O, 2004, FREE RADICAL BIO MED, V36, P1224, DOI 10.1016/j.freeradbiomed.2004.02.076
   Augusto O, 2002, FREE RADICAL BIO MED, V32, P841, DOI 10.1016/S0891-5849(02)00786-4
   Bajic A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076383
   Barbouti A, 2007, FREE RADICAL BIO MED, V43, P1377, DOI 10.1016/j.freeradbiomed.2007.06.020
   Bartesaghi S, 2007, AMINO ACIDS, V32, P501, DOI 10.1007/s00726-006-0425-8
   Bartesaghi S, 2008, METHOD ENZYMOL, V441, P217, DOI 10.1016/S0076-6879(08)01212-3
   Bartesaghi S, 2010, CHEM RES TOXICOL, V23, P821, DOI 10.1021/tx900446r
   Batthyany C, 2000, ARCH BIOCHEM BIOPHYS, V384, P335, DOI 10.1006/abbi.2000.2102
   Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066
   BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620
   Belardi V, 2013, J MAMMARY GLAND BIOL, V18, P277, DOI 10.1007/s10911-013-9303-7
   Bogeski I, 2006, CELL CALCIUM, V40, P1, DOI 10.1016/j.ceca.2006.03.003
   Bonini MG, 2013, IUBMB LIFE, V65, P889, DOI 10.1002/iub.1213
   Bonini MG, 2009, J BIOL CHEM, V284, P14618, DOI 10.1074/jbc.M804644200
   Bonini MG, 2004, J BIOL CHEM, V279, P51836, DOI 10.1074/jbc.M406929200
   Bonini MG, 2004, BIOCHEMISTRY-US, V43, P344, DOI 10.1021/bi035606p
   Bonini MG, 2001, J BIOL CHEM, V276, P9749, DOI 10.1074/jbc.M008456200
   Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802
   BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682
   Buettner GR, 2011, ANTI-CANCER AGENT ME, V11, P341
   BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074
   Burdisso JE, 2013, J CELL SCI, V126, P1820, DOI 10.1242/jcs.118828
   Burgoyne JR, 2012, CIRC RES, V111, P1091, DOI 10.1161/CIRCRESAHA.111.255216
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   Cai H, 2003, TRENDS PHARMACOL SCI, V24, P471, DOI 10.1016/S0165-6147(03)00233-5
   Carr AC, 2000, CIRC RES, V87, P349, DOI 10.1161/01.RES.87.5.349
   CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1
   Chen K, 2003, J BIOL CHEM, V278, P39527, DOI 10.1074/jbc.M304423200
   Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006
   Chen YY, 2008, J BIOL CHEM, V283, P35265, DOI 10.1074/jbc.M805287200
   Chen YR, 2004, J BIOL CHEM, V279, P18054, DOI 10.1074/jbc.M307706200
   Chen Y, 2007, MOL INTERV, V7, P147, DOI 10.1124/mi.7.3.6
   Cheng G, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-285
   Cho NL, 2012, BIOCHEM BIOPH RES CO, V421, P508, DOI 10.1016/j.bbrc.2012.04.034
   Coller HA, 2014, AM J PATHOL, V184, P4, DOI 10.1016/j.ajpath.2013.07.035
   Connor KM, 2005, J BIOL CHEM, V280, P16916, DOI 10.1074/jbc.M410690200
   Csibi A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010070
   Dalle-Donne I, 2008, ANTIOXID REDOX SIGN, V10, P445, DOI 10.1089/ars.2007.1716
   Dar AC, 2012, NATURE, V486, P80, DOI 10.1038/nature11127
   DarleyUsmar V, 1996, PHARM RES-DORDR, V13, P649, DOI 10.1023/A:1016079012214
   Davies MJ, 2003, BIOCHEM BIOPH RES CO, V305, P761, DOI 10.1016/S0006-291X(03)00817-9
   Davis MF, 2012, FREE RADICAL BIO MED, V53, P1339, DOI 10.1016/j.freeradbiomed.2012.07.009
   De Luca A, 2010, P NATL ACAD SCI USA, V107, P18628, DOI 10.1073/pnas.1010171107
   Delgado-Esteban M, 2007, J NEUROCHEM, V102, P194, DOI 10.1111/j.1471-4159.2007.04450.x
   DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031
   Di Cristofano A, 1998, NAT GENET, V19, P348
   Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1
   Diers AR, 2013, REDOX BIOL, V1, P1, DOI 10.1016/j.redox.2012.11.003
   Dilip A, 2013, ANTI-CANCER DRUG, V24, P881, DOI 10.1097/CAD.0b013e32836442c6
   Dodson M, 2013, FREE RADICAL BIO MED, V63, P207, DOI 10.1016/j.freeradbiomed.2013.05.014
   Drummond GR, 2011, NAT REV DRUG DISCOV, V10, P453, DOI 10.1038/nrd3403
   Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053
   EGOROV SY, 1989, CHEM PHYS LETT, V163, P421, DOI 10.1016/0009-2614(89)85161-9
   Ehrenshaft M, 2011, PHOTOCHEM PHOTOBIOL, V87, P1321, DOI 10.1111/j.1751-1097.2011.00979.x
   Ehrenshaft M, 2009, FREE RADICAL BIO MED, V46, P1260, DOI 10.1016/j.freeradbiomed.2009.01.020
   Eliades A, 2012, J CELL PHYSIOL, V227, P3355, DOI 10.1002/jcp.24071
   Emerling BM, 2009, FREE RADICAL BIO MED, V46, P1386, DOI 10.1016/j.freeradbiomed.2009.02.019
   Erickson JR, 2008, CELL, V133, P462, DOI 10.1016/j.cell.2008.02.048
   Erickson JR, 2011, PHYSIOL REV, V91, P889, DOI 10.1152/physrev.00018.2010
   Ferrer-Sueta G, 2009, ACS CHEM BIOL, V4, P161, DOI 10.1021/cb800279q
   Fink AL, 2006, ACCOUNTS CHEM RES, V39, P628, DOI 10.1021/ar050073t
   Finkel T, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002943
   Finley LWS, 2012, TRENDS MOL MED, V18, P516, DOI 10.1016/j.molmed.2012.05.004
   Forman HJ, 2010, BIOCHEMISTRY-US, V49, P835, DOI 10.1021/bi9020378
   Fridovich I, 2013, MED PRIN PRACT, V22, P131, DOI 10.1159/000339212
   Gallagher EJ, 2013, DIABETES, V62, P3553, DOI 10.2337/db13-0249
   Garcia-Heredia JM, 2012, FEBS LETT, V586, P154, DOI 10.1016/j.febslet.2011.12.007
   Ghanizadeh A, 2012, CURR MED CHEM, V19, P4000, DOI 10.2174/092986712802002572
   Giacco F, 2010, CIRC RES, V107, P1058, DOI 10.1161/CIRCRESAHA.110.223545
   GIESEG SP, 1993, BIOCHEMISTRY-US, V32, P4780, DOI 10.1021/bi00069a012
   Giorgio M, 2007, NAT REV MOL CELL BIO, V8, p722A
   Glaser CB, 2005, BBA-PROTEINS PROTEOM, V1703, P157, DOI 10.1016/j.bbapap.2004.10.008
   Greer A, 2006, ACCOUNTS CHEM RES, V39, P797, DOI 10.1021/ar050191g
   Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086
   Guo YA, 2013, MOL CANCER RES, V11, P282, DOI 10.1158/1541-7786.MCR-12-0558
   Halliwell B, 2012, NUTR REV, V70, P257, DOI 10.1111/j.1753-4887.2012.00476.x
   Hayes P, 2013, ANTIOXID REDOX SIGN, V18, P1937, DOI 10.1089/ars.2012.4895
   Headlam HA, 2006, FREE RADICAL BIO MED, V40, P1539, DOI 10.1016/j.freeradbiomed.2005.12.036
   Hobbs GA, 2013, FREE RADICAL BIO MED, V57, P221, DOI 10.1016/j.freeradbiomed.2012.10.531
   Hodges GR, 2000, FREE RADICAL BIO MED, V29, P434, DOI 10.1016/S0891-5849(00)00298-7
   Huang ZT, 2010, J NEURO-ONCOL, V100, P1, DOI 10.1007/s11060-010-0387-2
   Jang B, 2006, BIOCHIMIE, V88, P53, DOI 10.1016/j.biochi.2005.06.016
   JANSSEN YMW, 1993, LAB INVEST, V69, P261
   Janssen-Heininger YMW, 2008, FREE RADICAL BIO MED, V45, P1, DOI 10.1016/j.freeradbiomed.2008.03.011
   Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066
   Jeong W, 2006, J BIOL CHEM, V281, P14400, DOI 10.1074/jbc.M511082200
   Jeong W, 2012, FREE RADICAL BIO MED, V53, P447, DOI 10.1016/j.freeradbiomed.2012.05.020
   Jin H., 2013, BIOCH BIOPHYS ACTA
   Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963
   Kakihana T, 2012, ANTIOXID REDOX SIGN, V16, P763, DOI 10.1089/ars.2011.4238
   Kalyanaraman B, 2013, REDOX BIOL, V1, P244, DOI 10.1016/j.redox.2013.01.014
   Kalyanaraman B, 2014, BBA-GEN SUBJECTS, V1840, P739, DOI 10.1016/j.bbagen.2013.05.008
   Kettenhofen NJ, 2010, CHEM RES TOXICOL, V23, P1633, DOI 10.1021/tx100237w
   Kim HY, 2007, BIOCHEM J, V407, P321, DOI 10.1042/BJ20070929
   Kleikers PWM, 2012, J MOL MED, V90, P1391, DOI 10.1007/s00109-012-0963-3
   Klomsiri C, 2011, ANTIOXID REDOX SIGN, V14, P1065, DOI 10.1089/ars.2010.3376
   Knobbe CB, 2008, ONCOGENE, V27, P5398, DOI 10.1038/onc.2008.238
   KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159
   KOPPENOL WH, 1976, NATURE, V262, P420, DOI 10.1038/262420a0
   Koppenol WH, 2001, REDOX REP, V6, P229, DOI 10.1179/135100001101536373
   Koppenol WH, 2012, DALTON T, V41, P13779, DOI 10.1039/c2dt31526b
   Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004
   Kuimova MK, 2009, J AM CHEM SOC, V131, P7948, DOI 10.1021/ja901237s
   Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798
   Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3
   Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200
   Lenaz G, 2001, IUBMB LIFE, V52, P159, DOI 10.1080/15216540152845957
   Li N, 2009, J BIOL CHEM, V284, P23602, DOI 10.1074/jbc.M109.024323
   Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2
   Lim JC, 2008, J BIOL CHEM, V283, P28873, DOI 10.1074/jbc.M804087200
   Limon-Pacheco J, 2009, MUTAT RES-GEN TOX EN, V674, P137, DOI 10.1016/j.mrgentox.2008.09.015
   Linares E, 2001, FREE RADICAL BIO MED, V30, P1234, DOI 10.1016/S0891-5849(01)00516-0
   Low FM, 2008, ANTIOXID REDOX SIGN, V10, P1621, DOI 10.1089/ars.2008.2081
   Luo M, 2013, CIRC RES, V113, P690, DOI 10.1161/CIRCRESAHA.113.301651
   Luo M, 2013, J CLIN INVEST, V123, P1262, DOI 10.1172/JCI65268
   MacMillan-Crow LA, 1999, ARCH BIOCHEM BIOPHYS, V366, P82, DOI 10.1006/abbi.1999.1202
   Mallozzi C, 2013, BBA-MOL CELL RES, V1833, P110, DOI 10.1016/j.bbamcr.2012.10.022
   Mao M, 2012, FREE RADICAL BIO MED, V52, P427, DOI 10.1016/j.freeradbiomed.2011.09.020
   Maron BA, 2012, CIRC J, V76, P2497, DOI 10.1253/circj.CJ-12-1207
   Medinas DB, 2010, FREE RADICAL BIO MED, V49, P1046, DOI 10.1016/j.freeradbiomed.2010.06.018
   Meli R, 2002, J BIOL INORG CHEM, V7, P31, DOI 10.1007/s007750100262
   Mester J, 2013, AM J MED GENET C, V163C, P114, DOI 10.1002/ajmg.c.31364
   Mobasher MA, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.150
   Moghaddas S, 2003, ARCH BIOCHEM BIOPHYS, V414, P59, DOI 10.1016/S0003-9861(03)00166-8
   Monteiro G, 2007, P NATL ACAD SCI USA, V104, P4886, DOI 10.1073/pnas.0700481104
   Moreno DM, 2011, ARCH BIOCHEM BIOPHYS, V507, P304, DOI 10.1016/j.abb.2010.12.011
   Morin B, 1998, BIOCHEM J, V330, P1059, DOI 10.1042/bj3301059
   Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200
   Murphy MP, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003386
   Murphy MP, 2011, CELL METAB, V13, P361, DOI 10.1016/j.cmet.2011.03.010
   Nakai K, 2005, FREE RADICAL BIO MED, V39, P1050, DOI 10.1016/j.freeradbiomed.2005.05.019
   Nakamura Y, 2008, CIRC RES, V102, P1182, DOI 10.1161/CIRCRESAHA.107.167080
   Nelson KJ, 2010, METHOD ENZYMOL, V473, P95, DOI 10.1016/S0076-6879(10)73004-4
   OGILBY PR, 1983, J AM CHEM SOC, V105, P3423, DOI 10.1021/ja00349a007
   Oien Derek B, 2011, J Amino Acids, V2011, P721094, DOI 10.4061/2011/721094
   PALACIOS M, 1989, BIOCHEM BIOPH RES CO, V165, P802, DOI 10.1016/S0006-291X(89)80037-3
   Pan J, 2014, BIOPOLYMERS, V101, P165, DOI 10.1002/bip.22255
   Parker BW, 2013, J BIOL CHEM, V288, P32574, DOI 10.1074/jbc.M113.503516
   Paulsen CE, 2010, ACS CHEM BIOL, V5, P47, DOI 10.1021/cb900258z
   Pehar M, 2006, FREE RADICAL BIO MED, V41, P1632, DOI 10.1016/j.freeradbiomed.2006.08.010
   Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com
   Pfeiffer S, 2001, J BIOL CHEM, V276, P34051, DOI 10.1074/jbc.M100585200
   Pilon G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015912
   Pryor WA, 2006, AM J PHYSIOL-REG I, V291, pR491, DOI 10.1152/ajpregu.00614.2005
   Purohit A, 2013, CIRCULATION, V128, P1748, DOI 10.1161/CIRCULATIONAHA.113.003313
   Rains JL, 2011, FREE RADICAL BIO MED, V50, P567, DOI 10.1016/j.freeradbiomed.2010.12.006
   Ravi Y, 2013, HYPERTENSION, V61, P593, DOI 10.1161/HYPERTENSIONAHA.111.00514
   Ravichandran LV, 2001, MOL ENDOCRINOL, V15, P1768, DOI 10.1210/me.15.10.1768
   Rhee SG, 2012, J BIOL CHEM, V287, P4403, DOI 10.1074/jbc.R111.283432
   Rhee SG, 2010, MOL CELLS, V29, P539, DOI 10.1007/s10059-010-0082-3
   Rodriguez-Roldan V, 2008, BIOCHEMISTRY-US, V47, P12371, DOI [10.1021/bi801329s, 10.1021/bi800910v]
   Roede JR, 2013, REDOX BIOL, V1, P387, DOI 10.1016/j.redox.2013.06.003
   Ropelle ER, 2006, J PHYSIOL-LONDON, V577, P997, DOI 10.1113/jphysiol.2006.120006
   Roussel X, 2009, J BIOL CHEM, V284, P33048, DOI 10.1074/jbc.M109.035352
   Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935
   Salmeen A, 2005, ANTIOXID REDOX SIGN, V7, P560, DOI 10.1089/ars.2005.7.560
   Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680
   Samhan-Arias AK, 2011, J CLIN BIOCHEM NUTR, V48, P91, DOI 10.3164/jcbn.11-009FR
   Santos CXC, 2000, ARCH BIOCHEM BIOPHYS, V377, P146, DOI 10.1006/abbi.2000.1751
   Santos Janine H, 2006, Methods Mol Biol, V314, P183
   Schoneich C, 2005, BBA-PROTEINS PROTEOM, V1703, P111, DOI 10.1016/j.bbapap.2004.09.009
   Shchepin R, 2010, J AM CHEM SOC, V132, P17490, DOI 10.1021/ja106503a
   Sieracki NA, 2013, FREE RADICAL BIO MED, V61, P40, DOI 10.1016/j.freeradbiomed.2013.02.020
   SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x
   Sikora A, 2011, CHEM RES TOXICOL, V24, P687, DOI 10.1021/tx100439a
   SIMPSON JA, 1993, BIOCHIM BIOPHYS ACTA, V1156, P190, DOI 10.1016/0304-4165(93)90135-U
   Sohal RS, 2012, FREE RADICAL BIO MED, V52, P539, DOI 10.1016/j.freeradbiomed.2011.10.445
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Sovari AA, 2013, CIRC-ARRHYTHMIA ELEC, V6, P623, DOI 10.1161/CIRCEP.112.976787
   Stadler K, 2011, CURR MED CHEM, V18, P280, DOI 10.2174/092986711794088317
   Tajc SG, 2004, J AM CHEM SOC, V126, P10508, DOI 10.1021/ja047929u
   Talib J, 2012, FREE RADICAL BIO MED, V53, P20, DOI 10.1016/j.freeradbiomed.2012.04.018
   Thomas DD, 2001, P NATL ACAD SCI USA, V98, P355, DOI 10.1073/pnas.011379598
   Thomson E, 2010, FREE RADICAL BIO MED, V49, P1354, DOI 10.1016/j.freeradbiomed.2010.07.010
   TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B
   van Golen RF, 2012, FREE RADICAL BIO MED, V52, P1382, DOI 10.1016/j.freeradbiomed.2012.01.013
   Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220
   Waypa GB, 2008, EXP PHYSIOL, V93, P133, DOI 10.1113/expphysiol.2007.041236
   Weinberg F, 2009, CELL MOL LIFE SCI, V66, P3663, DOI 10.1007/s00018-009-0099-y
   WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263
   Winterbourn CC, 2000, FREE RADICAL BIO MED, V29, P403, DOI 10.1016/S0891-5849(00)00204-5
   Winterbourn CC, 2002, TOXICOLOGY, V181, P223, DOI 10.1016/S0300-483X(02)00286-X
   Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702
   Xiao CB, 2002, ANAL CHEM, V74, P2210, DOI 10.1021/ac015714m
   Xue B, 2009, MOL CELL BIOL, V29, P4563, DOI 10.1128/MCB.01914-08
   Yakovlev VA, 2010, BIOCHEMISTRY-US, V49, P5331, DOI 10.1021/bi100564w
   Zhang H, 2005, J BIOL CHEM, V280, P40684, DOI 10.1074/jbc.M504503200
   Zhang H, 2001, BIOCHEMISTRY-US, V40, P7675, DOI 10.1021/bi002958c
   Zhang H, 2009, ARCH BIOCHEM BIOPHYS, V484, P134, DOI 10.1016/j.abb.2008.11.018
   Zielonka J, 2008, NAT PROTOC, V3, P8, DOI 10.1038/nprot.2007.473
   Zielonka J, 2013, FREE RADICAL BIO MED, V65, P1310, DOI 10.1016/j.freeradbiomed.2013.09.017
   Zielonka J, 2013, METHOD ENZYMOL, V526, P145, DOI 10.1016/B978-0-12-405883-5.00009-0
   Zielonka J, 2012, J BIOL CHEM, V287, P2984, DOI 10.1074/jbc.M111.309062
NR 198
TC 10
Z9 11
U1 0
U2 31
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1521-6543
EI 1521-6551
J9 IUBMB LIFE
JI IUBMB Life
PD MAR
PY 2014
VL 66
IS 3
BP 167
EP 181
DI 10.1002/iub.1258
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA AE6QO
UT WOS:000334118800004
PM 24668617
OA Bronze
DA 2020-12-08
ER

PT J
AU Rocha-Brischiliari, SC
   Gimenes, F
   de Abreu, ALP
   Irie, MT
   Souza, RP
   Santana, RG
   Gravena, AAF
   Carvalho, MDD
   Consolaro, MEL
   Pelloso, SM
AF Rocha-Brischiliari, Sheila C.
   Gimenes, Fabricia
   de Abreu, Andre L. P.
   Irie, Marym T.
   Souza, Raquel P.
   Santana, Rosangela G.
   Gravena, Angela A. F.
   Carvalho, Maria D. de B.
   Consolaro, Marcia E. L.
   Pelloso, Sandra M.
TI Risk factors for cervical HPV infection and genotypes distribution in
   HIV-infected South Brazilian women
SO INFECTIOUS AGENTS AND CANCER
LA English
DT Article
DE HIV; HPV; Genotypes; Risk factors; Cervical lesions; Cervical cancer
ID SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN-PAPILLOMAVIRUS GENOTYPES;
   PREVALENCE; ABNORMALITIES
AB Background: Human Papillomavirus (HPV)infection is particularly burdensome for women infected with human immunodeficiency virus (HIV), which increases their risk of developing cervical lesions and cancer (CC). We conducted a molecular study of the distribution of cervical HPV genotypes and the risk factors for this infection in HIV-infected Brazilian women.
   Findings: Cervical and endocervical samples for Papanicolaou screening and HPV detection were collected from 178 HIV-infected women using highly active antiretroviral therapy (HAART) of Maringa city/Brazil. Risk factors were assessed using a standardized questionnaire, and the data regarding to HIV infection from medical records. HPV was detected by polymerase chain reaction (PCR), and genotyping using PCR-restriction fragment length polymorphism analysis. HIV infection was well controlled, but women with a current CD4+ T lymphocyte count between 200-350 cells/mm(3) (37.6%) had a two-fold greater risk of HPV infection than those with > 350 cells/mm(3) (26.4%). HPV was associated with parity >= 3, hormonal contraceptive use and current smoker. HPV infection occurred with high frequency (46.6%) but a low frequency of cervical abnormalities was detected (7.30%), mainly low-grade squamous intraephitelial cervical lesions (LSIL) (84.6%). A high frequency of multiple HPV infections was detected (23.0%), and the most frequent HPV genotype was HPV-72 (6.7%), followed by -16, -31 and -51 (6.14% each).
   Conclusions: We showed that HAART use does not protect HIV-infected women from HPV, but appear to exert some protection against cervical lesions development. This study provides other important information about risk factors and cervical HPV in HIV-infected women, which can contribute to planning protocols.
C1 [Rocha-Brischiliari, Sheila C.; Gravena, Angela A. F.; Pelloso, Sandra M.] Univ Estadual Maringa, Dept Nursing, Maringa, Parana, Brazil.
   [Gimenes, Fabricia; de Abreu, Andre L. P.; Irie, Marym T.; Souza, Raquel P.; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Maringa, Parana, Brazil.
   [Santana, Rosangela G.] Univ Estadual Maringa, Dept Stat, Maringa, Parana, Brazil.
   [Carvalho, Maria D. de B.] Univ Estadual Maringa, Dept Med, Maringa, Parana, Brazil.
RP Pelloso, SM (corresponding author), Univ Estadual Maringa, Dept Nursing, Maringa, Parana, Brazil.
EM smpelloso@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico
   do Parana/Ministerio da Saude do Brasil/PPSUS [20533, 521/2010];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCAPES
   [23038.006960/2010-31]
FX This work was supported by grants from Fundacao Araucaria de Apoio ao
   Desenvolvimento Cientifico e Tecnologico do Parana/Ministerio da Saude
   do Brasil/PPSUS (Grant number 20533, 521/2010) and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (project
   23038.006960/2010-31).
CR Adler DH, 2010, CURR HIV RES, V8, P493, DOI 10.2174/157016210793499240
   Blossom DB, 2007, J MED VIROL, V79, P758, DOI 10.1002/jmv.20817
   Brazil MH, 2012, REC ANT THER AD LIV
   da Silva MC, 2012, ARCH GYNECOL OBSTET, V286, P1015, DOI 10.1007/s00404-012-2399-y
   Ferlay J S H, 2010, IARC CANC BASE
   INCA/MS, 2012, CANC SURV DAT BRAZ
   Kling M, 2010, INT J DERMATOL, V49, P377, DOI 10.1111/j.1365-4632.2010.04316.x
   Kreitchmann R, 2013, ARCH GYNECOL OBSTET, V288, P1107, DOI 10.1007/s00404-013-2871-3
   Luque AE, 2006, J INFECT DIS, V194, P428, DOI 10.1086/505876
   Luque AE, 2010, INT J INFECT DIS, V14, pE810, DOI 10.1016/j.ijid.2010.03.016
   McKenzie ND, 2010, GYNECOL ONCOL, V116, P572, DOI 10.1016/j.ygyno.2009.10.058
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
   Schuman P, 2003, J INFECT DIS, V188, P128, DOI 10.1086/375783
   Solomon D, 2005, BETHESDA SYSTEM CERV, P67
   Spangle JM, 2010, J VIROL, V84, P9398, DOI 10.1128/JVI.00974-10
NR 15
TC 16
Z9 18
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1750-9378
J9 INFECT AGENTS CANCER
JI Infect. Agents Cancer
PD FEB 11
PY 2014
VL 9
AR 6
DI 10.1186/1750-9378-9-6
PG 6
WC Oncology; Immunology
SC Oncology; Immunology
GA AD3SH
UT WOS:000333165900001
PM 24517499
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Gunther, LSA
   Martins, HPR
   Gimenes, F
   de Abreu, ALP
   Consolaro, MEL
   Svidzinski, TIE
AF Akimoto Gunther, Luciene Setsuko
   Rodrigues Martins, Helen Priscila
   Gimenes, Fabricia
   Pimenta de Abreu, Andre Luelsdorf
   Lopes Consolaro, Marcia Edilaine
   Estivalet Svidzinski, Terezinha Inez
TI Prevalence of Candida albicans and non-albicans isolates from vaginal
   secretions: comparative evaluation of colonization, vaginal candidiasis
   and recurrent vaginal candidiasis in diabetic and non-diabetic women
SO SAO PAULO MEDICAL JOURNAL
LA English
DT Article
DE Candida; Candidiasis, vulvovaginal; Diabetes mellitus; Fluconazole;
   Therapeutics
AB CONTEXT AND OBJECTIVE: Vulvovaginal candidiasis (VVC) is caused by abnormal growth of yeast-like fungi on the female genital tract mucosa. Patients with diabetes mellitus (DM) are more susceptible to fungal infections, including those caused by species of Candida. The present study investigated the frequency of total isolation of vaginal Candida spp., and its different clinical profiles - colonization, VVC and recurrent VVC (RVVC) - in women with DM type 2, compared with non-diabetic women. The cure rate using fluconazole treatment was also evaluated.
   DESIGN AND SETTING: Cross-sectional study conducted in the public healthcare system of Maringa, Parana, Brazil.
   METHODS: The study involved 717 women aged 17-74 years, of whom 48 (6.7%) had DM type 2 (mean age: 53.7 years), regardless of signs and symptoms of VVC. The yeasts were isolated and identified using classical phenotypic methods.
   RESULTS: In the non-diabetic group (controls), total vaginal yeast isolation occurred in 79 (11.8%) women, and in the diabetic group in 9 (18.8%) (P = 0.000). The diabetic group showed more symptomatic (VVC + RVVC = 66.66%) than colonized (33.33%) women, and showed significantly more colonization, VVC and RVVC than seen among the controls. The mean cure rate using fluconazole was 75.0% in the diabetic group and 86.7% in the control group (P = 0.51).
   CONCLUSION: We found that DM type 2 in Brazilian women was associated with yeast colonization, VVC and RVVC, and similar isolation rates for C. albicans and non-albicans species. Good cure rates were obtained using fluconazole in both groups.
C1 [Akimoto Gunther, Luciene Setsuko; Rodrigues Martins, Helen Priscila; Gimenes, Fabricia; Pimenta de Abreu, Andre Luelsdorf; Lopes Consolaro, Marcia Edilaine; Estivalet Svidzinski, Terezinha Inez] Univ Estadual Maringa, Dept Anal Clin & Biomed, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin & Biomed, Av Colombo 5-790,Zona 07, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Fundacao Araucaria de Apoio ao Desenvolvimento Tecnologico e Cientifico
   do Parana, BrazilFundacao Araucaria [15.025/2009]
FX The present study was supported by a grant from Fundacao Araucaria de
   Apoio ao Desenvolvimento Tecnologico e Cientifico do Parana, Brazil,
   protocol number 15.025/2009
CR Antony G, 2009, REV IBEROAM MICOL, V26, P202, DOI 10.1016/j.riam.2009.03.001
   Brumar A., 2012, EUROPEAN J HOSP PHAR, V19, P213
   Carrara MA, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.011
   Chassot F, 2010, CONTRACEPTION, V81, P331, DOI 10.1016/j.contraception.2009.12.011
   Correa PD, 2009, REV BRAS GINECOL OBS, V31, P177, DOI 10.1590/S0100-72032009000400004
   Dalben-Dota KF, 2010, J ALTERN COMPLEM MED, V16, P285, DOI 10.1089/acm.2009.0281
   Faraji R, 2012, AFR J MICROBIOL RES, V6, P2773, DOI 10.5897/AJMR11.1443
   Hetticarachchi N, 2010, SEX TRANSM INFECT, V86, P99, DOI 10.1136/sti.2009.040386
   Kurtzman C, 1998, YEASTS TAXONOMIC STU
   Lattif AA, 2011, J MICROBIOL IMMUNOL, V44, P166, DOI 10.1016/j.jmii.2011.01.020
   Reese RE, 1991, PRACTICAL APPROACH I, P821
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Souza PC, 2009, ARCH GYNECOL OBSTET, V279, P625, DOI 10.1007/s00404-008-0765-6
   Wei YP, 2010, INT J GYNECOL OBSTET, V110, P227, DOI 10.1016/j.ijgo.2010.04.026
NR 14
TC 35
Z9 38
U1 0
U2 12
PU ASSOCIACAO PAULISTA MEDICINA
PI SAO PAULO
PA AV BRIG LUIS ANTONIO, 278-7 ANDAR, SAO PAULO, CEP01318-901, BRAZIL
SN 1516-3180
J9 SAO PAULO MED J
JI Sao Paulo Med. J.
PY 2014
VL 132
IS 2
BP 116
EP 120
DI 10.1590/1516-3180.2014.1322640
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA AF3GK
UT WOS:000334599500009
PM 24714993
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Souza, RP
   de Abreu, ALP
   Ferreira, EC
   Rocha-Brischiliari, SC
   Carvalho, MDD
   Pelloso, SM
   Bonini, MG
   Gimenes, F
   Consolaro, MEL
AF Souza, Raquel P.
   de Abreu, Andre L. P.
   Ferreira, Erika C.
   Rocha-Brischiliari, Sheila C.
   Carvalho, Maria D. de B.
   Pelloso, Sandra M.
   Bonini, Marcelo G.
   Gimenes, Fabricia
   Consolaro, Marcia E. L.
TI Short Report: Simultaneous Detection of Seven Sexually Transmitted
   Agents in Human Immunodeficiency Virus-Infected Brazilian Women by
   Multiplex Polymerase Chain Reaction
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID TRICHOMONAS-VAGINALIS; RAPID DETECTION; AFRICAN WOMEN; DISEASE; PCR;
   ACQUISITION; MYCOPLASMA; UREAPLASMA; ASSAY; TIME
AB We determined the prevalence of seven clinically important pathogens that cause sexually transmitted infections (STIs) (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis, herpes simplex virus 1 [HSV-1], HSV-2, and Treponema pallidum), by using a multiplex polymerase chain reaction (M-PCR) in samples from Brazilian woman infected with human immunodeficiency virus 1 (HIV-1) and uninfected Brazilian women (controls). The M-PCR assay identified all STIs tested for and surprisingly, occurred association between the control and STIs. This association was probably caused by excellent HIV infection control and regular monitoring in these women established by public health strategies in Brazil to combat HIV/acquired immunodeficiency syndrome. Studies using this M-PCR in different populations may help to better elucidate the roles of STIs in several conditions.
C1 [Souza, Raquel P.; de Abreu, Andre L. P.; Gimenes, Fabricia; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Anal Clin & Biomed, BR-87020900 Maringa, Parana, Brazil.
   [Ferreira, Erika C.] Univ Estadual Maringa, Dept Estat, BR-87020900 Maringa, Parana, Brazil.
   [Rocha-Brischiliari, Sheila C.; Carvalho, Maria D. de B.; Pelloso, Sandra M.] Univ Estadual Maringa, Dept Enfermagem, BR-87020900 Maringa, Parana, Brazil.
   [Bonini, Marcelo G.] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL USA.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin & Biomed, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM raquelpantarotto@hotmail.com.br; andreluelsdorf@gmail.com;
   erikacris84@hotmail.com; sheilarocha.enfermeira@hotmail.com;
   mdbcarvalho@gmail.com; smpelloso@gmail.com; mbonini@uic.edu;
   fabricia.gimenes@gmail.com; melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazilian
   Government [AUX-PE-PRODOC 2571/2010]
FX This work was supported by grants from Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior, AUX-PE-PRODOC 2571/2010, Brazilian
   Government.
CR Diaz N, 2010, DIAGN MICR INFEC DIS, V67, P30, DOI 10.1016/j.diagmicrobio.2009.12.022
   Gore-Felton C, 2003, INT J STD AIDS, V14, P539, DOI 10.1258/095646203767869156
   McIver CJ, 2009, J CLIN MICROBIOL, V47, P1358, DOI 10.1128/JCM.01873-08
   McKechnie ML, 2009, J CLIN MICROBIOL, V47, P1871, DOI 10.1128/JCM.00120-09
   Muvunyi CM, 2011, DIAGN MICR INFEC DIS, V71, P29, DOI 10.1016/j.diagmicrobio.2011.06.005
   Quint KD, 2009, GYNECOL ONCOL, V114, P390, DOI 10.1016/j.ygyno.2009.05.013
   Sankuntaw N, 2011, MOL CELL PROBE, V25, P114, DOI 10.1016/j.mcp.2011.03.004
   Simms I, 2003, SEX TRANSM INFECT, V79, P491, DOI 10.1136/sti.79.6.491
   Teixeira PR, 2004, AIDS, V18, pS5, DOI 10.1097/00002030-200406003-00002
   van de Wijgert JHHM, 2009, SEX TRANSM DIS, V36, P357, DOI 10.1097/OLQ.0b013e3181a4f695
   Van Der Pol B, 2008, J INFECT DIS, V197, P548, DOI 10.1086/526496
   World Health Organization, 2006, STAT TABLES
NR 12
TC 19
Z9 18
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2013
VL 89
IS 6
BP 1199
EP 1202
DI 10.4269/ajtmh.13-0315
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 276CQ
UT WOS:000328726100023
PM 24080632
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Nogara, PRB
   Manfroni, LAR
   Consolaro, MEL
AF Nogara, P. R. B.
   Manfroni, L. A. R.
   Consolaro, M. E. L.
TI Frequency of cervical intraepithelial neoplasia grade II or worse in
   women with a persistent low-grade squamous intraepithelial lesion seen
   by Papanicolaou smears
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE LSIL; Persistent; Cytology; CIN II/III; Cervical cancer prevention
ID LOOP EXCISION; RESIDUAL DISEASE; RISK-FACTORS; CONIZATION; MANAGEMENT;
   LASER; COLPOSCOPY; CYTOLOGY; SEE
AB We investigated the frequency of cervical intraepithelial neoplasia (CIN) grade II or worse in low-income Brazilian women with persistent low-grade squamous intraepithelial lesions (LSIL).
   A retrospective review of medical records was performed for all patients who underwent a loop electrosurgical excision procedure (LEEP) with "see and treat" strategy for persistent LSIL seen on Papanicolaou (Pap) smears (persisting > 12 months in at least two consecutive tests, over a 50-month period. We assessed the colposcopy and histopathology results at the time of the procedure and at follow-up, using Pap and histopathology.
   Of 106 women, 48 (45.3 %) had no dysplasia by histopathology, 18 (17.0 %) had CIN I, 29 (27.4 %) had CIN II and 10 (9.4 %) had CIN III. Among the patients with CIN, 38 (66.7 %) performed the follow-up. Of these, only 4 (10.5 %) were classified as follow-up (+), all had CIN I. Women with initial CIN I had 16.7 % (n = 2) recurrences; those with initial CIN II had 5.9 % (n = 1); and those with initial CIN III had 11.1 % (n = 1) (p > 0.05).
   A very high proportion of the women with persistent LSIL had CIN II/III on post-LEEP histopathology. Recurrence rates were equal to than those that originally caused the patients to be subjected to LEEP (LSIL). The benefits of the "see and treat" protocol by LEEP for persistent LSIL outweigh the risk of overtreatment, principally in low-resource settings where poor patient compliance is expected, as in Brazil.
C1 [Nogara, P. R. B.; Consolaro, M. E. L.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol Lab, Maringa, Parana, Brazil.
   [Manfroni, L. A. R.] Sixth Reg Publ Hlth Parana CISVALI Hosp, Div Gynecol, Uniao Da Vitoria, Parana, Brazil.
   [Consolaro, M. E. L.] Univ Estadual Maringa, Dept Anal Clin & Biomed DAB, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin & Biomed DAB, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@yahoo.com.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico
   do Parana e Ministerio da Saude from BrazilFundacao Araucaria [EFP
   00002873-SISCT]
FX This work was supported by Grants from Fundacao Araucaria de Apoio ao
   Desenvolvimento Cientifico e Tecnologico do Parana e Ministerio da Saude
   from Brazil, project EFP 00002873-SISCT.
CR Acharya Ganesh, 2005, Archives of Gynecology and Obstetrics, V272, P109, DOI 10.1007/s00404-005-0727-1
   Armarnik S, 2011, ARCH GYNECOL OBSTET, V283, P765, DOI 10.1007/s00404-011-1848-3
   Baloglu A, 2010, ARCH GYNECOL OBSTET, V282, P69, DOI 10.1007/s00404-009-1298-3
   Bar-Am A, 2000, GYNECOL ONCOL, V78, P47, DOI 10.1006/gyno.2000.5825
   BIBBO M, 1997, COMPREHENSIVE CYTOPA
   Bradford L, 2013, CLIN OBSTET GYNECOL, V56, P76, DOI 10.1097/GRF.0b013e31828237ac
   Chute DJ, 2006, DIAGN CYTOPATHOL, V34, P503, DOI 10.1002/dc.20462
   Dietrich CS, 2002, OBSTET GYNECOL, V99, P188, DOI 10.1016/S0029-7844(01)01716-1
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Ferris DG, 1996, J FAM PRACTICE, V42, P253
   Gray NM, 2006, BRIT J CANCER, V94, P1253, DOI 10.1038/sj.bjc.6603086
   INCA-Nacional Cancer Institute/Brazil (Instituto Nacional do Cancer), EST 2012 CANC INC BR
   Instituto Nacional de Cancer (Brazil), 2006, REV BRAS CANCEROL, V52, P213
   KEIJSER KGG, 1992, AM J OBSTET GYNECOL, V166, P1281, DOI 10.1016/S0002-9378(11)90622-X
   Kietpeerakool C, 2009, J OBSTET GYNAECOL RE, V35, P507, DOI 10.1111/j.1447-0756.2008.00992.x
   Kim HJ, 2007, GYNECOL ONCOL, V105, P434, DOI 10.1016/j.ygyno.2006.12.036
   Livasy CA, 2004, OBSTET GYNECOL, V104, P250, DOI 10.1097/01.AOG.0000132803.88049.84
   Maeda Marina Yoshiê Sakamoto, 2004, J. Bras. Patol. Med. Lab., V40, P425, DOI 10.1590/S1676-24442004000600011
   Mathevet P, 2003, EUR J OBSTET GYN R B, V106, P214, DOI 10.1016/S0301-2115(02)00245-2
   Munk AC, 2012, INFECT AGENTS CANCER, V7, DOI 10.1186/1750-9378-7-30
   Nogara PRB, 2012, INT J GYNECOL OBSTET, V117, P289, DOI 10.1016/j.ijgo.2012.01.003
   Nogara PR, 2011, ARCH GYN OBSTET, V283, P781
   Phongnarisorn C, 2006, INT J GYNECOL CANCER, V16, P1565, DOI 10.1111/j.1525-1438.2006.00405.x
   Raio L, 1997, OBSTET GYNECOL, V90, P978, DOI 10.1016/S0029-7844(97)00489-4
   Sandweiss L, 2008, INT J GYNECOL OBSTET, V100, P284, DOI 10.1016/j.ijgo.2007.09.017
   Schiffman M, 2011, JNCI-J NATL CANCER I, V103, P1
   Silva MC, 2012, ARCH GYN OBST, V286, P1015, DOI [10.1007/s00404-012-2399-y, DOI 10.1007/S00404-012-2399-Y]
   Solomon D, 2005, BETHESDA SYSTEM CERV, P67
   Spracklen CN, 2013, BJOG-INT J OBSTET GY, V120, P960, DOI 10.1111/1471-0528.12209
   Storti-Filho A, 2011, ARCH GYNECOL OBSTET, V283, P781, DOI 10.1007/s00404-010-1400-x
   Szurkus DC, 2003, AM J OBSTET GYNECOL, V188, P1180, DOI 10.1067/mob.2003.282
   Wright TC, 2007, AM J OBSTET GYNECOL, V197, P346, DOI 10.1016/j.ajog.2007.07.047
NR 32
TC 4
Z9 4
U1 0
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD NOV
PY 2013
VL 288
IS 5
BP 1125
EP 1130
DI 10.1007/s00404-013-2872-2
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 236CM
UT WOS:000325771400028
PM 23644924
DA 2020-12-08
ER

PT J
AU Souza, RP
   Gimenes, F
   de Abreu, ALP
   Rocha-Brischiliari, SC
   de Carvalho, MDB
   Ferreira, EC
   Bonini, MG
   Pelloso, SM
   Consolaro, MEL
AF Souza, Raquel P.
   Gimenes, Fabricia
   de Abreu, Andre L. P.
   Rocha-Brischiliari, Sheila C.
   de Carvalho, Maria D. B.
   Ferreira, Erika C.
   Bonini, Marcelo G.
   Pelloso, Sandra M.
   Consolaro, Marcia E. L.
TI Differences in the mutation of the p53 gene in exons 6 and 7 in cervical
   samples from HIV- and HPV-infected women
SO INFECTIOUS AGENTS AND CANCER
LA English
DT Article
DE HIV; HPV; Cervical lesions; p53 gene; Mutations; Exons 5-8
ID TUMOR-SUPPRESSOR; LESIONS
AB Background: Human Papillomavirus (HPV) infection is a serious problem for human immunodeficiency virus (HIV)-infected women, increases their risk of cervical lesions and cancer. In cervical carcinogenesis, mutations in the p53 gene occur most frequently within exons 5-8. To our knowledge, no previous studies have analyzed mutations in exons 5-8 of the p53 gene in HIV- and HPV-infected women. In our study, we verified these mutations in women with and without cervical abnormalities.
   Findings: The study included 160 women, divided into three groups: (1) 83 HPV- and HIV-infected women (HIV group); (2) 37 HPV-infected/HIV-uninfected (control group); and (3) 40 normal cytology/DNA-HPV negative/HIV-uninfected women (negative control p53 reactions). HPV-DNA was detected using polymerase chain reaction (PCR) and genotyping by PCR-restriction fragment length polymorphism analysis. Using primers for exons 5-8, the mutation of the p53 gene was verified by PCR-single strand conformational polymorphism. The total mutation of the p53 gene in exons 5-8 was not significantly associated with the HIV and control groups. The mutations in exon 7 were the highest in the HIV group (43.8%) and in exon 6 in the control group (57.2%) (p = 0.0793) suggesting a tendency toward differential mutation in exon 7 in the HIV group.
   Conclusions: Our study provides preliminary evidence that the mutation in exon 7 might be an important differentiating factor for cervical carcinogenesis in HIV-infected women. This aspect deserves an additional cross-sectional and longitudinal study using a larger sample size with a higher number of High-grade squamous intraephitelial lesion (HSIL) to observe the evolution of cervical lesions.
C1 [Souza, Raquel P.; Gimenes, Fabricia; de Abreu, Andre L. P.; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Clin Anal & Biomed, BR-87020900 Maringa, Parana, Brazil.
   [Rocha-Brischiliari, Sheila C.; Pelloso, Sandra M.] Univ Estadual Maringa, Dept Nursing, BR-87020900 Maringa, Parana, Brazil.
   [de Carvalho, Maria D. B.] Univ Estadual Maringa, Dept Med, BR-87020900 Maringa, Parana, Brazil.
   [Ferreira, Erika C.] Univ Estadual Maringa, Dept Stat, BR-87020900 Maringa, Parana, Brazil.
   [Bonini, Marcelo G.] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Clin Anal & Biomed, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico
   do Parana e Ministerio da Saude do BrasilFundacao Araucaria [EFP
   00002873-SISCT]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   SuperiorCAPES [23038.006960/2010-31]
FX This work was supported by grants from Fundacao Araucaria de Apoio ao
   Desenvolvimento Cientifico e Tecnologico do Parana e Ministerio da Saude
   do Brasil, (project EFP 00002873-SISCT), and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (project
   23038.006960/2010-31).
CR Andersson S, 2006, MED ONCOL, V23, P113, DOI 10.1385/MO:23:1:113
   De- Robertis EDP, 2008, MITOSIS CELL CYCLE C
   Oliveira Ledy do Horto dos Santos, 2003, Sao Paulo Med. J., V121, P67, DOI 10.1590/S1516-31802003000200007
   Feola TD, 2012, J ASS NURSES AIDS CA
   Ferenczy A, 2002, LANCET ONCOL, V3, P11, DOI 10.1016/S1470-2045(01)00617-9
   Hanprasertpong J, 2010, J OBSTET GYNAECOL RE, V36, P572, DOI 10.1111/j.1447-0756.2010.01227.x
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Luque AE, 2010, INT J INFECT DIS, V14, pE810, DOI 10.1016/j.ijid.2010.03.016
   MANOS MM, 1994, J INFECT DIS, V170, P1096, DOI 10.1093/infdis/170.5.1096
   Martinez-Rivera M, 2012, BIOCHEM PHARMACOL, V83, P1049, DOI 10.1016/j.bcp.2011.12.026
   Moodley JR, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-135
   Palefsky J, 2006, Adv Dent Res, V19, P99
   Rezza G, 2001, CANCER EPIDEM BIOMAR, V10, P565
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
   Shumaker JM, 2001, BIOORGAN MED CHEM, V9, P2269, DOI 10.1016/S0968-0896(01)00104-3
   Sigal A, 2000, CANCER RES, V60, P6788
   Solomon D, 2005, BETHESDA SYSTEM CERV
NR 17
TC 3
Z9 3
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1750-9378
J9 INFECT AGENTS CANCER
JI Infect. Agents Cancer
PD OCT 7
PY 2013
VL 8
AR 38
DI 10.1186/1750-9378-8-38
PG 5
WC Oncology; Immunology
SC Oncology; Immunology
GA 241LO
UT WOS:000326168600001
PM 24098975
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Zanni, PCMD
   Bonfim-Mendonca, PS
   Kioshima-Cotica, ES
   Negri, M
   Svidizinski, TIE
   Consolaro, MEL
AF Zanni, P. C. M. D.
   Bonfim-Mendonca, P. S.
   Kioshima-Cotica, E. S.
   Negri, M.
   Svidizinski, T. I. E.
   Consolaro, M. E. L.
TI Adhesion and biofilm formation by Candida albicans isolates from
   vulvovaginal candidiasis in human immunodeficiency virus (HIV) positive
   women
SO MYCOSES
LA English
DT Meeting Abstract
C1 [Zanni, P. C. M. D.; Bonfim-Mendonca, P. S.; Kioshima-Cotica, E. S.; Negri, M.; Svidizinski, T. I. E.; Consolaro, M. E. L.] Univ Estadual Maringa, Maringa, Parana, Brazil.
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
NR 0
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0933-7407
EI 1439-0507
J9 MYCOSES
JI Mycoses
PD OCT
PY 2013
VL 56
SU 3
SI SI
BP 124
EP 124
PG 1
WC Dermatology; Mycology
SC Dermatology; Mycology
GA 227ZX
UT WOS:000325155400259
DA 2020-12-08
ER

PT J
AU Damke, E
   Tsuzuki, JK
   Chassot, F
   Cortez, DAG
   Ferreira, ICP
   Mesquita, CSS
   da-Silva, VRS
   Svidzinski, TIE
   Consolaro, MEL
AF Damke, Edilson
   Tsuzuki, Joyce K.
   Chassot, Francieli
   Cortez, Diogenes A. G.
   Ferreira, Izabel C. P.
   Mesquita, Cristiane S. S.
   da-Silva, Vania R. S.
   Svidzinski, Terezinha I. E.
   Consolaro, Marcia E. L.
TI Spermicidal and anti-Trichomonas vaginalis activity of Brazilian
   Sapindus saponaria
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Sapindus saponaria; Saponins; Spermicidal; Anti-Trichomonas vaginalis
   activity; Contraceptive
ID SAPONINS; NONOXYNOL-9; SUSCEPTIBILITY; PREVENTION; EXTRACT; POTENT; L.
AB Background: Sapindus saponaria is used traditionally for curing ulcers, external wounds and inflammations. The spermicidal and anti-Trichomonas activity of S. saponaria and its effect on Lactobacillus acidophilus were evaluated.
   Methods: Water-ethanol (WE) and butanolic (BE) extracts, as well as a purified sample of saponins (SP) from S. saponaria were tested for spermicidal and anti-Trichomonas activity and for their effect on L. acidophilus.
   Results: WE, BE and SP immobilized spermatozoa at a minimum effective concentration (MEC) of 2.5 (gram %) for extracts and 1.25 (gram %) for SP. The effective concentrations that caused 50% immobilization of spermatozoa (EC50) were 0.5 (gram %) for WE and SP, and 0.1 (gram %) for BE. The compounds were effective against Trichomonas vaginalis (Minimum Inhibitory Concentration = 0.156 mg/mL for WE and BE, and 0.078 mg/mL for SP against a clinical strain (CS); and 0.312, 0.156 and 0.078 mg/mL for WE, BE and SP, respectively, against an ATCC strain). In all concentrations tested, the growth of L. acidophilus was not reduced.
   Conclusion: The in vitro study proved the spermicidal and anti-Trichomonas activity of S. saponaria. Complementary in vivo studies should be made for establish the use as a vaginal spermicide, particularly in Brazil and Latin America.
C1 [Damke, Edilson; Chassot, Francieli; da-Silva, Vania R. S.; Consolaro, Marcia E. L.] Univ Estadual Maringa, Div Clin Cytol, Dept Clin Anal & Biomed, BR-4860 Maringa, Parana, Brazil.
   [Tsuzuki, Joyce K.; Cortez, Diogenes A. G.; Ferreira, Izabel C. P.] Univ Estadual Maringa, Dept Pharm, BR-4860 Maringa, Parana, Brazil.
   [Mesquita, Cristiane S. S.; Svidzinski, Terezinha I. E.] Univ Estadual Maringa, Div Med Mycol, Dept Clin Anal & Biomed, BR-4860 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Div Clin Cytol, Dept Clin Anal & Biomed, BR-4860 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Fundacao Araucaria de Apoio ao Desenvolvimento Cientifico e Tecnologico
   do ParanaFundacao Araucaria [15025/2009]
FX This work was supported by grants from Fundacao Araucaria de Apoio ao
   Desenvolvimento Cientifico e Tecnologico do Parana (15025/2009 project).
CR Albiero Adriana Lenita Meyer, 2001, Acta Scientiarum Universidade Estadual de Maringa, V23, P549
   Albiero ALM, 2002, J ETHNOPHARMACOL, V82, P41, DOI 10.1016/S0378-8741(02)00094-6
   Brasil. Ministerio da Saude, 2006, HIV AIDS HEP OUTR DS
   Consolaro MEL, 2012, CITOLOGIA CLIN CERVI, P73
   Damke E, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-35
   Falagas ME, 2006, J ANTIMICROB CHEMOTH, V58, P266, DOI 10.1093/jac/dkl246
   Forbes A, 2000, REPROD HEALTH MATTER, V8, P156, DOI 10.1016/S0968-8080(00)90199-X
   GARG S, 1994, CONTRACEPTION, V50, P185, DOI 10.1016/0010-7824(94)90054-X
   Gupta G, 2005, EUR J CONTRACEP REPR, V10, P212, DOI 10.1080/13625180500280753
   Gupta G, 2005, HUM REPROD, V20, P2301, DOI 10.1093/humrep/dei041
   Kirby J, 2001, Posit Living, V10, P20
   KLEBANOFF SJ, 1992, J INFECT DIS, V165, P19, DOI 10.1093/infdis/165.1.19
   Lorenzi H., 2004, ARVORES BRASILEIRAS
   Maikhuri JP, 2003, CONTRACEPTION, V67, P403, DOI 10.1016/S0010-7824(03)00022-2
   MCGROARTY JA, 1992, J INFECT DIS, V165, P1142, DOI 10.1093/infdis/165.6.1142
   Murgu M, 2006, J BRAZIL CHEM SOC, V17, P1281, DOI 10.1590/S0103-50532006000700013
   Pelegrini DD, 2008, LAT AM J PHARM, V27, P922
   Qjha P, 2003, CONTRACEPTION, V68, P135, DOI 10.1016/S0010-7824(03)00138-0
   Reid G, 1996, FEMS IMMUNOL MED MIC, V15, P23, DOI 10.1016/0928-8244(96)00039-9
   RIBEIRO A, 1995, INT J PHARMACOGN, V33, P177, DOI 10.3109/13880209509065359
   Richardson BA, 2001, SEX TRANSM DIS, V28, P394, DOI 10.1097/00007435-200107000-00006
   Richardson BA, 1998, J INFECT DIS, V178, P441, DOI 10.1086/515636
   Rocha TD, 2012, PARASITOL RES, V110, P2551, DOI 10.1007/s00436-011-2798-1
   Sanders ME, 2001, J DAIRY SCI, V84, P319, DOI 10.3168/jds.S0022-0302(01)74481-5
   Souad K, 2007, CONTRACEPTION, V75, P152, DOI 10.1016/j.contraception.2006.10.006
   Sridhar C, 2010, PHARM SINICA, V1, P151
   Stewart F, 1998, CONTRACEPTIVE TECHNO, P357
   SWEET SP, 1987, FEMS MICROBIOL LETT, V48, P159, DOI 10.1111/j.1574-6968.1987.tb02534.x
   Talwar GP, 2008, INT J ANTIMICROB AG, V32, P180, DOI 10.1016/j.ijantimicag.2008.03.004
   Talwar GP, 2000, AM J REPROD IMMUNOL, V43, P144, DOI 10.1111/j.8755-8920.2000.430303.x
   Tiwari P, 2008, J ANTIMICROB CHEMOTH, V62, P526, DOI 10.1093/jac/dkn223
   Treter J, 2010, LAT AM J PHARM, V29, P914
   Tsuzuki JK, 2007, AN ACAD BRAS CIENC, V79, P577, DOI 10.1590/S0001-37652007000400002
   Upcroft JA, 2001, ANTIMICROB AGENTS CH, V45, P1810, DOI 10.1128/AAC.45.6.1810-1814.2001
   WHO World Health Organization, 2003, GUID MAN SEX TRANSM
   World Health Organization, 2010, UN ACC
   World Health Organization, 2002, PROGR REPROD HLTH RE, V59, P1
   World Health Organization, 2010, WHO LAB MAN EX PROC
   World Health Organization, 2011, SEXUALLY TRANSMITTED
NR 39
TC 11
Z9 14
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472-6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD JUL 28
PY 2013
VL 13
AR 196
DI 10.1186/1472-6882-13-196
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 192KA
UT WOS:000322481900001
PM 23890053
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Marangon, AV
   Guelsin, GAS
   Visentainer, JEL
   Borelli, SD
   Watanabe, MAE
   Consolaro, MEL
   Caleffi-Ferracioli, KR
   Rudnick, CCC
   Sell, AM
AF Marangon, Amanda Vansan
   Soares Guelsin, Glaucia Andreia
   Laguila Visentainer, Jeane Eliete
   Borelli, Sueli Donizete
   Ehara Watanabe, Maria Angelica
   Lopes Consolaro, Marcia Edilaine
   Caleffi-Ferracioli, Katiany Rizzieri
   Chagas Rudnick, Cristiane Conceicao
   Sell, Ana Maria
TI The Association of the Immune Response Genes to Human
   Papillomavirus-Related Cervical Disease in a Brazilian Population
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID ANTIGEN CLASS-II; IMMUNOGLOBULIN-LIKE RECEPTOR; HIGH-GRADE; KIR GENES;
   HLA-DRB1 ALLELES; CANCER; HLA; POLYMORPHISMS; RISK; HPV
AB The genetic variability of the host contributes to the risk of human papillomavirus (HPV)-related cervical disease. Immune response genes to HPV must be investigated to define patients with the highest risk of developing malignant disease. The aim of this study was to investigate the association of polymorphic immune response genes, namely KIR, HLA class I and II, and single-nucleotide polymorphisms (SNPs) of cytokines with HPV-related cervical disease. We selected 79 non-related, admixed Brazilian women from the state of Parana, southern region of Brazil, who were infected with high carcinogenic risk HPV and present cervical intraepithelial neoplasia grade 3 (CIN3), and 150 HPV-negative women from the same region matched for ethnicity. KIR genes were genotyped using an in-house PCR-SSP. HLA alleles were typed using a reverse sequence-specific oligonucleotide technique. SNPs of TNF -308G>A, IL6 -174G>C, IFNG +874T>A, TGFB1 +869T>C +915G>C, and IL10 -592C>A -819C>T -1082G>A were evaluated using PCR-SSP. The KIR genes were not associated with HPV, although some pairs of i(inhibitory)KIR-ligands occurred more frequently in patients, supporting a role for NK in detrimental chronic inflammatory and carcinogenesis. Some HLA haplotypes were associated with HPV. The associations of INFG and IL10 SNPs potentially reflect impaired or invalid responses in advanced lesions.
C1 [Marangon, Amanda Vansan; Soares Guelsin, Glaucia Andreia] Univ Estadual Campinas, BR-13083878 Campinas, SP, Brazil.
   [Laguila Visentainer, Jeane Eliete; Borelli, Sueli Donizete; Sell, Ana Maria] Univ Estadual Maringa, Basic Hlth Sci Dept, BR-87020900 Maringa, PR, Brazil.
   [Ehara Watanabe, Maria Angelica] Univ Estadual Londrina, Dept Pathol Sci, BR-86051970 Londrina, PR, Brazil.
   [Lopes Consolaro, Marcia Edilaine; Caleffi-Ferracioli, Katiany Rizzieri] Univ Estadual Maringa, Dept Clin Anal & Biomed, BR-87020900 Maringa, PR, Brazil.
   [Chagas Rudnick, Cristiane Conceicao] Univ Estadual Maringa, Dept Clin Anal & Biomed, Program Biosci Appl Pharm, BR-87020900 Maringa, PR, Brazil.
RP Sell, AM (corresponding author), Univ Estadual Maringa, Basic Hlth Sci Dept, Ave Colombo 5790, BR-87020900 Maringa, PR, Brazil.
EM anamsell@gmail.com
RI Visentainer, Jeane Eliete Laguila/B-3510-2009; Consolaro, Marcia
   Edilaine Lopes/I-4932-2014; Watanabe, Maria Angelica/AAO-4970-2020
OI Visentainer, Jeane Eliete Laguila/0000-0002-5815-7903; Consolaro, Marcia
   Edilaine Lopes/0000-0001-9102-4865; Sell, Ana/0000-0001-7315-3567
CR Ades S, 2008, INT J CANCER, V122, P2820, DOI 10.1002/ijc.23459
   Alaez-Verson C, 2011, ARCH MED RES, V42, P421, DOI 10.1016/j.arcmed.2011.07.002
   Arnheim L, 2005, TISSUE ANTIGENS, V65, P252, DOI 10.1111/j.1399-0039.2005.00359.x
   Awad MR, 1998, TRANSPLANTATION, V66, P1014, DOI 10.1097/00007890-199810270-00009
   Badano I, 2012, J CLIN VIROL, V53, P54, DOI 10.1016/j.jcv.2011.09.030
   Barbisan G, 2012, TUMOR BIOL, V33, P1549, DOI 10.1007/s13277-012-0408-1
   Ben Othmane Y, 2012, B CANCER, V99, pE81, DOI 10.1684/bdc.2012.1623
   Bolpetti A, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-27
   Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003
   Carrington M, 2005, J EXP MED, V201, P1069, DOI 10.1084/jem.20042158
   Carrington M, 2003, THE KIR GENE CLUSTER
   Castro FA, 2009, INT J CANCER, V125, P1851, DOI 10.1002/ijc.24529
   Cervantes J, 2003, HUM IMMUNOL, V64, P890, DOI 10.1016/S0198-8859(03)00163-0
   Rudnick CCC, 2008, HUM IMMUNOL, V69, P872, DOI 10.1016/j.humimm.2008.09.002
   Chan PKS, 2007, GYNECOL ONCOL, V105, P736, DOI 10.1016/j.ygyno.2007.02.013
   Chattopadhyay Koushik, 2011, Indian J Hum Genet, V17, P132, DOI 10.4103/0971-6866.92087
   Chen D, 2013, JNCI-J NATL CANCER I, V105, P624, DOI 10.1093/jnci/djt051
   Chuang LC, 2012, CANCER-AM CANCER SOC, V118, P223, DOI 10.1002/cncr.26227
   Dao DD, 2005, GYNECOL ONCOL, V96, P349, DOI 10.1016/j.ygyno.2004.10.002
   Eiguchi K, 2008, J LOW GENIT TRACT DI, V12, P262, DOI 10.1097/LGT.0b013e3181729285
   Feng QH, 2012, GYNECOL ONCOL, V127, P412, DOI 10.1016/j.ygyno.2012.07.098
   Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629
   GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403
   GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296
   Guzalinuer Abliz, 2010, Zhonghua Zhong Liu Za Zhi, V32, P492
   Han M, 2007, HUM IMMUNOL, V68, P507, DOI 10.1016/j.humimm.2007.02.001
   Hernandez-Hernandez DM, 2009, INT J GYNECOL CANCER, V19, P1099, DOI 10.1111/IGC.0b013e3181a83cf4
   Hibma Merilyn H, 2012, Open Virol J, V6, P241, DOI 10.2174/1874357901206010241
   Iancu Iulia Virginia, 2010, Roum Arch Microbiol Immunol, V69, P113
   Kohaar I, 2009, HUM IMMUNOL, V70, P222, DOI 10.1016/j.humimm.2009.01.003
   Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7
   Visentainer JE, 2008, INT J IMMUNOGENET, V35, P287, DOI 10.1111/j.1744-313X.2008.00778.x
   Lema C, 2006, INT J GYNECOL CANCER, V16, P1269, DOI 10.1111/j.1525-1438.2006.00459.x
   Liang JX, 2008, CANCER GENET CYTOGEN, V187, P95, DOI 10.1016/j.cancergencyto.2008.07.011
   Maciag PC, 2000, CANCER EPIDEM BIOMAR, V9, P1183
   Madeleine MM, 2002, J INFECT DIS, V186, P1565, DOI 10.1086/345285
   Martin MP, 2010, IMMUNOGENETICS, V62, P761, DOI 10.1007/s00251-010-0477-5
   Martin MP, 2002, J IMMUNOL, V169, P2818, DOI 10.4049/jimmunol.169.6.2818
   Matsumoto K, 2012, INT J GYNECOL CANCER, V22, P471, DOI 10.1097/IGC.0b013e3182439500
   Mocellin S, 2008, FRONT BIOSCI-LANDMRK, V13, P2774, DOI 10.2741/2884
   Parham P, 2005, NAT REV IMMUNOL, V5, P201, DOI 10.1038/nri1570
   Petersdorf EW, 2007, BEST PRACT RES CL HA, V20, P155, DOI 10.1016/j.beha.2006.09.001
   Pravica V, 1999, EUR J IMMUNOGENET, V26, P1, DOI 10.1046/j.1365-2370.1999.00122.x
   Probst CM, 2000, HUM BIOL, V72, P597
   Qu WM, 1997, J CLIN MICROBIOL, V35, P1304, DOI 10.1128/JCM.35.6.1304-1310.1997
   Rajagopalan S, 2005, J EXP MED, V201, P1025, DOI 10.1084/jem.20050499
   Rudnick Cristiane Conceição Chagas, 2010, J. Bras. Patol. Med. Lab., V46, P215, DOI 10.1590/S1676-24442010000300008
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
   Sasagawa T, 2012, J INFECT CHEMOTHER, V18, P807, DOI 10.1007/s10156-012-0485-5
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Sharma A, 2009, INT J GYNECOL CANCER, V19, P1269, DOI 10.1111/IGC.0b013e3181a8efcc
   Shi TY, 2013, HUM GENET, V132, P301, DOI 10.1007/s00439-012-1245-4
   Solomon D, 2005, BETHESDA SYSTEM CERV
   Song MJ, 2013, TISSUE ANTIGENS, V81, P164, DOI 10.1111/tan.12068
   Souza PSD, 2003, MUTAT RES-REV MUTAT, V544, P375, DOI 10.1016/j.mrrev.2003.06.013
   Subramanya D, 2008, POSTGRAD MED, V120, P7, DOI 10.3810/pgm.2008.11.1928
   Szurkus DC, 2003, AM J OBSTET GYNECOL, V188, P1180, DOI 10.1067/mob.2003.282
   Telesheva L. F., 2012, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P118
   Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x
   Wang N., 2012, PLOS ONE, V7
   Woodworth CD, 2002, FRONT BIOSCI-LANDMRK, V7, pD2058, DOI 10.2741/woodworth
   Wu YP, 2007, HUM IMMUNOL, V68, P192, DOI 10.1016/j.humimm.2006.07.005
   Yang YC, 2006, HUM IMMUNOL, V67, P331, DOI 10.1016/j.humimm.2006.03.017
   Yusa SI, 2004, J IMMUNOL, V172, P7385, DOI 10.4049/jimmunol.172.12.7385
   Zhi-Ming L, 2007, CROAT MED J, V48, P800, DOI 10.3325/cmj.2007.6.800
NR 65
TC 11
Z9 11
U1 0
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2013
VL 2013
AR 146079
DI 10.1155/2013/146079
PG 11
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 189AJ
UT WOS:000322238900001
PM 23936772
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Abreu, ALP
   Nogara, PRB
   Souza, RP
   da Silva, MC
   Uchimura, NS
   Zanko, RL
   Ferreira, EC
   Tognim, MCB
   Teixeira, JJV
   Gimenes, F
   Consolaro, MEL
AF de Abreu, Andre L. P.
   Nogara, Paula R. B.
   Souza, Raquel P.
   da Silva, Mariana C.
   Uchimura, Nelson S.
   Zanko, Rodrigo L.
   Ferreira, Erika C.
   Tognim, Maria C. B.
   Teixeira, Jorge J. V.
   Gimenes, Fabricia
   Consolaro, Marcia E. L.
TI Short Report: Molecular Detection of HPV and Chlamydia trachomatis
   Infections in Brazilian Women with Abnormal Cervical Cytology
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID RISK
AB The question of whether Chlamydia trachomatis (Ct) is a cofactor for human Papillomavirus (HPV) in cervical carcinogenesis is still controversial. We conducted a molecular detection study of both infections in 622 Brazilian women, including 252 women with different grades of abnormal cervical cytology and cervical cancer (CC; cases) and 370 women with normal cytology (controls). Although Ct infection did not seem related to CC carcinogenicity, women with abnormal cytology had a significant high rate of Ct infection. Therefore, it is important to adopt protocols for diagnosis and treatment of this bacterium in conjunction with screening for CC in this population.
C1 [de Abreu, Andre L. P.; Nogara, Paula R. B.; Souza, Raquel P.; da Silva, Mariana C.; Teixeira, Jorge J. V.; Gimenes, Fabricia; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Anal Clin & Biomed, BR-87020900 Maringa, Parana, Brazil.
   [Uchimura, Nelson S.; Zanko, Rodrigo L.] Univ Estadual Maringa, Dept Med, BR-87020900 Maringa, Parana, Brazil.
   [Tognim, Maria C. B.] Univ Estadual Maringa, Dept Basic Sci Hlth, BR-87020900 Maringa, Parana, Brazil.
   [Ferreira, Erika C.] Univ Estadual Maringa, Programa Posgrad Ciencias Saude, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin & Biomed, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM andreluelsdorf@gmail.com; paularbnogara@yahoo.com.br;
   raquelpantarotto@hotmail.com.br; mariclivati@gmail.com;
   nuchimura@hotmail.com; rodzanko@hotmail.com; erikacris84@gmail.com;
   mcbtognim@uem.br; jjvteixeira@gmail.com; fabricia.gimenes@gmail.com;
   melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Fundacao Araucaria Apoio ao Desenvolvimento Cientifico e Tecnologico do
   Parana, Ministerio da Snide do BrasilFundacao Araucaria [EFP
   00002873-SISCT]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES [AUX-PE-PRODOC 2571/2010]; Brazilian Government
FX This study was supported by the Fundacao Araucaria Apoio ao
   Desenvolvimento Cientifico e Tecnologico do Parana, Ministerio da Snide
   do Brasil Grant EFP 00002873-SISCT, Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES) Grant AUX-PE-PRODOC 2571/2010, and the
   Brazilian Government.
CR Bodily J, 2011, TRENDS MICROBIOL, V19, P33, DOI 10.1016/j.tim.2010.10.002
   Calil LN, 2011, BRAZ J INFECT DIS, V15, P126, DOI 10.1016/S1413-8670(11)70157-X
   Gopalkrishna V, 2000, CLIN MICROBIOL INFEC, V6, P88, DOI 10.1046/j.1469-0691.2000.00024.x
   Instituto Nacional do Cancer (BR), 2012, EST 2012 INC CANC BR
   Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115
   Kling M, 2010, INT J DERMATOL, V49, P377, DOI 10.1111/j.1365-4632.2010.04316.x
   Lehtinen M, 2011, SEX TRANSM INFECT, V87, P372, DOI 10.1136/sti.2010.044354
   Lizano M, 2009, ARCH MED RES, V40, P428, DOI 10.1016/j.arcmed.2009.06.001
   Miller WC, 2011, SEX TRANSM INFECT, V87, P366, DOI 10.1136/sti.2011.049775
   Naucler P, 2007, J GEN VIROL, V88, P814, DOI 10.1099/vir.0.82503-0
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
   Solomon D, 2005, BETHESDA SYSTEM CERV, P67
NR 12
TC 13
Z9 13
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2012
VL 87
IS 6
BP 1149
EP 1151
DI 10.4269/ajtmh.2012.12-0287
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 052YG
UT WOS:000312236000032
PM 23128289
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Abreu, ALP
   Souza, RP
   Gimenes, F
   Consolaro, MEL
AF Abreu, Andre L. P.
   Souza, Raquel P.
   Gimenes, Fabricia
   Consolaro, Marcia E. L.
TI A review of methods for detect human Papillomavirus infection
SO VIROLOGY JOURNAL
LA English
DT Review
DE Human Papillomavirus; Detection methods; Biomarkers; Cervical cancer;
   Cervical lesions progression
ID RISK HUMAN-PAPILLOMAVIRUS; POLYMERASE-CHAIN-REACTION; HPV GENOTYPING
   TEST; CERVICAL-CANCER; CLINICAL-PERFORMANCE; NATURAL-HISTORY; DNA LOAD;
   WOMEN; PCR; PREVALENCE
AB Human Papillomavirus (HPV) is the most common sexually transmitted virus. Worldwide, the most common high-risk (HR)-HPV are -16/18, and approximately 70% of cervical cancers (CC) are due to infection by these genotypes. Persistent infection by HR-HPV is a necessary but not sufficient cause of this cancer, which develops over a long period through precursor lesions, which can be detected by cytological screening. Although this screening has decreased the incidence of CC, HPV-related cervical disease, including premalignant and malignant lesions, continues to be a major burden on health-care systems. Although not completely elucidated, the HPV-driven molecular mechanisms underlying the development of cervical lesions have provided a number of potential biomarkers for both diagnostic and prognostic use in the clinical management of women with HPV-related cervical disease, and these biomarkers can also be used to increase the positive predictive value of current screening methods. In addition, they can provide insights into the biology of HPV-induced cancer and thus lead to the development of nonsurgical therapies. Considering the importance of detecting HPV and related biomarkers, a variety of methods are being developed for these purposes. This review summarizes current knowledge of detection methods for HPV, and related biomarkers that can be used to discriminate lesions with a high risk of progression to CC.
C1 [Abreu, Andre L. P.; Souza, Raquel P.; Gimenes, Fabricia; Consolaro, Marcia E. L.] Univ Estadual Maringa, Div Clin Cytol, Dept Clin Anal & Biomed, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Div Clin Cytol, Dept Clin Anal & Biomed, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel superior (CAPES),
   Brazilian GovernmentCAPES [AUX-PE-PRODOC 2571/2010]
FX This work was supported by grants from Coordenacao de Aperfeicoamento de
   Pessoal de Nivel superior (CAPES), AUX-PE-PRODOC 2571/2010, Brazilian
   Government.
CR Barcellos RB, 2011, J VIROL METHODS, V177, P38, DOI 10.1016/j.jviromet.2011.06.010
   Bartholomew DA, 2011, J CLIN VIROL, V51, P38, DOI 10.1016/j.jcv.2011.01.016
   Martinez SB, 2012, J VIROL METHODS, V180, P7, DOI 10.1016/j.jviromet.2011.12.002
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Bozzetti, 2000, Ann Epidemiol, V10, P466, DOI 10.1016/S1047-2797(00)00147-2
   Brandstetter T, 2010, J VIROL METHODS, V163, P40, DOI 10.1016/j.jviromet.2009.07.027
   Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321
   Bryant D, 2011, J MED VIROL, V83, P1358, DOI 10.1002/jmv.22107
   Camargo M, 2011, J VIROL METHODS, V178, P68, DOI 10.1016/j.jviromet.2011.08.014
   Carvalho ND, 2010, MEM I OSWALDO CRUZ, V105, P73, DOI 10.1590/S0074-02762010000100011
   Chow LT, 2010, APMIS, V118, P422, DOI 10.1111/j.1600-0463.2010.02625.x
   Coser J, 2011, BRAZ J INFECT DIS, V15, P467, DOI [10.1016/S1413-8670(11)70229-X, 10.1590/S1413-86702011000500009]
   Cricca M, 2009, J VIROL METHODS, V158, P180, DOI 10.1016/j.jviromet.2009.01.005
   Cuschieri K, 2008, CANCER EPIDEM BIOMAR, V17, P2536, DOI 10.1158/1055-9965.EPI-08-0306
   Cuzick J, 2008, VACCINE, V26, pK29, DOI 10.1016/j.vaccine.2008.06.019
   Dalstein V, 2011, J MED VIROL, V83, P1377
   de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033
   de Wilde J, 2008, INT J CANCER, V122, P877, DOI 10.1002/ijc.23210
   Didelot MN, 2011, J MED VIROL, V83, P1377, DOI 10.1002/jmv.22148
   Oliveira Ledy do Horto dos Santos, 2003, Sao Paulo Med. J., V121, P67, DOI 10.1590/S1516-31802003000200007
   Dobec M, 2011, J MED VIROL, V83, P1370, DOI 10.1002/jmv.22126
   Dockter J, 2009, J CLIN VIROL, V45, pS39, DOI 10.1016/S1386-6532(09)70007-1
   Einstein MH, 2010, GYNECOL ONCOL, V118, P116, DOI 10.1016/j.ygyno.2010.04.013
   Faridi R, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-269
   Forinash AB, 2011, ANN PHARMACOTHER, V45, P258, DOI 10.1345/aph.1P396
   Frazer IH, 2011, ANNU REV IMMUNOL, V29, P111, DOI 10.1146/annurev-immunol-031210-101308
   Gallo G, 2003, J CLIN PATHOL, V56, P532, DOI 10.1136/jcp.56.7.532
   Gravitt PE, 2007, INT J CANCER, V121, P2787, DOI 10.1002/ijc.23012
   Heideman DAM, 2011, J CLIN MICROBIOL, V49, P3983, DOI 10.1128/JCM.05552-11
   Hesselink AT, 2008, J CLIN MICROBIOL, V46, P3215, DOI 10.1128/JCM.00476-08
   Ho CM, 2006, GYNECOL ONCOL, V102, P54, DOI 10.1016/j.ygyno.2005.11.035
   Ho CM, 2011, VIRUS RES, V161, P124, DOI 10.1016/j.virusres.2011.06.012
   Hoheisel JD, 2006, NAT REV GENET, V7, P200, DOI 10.1038/nrg1809
   Hwang SJ, 2012, J ONCOL, V2012, DOI 10.1155/2012/507286
   IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007, IARC Monogr Eval Carcinog Risks Hum, V90, P1
   Jin Y, 2011, ASIAN PAC J CANCER P, V12, P1167
   Johnson LR, 2008, AM J CLIN PATHOL, V130, P401, DOI 10.1309/4DXEAFG2JXYF34N3
   Katzenellenbogen RA, 2007, J VIROL, V81, P3786, DOI 10.1128/JVI.02007-06
   Khan S, 2007, INT J INFECT DIS, V11, P313, DOI 10.1016/j.ijid.2006.06.007
   Kocjan BJ, 2011, J VIROL METHODS, V175, P117, DOI 10.1016/j.jviromet.2011.04.006
   Kulmala SMA, 2006, J CLIN PATHOL, V59, P513, DOI 10.1136/jcp.2004.024570
   LEE LG, 1992, NUCLEIC ACIDS RES, V20, P2471, DOI 10.1093/nar/20.10.2471
   Lenselink CH, 2009, J CLIN MICROBIOL, V47, P2564, DOI 10.1128/JCM.00285-09
   Liu XF, 2005, J BIOL CHEM, V280, P10807, DOI 10.1074/jbc.M410343200
   Lowe B, 2011, J VIROL METHODS, V173, P150, DOI 10.1016/j.jviromet.2011.01.018
   Mateos ML, 2011, ENFERM INFEC MICR CL, V29, P411, DOI 10.1016/j.eimc.2011.01.007
   Matovina M, 2009, GYNECOL ONCOL, V113, P120, DOI 10.1016/j.ygyno.2008.12.004
   Maver PJ, 2010, J VIROL METHODS, V169, P215, DOI 10.1016/j.jviromet.2010.07.007
   Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3
   Monnier-Benoit S, 2006, J CLIN VIROL, V35, P270, DOI 10.1016/j.jcv.2005.09.001
   Munoz N, 2009, LANCET, V373, P1949, DOI 10.1016/S0140-6736(09)60691-7
   Naqvi SH, 2004, J VIROL METHODS, V117, P91, DOI 10.1016/j.jviromet.2003.12.002
   Nogara PRB, 2012, INT J GYNECOL OBSTET, V117, P289, DOI 10.1016/j.ijgo.2012.01.003
   Novais RC, 2011, J MICROBIOL METH, V86, P1, DOI 10.1016/j.mimet.2011.04.006
   Pannier-Stockman C, 2008, J CLIN VIROL, V42, P353, DOI 10.1016/j.jcv.2008.03.022
   Otero-Motta AP, 2011, APMIS, V119, P204, DOI 10.1111/j.1600-0463.2010.02711.x
   Pista A, 2011, J MED VIROL, V83, P272, DOI 10.1002/jmv.21952
   Porras C, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-238
   Rahman M, 2011, J MED VIROL, V83, P1988, DOI 10.1002/jmv.22203
   Roberts I, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-57
   Rosenblatt C, 2005, HPV IN CLINICAL PRAC, P25
   Sanger F, 1992, Biotechnology, V24, P104
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
   Schmeink CE, 2011, REV MED VIROL, V21, P139, DOI 10.1002/rmv.686
   Schopp B, 2010, J MED VIROL, V82, P605, DOI 10.1002/jmv.21719
   Shen-Gunther J, 2011, GYNECOL ONCOL, V123, P263, DOI 10.1016/j.ygyno.2011.07.017
   Sheng J, 2010, CHINESE MED J-PEKING, V123, P1000, DOI 10.3760/cma.j.issn.0366-6999.2010.08.005
   SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0
   Stanley M, 2010, GYNECOL ONCOL, V117, pS5, DOI [10.1016/j.ygyno.2010.01.024, 10.1016/j.ygyno.2010.04.002]
   Sukasem C, 2011, J MED VIROL, V83, P119, DOI 10.1002/jmv.21948
   Termini L, 2008, J BRAS DOENCAS SEX T, V20, P125
   van Hamont D, 2006, J CLIN MICROBIOL, V44, P3122, DOI 10.1128/JCM.00517-06
   Villa LL, 2006, INT J GYNECOL OBSTET, V94, pS71, DOI 10.1016/S0020-7292(07)60013-7
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Weaver B, 2011, J MED VIROL, V83, P1362, DOI 10.1002/jmv.22116
   Wentzensen N, 2007, DIS MARKERS, V23, P315, DOI 10.1155/2007/678793
   Wentzensen N, 2009, PATHOBIOLOGY, V76, P82, DOI 10.1159/000201676
   Wright TC, 2003, NEW ENGL J MED, V348, P489, DOI 10.1056/NEJMp020178
   Xi LF, 2009, JNCI-J NATL CANCER I, V101, P153, DOI 10.1093/jnci/djn461
   Yoshida T, 2008, INT J GYNECOL CANCER, V18, P121, DOI 10.1111/j.1525-1438.2007.00979.x
   Zaravinos A, 2009, INT J BIOL MARKER, V24, P215
NR 81
TC 123
Z9 132
U1 0
U2 43
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD NOV 6
PY 2012
VL 9
AR 262
DI 10.1186/1743-422X-9-262
PG 9
WC Virology
SC Virology
GA 043OP
UT WOS:000311554100001
PM 23131123
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU da Silva, MC
   Martins, HPR
   de Souza, JL
   Tognim, MCB
   Svidzinski, TIE
   Teixeira, JJV
   Consolaro, MEL
AF da Silva, Mariana Clivati
   Rodrigues Martins, Helen Priscila
   de Souza, Jamile Lopes
   Bronharo Tognim, Maria Cristina
   Estivalet Svidzinski, Terezinha Inez
   Vieira Teixeira, Jorge Juarez
   Lopes Consolaro, Marcia Edilaine
TI Prevalence of HPV infection and genotypes in women with normal cervical
   cytology in the state of Parana, Brazil
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE HPV; Genotypes; Prevalence; Normal cytology
ID HUMAN-PAPILLOMAVIRUS TYPES; CANCER; POPULATION
AB We investigated the prevalence of the human Papillomavirus (HPV) and its genotypes in women with normal cervical cytology in the state of Parana, Brazil, and also epidemiological characteristics.
   The enrolled patients were seen at six primary health-care units in Pai double dagger andA(0) City, Parana. Through polymerase chain reaction (PCR) and PCR-RFLP (restriction fragment length polymorphism) techniques, 40 HPV genotypes were found, including 15 high risk, 3 undetermined risk and 22 low risk. Socio-demographic characteristics and sexual behavior were also recorded by interviews based on a structured questionnaire completed at the time of enrollment.
   Among 418 patients examined, HPV was detected in 6.7 %, mainly in women aged < 25 years. The overall prevalence of high-risk, low-risk and undetermined-risk HPV types was 42.9, 45.7, and 11.7 %, respectively. HPV-16 was the most common type detected (14.3 %), followed by types 66 (11.4 %) and 31 and 70 (8.6 % each). Detection of HPV DNA was positively associated with the number of sexual partners within the previous 12 months (p < 0.031; OR = 5.4; CI = 0.98-29.8).
   When considering the lack of studies in Parana on women with normal cytology, the results of this study will improve estimates of HPV DNA populations, and provide baseline values against which the impact of vaccination can be assessed in the future.
C1 [da Silva, Mariana Clivati; Rodrigues Martins, Helen Priscila; de Souza, Jamile Lopes; Estivalet Svidzinski, Terezinha Inez; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Clin Cytol Lab, Dept Clin Anal & Biomed, BR-87020900 Maringa, Parana, Brazil.
   [Bronharo Tognim, Maria Cristina] Univ Estadual Maringa, Basic Microbiol Lab, Dept Basic Sci Hlth, BR-87020900 Maringa, Parana, Brazil.
   [Vieira Teixeira, Jorge Juarez] Univ Estadual Maringa, Div Epidemiol, Dept Clin Anal & Biomed, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Clin Cytol Lab, Dept Clin Anal & Biomed, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@yahoo.com.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
CR Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321
   Clifford GM, 2005, LANCET, V366, P991, DOI 10.1016/S0140-6736(05)67069-9
   Confortini M, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-157
   De Sanjose S, 2003, SEX TRANSM DIS, V30, P788, DOI 10.1097/01.OLQ.0000080177.82204.E0
   de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5
   Eluf-Neto J, 2001, SEMIN ONCOL, V28, P188, DOI 10.1053/sonc.2001.21966
   European Cervical Cancer Association, 2009, HPV VACC EUR
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fernandes JV, 2009, INT J GYNECOL OBSTET, V105, P21, DOI 10.1016/j.ijgo.2008.12.004
   Forinash AB, 2011, ANN PHARMACOTHER, V45, P258, DOI 10.1345/aph.1P396
   Gontijo RC, 2007, EUR J OBSTET GYN R B, V133, P239, DOI 10.1016/j.ejogrb.2006.05.012
   Kjaer SK, 2008, INT J CANCER, V123, P1864, DOI 10.1002/ijc.23712
   Krambeck WM, 2008, CLIN EXP OBSTET GYN, V35, P175
   Lippman SA, 2010, INT J STD AIDS, V21, P105, DOI 10.1258/ijsa.2009.008436
   Lorenzato F, 2000, INT J GYNECOL CANCER, V10, P143, DOI 10.1046/j.1525-1438.2000.00007.x
   Merck. Broad Spectrum HPV, BROAD SPECTR HPV HUM
   Molano M, 2002, BRIT J CANCER, V87, P324, DOI 10.1038/sj.bjc.6600442
   National Cancer Institute, 2009, EST 2010 CANC INC BR
   Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X
   Qu WM, 1997, J CLIN MICROBIOL, V35, P1304, DOI 10.1128/JCM.35.6.1304-1310.1997
   Rosa MI, 2008, AM J OBSTET GYNECOL, V99, P1
   Rossi PG, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-214
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
   Schiffman M, 2011, JNCI-J NATL CANCER I, V103, P1
   Solomon D, 2005, BETHESDA SYSTEM CERV, P67
   Stamataki P, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-27
   Uuskula A, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-63
NR 27
TC 13
Z9 13
U1 0
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD OCT
PY 2012
VL 286
IS 4
BP 1015
EP 1022
DI 10.1007/s00404-012-2399-y
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 003YL
UT WOS:000308647200030
PM 22699514
DA 2020-12-08
ER

PT J
AU Nogara, PRB
   Manfroni, LAR
   da Silva, MC
   Consolaro, MEL
AF Nogara, Paula R. B.
   Manfroni, Luis A. R.
   da Silva, Mariana C.
   Consolaro, Marcia E. L.
TI The "see and treat" strategy for identifying cytologic high-grade
   precancerous cervical lesions among low-income Brazilian women
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Cervical cancer prevention; High-grade squamous intraepithelial lesion;
   Loop electrosurgical excision procedure; Recurrence; See and treat
ID SQUAMOUS INTRAEPITHELIAL LESION; LOOP EXCISION; RESIDUAL DISEASE; LEEP
   CONIZATION; RISK-FACTORS; LASER; MANAGEMENT; DYSPLASIA
AB Objective:. To evaluate the strategy of "see and treat" by loop electrosurgical excision procedure (LEEP) for cytologic high-grade precancerous cervical lesions (squamous intraepithelial lesions; HSIL) and post-LEEP recurrence among low-income Brazilian women. Methods: In a retrospective survey of women who underwent LEEP for cytologic HSIL without prior cervical biopsy between January 2004 and March 2008 at CISVALI, Uniao da Vitoria, Parana, Brazil, LEEP sample histology and patient follow-up by Papanicolaou smear were assessed. Results: Among 117 women treated, 24% had no lesions, 67.5% had cervical intraepithelial neoplasia (CIN) grade 2/3, and 5.2% had squamous cell carcinoma or adenocarcinoma on LEEP histology. Among patients with follow-up, recurrences occurred in those with no lesions (16.7%) and CIN 2/3 (25%) (P>0.05). HSIL was the most frequent type of recurrence (87%) (P<0.001). In total, 6.3% of patients had positive ectocervical (ecto-positive) and endocervical (endo-positive) margins, 3.8% had ecto-positive, and 33.0% had endo-positive margins. Recurrences occurred in women with endo-positive (26.3%), no margin (17.4%), and cautery artifact margin (25.0%) involvement (P>0.05). Conclusion: For cytologic HSIL, the benefits of the strategy of "see and treat" by LEEP outweighed the risk of overtreatment. Patients with both positive and negative margins on LEEP should be followed carefully. (C) 2012 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Nogara, Paula R. B.; da Silva, Mariana C.; Consolaro, Marcia E. L.] Univ Estadual Maringa, Postgrad Program Appl Biosci Pharm, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Postgrad Program Appl Biosci Pharm, 5790 Av Colombo, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Fundacao Araucaria do Parana e Ministerio da Saude do Brasil [EFP
   00002873-SISCT]
FX The Fundacao Araucaria do Parana e Ministerio da Saude do Brasil
   supported the present study (project EFP 00002873-SISCT).
CR Acharya Ganesh, 2005, Archives of Gynecology and Obstetrics, V272, P109, DOI 10.1007/s00404-005-0727-1
   Baloglu A, 2010, ARCH GYNECOL OBSTET, V282, P69, DOI 10.1007/s00404-009-1298-3
   Bar-Am A, 2000, GYNECOL ONCOL, V78, P47, DOI 10.1006/gyno.2000.5825
   BIBBO M, 1997, COMPREHENSIVE CYTOPA
   Diakomanolis E, 2003, J REPROD MED, V48, P617
   Dietrich CS, 2002, OBSTET GYNECOL, V99, P188, DOI 10.1016/S0029-7844(01)01716-1
   Ferris DG, 1996, J FAM PRACTICE, V42, P253
   Instituto Nacional de Cancer (Brazil), 2006, REV BRAS CANCEROL, V52, P213
   KEIJSER KGG, 1992, AM J OBSTET GYNECOL, V166, P1281, DOI 10.1016/S0002-9378(11)90622-X
   Kietpeerakool C, 2009, J OBSTET GYNAECOL RE, V35, P507, DOI 10.1111/j.1447-0756.2008.00992.x
   Kim HJ, 2007, GYNECOL ONCOL, V105, P434, DOI 10.1016/j.ygyno.2006.12.036
   Kjellberg L, 2007, ACTA OBSTET GYN SCAN, V86, P1140, DOI 10.1080/00016340701505267
   Livasy CA, 2004, OBSTET GYNECOL, V104, P250, DOI 10.1097/01.AOG.0000132803.88049.84
   Maeda Marina Yoshiê Sakamoto, 2004, J. Bras. Patol. Med. Lab., V40, P425, DOI 10.1590/S1676-24442004000600011
   Mathevet P, 2003, EUR J OBSTET GYN R B, V106, P214, DOI 10.1016/S0301-2115(02)00245-2
   National Institute of Cancer/Brazil, EST CANC BRAZ 2010
   Nogara PRB, 2011, ARCH GYNECOL OBSTET, V284, P965, DOI 10.1007/s00404-010-1731-7
   Raio L, 1997, OBSTET GYNECOL, V90, P978, DOI 10.1016/S0029-7844(97)00489-4
   Sandweiss L, 2008, INT J GYNECOL OBSTET, V100, P284, DOI 10.1016/j.ijgo.2007.09.017
   Solomon D, 2005, BETHESDA SYSTEM CERV
   Szurkus DC, 2003, AM J OBSTET GYNECOL, V188, P1180, DOI 10.1067/mob.2003.282
NR 21
TC 8
Z9 8
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0020-7292
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD AUG
PY 2012
VL 118
IS 2
BP 103
EP 106
DI 10.1016/j.ijgo.2012.02.017
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 977BB
UT WOS:000306630200004
PM 22608027
DA 2020-12-08
ER

PT J
AU Nogara, PRB
   Gimenes, F
   Consolaro, MEL
AF Nogara, Paula R. B.
   Gimenes, Fabricia
   Consolaro, Marcia E. L.
TI Distribution of HPV genotypes and HPV-16 and HPV-18 E2 gene disruption
   in South Brazilian women with cervical abnormalities
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Editorial Material
DE Cervical abnormalities; Genotypes; HPV 16; HPV 18; Oncogene protein E2
C1 [Nogara, Paula R. B.; Gimenes, Fabricia; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@gmail.com
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
CR Collins SI, 2009, CANCER RES, V69, P3828, DOI 10.1158/0008-5472.CAN-08-3099
   Cricca M, 2009, J VIROL METHODS, V158, P180, DOI 10.1016/j.jviromet.2009.01.005
   Oliveira Ledy do Horto dos Santos, 2003, Sao Paulo Med. J., V121, P67, DOI 10.1590/S1516-31802003000200007
   Santiago E, 2006, J CLIN VIROL, V37, P38, DOI 10.1016/j.jcv.2006.06.001
NR 4
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0020-7292
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD JUN
PY 2012
VL 117
IS 3
BP 289
EP 290
DI 10.1016/j.ijgo.2012.01.003
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 948ND
UT WOS:000304509000020
PM 22425011
DA 2020-12-08
ER

PT J
AU Paiva, LCF
   Vidigal, PG
   Donatti, L
   Svidzinski, TIE
   Consolaro, MEL
AF Paiva, Luciene C. F.
   Vidigal, Pedrina G.
   Donatti, Lucelia
   Svidzinski, Terezinha I. E.
   Consolaro, Marcia E. L.
TI Assessment of in vitro biofilm formation by Candida species isolates
   from vulvovaginal candidiasis and ultrastructural characteristics
SO MICRON
LA English
DT Review
DE Vulvovaginal candidiasis; Adherence; Biofilm; SEM; CSLM
ID CELL-SURFACE HYDROPHOBICITY; SCANNING-ELECTRON; FUNGAL PATHOGEN;
   ALBICANS; SUSCEPTIBILITY; PARAPSILOSIS; ADHESION; INFECTIONS; ADHERENCE
AB Vulvovaginal candidiasis (VVC) is a very common cause of fungal infection that remains a significant problem worldwide, especially concerning its complex pathogenicity. Biofilm dynamics from vaginal isolates requires further investigation. Different assays, such as cell surface hydrophobicity (CSH), biofilm production, fungal metabolism by 2H-tetrazolium-5-carboxanilide (XTT)and phenazine methosulfate (PMS), scanning electron microscopy (SEM) and confocal scanning laser microscopy (CSLM) were used in order to determine the ability of five Candida species isolates from VVC patients to form in vitro biofilms and their ultrastructural characteristics. All yeasts demonstrated the ability to produce biofilm and showed viability up to 48 h after the completion of assay, confirmed by SEM and CSLM, but differences were observed between them. SEM and CSLM also revealed that all VVC isolates adhered only in blastoconidia form, except for Candida parapsilosis. Even though, only one isolate from each Candida species has been used, the results of high biofilm formation, metabolic activity and CSH showed by Candida albicans and C. parapsilosis, as well as by the ultrastructural characteristics, suggest that these species exhibit greater ability of adherence in relation to the others. Ours results support the theory that virulence potential is multifactorial and that other factors not evaluated in this study could be involved in the CVV physiopathogeny. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Paiva, Luciene C. F.; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol Lab, BR-87020900 Maringa, Parana, Brazil.
   [Vidigal, Pedrina G.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Med Mycol Lab, BR-87020900 Maringa, Parana, Brazil.
   [Donatti, Lucelia; Svidzinski, Terezinha I. E.] Univ Fed Parana, Dept Cell Biol, Electron Microscopy Lab, BR-80060000 Curitiba, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Ctr Ciencias Saude, Dept Anal Clin, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@yahoo.com.br
RI Donatti, Lucelia/E-1930-2013; Consolaro, Marcia Edilaine
   Lopes/I-4932-2014
OI Donatti, Lucelia/0000-0002-9023-2483; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865; Svidzinski, Terezinha/0000-0003-2525-9046
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); Fundacao Araucaria-BrazilFundacao Araucaria
FX This work received financial support from CAPES, CNPq and Fundacao
   Araucaria-Brazil. T.I.E.S. and L.C.F.P. are fellowship-holders from CNPq
   and CAPES, respectively.
CR Ahmad S, 2002, J CLIN MICROBIOL, V40, P2483, DOI 10.1128/JCM.40.7.2483-2489.2002
   Andes D, 2004, INFECT IMMUN, V72, P6023, DOI 10.1128/IAI.72.10.6023-6031.2004
   Auler ME, 2009, MED MYCOL, V7, P1
   Camacho DP, 2007, MYCOPATHOLOGIA, V163, P261, DOI 10.1007/s11046-007-9007-x
   Chandra J, 2001, J BACTERIOL, V183, P5385, DOI 10.1128/JB.183.18.5385-5394.2001
   Chassot F, 2008, CONTRACEPTION, V77, P355, DOI 10.1016/j.contraception.2008.01.007
   Chassot F, 2010, CONTRACEPTION, V81, P331, DOI 10.1016/j.contraception.2009.12.011
   Consolaro Marcia Edilaine Lopes, 2004, Revista Iberoamericana de Micologia, V21, P202
   Consolaro MEL, 2005, MYCOPATHOLOGIA, V159, P501, DOI 10.1007/s11046-005-1149-0
   Correa PD, 2009, REV BRAS GINECOL OBS, V31, P177, DOI 10.1590/S0100-72032009000400004
   Corsello S, 2003, EUR J OBSTET GYN R B, V110, P66, DOI 10.1016/S0301-2115(03)00096-4
   Dan M, 2002, MED MYCOL, V40, P383, DOI 10.1080/714031124
   De Vos MM, 2005, CLIN MICROBIOL INFEC, V11, P1005, DOI 10.1111/j.1469-0691.2005.01281.x
   Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002
   Doyle R.J., 1990, MICROBIAL CELL SURFA
   Paiva LCF, 2010, MICROSC MICROANAL, V16, P537, DOI 10.1017/S1431927610093773
   Folkesson A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001891
   Hazen KC, 2001, INFECT IMMUN, V69, P779, DOI 10.1128/IAI.69.2.779-786.2001
   Jabra-Rizk Mary Ann, 2001, Revista Iberoamericana de Micologia, V18, P17
   Kurtzman C.P., 1998, YEAST TAXONOMIA STUD
   Luo G, 2002, APMIS, V110, P601, DOI 10.1034/j.1600-0463.2002.1100902.x
   Moreira D, 2006, INT J GYNECOL OBSTET, V92, P266, DOI 10.1016/j.ijgo.2005.12.007
   O'Toole G, 2000, ANNU REV MICROBIOL, V54, P49, DOI 10.1146/annurev.micro.54.1.49
   Oliveira MT, 2010, MICRON, V41, P604, DOI 10.1016/j.micron.2010.03.011
   Panagoda GJ, 2001, MYCOSES, V44, P29, DOI 10.1046/j.1439-0507.2001.00611.x
   PFALLER MA, 1995, DIAGN MICR INFEC DIS, V21, P9, DOI 10.1016/0732-8893(94)00114-C
   Ribeiro MA, 2001, MYCOPATHOLOGIA, V151, P5, DOI 10.1023/A:1010909504071
   Ringdahl Erika N, 2006, Mo Med, V103, P165
   Shin JH, 2002, J CLIN MICROBIOL, V40, P1244, DOI 10.1128/JCM.40.4.1244-1248.2002
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Sojakova M, 2004, MYCOPATHOLOGIA, V157, P163, DOI 10.1023/B:MYCO.0000020594.35357.b0
   Souza PC, 2009, ARCH GYNECOL OBSTET, V279, P625, DOI 10.1007/s00404-008-0765-6
   Irie MMT, 2006, J CLIN LAB ANAL, V20, P195, DOI 10.1002/jcla.20132
   Thein ZM, 2007, ARCH ORAL BIOL, V52, P761, DOI 10.1016/j.archoralbio.2007.01.009
   Tumbarello M, 2007, J CLIN MICROBIOL, V45, P1843, DOI 10.1128/JCM.00131-07
   Walker JT, 2000, APPL ENVIRON MICROB, V66, P3363, DOI 10.1128/AEM.66.8.3363-3367.2000
   Wisplinghoff H, 2004, CLIN INFECT DIS, V39, P309, DOI 10.1086/421946
   Ziarrusta Gorka Barrenetxea, 2002, Revista Iberoamericana de Micologia, V19, P22
NR 38
TC 32
Z9 33
U1 3
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-4328
J9 MICRON
JI Micron
PD FEB
PY 2012
VL 43
IS 2-3
BP 497
EP 502
DI 10.1016/j.micron.2011.09.013
PG 6
WC Microscopy
SC Microscopy
GA 883AP
UT WOS:000299605300057
PM 22001373
DA 2020-12-08
ER

PT J
AU Martins, HPR
   da Silva, MC
   Paiva, LCF
   Svidzinski, TIE
   Consolaro, MEL
AF Rodrigues Martins, Helen Priscila
   da Silva, Mariana Clivati
   Farias Paiva, Luciene Cassia
   Estivalet Svidzinski, Terezinha Inez
   Lopes Consolaro, Marcia Edilaine
TI Efficacy of Fluconazole and Nystatin in the Treatment of Vaginal Candida
   Species
SO ACTA DERMATO-VENEREOLOGICA
LA English
DT Article
DE efficacy; fluconazole; nystatin; treatment; vaginal Candida spp
ID ANTIFUNGAL; YEASTS; WOMEN
AB The aim of this study was to determine and compare the efficacy of treatment with fluconazole and nystatin in Brazilian women with vaginal Candida. In a population of 932 women, vaginal cultures were performed for yeasts, whether or not the women showed signs and symptoms of vulvovaginal candidiasis. Yeasts were isolated from 12.2% of the women (114/932): 53.2% of the yeasts were Candida albicans, 27.0% C. glabrata, 13.5% C. tropicalis and 6.3% C. parapsilosis. Treatment was carried out with both drugs. The overall mean cure rates with fluconazole (87.0%) and nystatin (74.0%) were similar; among women with non-albicans, the cure rate with fluconazole was 100%, whereas that with nystatin was 44.4%. The cure rate for women with C. albicans was high with both fluconazole and nystatin; however, for those with non-albicans species the cure rate was excellent with fluconazole and very low with nystatin, differing from the majority of in vitro studies.
C1 [Rodrigues Martins, Helen Priscila; da Silva, Mariana Clivati; Farias Paiva, Luciene Cassia; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol Lab, Maringa, Parana, Brazil.
   [Estivalet Svidzinski, Terezinha Inez] Univ Estadual Maringa, Dept Clin Anal & Biomed, Med Mycol Lab, Maringa, Parana, Brazil.
RP Martins, HPR (corresponding author), Univ Estadual Maringa, Dept Clin Anal & Biomed, Clin Cytol Lab, Maringa, Parana, Brazil.
EM melconsolaro@yahoo.com.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Fundacao Araucaria de Apoio ao Desenvolvimento Tecnologico e Cientifico
   do Parana/BrazilFundacao Araucaria
FX Fundacao Araucaria de Apoio ao Desenvolvimento Tecnologico e Cientifico
   do Parana/Brazil provided financial support for this study.
CR Consolaro Marcia Edilaine Lopes, 2004, Revista Iberoamericana de Micologia, V21, P202
   Dota KFD, 2008, ACTA BIOQUIM CLIN L, V42, P561
   Dalben-Dota KF, 2010, J ALTERN COMPLEM MED, V16, P285, DOI 10.1089/acm.2009.0281
   Fan SR, 2008, J OBSTET GYNAECOL RE, V34, P561, DOI 10.1111/j.1447-0756.2008.00817.x
   Ferrazza MHSH, 2005, REV BRAS GINECOL OBS, V27, P58, DOI 10.1590/S0100-72032005000200003
   Ghannoum MA, 1999, CLIN MICROBIOL REV, V12, P501, DOI 10.1128/CMR.12.4.501
   Hetticarachchi N, 2010, SEX TRANSM INFECT, V86, P99, DOI 10.1136/sti.2009.040386
   Holland J, 2003, SEX TRANSM INFECT, V79, P249, DOI 10.1136/sti.79.3.249
   Kurtzman C.P., 1998, YEAST TAXONOMIC STUD
   Mardh PA, 2002, INT J STD AIDS, V13, P522, DOI 10.1258/095646202760159639
   Nyirjesy P, 2005, INF DIS OBSTET GYNEC, V13, P3741
   Paulitsch A, 2006, MYCOSES, V49, P471, DOI 10.1111/j.1439-0507.2006.01284.x
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Sobel JD, 1998, AM J OBSTET GYNECOL, V178, P203, DOI 10.1016/S0002-9378(98)80001-X
   SPINILLO A, 1992, J REPROD MED, V37, P343
   Vermitsky JP, 2008, J CLIN MICROBIOL, V46, P1501, DOI 10.1128/JCM.02485-07
   Wei YP, 2010, INT J GYNECOL OBSTET, V110, P227, DOI 10.1016/j.ijgo.2010.04.026
NR 17
TC 20
Z9 21
U1 0
U2 0
PU ACTA DERMATO-VENEREOLOGICA
PI UPPSALA
PA TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN
SN 0001-5555
EI 1651-2057
J9 ACTA DERM-VENEREOL
JI Acta Derm.-Venereol.
PY 2012
VL 92
IS 1
BP 78
EP 82
DI 10.2340/00015555-1194
PG 5
WC Dermatology
SC Dermatology
GA 893WM
UT WOS:000300388400016
PM 21918792
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Nogara, PRB
   Manfroni, LAR
   Consolaro, MEL
AF Nogara, P. R. B.
   Manfroni, L. A. R.
   Consolaro, M. E. L.
TI Cervical cytology of atypical squamous cells cannot exclude high-grade
   squamous intraepithelial lesion (ASC-H): histological results and
   recurrence after a loop electrosurgical excision procedure
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Atypical squamous cell; ASC-H; LEEP; Histology; Recurrence
ID RISK-FACTORS; MANAGEMENT; CONIZATION; LASER; RULE
AB Objectives To evaluate the histology of the loop electrosurgical excision procedure (LEEP) surgical tissues of patients with ASC-H and post-LEEP recurrence.
   Methods Medical records of patients with ASC-H treated with LEEP between January 2004 and March 2008 in the town of Unio da Vitria, Parana, seat of the Sixth Public Health Region of Parana (CISVALI), were evaluated. The LEEP was carried out solely for ASC-H immediately after colposcopy, but without a histological diagnosis.
   Results Most patients were less than 40 years old (71.1%), with the largest group 20-39 years old (p < 0.0001). Twenty-eight patients (73.3%) showed histological lesions. Cervical intraepithelial neoplasias (CIN) I was present in 7 (18.4%), CIN II and CIN III in 9 (23.7%) each, microinvasive squamous cell carcinoma (SCMCA) in 2 (5.3%), and SCMCA plus in situ adenocarcinoma in 1 (2.2%). In 32 patients (84.2%), there was no involvement of the margins, including 100% with no dysplasia histology and CIN I, 80.0% of those with CIN II, and 88.9% of those with CIN III. Two patients (5.3%) had endocervical involvement, all of them with CIN II. Four patients (10.5%) had ectocervical and endocervical involvement, one of them with CIN III, and three of them with carcinomas. All patients with follow-up (+) were ASC-US, with no patients with dysplasia or CIN I.
   Conclusions A very high portion of the women with ASC-H had lesions on post-LEEP histological examination, principally CIN II and III. These data show the benefits of treatment for ASC-H by LEEP immediately after colposcopy but without any previous histology.
C1 [Consolaro, M. E. L.] Univ Estadual Maringa, DAC, Dept Anal Clin, BR-87020900 Maringa, Parana, Brazil.
   [Manfroni, L. A. R.] Sixth Reg Publ Hlth Parana CISVALI, Uniao Da Vitoria, Parana, Brazil.
   [Nogara, P. R. B.; Consolaro, M. E. L.] Univ Estadual Maringa, Div Clin Cytol, Clin Anal Dept, Teaching & Res Lab Clin Anal, Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, DAC, Dept Anal Clin, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@yahoo.com.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
CR Acharya Ganesh, 2005, Archives of Gynecology and Obstetrics, V272, P109, DOI 10.1007/s00404-005-0727-1
   Alli PM, 2003, DIAGN CYTOPATHOL, V28, P308, DOI 10.1002/dc.10286
   Baloglu A, 2010, ARCH GYNECOL OBSTET, V282, P69, DOI 10.1007/s00404-009-1298-3
   *BRAS MIN SAUD SEC, 2006, REV BRASILEIRA CANCE, V52, P213
   CARDOSO MS, 2001, REV BRAS GINECOL OBS, V23, P349
   Dietrich CS, 2002, OBSTET GYNECOL, V99, P188, DOI 10.1016/S0029-7844(01)01716-1
   FREGNANI JHT, 2007, J MED SAO PAULO, V25, P231
   Howells REJ, 2000, BRIT J OBSTET GYNAEC, V107, P1075, DOI 10.1111/j.1471-0528.2000.tb11103.x
   Huitron S, 2008, ANN DIAGN PATHOL, V12, P187, DOI 10.1016/j.anndiagpath.2007.09.001
   *INCA, EST CANC BRAS 2007
   Juliato CRT, 2000, REV BRAS GINECOL OBS, V22, P65, DOI [10.1590/S0100-72032000000200002, DOI 10.1590/S0100-72032000000200002]
   Kietpeerakool C, 2009, J OBSTET GYNAECOL RE, V35, P507, DOI 10.1111/j.1447-0756.2008.00992.x
   Kim HJ, 2007, GYNECOL ONCOL, V105, P434, DOI 10.1016/j.ygyno.2006.12.036
   Lima Daisy N.O., 2002, J. Bras. Patol. Med. Lab., V38, P45, DOI 10.1590/S1676-24442002000100009
   Lindeque BG, 2005, BEST PRACT RES CL OB, V19, P545, DOI 10.1016/j.bpobgyn.2005.02.008
   Maeda Marina Yoshiê Sakamoto, 2004, J. Bras. Patol. Med. Lab., V40, P425, DOI 10.1590/S1676-24442004000600011
   Mathevet P, 2003, EUR J OBSTET GYN R B, V106, P214, DOI 10.1016/S0301-2115(02)00245-2
   MCHALE MT, 2007, J LOW GENIT TRACT DI, V1, P86
   Raio L, 1997, OBSTET GYNECOL, V90, P978, DOI 10.1016/S0029-7844(97)00489-4
   Scheungraber C, 2004, BRIT J CANCER, V90, P975, DOI 10.1038/sj.bjc.6601415
   Sherman ME, 2006, CANCER CYTOPATHOL, V108, P298, DOI 10.1002/cncr.21844
   Simsir A, 2006, DIAGN CYTOPATHOL, V34, P62, DOI 10.1002/dc.20334
   SOLOMON D, 2005, SISTEMA BETHESDA CIT, P67
   Szurkus DC, 2003, AM J OBSTET GYNECOL, V188, P1180, DOI 10.1067/mob.2003.282
NR 24
TC 4
Z9 5
U1 0
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD OCT
PY 2011
VL 284
IS 4
BP 965
EP 971
DI 10.1007/s00404-010-1731-7
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 819JS
UT WOS:000294821800027
PM 21052702
DA 2020-12-08
ER

PT J
AU Damke, E
   Tsuzuki, JK
   Cortez, DAG
   Ferreira, ICP
   Bertoni, TA
   Batista, MR
   Donati, L
   Svidzinski, TIE
   Consolaro, MEL
AF Damke, Edilson
   Tsuzuki, Joyce K.
   Cortez, Diogenes A. G.
   Ferreira, Izabel C. P.
   Bertoni, Thamara A.
   Batista, Marcia R.
   Donati, Lucelia
   Svidzinski, Terezinha I. E.
   Consolaro, Marcia E. L.
TI In vivo activity of Sapindus saponaria against azole-susceptible and
   -resistant human vaginal Candida species
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Sapindus saponaria vaginal yeasts; antifungal activity; in vivo
ID SAPONINS; GLYCOSIDES; YEAST; L.
AB Background: Study of in vivo antifungal activity of the hydroalcoholic extract (HE) and n-BuOH extract (BUTE) of Sapindus saponaria against azole-susceptible and -resistant human vaginal Candida spp.
   Methods: The in vitro antifungal activity of HE, BUTE, fluconazole (FLU), and itraconazole (ITRA) was determined by the broth microdilution method. We obtained values of minimal inhibitory concentration (MIC) and minimum fungicide concentration (MFC) for 46 strains of C. albicans and 10 of C. glabrata isolated from patients with vulvovaginal candidiasis (VVC). VVC was induced in hyperestrogenic Wistar rats with azole-susceptible C. albicans (SCA), azole-resistant C. albicans (RCA), and azole-resistant C. glabrata (RCG). The rats were treated intravaginally with 0.1 mL of HE or BUTE at concentrations of 1%, 2.5% and 5%; 100 mu g/mL of FLU (treatment positive control); or distilled water (negative control) at 1, 24, and 48 h after induction of the infection, and the progress of VVC was monitored by culturing and scanning electron microscopy (SEM). The toxicity was evaluated in cervical cells of the HeLa cell line.
   Results: The extracts showed in vitro inhibitory and fungicidal activity against all the isolates, and the MIC and MFC values for the C. glabrata isolates were slightly higher. In vivo, the SCA, RCA, and RCG infections were eliminated by 21 days post-infection, with up to 5% HE and BUTE, comparable to the activity of FLU. No cytotoxic action was observed for either extract.
   Conclusions: Our results demonstrated that HE and BUTE from S. saponaria show inhibitory and fungicidal activity in vitro, in addition to in vivo activity against azole-resistant vaginal isolates of C. glabrata and azole-susceptible and resistant isolates of C. albicans. Also considering the lack of cytotoxicity and the low concentrations of the extracts necessary to eliminate the infection in vivo, HE and BUTE show promise for continued studies with purified antifungal substances in VVC yeast isolates.
C1 [Damke, Edilson; Bertoni, Thamara A.; Batista, Marcia R.; Svidzinski, Terezinha I. E.; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Clin Anal & Biomed, Maringa, Parana, Brazil.
   [Tsuzuki, Joyce K.; Cortez, Diogenes A. G.; Ferreira, Izabel C. P.] Univ Estadual Maringa, Dept Pharm & Pharmacol, Maringa, Parana, Brazil.
   [Donati, Lucelia] Univ Fed Parana, Dept Cell Biol, BR-80060000 Curitiba, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Clin Anal & Biomed, Maringa, Parana, Brazil.
EM melconsolaro@yahoo.com.br
RI Donatti, Lucelia/E-1930-2013; Consolaro, Marcia Edilaine
   Lopes/I-4932-2014
OI Donatti, Lucelia/0000-0002-9023-2483; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865
FU Fundacao Araucaria (Parana State, Brazil)Fundacao Araucaria [15.025,
   421/09]
FX This study was financial supported of Fundacao Araucaria (Parana State,
   Brazil), Proc. 15.025, 421/09.
CR Albiero ALM, 2002, J ETHNOPHARMACOL, V82, P41, DOI 10.1016/S0378-8741(02)00094-6
   Barile E, 2007, PHYTOCHEMISTRY, V68, P596, DOI 10.1016/j.phytochem.2006.10.009
   Clinical and Laboratory Standards Institute, 2002, M27A2 CLSI
   Consolaro Marcia Edilaine Lopes, 2004, Revista Iberoamericana de Micologia, V21, P202
   Corsello S, 2003, EUR J OBSTET GYN R B, V110, P66, DOI 10.1016/S0301-2115(03)00096-4
   De Bernardis F, 2006, INFECT IMMUN, V74, P4282, DOI 10.1128/IAI.01714-05
   DOTA KFD, 2010, J ALTERN COMPLEM MED, V16, P285
   Dota KFD, 2008, ACTA BIOQUIM CLIN L, V110, P66
   Du ZZ, 2003, PLANTA MED, V69, P547, DOI 10.1055/s-2003-40652
   Duarte MCT, 2005, J ETHNOPHARMACOL, V97, P305, DOI 10.1016/j.jep.2004.11.016
   Ferrazza MHSH, 2005, REV BRAS GINECOL OBS, V27, P58, DOI 10.1590/S0100-72032005000200003
   Ferrer J, 2000, INT J GYNECOL OBSTET, V71, pS21, DOI 10.1016/S0020-7292(00)00350-7
   Francis G, 2002, BRIT J NUTR, V88, P587, DOI 10.1079/BJN2002725
   Jacobs WA, 1925, J BIOL CHEM, V64, P379
   KUETE V, 2006, J ETHN, V104, P8
   KURTZMANN CP, 1998, YEAST TAXONOMY STUDY
   Larone D. H., 2005, MED IMPORTANT FUNGI
   Lee MW, 2001, BIOL PHARM BULL, V24, P718, DOI 10.1248/bpb.24.718
   Mandal P, 2005, FITOTERAPIA, V76, P462, DOI 10.1016/j.fitote.2005.03.004
   Matos FJA, 2002, FARMACIAS VIVAS SIST
   Meyer Albiero Adriana Lenita, 2001, Acta Farmaceutica Bonaerense, V20, P169
   Murgu M, 2006, J BRAZIL CHEM SOC, V17, P1281, DOI 10.1590/S0103-50532006000700013
   QUETINLECLERCQ J, 1992, PLANTA MED, V58, P279, DOI 10.1055/s-2006-961456
   RIBEIRO A, 1995, INT J PHARMACOGN, V33, P177, DOI 10.3109/13880209509065359
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Sojakova M, 2004, MYCOPATHOLOGIA, V157, P163, DOI 10.1023/B:MYCO.0000020594.35357.b0
   Sugita T, 2002, MICROBIOL IMMUNOL, V46, P881, DOI 10.1111/j.1348-0421.2002.tb02776.x
   Tamura Yukiyoshi, 2001, Natural Medicines, V55, P11
   Tsuzuki JK, 2007, AN ACAD BRAS CIENC, V79, P577, DOI 10.1590/S0001-37652007000400002
NR 29
TC 17
Z9 20
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472-6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD MAY 4
PY 2011
VL 11
AR 35
DI 10.1186/1472-6882-11-35
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 766GT
UT WOS:000290769700001
PM 21542936
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Dota, KFD
   Freitas, AR
   Consolaro, MEL
   Svidzinski, TIE
AF Dota, Kellen F. D.
   Freitas, Alessandra R.
   Consolaro, Marcia E. L.
   Svidzinski, Terezinha I. E.
TI A Challenge for Clinical Laboratories: Detection of Antifungal
   Resistance in Candida Species Causing Vulvovaginal Candidiasis
SO LABMEDICINE
LA English
DT Article
DE vulvovaginal candidiasis; vaginal yeasts; disk diffusion; broth
   microdilution; correlation; laboratory test
ID DISK DIFFUSION; IN-VITRO; FLUCONAZOLE SUSCEPTIBILITY; MICRODILUTION
   METHODS; BROTH MICRODILUTION; VAGINITIS; ASSOCIATION; PREVALENCE;
   PROFILE; TRENDS
AB Background To determine the in vitro susceptibility of vaginal yeasts against 7 antifungals by using 2 different methods and to evaluate if, here is a possibility to use disk-diffusion (DD) method in the daily routine.
   Methods: Eighty-eight vaginal yeasts were tested against 5 antifungal azoles and 2 polyenes, according to Clinical and Laboratory Standards Institute (CLSI) documents DD (M44-A) and broth microdilution (MD) (M27-A3).
   Results: Resistance was recorded for ketoconazole (KETO), itraconazole (ITR), micoconazole amphotericin B (AMB), and nystatin (NYS). Between DD and MD, higher rates of agreement were observed for AMB (98.9%), voriconazole (VOR) (84.1%), and NYS (77.3%). For the other antifungals, the agreement varied from 34.1% (KETO) to 71.0% fluconazole (FLU).
   Conclusion: While the DD method may be a useful tool to determine the antifungal susceptibility profile in clinical laboratories in the future, it still requires improvements in its standardization since it was not reliable in detecting resistance in vitro.
C1 [Dota, Kellen F. D.; Freitas, Alessandra R.; Consolaro, Marcia E. L.; Svidzinski, Terezinha I. E.] Univ Estadual Maringa, Div Med Mycol, Teaching & Res Clin Anal Lab, Maringa, Parana, Brazil.
RP Svidzinski, TIE (corresponding author), Univ Estadual Maringa, Div Med Mycol, Teaching & Res Clin Anal Lab, Maringa, Parana, Brazil.
EM tiesvidzinski@uem.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
FU Fundacao AraucariaFundacao Araucaria; Conselho Nacional de
   Desenvolvimento Cientifico e TecnologicoNational Council for Scientific
   and Technological Development (CNPq)
FX This work has been financially supported by Fundacao Araucaria.
   Terezinha Inez Estivalet Svidzinski, PhD, is a recipient of grants from
   The Conselho Nacional de Desenvolvimento Cientifico e Tecnologico.
CR [Anonymous], 1997, M27A NCCLS
   [Anonymous], 2004, M44A CLSI
   Asticcioli S, 2009, NEW MICROBIOL, V32, P199
   Barry AL, 2002, ANTIMICROB AGENTS CH, V46, P1781, DOI 10.1128/AAC.46.6.1781-1784.2002
   Bauters TGM, 2002, AM J OBSTET GYNECOL, V187, P569, DOI 10.1067/mob.2002.125897
   Boatto HF, 2007, REV BRAS GINECOL OBS, V29, P80, DOI 10.1590/S0100-72032007000200004
   CLSI, 2008, M27A3 CLSI
   Dota KFD, 2008, ACTA BIOQUIM CLIN L, V42, P561
   Dalben-Dota KF, 2010, J ALTERN COMPLEM MED, V16, P285, DOI 10.1089/acm.2009.0281
   Donders G, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.029
   Fan SR, 2007, INT J GYNECOL OBSTET, V98, P158, DOI 10.1016/j.ijgo.2007.03.045
   Fan SR, 2007, INT J GYNECOL OBSTET, V97, P207, DOI 10.1016/j.ijgo.2007.03.017
   Fan SR, 2008, J OBSTET GYNAECOL RE, V34, P561, DOI 10.1111/j.1447-0756.2008.00817.x
   Ferrazza MHSH, 2005, REV BRAS GINECOL OBS, V27, P58, DOI 10.1590/S0100-72032005000200003
   Ferrer J, 2000, INT J GYNECOL OBSTET, V71, pS21, DOI 10.1016/S0020-7292(00)00350-7
   Galle Leonilda Chiari, 2004, J. Bras. Patol. Med. Lab., V40, P229, DOI 10.1590/S1676-24442004000400004
   Larone D. H., 2005, MED IMPORTANT FUNGI
   Lopes Consolaro Marcia Edilaine, 2004, Rev Iberoam Micol, V21, P202
   Matar MJ, 2003, ANTIMICROB AGENTS CH, V47, P1647, DOI 10.1128/AAC.47.5.1647-1651.2003
   McCaig LF, 2005, PHARMACOEPIDEM DR S, V14, P113, DOI 10.1002/pds.960
   Mock M, 1998, DERMATOLOGY, V197, P361, DOI 10.1159/000018032
   Muriel M A, 2000, Enferm Infecc Microbiol Clin, V18, P120
   Negri M, 2009, J CLIN LAB ANAL, V23, P324, DOI 10.1002/jcla.20337
   Nyirjesy P, 2008, INFECT DIS CLIN N AM, V22, P637, DOI 10.1016/j.idc.2008.05.002
   Ozcan SK, 2006, APMIS, V114, P139, DOI 10.1111/j.1600-0463.2006.apm_360.x
   Pfaller MA, 2004, J CLIN MICROBIOL, V42, P1288, DOI 10.1128/JCM.42.3.1288-1289.2004
   Pfaller MA, 2003, J CLIN MICROBIOL, V41, P1440, DOI 10.1128/JCM.41.4.1440-1446.2003
   Ribeiro MA, 2001, MYCOPATHOLOGIA, V151, P5, DOI 10.1023/A:1010909504071
   Richter SS, 2005, J CLIN MICROBIOL, V43, P2155, DOI 10.1128/JCM.43.5.2155-2162.2005
   Rivera-Sanchez R, 2006, ENFERM INFEC MICR CL, V24, P634, DOI 10.1157/13095375
   Saporiti A. M., 2001, Revista Argentina de Microbiologia, V33, P217
   Shinobu CS, 2007, BRAZ J MICROBIOL, V38, P467, DOI 10.1590/S1517-83822007000300015
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Sobel JD, 2003, ANTIMICROB AGENTS CH, V47, P34, DOI 10.1128/AAC.47.1.34-38.2003
   SOBEL JD, 1993, CLIN OBSTET GYNECOL, V36, P153, DOI 10.1097/00003081-199303000-00021
   Sobel JD, 1998, MYCOSES, V41, P18, DOI 10.1111/j.1439-0507.1998.tb00594.x
   Watson C, 2007, AUST NZ J OBSTET GYN, V47, P262, DOI 10.1111/j.1479-828X.2007.00736.x
NR 37
TC 9
Z9 9
U1 0
U2 3
PU AMER SOC CLINICAL PATHOLOGY
PI CHICAGO
PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA
SN 0007-5027
EI 1943-7730
J9 LABMEDICINE
JI Labmedicine
PD FEB
PY 2011
VL 42
IS 2
BP 87
EP 93
DI 10.1309/LMDFCA8YEZ0MQULA
PG 7
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 710BQ
UT WOS:000286486300004
OA Bronze
DA 2020-12-08
ER

PT J
AU Storti, A
   Damke, E
   Carrara, MA
   Batista, MR
   Donatti, L
   Boer, CG
   Svizdinski, TIE
   Consolaro, MEL
AF Storti-Filho, Agenor
   Damke, Edilson
   Carrara, Marcia Aparecida
   Batista, Marcia Regina
   Donatti, Lucelia
   Boer, Cinthia Gandolfi
   Estivalet Svizdinski, Terezinha Inez
   Lopes Consolaro, Marcia Edilaine
TI Effects of depomedroxyprogesterone acetate on the development and
   maintenance of Candida albicans in the vagina of oophorectomized Wistar
   rats (Rattus norvegicus)
SO BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Depomedroxyprogesterone acetate/effects/experimental study; Vulvovaginal
   candidiasis; Candida albicans
ID ADHERENCE; MUCOSA; YEASTS; MICE
AB The objective of this study was to determine the effect of medroxyprogesterone acetate (DMPA) on the development and maintenance of Candida albicans in the vagina of oophorectomized Wistar rats. The animals were divided into negative control groups (NCG), which received injections of sterile saline; positive control groups (PCG), which were given injections of estradiol valerate; and progesterone groups (PG), which were given injections of Depo-Provera (R). After one week of hormonal induction, vaginal infection by C. albicans was induced in all the groups and detected by vaginal yeast culture and Papanicolaou smear. In addition, scanning and transmission electron microscopy images were obtained to confirm the vaginal infection by yeast in PG. A difference in progesterone levels in PG was observed between the basal level and after hormonal induction (P<0.0001). In this group, 100% of the rats acquired vaginal infection in the first week, but did not maintain it until the third week. The pharmaceutical brand of DMPA was effective for inducing the metestrus or diestrus phase of the estrous cycle in rats, similar to the use of pure progesterone. In contrast to estrogen treatment, progesterone alone could not support an experimental vaginal infection by C. albicans for any significant period of time.
C1 [Storti-Filho, Agenor; Damke, Edilson; Carrara, Marcia Aparecida; Batista, Marcia Regina; Boer, Cinthia Gandolfi; Estivalet Svizdinski, Terezinha Inez; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Dept Anal Clin, BR-87020900 Maringa, PR, Brazil.
   [Donatti, Lucelia] Univ Fed Parana, Dept Biol, BR-80060000 Curitiba, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin, Av Colombo 5790, BR-87020900 Maringa, PR, Brazil.
EM melconsolaro@uem.com.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Donatti,
   Lucelia/E-1930-2013
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Donatti,
   Lucelia/0000-0002-9023-2483
CR Banerjee D, 2008, EUKARYOT CELL, V7, P68, DOI 10.1128/EC.00256-07
   BIBBO M., 1997, COMPREHENSIVE CYTOPA, P101
   Clemons KV, 2004, INFECT IMMUN, V72, P4878, DOI 10.1128/IAI.72.8.4878-4880.2004
   Corsello S, 2003, EUR J OBSTET GYN R B, V110, P66, DOI 10.1016/S0301-2115(03)00096-4
   Cundy T, 1998, OBSTET GYNECOL, V92, P569, DOI 10.1016/S0029-7844(98)00270-1
   FIDEL PL, 1993, INFECT IMMUN, V61, P1990, DOI 10.1128/IAI.61.5.1990-1995.1993
   Junqueira JC, 2005, MICROBIOL IMMUNOL, V49, P199, DOI 10.1111/j.1348-0421.2005.tb03721.x
   KALO A, 1988, CAN J MICROBIOL, V34, P224, DOI 10.1139/m88-042
   KALOKLEIN A, 1989, AM J OBSTET GYNECOL, V161, P1132, DOI 10.1016/0002-9378(89)90649-2
   KINSMAN OS, 1986, INFECT IMMUN, V53, P498, DOI 10.1128/IAI.53.3.498-504.1986
   KURTZMANN C. P., 1998, YEASTS TAXONOMIC STU, P891
   MANDL AM, 1951, J ENDOCRINOL, V7, P112, DOI 10.1677/joe.0.0070112
   Mendonca Fabio De Souza, 2007, Ciencia Animal Brasileira, V8, P313
   Miller L, 2000, OBSTET GYNECOL, V96, P431, DOI 10.1016/S0029-7844(00)00906-6
   National Association of Real Estate Investment Trusts, 1998, REP C EFF INCR SPEED, P1
   Patel DA, 2004, AM J OBSTET GYNECOL, V190, P644, DOI 10.1016/j.ajog.2003.11.027
   SEGAL E, 1984, SABOURAUDIA, V22, P191
   SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   SOBEL JD, 1993, CLIN OBSTET GYNECOL, V36, P153, DOI 10.1097/00003081-199303000-00021
   Sugita T, 2002, MICROBIOL IMMUNOL, V46, P881, DOI 10.1111/j.1348-0421.2002.tb02776.x
   Irie MMT, 2006, J CLIN LAB ANAL, V20, P195, DOI 10.1002/jcla.20132
NR 22
TC 0
Z9 0
U1 0
U2 0
PU UNIV SAO PAULO, CONJUNTO QUIMICAS
PI SAO PAULO
PA SERVICO PUBLICACOES E CIRCULACAO, CAIXA POSTAL 66083, SAO PAULO, 00000,
   BRAZIL
SN 1984-8250
EI 2175-9790
J9 BRAZ J PHARM SCI
JI Braz. J. Pharm. Sci.
PD JAN-MAR
PY 2011
VL 47
IS 1
BP 167
EP 174
DI 10.1590/S1984-82502011000100021
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 776WS
UT WOS:000291571300021
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Dota, KFD
   Consolaro, MEL
   Svidzinski, TIE
   Bruschi, ML
AF Dalben Dota, Kelen Fatima
   Lopes Consolaro, Marcia Edilaine
   Estivalet Svidzinski, Terezinha Inez
   Bruschi, Marcos Luciano
TI Antifungal Activity of Brazilian Propolis Microparticles against Yeasts
   Isolated from Vulvovaginal Candidiasis
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID GELATIN MICROPARTICLES; ANTIMICROBIAL ACTIVITY; BIOLOGICAL-PROPERTIES;
   CHEMICAL-COMPOSITION; SUSCEPTIBILITY; ITRACONAZOLE; RESISTANCE; HPLC
AB Propolis, a resinous compound produced by Apis mellifera L. bees, is known to possess a variety of biological activities and is applied in the therapy of various infectious diseases. The aim of this study was to evaluate the in vitro antifungal activity of propolis ethanol extract (PE) and propolismicroparticles (PMs) obtained from a sample of Brazilian propolis against clinical yeast isolates of importance in the vulvovaginal candidiasis (VVC). PE was used to prepare the microparticles. Yeast isolates (n = 89), obtained from vaginal exudates of patients with VVC, were exposed to the PE and the PMs. Moreover, the main antifungal drugs used in the treatment of VVC (Fluconazole, Voriconazole, Itraconazole, Ketoconazole, Miconazole and Amphotericin B) were also tested. Minimum inhibitory concentration (MIC) was determined according to the standard broth microdilution method. Some Candida albicans isolates showed resistance or dose-dependent susceptibility for the azolic drugs and Amphotericin B. Non-C. albicans isolates showed more resistance and dose-dependent susceptibility for the azolic drugs than C. albicans. However, all of them were sensitive or dose-dependent susceptible for Amphotericin B. All yeasts were inhibited by PE and PMs, with small variation, independent of the species of yeast. The overall results provided important information for the potential application of PMs in the therapy of VVC and the possible prevention of the occurrence of new symptomatic episodes.
C1 [Bruschi, Marcos Luciano] Univ Estadual Maringa, Dept Pharm, BR-87020900 Maringa, Parana, Brazil.
   [Dalben Dota, Kelen Fatima; Lopes Consolaro, Marcia Edilaine; Estivalet Svidzinski, Terezinha Inez] Univ Estadual Maringa, Grad Program Hlth Sci, BR-87020900 Maringa, Parana, Brazil.
RP Bruschi, ML (corresponding author), Univ Estadual Maringa, Dept Pharm, Colombo Ave 5790, BR-87020900 Maringa, Parana, Brazil.
EM mlbruschi@uem.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Bruschi, Marcos
   Luciano/J-1871-2012
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Bruschi, Marcos
   Luciano/0000-0002-4838-5742
FU CAPES (Coordenadoria de Aperfeicoamento de Pessoal de Nivel
   Superior)CAPES
FX Brazilian agency CAPES (Coordenadoria de Aperfeicoamento de Pessoal de
   Nivel Superior).
CR Bankova V, 2005, EVID-BASED COMPL ALT, V2, P29, DOI 10.1093/ecam/neh059
   BANKOVA V, 1992, APIDOLOGIE, V23, P79, DOI 10.1051/apido:19920109
   Bigucci F, 2009, J PHARM PHARMACOL, V61, P41, DOI 10.1211/jpp/61.01.0006
   Bruschi M. L., 2004, Revista de Ciencias Farmaceuticas, V25, P79
   Bruschi ML, 2007, J PHARM SCI-US, V96, P2074, DOI 10.1002/jps.20843
   Bruschi ML, 2006, DRUG DEV IND PHARM, V32, P229, DOI 10.1080/03639040500466312
   Bruschi ML, 2003, J LIQ CHROMATOGR R T, V26, P2399, DOI 10.1081/JLC-120023254
   Bruschi ML, 2003, INT J PHARM, V264, P45, DOI 10.1016/S0378-5173(03)00386-7
   Bufalo MC, 2009, EVID-BASED COMPL ALT, V6, P483, DOI 10.1093/ecam/nem147
   Burdock GA, 1998, FOOD CHEM TOXICOL, V36, P347, DOI 10.1016/S0278-6915(97)00145-2
   Clinical and Laboratory Standards Institute, 2002, M27A2 CLIN LAB STAND
   Consolaro Marcia Edilaine Lopes, 2004, Revista Iberoamericana de Micologia, V21, P202
   Consolaro MEL, 2005, MYCOPATHOLOGIA, V159, P501, DOI 10.1007/s11046-005-1149-0
   Cushnie TPT, 2005, INT J ANTIMICROB AG, V26, P343, DOI 10.1016/j.ijantimicag.2005.09.002
   Dota KFD, 2008, ACTA BIOQUIM CLIN L, V42, P561
   Espinel-Ingroff A, 2008, J CLIN MICROBIOL, V46, P1793, DOI 10.1128/JCM.01883-07
   Ferrazza MHSH, 2005, REV BRAS GINECOL OBS, V27, P58, DOI 10.1590/S0100-72032005000200003
   Ghannoum MA, 1999, CLIN MICROBIOL REV, V12, P501, DOI 10.1128/CMR.12.4.501
   GHISALBERTI EL, 1979, BEE WORLD, V60, P59, DOI 10.1080/0005772X.1979.11097738
   Imhof M, 2005, INT J GYNECOL OBSTET, V89, P127, DOI 10.1016/j.ijgo.2005.01.033
   Kontoyiannis DP, 2002, LANCET, V359, P1135, DOI 10.1016/S0140-6736(02)08162-X
   Lai Chih-Cheng, 2008, Journal of Infection and Chemotherapy, V14, P77, DOI 10.1007/s10156-007-0595-7
   Larone D. H., 2005, MED IMPORTANT FUNGI
   Lynch ME, 1996, J MED VET MYCOL, V34, P337
   MARCUCCI MC, 1995, APIDOLOGIE, V26, P83, DOI 10.1051/apido:19950202
   MARCUCCI MC, 2000, PROCESS TYPING NATUR
   Markham KR, 1996, PHYTOCHEMISTRY, V42, P205, DOI 10.1016/0031-9422(96)83286-9
   National Committee for Clinical Laboratory Standard, 1997, M27A NAT COMM CLIN L
   NYIRJESY P, 1995, AM J OBSTET GYNECOL, V173, P820, DOI 10.1016/0002-9378(95)90347-X
   Ota C, 2001, MYCOSES, V44, P375, DOI 10.1046/j.1439-0507.2001.00671.x
   Paulino N, 2006, PLANTA MED, V72, P899, DOI 10.1055/s-2006-947185
   Oliveira ACP, 2006, MEM I OSWALDO CRUZ, V101, P493, DOI 10.1590/S0074-02762006000500002
   REESE RE, 1991, PRACTICAL APPROACH I
   Salatino A, 2005, EVID-BASED COMPL ALT, V2, P33, DOI 10.1093/ecam/neh060
   Salomao K, 2008, EVID-BASED COMPL ALT, V5, P317, DOI 10.1093/ecam/nem058
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Sojakova M, 2004, MYCOPATHOLOGIA, V157, P163, DOI 10.1023/B:MYCO.0000020594.35357.b0
   Sonmez S, 2005, J ETHNOPHARMACOL, V102, P371, DOI 10.1016/j.jep.2005.06.035
   Sugita T, 2002, MICROBIOL IMMUNOL, V46, P881, DOI 10.1111/j.1348-0421.2002.tb02776.x
   Teixeira EW, 2010, EVID-BASED COMPL ALT, V7, P307, DOI 10.1093/ecam/nem177
   Woisky RG, 1998, J APICULT RES, V37, P99, DOI 10.1080/00218839.1998.11100961
NR 41
TC 32
Z9 31
U1 0
U2 13
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2011
VL 2011
BP 1
EP 8
DI 10.1093/ecam/neq029
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 800VI
UT WOS:000293395300001
PM 21607012
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Carrara, MA
   Donatti, L
   Damke, E
   Svidizinski, TIE
   Consolaro, MEL
   Batista, MR
AF Carrara, Marcia A.
   Donatti, Lucelia
   Damke, Edilson
   Svidizinski, Terezinha I. E.
   Consolaro, Marcia E. L.
   Batista, Marcia R.
TI A New Model of Vaginal Infection by Candida albicans in Rats
SO MYCOPATHOLOGIA
LA English
DT Article
DE Vulvovaginal candidiasis; Rat model; In vivo; Candida albicans; Rats
ID EPITHELIAL-CELLS; VAGINITIS; MICE; SUSCEPTIBILITY; ADHERENCE; THERAPY;
   CYCLE
AB Vulvovaginal candidiasis (VVC) is regarded as an important public health issue, and several aspects of its pathogenesis are not yet sufficiently clear. Experimental in vivo models of vaginal infection with Candida albicans have been extremely useful in the identification of factors concerning hormonal influences on the infection, the virulence of the yeasts, the susceptibility, and the treatment of the infection. The development of easily manageable, reproducible, and economically viable animal models of VVC is highly important. We describe a simple experimental model of VVC in rats, using a pharmaceutical brand of estradiol hexa-hydrobenzoate for human treatment. All the steps of this model were standardized; and after the experiments, the rats were euthanized for further examination of their tissues by scanning and transmission electron microscopy. Standardized features included the use of non-ovariectomized rats, sterile distilled water as the hormone vehicle, estradiol hexa-hydrobenzoate administered at 0.20 mg/week/rat fractionated three times/week, and a yeast suspension of 5 x 10(8) yeasts/ml in a single vaginal administration 1 week after hormone induction. In this way, 100% of the rats were in pseudo-estrus and developed and maintained the infection until the third week of the experiment. Electron microscopy observation of the vagina of the rats confirmed the presence of both pseudo-estrus and vaginal infection. The standardized experimental model proved inexpensive, reproducible, and easily feasible for the induction of vaginal infection with C. albicans and may help to clarify important aspects of the pathogenesis and treatment of VVC.
C1 [Carrara, Marcia A.; Damke, Edilson; Svidizinski, Terezinha I. E.; Consolaro, Marcia E. L.; Batista, Marcia R.] Univ Estadual Maringa, Dept Clin Anal, BR-87020900 Maringa, Parana, Brazil.
   [Donatti, Lucelia] Fed Univ Curitiba, Dept Cell Biol, BR-85131990 Curitiba, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Clin Anal, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@yahoo.com.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Donatti,
   Lucelia/E-1930-2013
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Donatti,
   Lucelia/0000-0002-9023-2483
CR Álvares Cassiana Aparecida, 2007, J. Bras. Patol. Med. Lab., V43, P319, DOI 10.1590/S1676-24442007000500004
   Clemons KV, 2004, INFECT IMMUN, V72, P4878, DOI 10.1128/IAI.72.8.4878-4880.2004
   Corsello S, 2003, EUR J OBSTET GYN R B, V110, P66, DOI 10.1016/S0301-2115(03)00096-4
   CRUZ FCM, 2004, REV BRAS GINECOL OBS, V26, P597
   De Bernardis F, 2006, INFECT IMMUN, V74, P4282, DOI 10.1128/IAI.01714-05
   FIDEL PL, 1993, INFECT IMMUN, V61, P1990, DOI 10.1128/IAI.61.5.1990-1995.1993
   Fidel PL, 2000, INFECT IMMUN, V68, P651, DOI 10.1128/IAI.68.2.651-657.2000
   KALOKLEIN A, 1989, AM J OBSTET GYNECOL, V161, P1132, DOI 10.1016/0002-9378(89)90649-2
   Kaushic C, 2000, INFECT IMMUN, V68, P4207, DOI 10.1128/IAI.68.7.4207-4216.2000
   Kurtzman C.P., 1998, YEAST TAXONOMIC STUD
   MANDL AM, 1951, J ENDOCRINOL, V7, P112, DOI 10.1677/joe.0.0070112
   Mardh PA, 2002, INT J STD AIDS, V13, P522, DOI 10.1258/095646202760159639
   *NCCLS, 1998, REF TEMHOD
   Patel DA, 2004, AM J OBSTET GYNECOL, V190, P644, DOI 10.1016/j.ajog.2003.11.027
   Sobel J D, 1988, Ann N Y Acad Sci, V544, P547, DOI 10.1111/j.1749-6632.1988.tb40450.x
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   SOBEL JD, 1985, SABOURAUDIA, V23, P199
   SOBEL JD, 1993, CLIN OBSTET GYNECOL, V36, P153, DOI 10.1097/00003081-199303000-00021
   SOBEL JD, 1981, J INFECT DIS, V143, P76, DOI 10.1093/infdis/143.1.76
   Souza PC, 2009, ARCH GYNECOL OBSTET, V279, P625, DOI 10.1007/s00404-008-0765-6
   Sugita T, 2002, MICROBIOL IMMUNOL, V46, P881, DOI 10.1111/j.1348-0421.2002.tb02776.x
   Irie MMT, 2006, J CLIN LAB ANAL, V20, P195, DOI 10.1002/jcla.20132
   Wozniak KL, 2002, INFECT IMMUN, V70, P5790, DOI 10.1128/IAI.70.10.5790-5799.2002
   Yener T, 2007, ANAT HISTOL EMBRYOL, V36, P75, DOI 10.1111/j.1439-0264.2006.00743.x
NR 24
TC 12
Z9 15
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-486X
J9 MYCOPATHOLOGIA
JI Mycopathologia
PD NOV
PY 2010
VL 170
IS 5
BP 331
EP 338
DI 10.1007/s11046-010-9326-1
PG 8
WC Mycology
SC Mycology
GA 671MO
UT WOS:000283510400003
PM 20532984
DA 2020-12-08
ER

PT J
AU Damke, E
   Storti, A
   Irie, MMT
   Carrara, MA
   Batista, MR
   Donatti, L
   Gunther, LSA
   Patussi, EV
   Svidzinski, TIE
   Consolaro, MEL
AF Damke, Edilson
   Storti-Filho, Agenor
   Irie, Mary M. T.
   Carrara, Marcia A.
   Batista, Marcia R.
   Donatti, Lucelia
   Gunther, Luciene S. A.
   Patussi, Eliana V.
   Svidzinski, Terezinha I. E.
   Consolaro, Marcia E. L.
TI Ultrastructural Imaging of Candida albicans Adhesion to Rat Genital
   Epithelium through Scanning and Transmission Electron Microscopy
SO MICROSCOPY AND MICROANALYSIS
LA English
DT Article
DE Candida albicans; adhesion in vivo; ultrastructure; genital epithelium
ID ENDOTHELIAL-CELLS; INTERNALIZATION; ADHERENCE; INVASION; PATHOGENESIS;
   STRAINS
AB The adhesion of Candida albicans to the genital epithelium has not been fully investigated in vivo. The objective of this study was to evaluate the ultrastructural aspects of C. albicans adhesion in the lower genital system of female Wistar rats through scanning and transmission electron microscopy. The genital infection persisted until the end of the experiment, and all rats showed the same adhesion aspects. Various associated yeast/hyphae were observed in the lumen and adhered both at the vaginal and endocervical levels where the fungal filamentation process occurred. In the vaginal epithelium, closely adhered yeasts were observed as stretched strands bridging between yeasts and the epithelium surface. Different stages of the adhesion, where yeasts internalized into the epithelial cell inside a cytoplasmic vacuole, resembling endocytosis, and a wide fibrillar-floccular, glycocalyx-like layer on the yeasts were observed. On the endocervix, the adhesion occurred between the cilia. In the uterine body, only a yeast-like form was observed with superficial contact. This study reached the initial goal of demonstrating an experimental model for in vivo studies. Continuation of this line of research is important for studies of vulvovaginal candidiasis.
C1 [Damke, Edilson; Storti-Filho, Agenor; Irie, Mary M. T.; Carrara, Marcia A.; Batista, Marcia R.; Gunther, Luciene S. A.; Patussi, Eliana V.; Svidzinski, Terezinha I. E.; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Clin Anal, BR-87020900 Maringa, Parana, Brazil.
   [Donatti, Lucelia] Univ Fed Parana, Dept Cell Biol, BR-85131990 Curitiba, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Clin Anal, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@yahoo.com.br
RI Donatti, Lucelia/E-1930-2013; Consolaro, Marcia Edilaine
   Lopes/I-4932-2014
OI Donatti, Lucelia/0000-0002-9023-2483; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865
CR Bernhardt J, 2001, J INFECT DIS, V184, P1170, DOI 10.1086/323807
   BIBBO M, 1997, COMPREHENSIVE CYTOPA
   Calderone RA, 2001, TRENDS MICROBIOL, V9, P327, DOI 10.1016/S0966-842X(01)02094-7
   Clemons KV, 2004, INFECT IMMUN, V72, P4878, DOI 10.1128/IAI.72.8.4878-4880.2004
   Consolaro MEL, 2005, MYCOPATHOLOGIA, V159, P501, DOI 10.1007/s11046-005-1149-0
   De Bernardis F, 2006, INFECT IMMUN, V74, P4282, DOI 10.1128/IAI.01714-05
   Dehio C, 1997, J CELL SCI, V110, P2141
   Drago L, 2000, INT J ANTIMICROB AG, V16, P545, DOI 10.1016/S0924-8579(00)00296-X
   FILLER SG, 1995, INFECT IMMUN, V63, P976, DOI 10.1128/IAI.63.3.976-983.1995
   HOWLETT JA, 1980, INFECT IMMUN, V29, P252, DOI 10.1128/IAI.29.1.252-260.1980
   Jabra-Rizk Mary Ann, 2001, Revista Iberoamericana de Micologia, V18, P17
   Jayatilake JAMS, 2005, J ORAL PATHOL MED, V34, P240, DOI 10.1111/j.1600-0714.2005.00307.x
   Kamai Y, 2002, INFECT IMMUN, V70, P5256, DOI 10.1128/IAI.70.9.5256-5258.2002
   Kaposzta R, 1999, J CELL SCI, V112, P3237
   KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137
   KURTZMANN CP, 1998, YEAST TAXONOMIA STUD
   MANDL AM, 1951, J EXP BIOL, V28, P576
   Mardh PA, 2002, INT J STD AIDS, V13, P522, DOI 10.1258/095646202760159639
   Marodi L, 1997, PEDIATR INFECT DIS J, V16, P795, DOI 10.1097/00006454-199708000-00012
   MONTES LF, 1968, J BACTERIOL, V96, P1349, DOI 10.1128/JB.96.4.1349-1356.1968
   Palmer LM, 1997, INFECT IMMUN, V65, P2570, DOI 10.1128/IAI.65.7.2570-2575.1997
   Phan QT, 2000, INFECT IMMUN, V68, P3485, DOI 10.1128/IAI.68.6.3485-3490.2000
   Pichova I, 2001, EUR J BIOCHEM, V268, P2669, DOI 10.1046/j.1432-1327.2001.02152.x
   RAY TL, 1984, J INVEST DERMATOL, V83, P37, DOI 10.1111/1523-1747.ep12261661
   Shin JH, 2002, J CLIN MICROBIOL, V40, P1244, DOI 10.1128/JCM.40.4.1244-1248.2002
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   SOBEL JD, 1993, CLIN OBSTET GYNECOL, V36, P153, DOI 10.1097/00003081-199303000-00021
   Sugita T, 2002, MICROBIOL IMMUNOL, V46, P881, DOI 10.1111/j.1348-0421.2002.tb02776.x
   Irie MMT, 2006, J CLIN LAB ANAL, V20, P195, DOI 10.1002/jcla.20132
   Vitkov L, 2002, ORAL MICROBIOL IMMUN, V17, P60, DOI 10.1046/j.0902-0055.2001.00085.x
   YU L, 1994, INFECT IMMUN, V62, P2834, DOI 10.1128/IAI.62.7.2834-2842.1994
NR 31
TC 4
Z9 4
U1 0
U2 6
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1431-9276
EI 1435-8115
J9 MICROSC MICROANAL
JI Microsc. microanal.
PD JUN
PY 2010
VL 16
IS 3
BP 337
EP 345
DI 10.1017/S1431927610000164
PG 9
WC Materials Science, Multidisciplinary; Microscopy
SC Materials Science; Microscopy
GA 599HS
UT WOS:000277902600012
PM 20374679
DA 2020-12-08
ER

PT J
AU Chassot, F
   Camacho, DP
   Patussi, EV
   Donatti, L
   Svidzinski, TIE
   Consolaro, MEL
AF Chassot, Francieli
   Camacho, Daiane P.
   Patussi, Eliana Valeria
   Donatti, Lucelia
   Svidzinski, Terezinha I. E.
   Consolaro, Marcia E. L.
TI Can Lactobacillus acidophilus influence the adhesion capacity of Candida
   albicans on the combined contraceptive vaginal ring?
SO CONTRACEPTION
LA English
DT Article
DE Contraceptive vaginal ring; Adherence; Probiotics; Candida albicans;
   Lactobacillus acidophilus
ID ADHERENCE; BACTERIA; EFFICACY
AB Background: This study was conducted to evaluate the influence of Lactobacillus acidophilus on the adhesion capacity of Candida albicans on the combined contraceptive vaginal ring (CCVR).
   Study Design: Two vaginal isolates of C. albicans and an ATCC strain of lactobacilli were used. Isolated and associated yeasts and bacteria (co-aggregated) were employed on the CCVR adherence assays and scanning electron microscopy (SEM).
   Results: Isolated yeasts and lactobacilli adhered strongly to the CCVR. After the co-aggregation, there were an increase in adhesion capacity of the yeasts (p<.001) and a diminished adhesion of the lactobacilli (p<.001). SEM showed the isolated and co-aggregated microorganisms intimately attached to the irregularities of the CCVR.
   Conclusions: If these findings correlated with the conditions in vivo, the use of probiotics based on L. acidophilus or its presence in the vaginal microbiota would not protect against the adhesion of C. albicans to the ring. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Consolaro, Marcia E. L.] Univ Estadual Maringa, Div Clin Cytol, Dept Clin Anal, Teaching & Res Clin Anal Lab, BR-87020900 Maringa, Parana, Brazil.
   [Camacho, Daiane P.] UNINGA Unit Teaching Super Maringa, Clin Anal Lab, BR-87070000 Maringa, Parana, Brazil.
   [Patussi, Eliana Valeria; Svidzinski, Terezinha I. E.] Univ Estadual Maringa, Div Med Mycol, Teaching & Res Clin Anal Lab, BR-87020900 Maringa, Parana, Brazil.
   [Donatti, Lucelia] Univ Fed Parana, Dept Cell Biol, BR-85131900 Curitiba, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Div Clin Cytol, Dept Clin Anal, Teaching & Res Clin Anal Lab, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@yahoo.com.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; Donatti,
   Lucelia/E-1930-2013
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; Donatti,
   Lucelia/0000-0002-9023-2483; Svidzinski, Terezinha/0000-0003-2525-9046
CR Aroutcheva A, 2001, AM J OBSTET GYNECOL, V185, P375, DOI 10.1067/mob.2001.115867
   Boris S, 1998, INFECT IMMUN, V66, P1985, DOI 10.1128/IAI.66.5.1985-1989.1998
   Carnacho DP, 2007, CONTRACEPTION, V76, P439, DOI 10.1016/j.contraception.2007.07.012
   Chassot F, 2008, CONTRACEPTION, V77, P355, DOI 10.1016/j.contraception.2008.01.007
   Falagas ME, 2006, J ANTIMICROB CHEMOTH, V58, P266, DOI 10.1093/jac/dkl246
   KURTZMANN C. P., 1998, YEASTS TAXONOMIC STU, P891
   Oddsson K, 2005, CONTRACEPTION, V71, P176, DOI 10.1016/j.contraception.2004.09.001
   REID G, 1990, CURR MICROBIOL, V20, P47, DOI 10.1007/BF02094024
   Ringdahl EN, 2000, AM FAM PHYSICIAN, V61, P3306
   Ronnqvist PDJ, 2006, ACTA OBSTET GYN SCAN, V85, P726, DOI 10.1080/00016340600578357
   Roumen FJME, 2001, HUM REPROD, V16, P469, DOI 10.1093/humrep/16.3.469
   Sanders ME, 2001, J DAIRY SCI, V84, P319, DOI 10.3168/jds.S0022-0302(01)74481-5
   Sobel JD, 1996, J CLIN MICROBIOL, V34, P2497, DOI 10.1128/JCM.34.10.2497-2499.1996
   Strus Magdalena, 2005, Infect Dis Obstet Gynecol, V13, P69, DOI 10.1080/10647440400028136
   Sugita T, 2002, MICROBIOL IMMUNOL, V46, P881, DOI 10.1111/j.1348-0421.2002.tb02776.x
   SWEET SP, 1987, FEMS MICROBIOL LETT, V48, P159, DOI 10.1111/j.1574-6968.1987.tb02534.x
   Irie MMT, 2006, J CLIN LAB ANAL, V20, P195, DOI 10.1002/jcla.20132
   Wagner RD, 1997, INFECT IMMUN, V65, P4165, DOI 10.1128/IAI.65.10.4165-4172.1997
   Zurawin RK, 2007, CLIN OBSTET GYNECOL, V50, P425, DOI 10.1097/GRF.0b013e31804b1be6
NR 19
TC 16
Z9 19
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD APR
PY 2010
VL 81
IS 4
BP 331
EP 335
DI 10.1016/j.contraception.2009.12.011
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 582LS
UT WOS:000276599500012
PM 20227551
DA 2020-12-08
ER

PT J
AU Storti, A
   Souza, PC
   Chassot, F
   Pereira, MW
   Souza, RJS
   Mello, ICJ
   Svidizinski, TIE
   Consolaro, MEL
AF Storti-Filho, A.
   Souza, P. C.
   Chassot, F.
   Pereira, M. W.
   Souza, R. J. S.
   Mello, I. C. J.
   Svidizinski, T. I. E.
   Lopes Consolaro, Marcia Edilaine
TI Association of public versus private health care utilization and
   prevalence of Trichomonas vaginalis in Maringa, Parana, Brazil
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Trichomoniasis; Health care; Association; Prevalence
ID MYCOPLASMA-HOMINIS; PAPANICOLAOU-SMEAR; INFECTION; WOMEN; REPLICATION;
   CELLS; MODEL
AB To determine the association of public versus private health care utilization and prevalence of Trichomonas vaginalis in Maringa, Parana, Brazil.
   A retrospective study on the results of 133,966 cytology examinations of patients from the Brazilian Public Health System (better socio-economic status, SES) and from the Private Network (low SES) done by the Souza Anatomy Laboratory in Maringa, Brazil, from 2004 to 2007.
   In patients using the SUS, the prevalence of trichomoniasis was 1.44% (n = 782), higher (P < 0.0001) than for RP users (0.18%, n = 147). The infection predominated in age ranges of the 30-39 years and 40-49 years old from the SUS (P < 0.0001) and in ages ranges from 40 to 49 years old from the RP (P < 0.0001). The infection prevalence and age range did not vary among the 4 years (P > 0.05).
   The prevalence of Trichomonas spp. was low and stable in both populations in the 4 years, indicating an equilibrium in terms of numbers of this agent in Maringa, Parana, Brazil. The results corroborate the hypothesis that SES may influence the epidemiology of trichomoniasis. The prevalence of the infection increases with age, a phenomenon not observed with other sexually transmitted infections, such as gonorrhoea or Chlamydia trachomatis.
C1 [Chassot, F.; Svidizinski, T. I. E.; Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Div Clin Cytol, Clin Anal Dept, Teaching & Res Lab Clin Anal, BR-87020900 Maringa, Parana, Brazil.
   [Storti-Filho, A.; Souza, P. C.; Pereira, M. W.; Souza, R. J. S.; Mello, I. C. J.] Souza Lab Pathol, Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Div Clin Cytol, Clin Anal Dept, Teaching & Res Lab Clin Anal, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@yahoo.com.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
CR ABBES C, 2008, REDE HUMANIZA SUS BR
   Adad S J, 2001, Sao Paulo Med J, V119, P200
   Amaral Rita Goreti, 2003, J. Bras. Patol. Med. Lab., V39, P151, DOI 10.1590/S1676-24442003000200010
   AVILES AGP, 2001, ATEN PRIM, V27, P222
   Bowden FJ, 2000, SEX TRANSM INFECT, V76, P248, DOI 10.1136/sti.76.4.248
   Bowden FJ, 2003, SEX TRANSM INFECT, V79, P263, DOI 10.1136/sti.79.3.263
   Chiuchetta GIR, 2002, ARQ CIEN SAUDE UNIPA, V6, P123
   de Carli G.A., 1987, Revista Latinoamericana de Microbiologia, V29, P301
   Dessi D, 2005, INFECT IMMUN, V73, P1180, DOI 10.1128/IAI.73.2.1180-1186.2005
   Guenthner PC, 2005, INFECT IMMUN, V73, P4155, DOI 10.1128/IAI.73.7.4155-4160.2005
   Klinger EV, 2006, SEX TRANSM DIS, V33, P712, DOI 10.1097/01.olq.0000222667.42207.08
   Lippman SA, 2007, SEX TRANSM DIS, V34, P421, DOI 10.1097/01.olq.0000245958.34961.27
   Mabey D, 2006, SEX TRANSM INFECT, V82, P26, DOI 10.1136/sti.2006.023150
   Maeda Marina Yoshiê Sakamoto, 2004, J. Bras. Patol. Med. Lab., V40, P425, DOI 10.1590/S1676-24442004000600011
   MARTINS MCL, 2007, REV BRAS ANAL CLIN, V39, P217
   Neves DP, 2004, PARASITOLOGIA HUMANA
   Patton DL, 2006, SEX TRANSM DIS, V33, P743, DOI 10.1097/01.olq.0000218871.89901.61
   PETERSEN CS, 1995, GENITOURIN MED, V71, P257
   Petrin D, 1998, CLIN MICROBIOL REV, V11, P300, DOI 10.1128/CMR.11.2.300
   PUNDEL JP, 1957, GYNAECOLOGIA, V144, P58, DOI 10.1159/000307391
   Rappelli P, 2001, ARCH MICROBIOL, V175, P70, DOI 10.1007/s002030000240
   Schwebke JR, 2002, SEX TRANSM INFECT, V78, P378, DOI 10.1136/sti.78.5.378
   SOLOMON D, 2005, REVINTER RIO DE JANE
   Sorvillo F, 2001, EMERG INFECT DIS, V7, P927, DOI 10.3201/eid0706.010603
   STINGHEN AEM, 2004, REV BRAS ANAL CLIN R, V36, P111
   Swygard H, 2004, SEX TRANSM INFECT, V80, P91, DOI 10.1136/sti.2003.005124
   van Belkum A, 2001, FEMS IMMUNOL MED MIC, V32, P27, DOI 10.1016/S0928-8244(01)00268-1
   *WHO, 2001, GLOB PREV INC SEL CU, P27
NR 28
TC 1
Z9 1
U1 0
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD OCT
PY 2009
VL 280
IS 4
BP 593
EP 597
DI 10.1007/s00404-009-0971-x
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 486ON
UT WOS:000269206700014
PM 19225796
DA 2020-12-08
ER

PT J
AU Carrara, MA
   Bazotte, RB
   Donatti, L
   Svidzinski, TIE
   Consolaro, MEL
   Patussi, EV
   Batista, MR
AF Carrara, Marcia A.
   Bazotte, Roberto B.
   Donatti, Lucelia
   Svidzinski, Terezinha I. E.
   Consolaro, Marcia E. L.
   Patussi, Eliana V.
   Batista, Marcia R.
TI Effect of experimental diabetes on the development and maintenance of
   vulvovaginal candidiasis in female rats
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE alloxan; diabetes; rats; vulvovaginal candidiasis
AB OBJECTIVE: The purpose of this study was to develop an experimental model of diabetes in female rats and verify its influence on vulvovaginal candidiasis.
   STUDY DESIGN: The animals were divided into control and diabetic groups. Diabetes was induced with the use of an intravenous solution of alloxan (42 mg/kg bodyweight). One week after confirmation of hyperglycemia, the inoculation of Candida albicans yeast, previously standardized from a vaginal isolate, in concentrations of about 5 X 10(8), was performed. Infection control was made through vaginal culture, Papanicolaou cytology, and scanning electron microscopy (SCEM).
   RESULTS: The results pointed to different glycemias between the control (74.8 +/- 2.6) and experimental groups (543.1 +/- 12.1) and a significant bodyweight decrease (227.6 +/- 4.77 and 204 +/- 6.39, respectively). The positive infection was shown by culture, Papanicolaou test, and SCEM in the experimental group.
   CONCLUSION: Diabetes mellitus causes hyperglycemia, which was favorable to the vaginal colonization and infection by C albicans.
C1 [Carrara, Marcia A.; Svidzinski, Terezinha I. E.; Consolaro, Marcia E. L.; Patussi, Eliana V.; Batista, Marcia R.] Univ Estadual Maringa, Postgrad Program Clin Anal, Maringa, Parana, Brazil.
   [Bazotte, Roberto B.] Univ Estadual Maringa, Dept Clin Anal, Maringa, Parana, Brazil.
   [Bazotte, Roberto B.] Univ Estadual Maringa, Dept Pharm & Pharmacol, Maringa, Parana, Brazil.
   [Donatti, Lucelia] Univ Fed Parana, Ctr Electron Microscopy, BR-80060000 Curitiba, Parana, Brazil.
RP Carrara, MA (corresponding author), Univ Estadual Maringa, Postgrad Program Clin Anal, Maringa, Parana, Brazil.
RI Donatti, Lucelia/E-1930-2013; BAZOTTE, ROBERTO/S-5851-2019; Consolaro,
   Marcia Edilaine Lopes/I-4932-2014
OI Donatti, Lucelia/0000-0002-9023-2483; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865
CR BIBBO M., 1997, COMPREHENSIVE CYTOPA, P101
   Bohannon NJV, 1998, DIABETES CARE, V21, P451, DOI 10.2337/diacare.21.3.451
   Calderon L, 2003, MED MYCOL, V41, P143, DOI 10.1080/mmy.41.2.143.147
   Fernandes CE, 1996, REV BRAS MED, V7, P100
   Ferrazza MHSH, 2005, REV BRAS GINECOL OBS, V27, P58, DOI 10.1590/S0100-72032005000200003
   Foss NT, 2005, REV SAUDE PUBL, V39, P677, DOI 10.1590/S0034-89102005000400024
   NOHMI T, 1995, MICROBIOL IMMUNOL, V39, P405, DOI 10.1111/j.1348-0421.1995.tb02220.x
   de Holanda AAR, 2007, REV BRAS GINECOL OBS, V29, P3
   SCHMID J, 1990, J CLIN MICROBIOL, V28, P1236, DOI 10.1128/JCM.28.6.1236-1243.1990
   Sobel JD, 1998, AM J OBSTET GYNECOL, V178, P203, DOI 10.1016/S0002-9378(98)80001-X
   TAKAHASHI M, 1982, COLOR ATLAS CANC CYT, P16480
   ZDOLSEK B, 1995, INFECTION, V23, P81, DOI 10.1007/BF01833870
   Ziarrusta Gorka Barrenetxea, 2002, Revista Iberoamericana de Micologia, V19, P22
NR 13
TC 8
Z9 8
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD JUN
PY 2009
VL 200
IS 6
AR 659.e1
DI 10.1016/j.ajog.2009.01.011
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 451XX
UT WOS:000266505300024
PM 19286145
DA 2020-12-08
ER

PT J
AU Dota, KFD
   Shinobu, CS
   Patussi, EV
   Consolaro, MEL
   Svidzinski, TIE
AF Dalben Dota, Kelen Fatima
   Shinobu, Cristiane Suemi
   Patussi, Eliana Valeria
   Lopes Consolaro, Marcia Edilaine
   Estivalet Svidzinski, Terezinha Inez
TI Susceptibility to vaginal yeast in most used antifungal in Maringa,
   Parana, Brazil
SO ACTA BIOQUIMICA CLINICA LATINOAMERICANA
LA Spanish
DT Article
DE vulvovaginal candidiasis; treatment; antifungal; in vitro resistance
AB In vitro antifungal susceptibility was determined in the 78 yeasts isolated from patients with vulvovaginal candidiasis (VVC) from the city of Maringa/Parana/Brazil, assisted in the Laboratory of Teaching and Research in Clinical Analysis of the State University of Maringa, from 01 January 2005 to December 31, 2006. Its sensibility in vitro was tested according to microdilution method in front of ketoconazol (KETO), fluconazole (FLU), itraconazole (ITRA), nistatin (NIS) and amphotericin B (AMB). For KET, 41.5% of the C. albicans and 96.0% of the C. non-albicans showed resistance (100.0% of C. glabrata) and for FLU, only 3.8% of the isolates of C. albicans and 8.0% of C. glabrata showed resistance. Only 1.9% of the C. albicans and 20% of the C. no-albicans were resistant. For AMB, 5.7% of the C. albicans and 8% of the C. no-albicans (only C. glabrata), were resistant. There were no isolations resistant from NIST, however, there was a high frequency of dose-dependent sensibility (SDD) in vitro. These data makes it possible to confirm the growing necessity of the performance of identification tests and in vitro antifungal susceptibility to antifungals to establish the correct treatment of CVV.
C1 [Patussi, Eliana Valeria; Lopes Consolaro, Marcia Edilaine; Estivalet Svidzinski, Terezinha Inez] Univ Estadual Maringa, Dept Anal Clin, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin, Av Colombo 5790,Campus Univ, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@uem.br
CR Álvares Cassiana Aparecida, 2007, J. Bras. Patol. Med. Lab., V43, P319, DOI 10.1590/S1676-24442007000500004
   Bustamante CI, 2005, CURR OPIN INFECT DIS, V18, P490, DOI 10.1097/01.qco.0000191516.43792.61
   Clinical and Laboratory Standards Institute, 2002, M27A2 CLIN LAB STAND
   Consolaro Marcia Edilaine Lopes, 2004, Revista Iberoamericana de Micologia, V21, P202
   Consolaro MEL, 2005, MYCOPATHOLOGIA, V159, P501, DOI 10.1007/s11046-005-1149-0
   Corsello S, 2003, EUR J OBSTET GYN R B, V110, P66, DOI 10.1016/S0301-2115(03)00096-4
   Cotran R. S., 2000, PATOLOGIA ESTRUTURAL
   Dan M, 2002, MED MYCOL, V40, P383, DOI 10.1080/714031124
   Ferrazza MHSH, 2005, REV BRAS GINECOL OBS, V27, P58, DOI 10.1590/S0100-72032005000200003
   Galle Leonilda Chiari, 2004, J. Bras. Patol. Med. Lab., V40, P229, DOI 10.1590/S1676-24442004000400004
   Maenza JR, 1996, J INFECT DIS, V173, P219, DOI 10.1093/infdis/173.1.219
   Martins MD, 1997, CLIN INFECT DIS, V25, P843, DOI 10.1086/515554
   Ozcan SK, 2006, APMIS, V114, P139, DOI 10.1111/j.1600-0463.2006.apm_360.x
   Pichova I, 2001, EUR J BIOCHEM, V268, P2669, DOI 10.1046/j.1432-1327.2001.02152.x
   Richter SS, 2005, J CLIN MICROBIOL, V43, P2155, DOI 10.1128/JCM.43.5.2155-2162.2005
   Rosenberg MJ, 1998, FAM PLANN PERSPECT, V30, P89, DOI 10.2307/2991665
   Saporiti A. M., 2001, Revista Argentina de Microbiologia, V33, P217
   SOBEL JD, 1993, CLIN OBSTET GYNECOL, V36, P153, DOI 10.1097/00003081-199303000-00021
   Sobel JD, 1998, MYCOSES, V41, P18, DOI 10.1111/j.1439-0507.1998.tb00594.x
   Sugita T, 2002, MICROBIOL IMMUNOL, V46, P881, DOI 10.1111/j.1348-0421.2002.tb02776.x
   Ventolini G, 2006, J REPROD MED, V51, P475
   Ziarrusta Gorka Barrenetxea, 2002, Revista Iberoamericana de Micologia, V19, P22
NR 22
TC 6
Z9 6
U1 0
U2 2
PU FEDERACION BIOQUIMICA PROVINCIA BUENOS AIRES
PI LA PLATA, BUENOS AIRES
PA CALLE 6, NO. 1344, 1900 LA PLATA, BUENOS AIRES, ARGENTINA
SN 0325-2957
EI 1851-6114
J9 ACTA BIOQUIM CLIN L
JI Acta Bioquim. Clin. Latinoam.
PD OCT-DEC
PY 2008
VL 42
IS 4
BP 561
EP 566
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA V12XJ
UT WOS:000207631600008
DA 2020-12-08
ER

PT J
AU Storti-Filho, A
   Svidizinski, TIE
   Souza, RJD
   Mello, ICJ
   Souza, PD
   Consolaro, MEL
AF Storti-Filho, Agenor
   Estivalet Svidizinski, Terezinha Inez
   da Silva Souza, Robson Jose
   Jorge de Mello, Ione Cristina
   Souza, Paola da Costa
   Lopes Consolaro, Marcia Edilaine
TI Oncotic colpocytology stained with Harris-Shorr in the observation of
   vaginal microorganisms
SO DIAGNOSTIC CYTOPATHOLOGY
LA English
DT Article
DE Harris-Shorr staining; oncotic colpocytology; vaginal microflora;
   cervicovaginal infections
ID BACTERIAL VAGINOSIS; INFECTION; TESTS
AB The purpose of this work was to evaluate the efficacy of oncotic colpocytology stained with Harris-Shorr in the identification of the cervicovaginal microflora and infectious agents. Results of microbiologic evaluation carried out in colpocytology exams, bacterioscopy (Gram), and direct exams of 2,017 women aged from 13 to 80 years were compared. Of these, 83.1% agreed between cytology and Grant, 3.6% partially agreed, and 12.8% disagreed. The predominant microflora was of lactobacilli (63.3%),followed by mixed flora (32.1%). The results of sensitivity to lactobacilli were 96. 1 % and to mixed flora 88.0%; the specificity values were 91.2 and 92.0%, respectively. Colpocytology detected all the instances of trichomoniasis observed at direct exam (0.6%). The most frequent infectious agents were of candidiasis (14.8%, sensitivity 80.3%) and bacterial vaginosis (11.9%, sensitivity 68.1%). Thus, Harris-Shorr stained cytology was shown to be an excellent diagnostic method for T. vaginalis, lactobacilli, mixed flora, and candidiasis.
C1 [Storti-Filho, Agenor; da Silva Souza, Robson Jose; Jorge de Mello, Ione Cristina; Souza, Paola da Costa] Souza Lab Pathol, Div Pathol Anat & Clin Cytol, Maringa, Parana, Brazil.
   [Estivalet Svidizinski, Terezinha Inez] Univ Estadual Maringa, Teaching & Res Lab Clin Anal, Clin Anal Dept, Div Med Microbiol, Maringa, Parana, Brazil.
   [Lopes Consolaro, Marcia Edilaine] Univ Estadual Maringa, Teaching & Res Lab Clin Anal, Clin Anal Dept, Div Clin Cytol, Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, LEPAC, DAC, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@yahoo.com.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
CR Adad S J, 2001, Sao Paulo Med J, V119, P200
   Atkins KA, 2002, ADV ANAT PATHOL, V9, P52, DOI 10.1097/00125480-200201000-00006
   Audisio T, 2001, J Low Genit Tract Dis, V5, P223, DOI 10.1046/j.1526-0976.2001.54007.x
   AVILES AGP, 2001, ATEN PRIM, V27, P222
   BROOKS GF, 2000, MELNICK ADELBERG MIC
   CARNEIRO SC, 2006, J BRAS DOENCAS SEX T, V18, P36
   Chiuchetta GIR, 2002, ARQ CIEN SAUDE UNIPA, V6, P123
   Consolaro Marcia Edilaine Lopes, 2004, Revista Iberoamericana de Micologia, V21, P202
   CRAVER RD, 1997, PED NEPH, P331
   Davis JD, 1997, AM J OBSTET GYNECOL, V177, P532, DOI 10.1016/S0002-9378(97)70141-8
   Gompel C., 1997, CITOLOGIA GINECOLOGI
   LACAZ CS, 1991, MICOLOGIA MEDICA
   Lamont RF, 1999, INT J STD AIDS, V10, P93, DOI 10.1258/0956462991913709
   McMillan A, 2006, CYTOPATHOLOGY, V17, P317, DOI 10.1111/j.1365-2303.2006.00411.x
   Murta E F, 2000, Sao Paulo Med J, V118, P105
   Papanicolaou GN, 1943, DIAGNOSIS UTERINE CA
   Petrin D, 1998, CLIN MICROBIOL REV, V11, P300, DOI 10.1128/CMR.11.2.300
   PUNDEL JP, 1957, GYNAECOLOGIA, V144, P58, DOI 10.1159/000307391
   Schmidt A, 1997, Zentralbl Gynakol, V119, P545
   SILVA FAM, 2000, COLO UTERINO VAGINA
   SOBEL JD, 1993, CLIN OBSTET GYNECOL, V36, P153, DOI 10.1097/00003081-199303000-00021
   Solomon D, 2005, SISTEMA BETHESDA CIT
   STINGHEN AEM, 2004, REV BRAS ANAL CLIN, V36, P11
   STINGHEN AEM, 2002, COLORACAO GRAMCOMO F
   Woods GL, 1996, CLIN MICROBIOL REV, V9, P382, DOI 10.1128/CMR.9.3.382
NR 25
TC 3
Z9 3
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-1039
EI 1097-0339
J9 DIAGN CYTOPATHOL
JI Diagn. Cytopathol.
PD JUN
PY 2008
VL 36
IS 6
BP 358
EP 362
DI 10.1002/dc.20820
PG 5
WC Medical Laboratory Technology; Pathology
SC Medical Laboratory Technology; Pathology
GA 312EN
UT WOS:000256652000002
PM 18478612
DA 2020-12-08
ER

PT J
AU Chassot, F
   Negri, MFN
   Svidzinski, AE
   Donatti, L
   Peralta, RM
   Svidzinski, TIE
   Consolaro, MEL
AF Chassot, Francieli
   Negri, Melyssa F. N.
   Svidzinski, Arthur E.
   Donatti, Lucelia
   Peralta, Rosane M.
   Svidzinski, Terezinha I. E.
   Consolaro, Marcia E. L.
TI Can intrauterine contraceptive devices be a Candida albicans reservoir?
SO CONTRACEPTION
LA English
DT Article
DE IUD; Vulvovaginal candidiasis; adherence; biofilm
ID BIOFILM FORMATION; WOMEN; STRAINS
AB Background: The in vitro adherence of Candida albicans isolated from vaginal exudates of patients with vulvovaginal candidiasis (VVC) to intrauterine contraceptive devices (IUDs) and biofilm formation capacity were evaluated.
   Study Design: This research was conducted with two vaginal C. albicans isolates. The adherence on IUD by both radiomarked adhesion assay and scanning electron microscopy, and the biofilm production capacity by spectropbotometric method were determined.
   Results: The yeasts adhered strongly to different parts of the IUD (covered with copper wire, without copper wire and tail), and there was no significant difference in the rates of adhesion to the different parts (p=.7771). The vaginal yeasts showed a high capacity to produce biofilm.
   Conclusions: Two vaginal yeasts evaluated showed a high capacity to produce biofilm on IUD. It was confirmed that all parts of the IUD allow the adherence of yeasts. The adherence of C. albicans to different parts of the IUD and its formation of biofilm seems to be important attributes influencing the occurrence of VVC and recurrent VVC. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Chassot, Francieli; Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Clin Anal, Div Clin Cytol, Teaching & Res Clin Anal Lab, BR-87020900 Maringa, Parana, Brazil.
   [Negri, Melyssa F. N.; Svidzinski, Arthur E.; Svidzinski, Terezinha I. E.] Univ Estadual Maringa, Teaching & Res Clin Anal Lab, Div Med Mycol, BR-87020900 Maringa, Parana, Brazil.
   [Donatti, Lucelia] Fed Univ Curitiba, Dept Cell Biol, BR-85131990 Curitiba, Parana, Brazil.
   [Peralta, Rosane M.] Univ Estadual Maringa, Dept Biochem, BR-87020900 Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Clin Anal, Div Clin Cytol, Teaching & Res Clin Anal Lab, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@yahoo.com.br
RI PERALTA, ROSANE MARINA/J-3912-2016; Donatti, Lucelia/E-1930-2013;
   Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI PERALTA, ROSANE MARINA/0000-0001-5749-0723; Donatti,
   Lucelia/0000-0002-9023-2483; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865; Negri, Melyssa/0000-0003-2071-8872;
   Svidzinski, Terezinha/0000-0003-2525-9046
CR Agarwal Krishna, 2004, Indian J Med Sci, V58, P394
   Baillie GS, 1999, METHOD ENZYMOL, V310, P644
   Barth T, 2002, ACTA OBSTET GYN SCAN, V81, P981, DOI 10.1034/j.1600-0412.2002.811014.x
   Chong PP, 2003, J MED MICROBIOL, V52, P657, DOI 10.1099/jmm.0.04973-0
   Consolaro Marcia Edilaine Lopes, 2004, Revista Iberoamericana de Micologia, V21, P202
   Demirezen S., 2005, Central European Journal of Public Health, V13, P32
   Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002
   Ellepola ANB, 1999, ORAL MICROBIOL IMMUN, V14, P358, DOI 10.1034/j.1399-302X.1999.140605.x
   Hodoglugil NNS, 2000, CONTRACEPTION, V61, P359, DOI 10.1016/S0010-7824(00)00118-9
   Karaer A, 2005, EUR J OBSTET GYN R B, V121, P211, DOI 10.1016/j.ejogrb.2004.11.030
   Larone DH, 1995, MED IMPORTANT FUNGI
   Li XG, 2003, MICROBIOL-SGM, V149, P353, DOI 10.1099/mic.0.25932-0
   Mukherjee PK, 2003, INFECT IMMUN, V71, P4333, DOI 10.1128/IAI.71.8.4333-4340.2003
   O'Toole G, 2000, ANNU REV MICROBIOL, V54, P49, DOI 10.1146/annurev.micro.54.1.49
   PAREWIJCK W, 1988, BRIT J OBSTET GYNAEC, V95, P408, DOI 10.1111/j.1471-0528.1988.tb06615.x
   Polaquini SRB, 2006, ARCH ORAL BIOL, V51, P482, DOI 10.1016/j.archoralbio.2005.11.007
   Segal D, 2001, SCAND J INFECT DIS, V33, P77, DOI 10.1080/003655401750064158
   Shin JH, 2002, J CLIN MICROBIOL, V40, P1244, DOI 10.1128/JCM.40.4.1244-1248.2002
   Sugita T, 2002, MICROBIOL IMMUNOL, V46, P881, DOI 10.1111/j.1348-0421.2002.tb02776.x
   Walker JT, 2000, APPL ENVIRON MICROB, V66, P3363, DOI 10.1128/AEM.66.8.3363-3367.2000
   Ziarrusta Gorka Barrenetxea, 2002, Revista Iberoamericana de Micologia, V19, P22
NR 21
TC 53
Z9 54
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD MAY
PY 2008
VL 77
IS 5
BP 355
EP 359
DI 10.1016/j.contraception.2008.01.007
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 291YJ
UT WOS:000255233100008
PM 18402852
DA 2020-12-08
ER

PT J
AU Carnacho, DP
   Consolaro, MEL
   Patussi, EV
   Donatti, L
   Gasparetto, A
   Svidzinski, TIE
AF Carnacho, Daiane Pereira
   Consolaro, Marcia E. L.
   Patussi, Eliana Valeria
   Donatti, Lucelia
   Gasparetto, Andre
   Svidzinski, Trezinha I. E.
TI Vaginal yeast adherence to the combined contraceptive vaginal ring
   (CCVR)
SO CONTRACEPTION
LA English
DT Article
DE NuvaRing((R)); adherence; candida sp; vulvovaginal candidiasis
ID CANDIDA-ALBICANS; HYDROPHOBICITY; EFFICACY
AB Background: The purpose of this study was to evaluate the in vitro adherence of different yeasts, isolated from vaginal exudates of patients with vulvovaginal candidiasis (VVC, to the combined contraceptive vaginal ring - NuvaRing((R)).
   Study Design: Four isolates of Candida sp. and one isolate of Saccharomyces cerevisiae were used. Adherence assays were carried out through colony-forming units per milliliter (CFU/mL), radiolabeled quantification and scanning electron microscopy (SEM) of the ring, and the cell surface hydrophobicity (CSH) of the yeasts was determined.
   Results: All the yeasts were capable of adhering to the vaginal ring, as determined by CFU/mL and in the radiolabeled assay. CSH was compatible with the adherence by CFU/mL.
   Conclusion: SEM proved the adhesion, which was different between Candida albicans and C. tropicalis. The adherence of the tested yeasts to the ring could potentially facilitate the development of VVC and recurrent VVC in susceptible patients using this contraceptive method. (c) 2007 Elsevier Inc. All rights reserved.
C1 [Carnacho, Daiane Pereira; Patussi, Eliana Valeria; Svidzinski, Trezinha I. E.] Univ Estadual Maringa, Dept Clin Anal, Div Med Mycol Teaching & Res, Clin Anal Lab, BR-87020900 Maringa, Parana, Brazil.
   [Consolaro, Marcia E. L.] Univ Estadual Maringa, Dept Clin Anal, Div Clin Cytol Teaching & Res, Clin Anal Lab, BR-87020900 Maringa, Parana, Brazil.
   [Donatti, Lucelia] Univ Fed Parana, Dept Biol Celular, BR-81531900 Curitiba, Parana, Brazil.
   [Gasparetto, Andre] Univ Estadual Maringa, Dept Dent, BR-87020900 Maringa, Parana, Brazil.
RP Svidzinski, TIE (corresponding author), Univ Estadual Maringa, DAC, LEPAC, Ave Colombo,5790 Bloco J90,Sala 11, BR-87020900 Maringa, Parana, Brazil.
EM tiesvidzinski@uem.br
RI Donatti, Lucelia/E-1930-2013; Consolaro, Marcia Edilaine
   Lopes/I-4932-2014
OI Donatti, Lucelia/0000-0002-9023-2483; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865
CR Camacho DP, 2007, MYCOPATHOLOGIA, V163, P261, DOI 10.1007/s11046-007-9007-x
   Cannon RD, 1999, CRIT REV ORAL BIOL M, V10, P359, DOI 10.1177/10454411990100030701
   Consolaro Marcia Edilaine Lopes, 2004, Revista Iberoamericana de Micologia, V21, P202
   Corsello S, 2003, EUR J OBSTET GYN R B, V110, P66, DOI 10.1016/S0301-2115(03)00096-4
   Dan M, 2002, MED MYCOL, V40, P383, DOI 10.1080/714031124
   DOYLE RJ, 1990, AM SOC MICROBIOLOGY, P8
   Ferrazza MHSH, 2005, REV BRAS GINECOL OBS, V27, P58, DOI 10.1590/S0100-72032005000200003
   Gilliam M, 2007, CONTRACEPTION, V76, P30, DOI 10.1016/j.contraception.2007.03.009
   Jabra-Rizk Mary Ann, 2001, Revista Iberoamericana de Micologia, V18, P17
   KURTZMANN C. P., 1998, YEASTS TAXONOMIC STU, P891
   Miller L, 2005, CONTRACEPTION, V71, P65, DOI 10.1016/j.contraception.2004.07.015
   Mulders TMT, 2002, HUM REPROD, V17, P2594, DOI 10.1093/humrep/17.10.2594
   Oddsson K, 2005, CONTRACEPTION, V71, P176, DOI 10.1016/j.contraception.2004.09.001
   Polaquini SRB, 2006, ARCH ORAL BIOL, V51, P482, DOI 10.1016/j.archoralbio.2005.11.007
   Rosenberg MJ, 1998, FAM PLANN PERSPECT, V30, P89, DOI 10.2307/2991665
   Roumen FJME, 2001, HUM REPROD, V16, P469, DOI 10.1093/humrep/16.3.469
   Roumen FJME, 2007, CONTRACEPTION, V75, P420, DOI 10.1016/j.contraception.2007.01.013
   Shin JH, 2002, J CLIN MICROBIOL, V40, P1244, DOI 10.1128/JCM.40.4.1244-1248.2002
   SOBEL JD, 1993, CLIN OBSTET GYNECOL, V36, P153, DOI 10.1097/00003081-199303000-00021
   STONE SC, 1995, CLIN OBSTET GYNECOL, V38, P821, DOI 10.1097/00003081-199538040-00017
   Sugita T, 2002, MICROBIOL IMMUNOL, V46, P881, DOI 10.1111/j.1348-0421.2002.tb02776.x
   SWEET SP, 1987, FEMS MICROBIOL LETT, V48, P159, DOI 10.1111/j.1574-6968.1987.tb02534.x
   Ziarrusta Gorka Barrenetxea, 2002, Revista Iberoamericana de Micologia, V19, P22
   Zurawin RK, 2007, CLIN OBSTET GYNECOL, V50, P425, DOI 10.1097/GRF.0b013e31804b1be6
NR 24
TC 24
Z9 25
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD DEC
PY 2007
VL 76
IS 6
BP 439
EP 443
DI 10.1016/j.contraception.2007.07.012
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 241KZ
UT WOS:000251656600005
PM 18061701
DA 2020-12-08
ER

PT J
AU Shinobu, CS
   Ogatta, SFY
   Bizerra, F
   Furlaneto, L
   Peralta, RM
   Svidzinski, TIE
   Consolaro, MEL
AF Shinobu, Cristiane Suemi
   Yamada Ogatta, Sueli Fumie
   Bizerra, Fenando
   Furlaneto, Luciana
   Peralta, Rosane Marina
   Estivalet Svidzinski, Terezinha Inez
   Lopes Consolaro, Marcia Edilaine
TI Lack of association between genotypes and virulence factors in
   C-albicans strains isolated from vaginal secretion
SO BRAZILIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE C. albicans; vulvovaginal candidiasis; genotype; virulence factors
ID PROTEINASES; WOMEN
AB The physiopathogenesis of vulvovaginal candidiasis (VVC) is still not completely elucidated. The objective of this study was to evaluate if there is a relationship between the different genotypes of Candida albicans, their main agent and the virulence of this yeast in vaginal isolates, and to check if there are laboratorial markers that can predict the ability of each isolate to develop VVC independently of symptoms. The production of exoenzymes protease, phospholipase and haemolysin, resistance to hydrogen peroxide, and the genotype were determined. Genotype A was predominant (75%), protease, phospholipase and haemolytic activity were highly expressed, and the majority of the yeasts were sensitive to H2O2 in 1 and 2 hours of exposure, suggesting that these factors are important in the virulence of vaginal isolates. However they did not have any correlation with the genotypes. The different isolates expressed similar virulence potential, suggesting that other factors relating to the yeasts and the host must participate in the development of the clinical disease.
C1 Univ Estadual Maringa, Dept Anal Clin, BR-87020900 Maringa, Parana, Brazil.
   Univ Estadual Londrina, Dept Microbiol, Londrina, Parana, Brazil.
   Univ Estadual Maringa, Dept Bioquim, Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Univ Estadual Maringa, Dept Anal Clin, Av Colombo,5790, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@yahoo.com.br
RI PERALTA, ROSANE MARINA/J-3912-2016; BIZERRA, FERNANDO/H-4807-2013;
   Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI PERALTA, ROSANE MARINA/0000-0001-5749-0723; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865
CR Ahmad S, 2002, J CLIN MICROBIOL, V40, P2483, DOI 10.1128/JCM.40.7.2483-2489.2002
   Calderone RA, 2001, TRENDS MICROBIOL, V9, P327, DOI 10.1016/S0966-842X(01)02094-7
   Candido R C, 2000, Rev Soc Bras Med Trop, V33, P437, DOI 10.1590/S0037-86822000000500005
   Chong PP, 2003, J MED MICROBIOL, V52, P657, DOI 10.1099/jmm.0.04973-0
   Consolaro MEL, 2005, MYCOPATHOLOGIA, V159, P501, DOI 10.1007/s11046-005-1149-0
   De Bernardis F, 2001, MED MYCOL, V39, P303, DOI 10.1080/mmy.39.4.303.313
   Fidel PL, 2004, INFECT IMMUN, V72, P2939, DOI 10.1128/IAI.72.5.2939-2946.2004
   Ghannoum MA, 2000, CLIN MICROBIOL REV, V13, P122, DOI 10.1128/CMR.13.1.122-143.2000
   Kurtzman C.P., 1998, YEAST TAXONOMIC STUD
   Larone DH, 1995, MED IMPORTANT FUNGI
   Luo G, 2001, J CLIN MICROBIOL, V39, P2971, DOI 10.1128/JCM.39.8.2971-2974.2001
   MANNS JM, 1994, INFECT IMMUN, V62, P5154, DOI 10.1128/IAI.62.11.5154-5156.1994
   Marrazzo J, 2003, BMJ-BRIT MED J, V326, P993, DOI 10.1136/bmj.326.7397.993
   OTTO BR, 1992, CRIT REV MICROBIOL, V18, P217, DOI 10.3109/10408419209114559
   PRICE MF, 1982, SABOURAUDIA, V20, P7
   Rosa Maria Inês da, 2004, Rev. Bras. Ginecol. Obstet., V26, P65, DOI 10.1590/S0100-72032004000100010
   RUCHEL R, 1982, SABOURAUDIA, V20, P233
   Sobel JD, 1997, CLIN INFECT DIS, V24, P649, DOI 10.1093/clind/24.4.649
   SOLL DR, 1991, J CLIN MICROBIOL, V29, P1702, DOI 10.1128/JCM.29.8.1702-1710.1991
   Sugita T, 2002, MICROBIOL IMMUNOL, V46, P881, DOI 10.1111/j.1348-0421.2002.tb02776.x
   Vidotto Valerio, 1999, Revista Iberoamericana de Micologia, V16, P208
   Vilela MMS, 2002, MED MYCOL, V40, P249, DOI 10.1080/mmy.40.3.249.257
   Ziarrusta Gorka Barrenetxea, 2002, Revista Iberoamericana de Micologia, V19, P22
NR 23
TC 7
Z9 8
U1 0
U2 0
PU SOC BRASILEIRA MICROBIOLOGIA
PI SAO PAULO
PA AV PROF LINEU PRESTES,1374, 05508 SAO PAULO, BRAZIL
SN 1517-8382
EI 1678-4405
J9 BRAZ J MICROBIOL
JI Braz. J. Microbiol.
PD JUL-SEP
PY 2007
VL 38
IS 3
BP 467
EP 471
DI 10.1590/S1517-83822007000300015
PG 5
WC Microbiology
SC Microbiology
GA 220RR
UT WOS:000250175500015
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Consolaro, MEL
   Gasparetto, A
   Svidzinski, TIE
   Peralta, RM
AF Consolaro, M. E. L.
   Gasparetto, A.
   Svidzinski, T. I. E.
   Peralta, R. M.
TI Effect of pepstatin A on the virulence factors of Candida albicans
   strains isolated from vaginal environment of patients in three different
   clinical conditions
SO MYCOPATHOLOGIA
LA English
DT Article
DE adherence; aspartate proteinase; Candida albicans; virulence factors;
   pepstatin A
ID PROTEOLYTIC CANDIDA; ACID PROTEINASE; YEAST-CELLS; ADHERENCE;
   EXPRESSION; KERATINOCYTES; MECHANISMS; RESISTANCE; INFECTION; BIOFILMS
AB The aspartate proteinase inhibitor pepstatin A was used to study a possible correlation among proteinase activity and other virulence factors of Candida albicans strains isolated from the vaginal environment of patients in three different clinical conditions: asympthomatic, vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (RVVC). The addition of 1.0 mu M pepstatin A did not have any significant effect on hyphae formation, biofilm production and in the cell surface hydrofobicity of isolates in the three different clinical conditions. However, pepstatin A reduced the adherence of C. albicans to vaginal mucosa epithelial cells (53.1, 48.7 and 59.9%, respectively to isolates from asymptomatic, VVC and RVVC patients). This result suggests that the secreted aspartate proteinases (Saps) of this fungal pathogen may have auxiliary roles in cellular adhesion.
C1 Univ Estadual Maringa, Div Med Mycol, Teaching & Res Clin Anal Lab, Maringa, Parana, Brazil.
   Univ Estadual Maringa, Dept Odontol, Maringa, Parana, Brazil.
   Univ Estadual Maringa, Dept Biochem, Maringa, Parana, Brazil.
RP Peralta, RM (corresponding author), Univ Estadual Maringa, Dept Bioquim, BR-87020900 Maringa, Parana, Brazil.
EM rmperalta@uem.br
RI PERALTA, ROSANE MARINA/J-3912-2016; Consolaro, Marcia Edilaine
   Lopes/I-4932-2014
OI PERALTA, ROSANE MARINA/0000-0001-5749-0723; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865
CR AGATENSI L, 1991, J CLIN PATHOL, V44, P826, DOI 10.1136/jcp.44.10.826
   BORG M, 1988, INFECT IMMUN, V56, P626, DOI 10.1128/IAI.56.3.626-631.1988
   CASSONE A, 1987, J INFECT DIS, V156, P777, DOI 10.1093/infdis/156.5.777
   Chandra J, 2001, J BACTERIOL, V183, P5385, DOI 10.1128/JB.183.18.5385-5394.2001
   Chong PP, 2003, J MED MICROBIOL, V52, P657, DOI 10.1099/jmm.0.04973-0
   Consolaro Marcia Edilaine Lopes, 2004, Revista Iberoamericana de Micologia, V21, P202
   DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201
   De Bernardis F, 2001, MED MYCOL, V39, P303, DOI 10.1080/mmy.39.4.303.313
   DEBERNARDIS F, 1990, J INFECT DIS, V161, P1276, DOI 10.1093/infdis/161.6.1276
   Douglas LJ, 2003, TRENDS MICROBIOL, V11, P30, DOI 10.1016/S0966-842X(02)00002-1
   ELMAGHRABI EA, 1990, CLIN EXP DERMATOL, V15, P183, DOI 10.1111/j.1365-2230.1990.tb02069.x
   Felk A, 2002, INFECT IMMUN, V70, P3689, DOI 10.1128/IAI.70.7.3689-3700.2002
   GLEE PM, 1995, INFECT IMMUN, V63, P1373, DOI 10.1128/IAI.63.4.1373-1379.1995
   HAZEN KC, 1991, INFECT IMMUN, V59, P907, DOI 10.1128/IAI.59.3.907-912.1991
   HOSTETTER MK, 1994, CLIN MICROBIOL REV, V7, P29, DOI 10.1128/CMR.7.1.29-42.1994
   Jabra-Rizk MA, 2004, EMERG INFECT DIS, V10, P14, DOI 10.3201/eid1001.030119
   KLOTZ SA, 1994, FEMS MICROBIOL LETT, V120, P257, DOI 10.1111/j.1574-6968.1994.tb07042.x
   Larone DH, 1995, MED IMPORTANT FUNGI
   Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X
   Marrazzo J, 2003, BMJ-BRIT MED J, V326, P993, DOI 10.1136/bmj.326.7397.993
   Masuoka J, 1999, FEMS IMMUNOL MED MIC, V24, P421, DOI 10.1111/j.1574-695X.1999.tb01314.x
   Monod M, 2002, CHEM IMMUNOL, V81, P114
   Moragues MD, 2003, INFECT IMMUN, V71, P5273, DOI 10.1128/IAI.71.9.5273-5279.2003
   Naglik J, 2004, CELL MICROBIOL, V6, P915, DOI 10.1111/j.1462-5822.2004.00439.x
   Nishimura M, 2002, MYCOPATHOLOGIA, V153, P125, DOI 10.1023/A:1014506115757
   Odds F. C., 1994, ASM News (Washington), V60, P313
   ODDS FC, 1988, J MED VET MYCOL, V26, P277
   OLLERT MW, 1993, INFECT IMMUN, V61, P4560, DOI 10.1128/IAI.61.11.4560-4568.1993
   RAY TL, 1988, INFECT IMMUN, V56, P1942, DOI 10.1128/IAI.56.8.1942-1949.1988
   RUCHEL R, 1982, SABOURAUDIA, V20, P233
   Schaller M, 2003, J MED MICROBIOL, V52, P247, DOI 10.1099/jmm.0.05048-0
   Shin JH, 2002, J CLIN MICROBIOL, V40, P1244, DOI 10.1128/JCM.40.4.1244-1248.2002
   STAIBE F, 1969, MYCOPATHOL MYCOL, V7, P55
   Sugita T, 2002, MICROBIOL IMMUNOL, V46, P881, DOI 10.1111/j.1348-0421.2002.tb02776.x
   SWEET SP, 1987, FEMS MICROBIOL LETT, V48, P159, DOI 10.1111/j.1574-6968.1987.tb02534.x
   Vidotto Valerio, 1999, Revista Iberoamericana de Micologia, V16, P208
   Vilela MMS, 2002, MED MYCOL, V40, P249, DOI 10.1080/mmy.40.3.249.257
   Watts HJ, 1998, FEMS MICROBIOL LETT, V159, P129, DOI 10.1111/j.1574-6968.1998.tb12851.x
NR 38
TC 9
Z9 11
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-486X
EI 1573-0832
J9 MYCOPATHOLOGIA
JI Mycopathologia
PD AUG
PY 2006
VL 162
IS 2
BP 75
EP 82
DI 10.1007/s11046-006-0026-9
PG 8
WC Mycology
SC Mycology
GA 071HS
UT WOS:000239591100001
PM 16897584
DA 2020-12-08
ER

PT J
AU Irie, MMT
   Consolaro, MEL
   Guedes, TA
   Donatti, L
   Patussi, EV
   Svidzinski, TIE
AF Tagut Irie, Mary Mayumi
   Lopes Consolaro, Mercia Edilaine
   Guedes, Terezinha Aparecida
   Donatti, Lucelia
   Patussi, Ellana Valeria
   Estivalet Svidzinski, Terezinha Inez
TI A simplified technique for evaluating the adherence of yeasts to human
   vaginal epithelial cells
SO JOURNAL OF CLINICAL LABORATORY ANALYSIS
LA English
DT Article
DE adhesion; C. albicans; non-C. albicans; Papanicolaou stain; vaginal
   epithelium
ID CANDIDA-ALBICANS; PATHOGENESIS; VAGINITIS; INVITRO; STRAINS
AB Thousands of women all over the world annually suffer of vulvovaginal candidiasis (VVC), an infection caused by yeasts, which mainly affect the mucosa of the vulva and vagina. The adherence of the yeasts to the mucosae is an essential step for colonization and predisposes the start of the infectious process. In this study, a technique capable of evaluating the adhesion of yeasts to human vaginal epithelial cells (HVEC) was employed. Twenty-five vaginal yeast isolates (10 Candida albicans, nine C. glabrata, two C. parapsilosis, one C. tropicalis, two Saccharomyces cerevisiae, and one Trichosporon sp.) were evaluated. A suspension of each yeast was co-incubated with HVEC obtained from a healthy donor in the ovulatory phase. After 1 hr, smears were made, stained with crystal violet and Papanicolaou, and the number of yeasts that adhered to 600 HVEC was evaluated. The adhesion of C. albicans was significantly greater than that of the other species and occurred mainly in the intermediate HVEC, rather than the superficial. In addition, the proposed technique, easy to execute and of low cost showed to be reproducible and enables the determination of the adherence capacity of different isolates, whose adhesion was confirmed by scanning electron microscopy.
C1 Univ Estadual Maringa, Dept Clin Anal, Div Med Mycol, Teaching & Res Clin Lab Anal, Maringa, Parana, Brazil.
   Univ Estadual Maringa, Dept Stat, Maringa, Parana, Brazil.
   Univ Fed Parana, Dept Biol, BR-80060000 Curitiba, Parana, Brazil.
RP Svidzinski, TIE (corresponding author), Univ Estadual Maringa, DAC, LEPAC, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM tiesvidzinski@uem.br
RI Donatti, Lucelia/E-1930-2013; Consolaro, Marcia Edilaine
   Lopes/I-4932-2014
OI Donatti, Lucelia/0000-0002-9023-2483; Consolaro, Marcia Edilaine
   Lopes/0000-0001-9102-4865
CR AYALA MJ, 1982, CITOLOGIA GINECOLOGI
   BAILEY A, 1995, INFECT IMMUN, V63, P569, DOI 10.1128/IAI.63.2.569-572.1995
   Biasoli Marisa Susana, 2003, Rev Iberoam Micol, V20, P160
   BIBBO M, 1997, COMPREHENSIVE CYTOPA, P892
   CONSOLARO MEL, 2004, REV IBEROAM MICOL, V21, P2002
   El-Azizi Mohamed, 1999, Indian Journal of Experimental Biology, V37, P941
   Ferrer J, 2000, INT J GYNECOL OBSTET, V71, pS21, DOI 10.1016/S0020-7292(00)00350-7
   Fidel PL, 2004, INFECT IMMUN, V72, P2939, DOI 10.1128/IAI.72.5.2939-2946.2004
   FRANZKE S, 1993, INFECT IMMUN, V61, P2662, DOI 10.1128/IAI.61.6.2662-2669.1993
   GHANNOUM MA, 1990, CANDIDA ADHERENCE EP
   Grimaudo NJ, 1997, ORAL MICROBIOL IMMUN, V12, P168, DOI 10.1111/j.1399-302X.1997.tb00374.x
   KALO A, 1988, CAN J MICROBIOL, V34, P224, DOI 10.1139/m88-042
   KALOKLEIN A, 1989, AM J OBSTET GYNECOL, V161, P1132, DOI 10.1016/0002-9378(89)90649-2
   Kamai Y, 2002, INFECT IMMUN, V70, P5256, DOI 10.1128/IAI.70.9.5256-5258.2002
   KEARNS MJ, 1983, SABOURAUDIA, V21, P93
   KENNEDY MJ, 1990, MYCOPATHOLOGIA, V109, P123, DOI 10.1007/BF00436792
   KURTZMANN C. P., 1998, YEASTS TAXONOMIC STU, P891
   Mardh PA, 2002, INT J STD AIDS, V13, P522, DOI 10.1258/095646202760159639
   ODDS FC, 1988, CANDIDA CANDIDIASIS, P85
   PERSI MA, 1985, INFECT IMMUN, V50, P82, DOI 10.1128/IAI.50.1.82-90.1985
   Pichova I, 2001, EUR J BIOCHEM, V268, P2669, DOI 10.1046/j.1432-1327.2001.02152.x
   Pires MDC, 2001, BRAZ J MICROBIOL, V32, P163
   Posteraro B, 1999, J CLIN MICROBIOL, V37, P2230, DOI 10.1128/JCM.37.7.2230-2235.1999
   SEGAL E, 1984, SABOURAUDIA, V22, P191
   SOBEL JD, 1993, CLIN OBSTET GYNECOL, V36, P153, DOI 10.1097/00003081-199303000-00021
   Sobel JD, 1998, MYCOSES, V41, P18, DOI 10.1111/j.1439-0507.1998.tb00594.x
   Sugita T, 2002, MICROBIOL IMMUNOL, V46, P881, DOI 10.1111/j.1348-0421.2002.tb02776.x
   TAKAHASHI M, 1982, ATLAS COLORIDO CITOL, P161
   Vidotto Valerio, 2003, Revista Iberoamericana de Micologia, V20, P52
   Williams DW, 1999, J CLIN PATHOL, V52, P529, DOI 10.1136/jcp.52.7.529
   ZIARRUSTA GB, 2001, REV IBEROAM MICOL, V19, P22
NR 31
TC 15
Z9 16
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-8013
EI 1098-2825
J9 J CLIN LAB ANAL
JI J. Clin. Lab. Anal.
PY 2006
VL 20
IS 5
BP 195
EP 203
DI 10.1002/jcla.20132
PG 9
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 089NO
UT WOS:000240887600005
PM 16960895
OA Green Published
DA 2020-12-08
ER

PT J
AU Consolaro, MEL
   Albertoni, TA
   Svidzinski, AE
   Peralta, RM
   Svidzinski, TIE
AF Consolaro, MEL
   Albertoni, TA
   Svidzinski, AE
   Peralta, RM
   Svidzinski, TIE
TI Vulvovaginal candidiasis is associated with the production of germ tubes
   by Candida albicans
SO MYCOPATHOLOGIA
LA English
DT Article
DE antifungal agents; Candida albicans; germ tube; vulvovaginal candidiasis
ID PATHOGENESIS; VAGINITIS; GLABRATA; GROWTH
AB Twenty Candida albicans strains isolated from women attended at the Teaching and Research in the Laboratory of Teaching and Research in Clinical Analysis of the State University of Maringa, Parana, Brazil, have been analyzed. Yeasts were identified by classical methods and patients subdivided into asymptomatic, vulvovaginal candidiasis(VVC) and recurrent vulvovaginal candidiasis (RVVC) groups. Yeasts were incubated in RPMI + fetal calf serum to analyze germ tubes every two hours, up to 10 h. In vitro sensitivity to fluconazole, itraconazole, ketoconazole, amphotericin B and nystatin was analyzed according to NCCLS-M27-A microdilution assay. Yeast isolated from symptomatic women produced significantly more germ tubes than asymptomatic women (P < 0.05). However, no significant difference between yeasts from VVC and RVVC occurred (P > 0.05). Variation between MIC50 and MIC90 of tested antifungal agents was slight among isolated yeasts, while no resistant yeasts were detected. Nevertheless, VVC yeasts were more DDS (reduced dose-dependent susceptibility) for nystatin and RVVC were more DDS for ketoconazole. Results suggest that colonization by yeast in the vagina and lack of symptoms may be partially explained by the yeast's sparse capacity to form germ tubes, On the other hand, RVVC was not associated with antimicrobial resistance. DDS high frequency for nystatin and ketoconazole indicates that identification, and susceptibility of antifungals tests are important to management of VVC.
C1 Univ Estadual Maringa, Div Med Mycol, Teaching & Res Clin Anal Lab, BR-87020900 Maringa, Parana, Brazil.
   Univ Estadual Maringa, Dept Biochem, BR-87020900 Maringa, Parana, Brazil.
RP Svidzinski, TIE (corresponding author), Univ Estadual Maringa, Div Med Mycol, Teaching & Res Clin Anal Lab, BR-87020900 Maringa, Parana, Brazil.
EM tiesvidzinski@uem.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014; PERALTA, ROSANE
   MARINA/J-3912-2016
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865; PERALTA, ROSANE
   MARINA/0000-0001-5749-0723
CR AKASHI T, 1994, MICROBIOL-SGM, V140, P271, DOI 10.1099/13500872-140-2-271
   Chaffin WL, 1998, MICROBIOL MOL BIOL R, V62, P130, DOI 10.1128/MMBR.62.1.130-180.1998
   Consolaro Marcia Edilaine Lopes, 2004, Revista Iberoamericana de Micologia, V21, P202
   Duerr A, 1997, OBSTET GYNECOL, V90, P252, DOI 10.1016/S0029-7844(97)00253-6
   ENWANI IB, 2001, REV IBEROAM MICOL, V18, P171
   Felk A, 2002, INFECT IMMUN, V70, P3689, DOI 10.1128/IAI.70.7.3689-3700.2002
   Fidel PL, 1996, CLIN MICROBIOL REV, V9, P335, DOI 10.1128/CMR.9.3.335
   Fidel PL, 1999, CLIN MICROBIOL REV, V12, P80, DOI 10.1128/CMR.12.1.80
   Fidel PL, 1997, J INFECT DIS, V176, P728
   Hammer KA, 2000, MED MYCOL, V38, P355, DOI 10.1080/mmy.38.5.354.361
   Hube B, 2001, MICROBIOL-SGM, V147, P879, DOI 10.1099/00221287-147-4-879
   Imanishi Yumi, 2004, Nihon Ishinkin Gakkai Zasshi, V45, P113, DOI 10.3314/jjmm.45.113
   JONES JM, 1990, CLIN MICROBIOL REV, V3, P32, DOI 10.1128/CMR.3.1.32-45.1990
   Kurtzman C.P., 1998, YEAST TAXONOMIC STUD
   Larone DH, 1995, MED IMPORTANT FUNGI
   Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X
   Lynch ME, 1996, J MED VET MYCOL, V34, P337
   *NCCLS, 1997, M27A NCCLS, V17, P1
   ODDS FC, 1988, J MED VET MYCOL, V26, P277
   Ribeiro MA, 2001, MYCOPATHOLOGIA, V151, P5, DOI 10.1023/A:1010909504071
   Sobel JD, 1997, CLIN INFECT DIS, V24, P649, DOI 10.1093/clind/24.4.649
   SOBEL JD, 1993, CLIN OBSTET GYNECOL, V36, P153, DOI 10.1097/00003081-199303000-00021
   SOBEL JD, 1984, INFECT IMMUN, V44, P576, DOI 10.1128/IAI.44.3.576-580.1984
   Sobel JD, 1998, MYCOSES, V41, P18, DOI 10.1111/j.1439-0507.1998.tb00594.x
   SOBEL JD, 1996, PRINCIPLES PRACTICE, P179
   Sugita T, 2002, MICROBIOL IMMUNOL, V46, P881, DOI 10.1111/j.1348-0421.2002.tb02776.x
   Vilela MMS, 2002, MED MYCOL, V40, P249, DOI 10.1080/mmy.40.3.249.257
   ZIARRUSTA GB, 2001, REV IBEROAM MICOL, V19, P22
NR 28
TC 23
Z9 33
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-486X
EI 1573-0832
J9 MYCOPATHOLOGIA
JI Mycopathologia
PD JUN
PY 2005
VL 159
IS 4
BP 501
EP 507
DI 10.1007/s11046-005-1149-0
PG 7
WC Mycology
SC Mycology
GA 940JW
UT WOS:000230141800003
PM 15983735
DA 2020-12-08
ER

PT J
AU Kaneshima, EN
   Suzuki, LE
   Irie, MMT
   Yoshida, CS
   da Silva, SFM
   Consolaro, MEL
AF Kaneshima, EN
   Suzuki, LE
   Irie, MMT
   Yoshida, CS
   da Silva, SFM
   Consolaro, MEL
TI The application and its importance in non-classic morphologic approaches
   to cytopathology diagnostic of human papillomavirus (HPV) previously
   detected for PCR
SO ACTA BIOQUIMICA CLINICA LATINOAMERICANA
LA Spanish
DT Article
DE HPV; PCR; non-classics approaches
ID CYTOLOGIC DIAGNOSIS; CERVICAL SMEARS; INFECTION; DNA; HYBRIDIZATION;
   CONDYLOMA; LESIONS; INSITU; PATTERNS; TYPE-16
AB There is great concern at present over the improvement in cytopathology diagnosis for HPV, and for this reason we have been studying the introduction of non-classic morfologic approaches, bearing in mind the high frequency of this viral infection as well as its carcinogenic potential. The object of this work is to make a new reading of 41 positive cases for HPV by PCR, introducing non-classic approaches, where as the initial ones were mad simply based on the classic ones. The most frequently observed cytopathology approaches were the non-classic, being two or many nucleuses the most frequent, with n = 37 (90.24%), followed by hypercromatic nucleus with n = 35 (85.36%) and nucleus in blot, with n = 24 (58.54%). In relation to the classic approaches, diskeratosis was observed in n = 17 cases (41.46%) and koilocytosis n= 10 (24.35%), representing the fourth and ninth approaches in numeric order of observation. It was also made clear that the more advanced the lesion diagnosed by the citopatology, the lower the frequency of classic criteria and the higher the frequency of non-classic criteria. After inclusion of the non classic approaches, diagnosis of HPV rose from 24.39% of the cases to 75.61% of the cases, being 40.00% of ASCUS and 100.00% of NIC I, NIC II, NIC III and cervical cancers became positive for the virus. This fact is of the highest importance for the improvement of the cytopathology services used to trace cervical cancers. Even so, the only normal case for the cytology, the two inflammatory cases, the four cases of scamous metaplasia and the three cases out of five cases of ASCUS remained negative for HPV, representing false-negative tests. That is quite preoccupying since, once patient are carriers of virus, independent of the clinical state, they haver higher probabilities of developing precursor lesions and even cervical cancers.
C1 Univ Estadual Maringa, Dept Anal Clin, Citol Clin, Maringa, Parana, Brazil.
   Univ Estadual Maringa, Curso Farm Habilitacao Anal Clin, Maringa, Parana, Brazil.
RP Consolaro, MEL (corresponding author), Av Colombo,5-790 Zona 7, BR-87020900 Maringa, Parana, Brazil.
EM melconsolaro@uem.br
RI Consolaro, Marcia Edilaine Lopes/I-4932-2014
OI Consolaro, Marcia Edilaine Lopes/0000-0001-9102-4865
CR AYRE JE, 1960, OBSTET GYNECOL, V17, P175
   AZOCAR J, 1990, INT J CANCER, V45, P622, DOI 10.1002/ijc.2910450408
   BAUER HB, 1993, DIAGNOSTIC MOL MICRO
   BIBBO M, 1998, LESOES RELACIONADAS
   BONFIGLIO T, 1997, GYNECOLOGY CYTOPATHO, P51
   CARVALHO JJL, 2000, CONSENSO BRASILEIRO, P49
   Cavaliere MJ, 1990, B INFORM UNION, V15, P24
   Collaco LM, 1994, J BRAS GINEC, V104, P419
   DEBORGES RJ, 1989, ACTA CYTOL, V33, P314
   FILHO AMS, 2000, COLO UTERNIO VAGINA, P123
   FRANCO EL, 1995, TRATADO ONCOLOGIA GE, P3
   GOMPEL C, 1997, CITOLOGIA GINECOLOGI, P79
   GROSS GE, 1999, INFECCAO PAPILOMAVIR, P1
   GUPTA JW, 1987, ACTA CYTOL, V31, P387
   HAUSEN HZ, 1977, CURR TOP MICROBIOL, P1
   HINCHLIFFE SA, 1995, BRIT J CANCER, V72, P943, DOI 10.1038/bjc.1995.438
   JACYNTHO C, 1996, HPV INFECCAO GENITAL, P5
   KERN SB, 1991, ACTA CYTOL, V53
   KOCHEL HG, 1990, INT J GYNECOL OBSTET, V31, P145, DOI 10.1016/0020-7292(90)90712-T
   Korobowicz Elzbieta, 1997, Polish Journal of Pathology, V48, P107
   KOSS LG, 1989, JAMA-J AM MED ASSOC, V261, P737, DOI 10.1001/jama.261.5.737
   KOSS LG, 1956, ANN NY ACAD SCI, V63, P1245, DOI 10.1111/j.1749-6632.1956.tb32134.x
   KOUTSKY LA, 1988, EPIDEMIOL REV, V10, P122, DOI 10.1093/oxfordjournals.epirev.a036020
   KURMAN RJ, 1997, BETHESDA SYSTEM REPO
   LANDRAC L, 1989, J VEN MARS, P2
   LEVI JE, 1996, NEWS LAB, V14, P66
   LORETO CD, 1992, B INFORM UNION, V15, P24
   LORINCZ AT, 1996, CLIN OBSTET GINECOLO, V3, P565
   LUZZATTO R, 1990, ACTA CYTOL, V34, P286
   MEISELS A, 1976, ACTA CYTOL, V20, P505
   MEISELS A, 1988, COMPENDIUM DIAGNOSTI, P63
   NAIB ZM, 1961, OBSTET GYNECOL, V18, P735
   NUOVO GJ, 1990, AM J SURG PATHOL, V14, P643, DOI 10.1097/00000478-199007000-00005
   PAPANICOLAOU GN, 1960, ATLAS EXFOLIATIVE CY, P18
   PINTO AP, 2001, J BRAS PATOL, V37, P57
   Poljak M, 1999, J CLIN MICROBIOL, V37, P796, DOI 10.1128/JCM.37.3.796-797.1999
   PUROLA E, 1977, ACTA CYTOL, V21, P26
   SADOUL G, 1986, REV PRATICIEN, V36, P876
   SCHNEIDER A, 1987, DIAGN CYTOPATHOL, V3, P250, DOI 10.1002/dc.2840030315
   SCHNEIDER ML, 1998, CITOLOGIA GINCOLOGIC, P59
   SHIH LWS, 1988, ACTA ONCOL BRAS, V8, P59
   SHROYER KR, 1990, DIAGN CYTOPATHOL, V6, P178, DOI 10.1002/dc.2840060307
   SUZUKI LE, 2000, EFICEINCIA TECHNICA
   SYRJANEN K, 1988, BRIT J OBSTET GYNAEC, V95, P1096, DOI 10.1111/j.1471-0528.1988.tb06785.x
   TAKAHASHI M, 1982, ATLAS CITOLOGIA CANC, P74
   Trofatter Kenneth F. Jr., 1997, American Journal of Medicine, V102, P21, DOI 10.1016/S0002-9343(97)00180-0
   UTAGAWA ML, 1997, J BRAS GIN, V107, P83
   Vince A, 2001, J CLIN VIROL, V20, P91, DOI 10.1016/S1386-6532(00)00161-X
   Yoshinouchi M, 1999, J CLIN MICROBIOL, V37, P3514, DOI 10.1128/JCM.37.11.3514-3517.1999
   ZURHAUSEN H, 1976, CANCER RES, V36, P794
NR 50
TC 2
Z9 2
U1 0
U2 0
PU FEDERACION BIOQUIMICA PROVINCIA BUENOS AIRES
PI LA PLATA, BUENOS AIRES
PA CALLE 6, NO. 1344, 1900 LA PLATA, BUENOS AIRES, ARGENTINA
SN 0325-2957
EI 1851-6114
J9 ACTA BIOQUIM CLIN L
JI Acta Bioquim. Clin. Latinoam.
PD MAR
PY 2005
VL 39
IS 1
BP 61
EP 68
PG 8
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 939VN
UT WOS:000230100700010
DA 2020-12-08
ER

EF